0001808805-24-00005810-Q Nautilus Biotechnology, Inc. 2024073020240730161044161044161044 0 0001808805-24-000058 10-Q 63 20240630 20240730 20240730 Nautilus Biotechnology, Inc. 0001808805 3826 981541723 1231 10-Q 34 001-39434 241157466 2701 EASTLAKE AVE EAST SEATTLE WA 98102 206-333-2001 2701 EASTLAKE AVE EAST SEATTLE WA 98102 ARYA Sciences Acquisition Corp III 20200408 10-Q 1 naut-20240630.htm 10-Q naut-20240630001808805FALSE12/312024Q2xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesnaut:segmentxbrli:pure00018088052024-01-012024-06-300001808805 2024-07-250001808805 2024-06-300001808805 2023-12-310001808805 2024-04-012024-06-300001808805 2023-04-012023-06-300001808805 2023-01-012023-06-300001808805us-gaap:CommonStockMember 2024-03-310001808805us-gaap:AdditionalPaidInCapitalMember 2024-03-310001808805us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-310001808805us-gaap:RetainedEarningsMember 2024-03-310001808805 2024-03-310001808805us-gaap:CommonStockMember 2024-04-012024-06-300001808805us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-300001808805us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-300001808805us-gaap:RetainedEarningsMember 2024-04-012024-06-300001808805us-gaap:CommonStockMember 2024-06-300001808805us-gaap:AdditionalPaidInCapitalMember 2024-06-300001808805us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-300001808805us-gaap:RetainedEarningsMember 2024-06-300001808805us-gaap:CommonStockMember 2023-03-310001808805us-gaap:AdditionalPaidInCapitalMember 2023-03-310001808805us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-310001808805us-gaap:RetainedEarningsMember 2023-03-310001808805 2023-03-310001808805us-gaap:CommonStockMember 2023-04-012023-06-300001808805us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-300001808805us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-300001808805us-gaap:RetainedEarningsMember 2023-04-012023-06-300001808805us-gaap:CommonStockMember 2023-06-300001808805us-gaap:AdditionalPaidInCapitalMember 2023-06-300001808805us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-300001808805us-gaap:RetainedEarningsMember 2023-06-300001808805 2023-06-300001808805us-gaap:CommonStockMember 2023-12-310001808805us-gaap:AdditionalPaidInCapitalMember 2023-12-310001808805us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-310001808805us-gaap:RetainedEarningsMember 2023-12-310001808805us-gaap:CommonStockMember 2024-01-012024-06-300001808805us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-06-300001808805us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-06-300001808805us-gaap:RetainedEarningsMember 2024-01-012024-06-300001808805us-gaap:CommonStockMember 2022-12-310001808805us-gaap:AdditionalPaidInCapitalMember 2022-12-310001808805us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-310001808805us-gaap:RetainedEarningsMember 2022-12-310001808805 2022-12-310001808805us-gaap:CommonStockMember 2023-01-012023-06-300001808805us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-06-300001808805us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-06-300001808805us-gaap:RetainedEarningsMember 2023-01-012023-06-300001808805us-gaap:PrivatePlacementMember 2021-06-092021-06-090001808805us-gaap:PrivatePlacementMember 2021-06-090001808805 2021-06-012021-06-300001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMemberus-gaap:FairValueInputsLevel1Member 2024-06-300001808805us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMemberus-gaap:FairValueInputsLevel1Member 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMembernaut:LongTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member 2024-06-300001808805us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member 2024-06-300001808805us-gaap:CashAndCashEquivalentsMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member 2024-06-300001808805us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member 2024-06-300001808805us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMembernaut:LongTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member 2024-06-300001808805us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member 2024-06-300001808805us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMembernaut:LongTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member 2024-06-300001808805us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member 2024-06-300001808805us-gaap:CashAndCashEquivalentsMemberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member 2024-06-300001808805us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember 2024-06-300001808805us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMembernaut:LongTermInvestmentsMemberus-gaap:FairValueInputsLevel2Member 2024-06-300001808805us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member 2024-06-300001808805us-gaap:CashAndCashEquivalentsMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member 2024-06-300001808805us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember 2024-06-300001808805us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMembernaut:LongTermInvestmentsMemberus-gaap:FairValueInputsLevel2Member 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2024-06-300001808805us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMembernaut:LongTermInvestmentsMemberus-gaap:FairValueInputsLevel2Member 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member 2024-06-300001808805us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMembernaut:LongTermInvestmentsMemberus-gaap:FairValueInputsLevel2Member 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMembernaut:LongTermInvestmentsMember 2024-06-300001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMemberus-gaap:FairValueInputsLevel1Member 2023-12-310001808805us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMemberus-gaap:FairValueInputsLevel1Member 2023-12-310001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member 2023-12-310001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MutualFundMembernaut:LongTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member 2023-12-310001808805us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member 2023-12-310001808805us-gaap:CashAndCashEquivalentsMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member 2023-12-310001808805us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member 2023-12-310001808805us-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMembernaut:LongTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member 2023-12-310001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member 2023-12-310001808805us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member 2023-12-310001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMember 2023-12-310001808805us-gaap:FairValueMeasurementsRecurringMembernaut:LongTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member 2023-12-310001808805us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member 2023-12-310001808805us-gaap:CashAndCashEquivalentsMemberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member 2023-12-310001808805us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember 2023-12-310001808805us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMembernaut:LongTermInvestmentsMemberus-gaap:FairValueInputsLevel2Member 2023-12-310001808805us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member 2023-12-310001808805us-gaap:CashAndCashEquivalentsMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member 2023-12-310001808805us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember 2023-12-310001808805us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMembernaut:LongTermInvestmentsMemberus-gaap:FairValueInputsLevel2Member 2023-12-310001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2023-12-310001808805us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2023-12-310001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember 2023-12-310001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMembernaut:LongTermInvestmentsMemberus-gaap:FairValueInputsLevel2Member 2023-12-310001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member 2023-12-310001808805us-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member 2023-12-310001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMember 2023-12-310001808805us-gaap:FairValueMeasurementsRecurringMembernaut:LongTermInvestmentsMemberus-gaap:FairValueInputsLevel2Member 2023-12-310001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-310001808805us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember 2023-12-310001808805us-gaap:FairValueMeasurementsRecurringMembernaut:LongTermInvestmentsMember 2023-12-310001808805us-gaap:USTreasurySecuritiesMember 2024-06-300001808805us-gaap:CommercialPaperMember 2024-06-300001808805us-gaap:CorporateDebtSecuritiesMember 2024-06-300001808805us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-300001808805us-gaap:USTreasurySecuritiesMember 2023-12-310001808805us-gaap:CommercialPaperMember 2023-12-310001808805us-gaap:CorporateDebtSecuritiesMember 2023-12-310001808805us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-310001808805naut:LaboratoryEquipmentMember 2024-06-300001808805naut:LaboratoryEquipmentMember 2023-12-310001808805us-gaap:LeaseholdImprovementsMember 2024-06-300001808805us-

gaap:LeaseholdImprovementsMember2023-12-310001808805us-gaap:ComputerEquipmentMember2024-06-300001808805us-gaap:ComputerEquipmentMember2023-12-310001808805naut:FurnitureFixturesAndOfficeEquipmentMember2024-06-300001808805naut:FurnitureFixturesAndOfficeEquipmentMember2023-12-310001808805naut:PrototypeEquipmentMember2024-06-300001808805naut:PrototypeEquipmentMember2023-12-310001808805us-gaap:ConstructionInProgressMember2024-06-300001808805us-gaap:ConstructionInProgressMember2023-12-310001808805naut:A2021EquityIncentivePlanMember2024-06-300001808805naut:A2021EquityIncentivePlanMember2023-12-310001808805naut:A2021EmployeeStockPurchasePlanMember2024-06-300001808805naut:A2021EmployeeStockPurchasePlanMember2023-12-310001808805naut:A2021EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2024-06-300001808805naut:A2021EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2024-01-012024-06-300001808805naut:A2021EmployeeStockPurchasePlanMember2024-01-012024-06-300001808805naut:A2021EmployeeStockPurchasePlanMember2024-01-010001808805naut:A2021EquityIncentivePlanMember2024-01-012024-06-300001808805naut:A2021EquityIncentivePlanMember2024-01-010001808805us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-04-012024-06-300001808805us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-04-012024-06-300001808805us-gaap:EmployeeStockOptionMembersrt:MinimumMember2023-04-012023-06-300001808805us-gaap:EmployeeStockOptionMembersrt:MaximumMember2023-04-012023-06-300001808805us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-01-012024-06-300001808805us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-06-300001808805us-gaap:EmployeeStockOptionMembersrt:MinimumMember2023-01-012023-06-300001808805us-gaap:EmployeeStockOptionMembersrt:MaximumMember2023-01-012023-06-300001808805us-gaap:EmployeeStockOptionMember2024-04-012024-06-300001808805us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001808805us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001808805us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001808805us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001808805us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001808805us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001808805us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001808805us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001808805us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001808805us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001808805us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001808805us-gaap:EmployeeStockOptionMember2024-01-012024-06-300001808805us-gaap:EmployeeStockOptionMember2024-04-012024-06-300001808805us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001808805us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001808805naut:EmployeeStockPurchasePlanMember2024-04-012024-06-300001808805naut:EmployeeStockPurchasePlanMember2024-01-012024-06-300001808805naut:EmployeeStockPurchasePlanMember2023-04-012023-06-300001808805naut:EmployeeStockPurchasePlanMember2023-01-012023-06-30Â Â Â Â Â Â Â Â Â Â UNITED STATESSECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549FORM 10-Q (Mark One)xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended JuneÂ 30, 2024 ORoTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from _____ to _____ Commission File Number 001-39434NAUTILUS BIOTECHNOLOGY, INC.(Exact name of registrant as specified in its charter) Delaware98-1541723(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)2701 Eastlake Avenue East Seattle, Washington 98102(Address of principal executive offices)(Zip Code)(206) 333-2001 (Registrant's telephone number, including area code)(Former name, former address and former fiscal year, if changed since last report)Securities registered pursuant to Section 12(b) of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, par value $0.0001 per shareNAUTThe Nasdaq Stock Market LLCIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Â Â Â Â Yes â˜’ No â˜Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Â Â Â Yes â˜’ No â˜Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.LargeÂ acceleratedÂ fileroAcceleratedÂ fileroNon-accelerated filerâ˜’SmallerÂ reportingÂ companyâ˜’EmergingÂ growthÂ companyâ˜’If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Â oIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Â Â Â Â YesÂ Â Â oÂ Â Â Â Â NoÂ Â xAs of JulyÂ 25, 2024, the registrant had 125,411,248 shares of common stock, $0.0001 par value per share, outstanding.NAUTILUS BIOTECHNOLOGY, INC.TABLE OF CONTENTSPagePART I. FINANCIAL INFORMATIONiiiItem 1.Financial StatementsCondensed Consolidated Financial Statements (Unaudited)iiiCondensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 (unaudited)1Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2024 and 2023 (unaudited)2Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June 30, 2024 and 2023 (unaudited)3Condensed Consolidated Statements of Stockholdersâ€™ Equity for the Three and Six Months Ended June 30, 2024 and 2023 (unaudited)4Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2024 and 2023 (unaudited)6Notes to Condensed Consolidated Financial Statements (unaudited)7Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations18Item 3.Quantitative and Qualitative Disclosures About Market Risk28Item 4.Controls and Procedures29PART II - OTHER INFORMATIONItem 1.Legal Proceedings30Item 1A.Risk Factors30Item 2.Unregistered Sales of Equity Securities and Use of Proceeds74Item 3.Defaults Upon Senior Securities74Item 4.Mine Safety Disclosures74Item 5.Other Information74Item 6.Exhibits75SIGNATURES76iSPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTSThis Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on our managementâ€™s beliefs and assumptions and on information currently available to our management. The forward-looking statements are contained principally in the section entitled â€œRisk Factorsâ€ and â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.â€ Forward-looking statements include, but are not limited to, statements concerning the following:â€¢our dependence on the success of our proteomics platform (the â€œNautilus platformâ€), which remains in the development stage and subject to scientific and technical validation;â€¢our expectations regarding the timing and progress of the development of the Nautilus platform and any commercialization timelines;â€¢our expectations regarding the functionality of the Nautilus platform;â€¢our estimates of our addressable market, market growth, future revenue, key performance indicators, expenses, capital requirements and needs for additional financing;â€¢our expectations regarding the rate and degree of market acceptance of the Nautilus platform;â€¢the impact of the Nautilus platform on the field of proteomics and the size and growth of the addressable proteomics market;â€¢our ability to manage and grow our business and commercialize our Nautilus platform;â€¢our ability to successfully implement our three phase commercial launch plan;â€¢the implementation of our business model and strategic plans for the Nautilus platform;â€¢our ability to establish and maintain intellectual property protection for our products or avoid or defend claims of infringement;â€¢our expectations regarding the use of proceeds from the Business Combination (as defined in Part I, Item I, Note 1, â€œDescription of Business and Basis of Presentation,â€ in our notes to condensed consolidated financial statements in this Quarterly Report on Form 10-Q);â€¢the performance of third-party partners, manufacturers and suppliers;â€¢changes in applicable laws or regulations;â€¢our ability to raise financing in the future;â€¢our success in retaining or recruiting, or changes required in, our officers, key employees or directors or other key personnel;â€¢the volatility of the trading price of our common stock;â€¢our ability to develop and commercialize new products;â€¢our expectations about market trends;â€¢the impact of local, regional, national and international economic conditions and events including the COVID-19 pandemic, the conflicts in Eastern Europe and the Middle East, changing interest rates, instability in the global financial markets and general economic downturns, on the foregoing; andâ€¢other factors including but not limited to those detailed under the section entitled â€œRisk Factors.â€iiForward-looking statements include statements that are not historical facts and can be identified by terms such as â€œanticipates,â€ â€œbelieves,â€ â€œcould,â€ â€œseeks,â€ â€œestimates,â€ â€œexpects,â€ â€œintends,â€ â€œmay,â€ â€œplans,â€ â€œpotential,â€ â€œpredicts,â€ â€œprojects,â€ â€œshould,â€ â€œwill,â€ â€œwould,â€ or similar expressions and the negatives of those terms.Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in Part II, Item 1A, â€œRisk Factors,â€ elsewhere in this Quarterly Report on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Quarterly Report on Form 10-Q may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.The forward-looking statements made in this Quarterly Report on Form 10-Q relate only to events as of the date on which the statements are made. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business, and market opportunity, including data regarding the estimated size of the market. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.This Quarterly Report on Form 10-Q contains references to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Quarterly Report on Form 10-Q may appear without the Â® or TM symbols, but such references are not intended to indicate, in any way, that the applicable licensor will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use or display of other companiesâ€™ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of it by, any other companies. PART I. FINANCIAL INFORMATIONITEM 1. FINANCIAL STATEMENTSiiiNautilus Biotechnology, Inc.Condensed Consolidated Balance SheetsAs of June 30, 2024 and December 31, 2023 (Unaudited)(in thousands, except share and per share amounts)June 30, 2024December 31, 2023AssetsCurrent assets:Cash and cash equivalents$24,885Â $19,397Â Short-term investments142,558Â 154,021Â Prepaid expenses and other current assets3,490Â 3,419Â Total current assets170,933Â 176,837Â Property and equipment, net4,694Â 4,267Â Operating lease right-of-use assets30,474Â 32,634Â Long-term investments65,466Â 90,647Â Other long-term assets1,180Â 1,180Â Total assets$272,747Â $305,565Â Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable$1,627Â $1,639Â Accrued expenses and other liabilities3,239Â 3,945Â Current portion of operating lease liabilities3,815Â 3,538Â Total current liabilities8,681Â 9,122Â Operating lease liabilities, net of current portion28,787Â 31,090Â Total liabilities37,468Â 40,212Â Commitments and contingencies (Note 8)Stockholders' equity:Preferred stock, $0.0001 par value, 200,000,000 authorized as of JuneÂ 30, 2024 and DecemberÂ 31, 2023; 0 shares issued and outstanding as of JuneÂ 30, 2024 and DecemberÂ 31, 2023â€”Â â€”Â Common stock, $0.0001 par value, 1,000,000,000 shares authorized as of JuneÂ 30, 2024 and DecemberÂ 31, 2023; 125,406,748 and 125,068,601 shares issued and outstanding as of JuneÂ 30, 2024 and

DecemberÂ 31, 2023, respectively13Â 13Â Additional paid-in capital474,791Â 467,834Â Accumulated other comprehensive income (loss)(546)(255)Accumulated deficit(238,979)(202,239)Total stockholdersâ€™ equity235,279Â 265,353Â Total liabilities and stockholders' equity$272,747Â $305,565Â The accompanying notes are an integral part of these condensed consolidated financial statements.1Nautilus Biotechnology, Inc.Condensed Consolidated Statements of OperationsThree and Six Months Ended June 30, 2024 and 2023 (Unaudited)Three Months Ended June 30,Six Months Ended June 30,(in thousands, except share and per share data)20242023202420232023Operating expensesResearch and development$12,436Â $11,912Â $25,366Â $22,789Â General and administrative8,353Â 7,104Â 17,030Â 14,287Â Total operating expenses20,789Â 19,016Â 42,396Â 37,076Â Other income (expense)Interest income2,798Â 3,222Â 5,675Â 6,320Â Other expense(19)(14)(19)(17)Total other income$2,779Â $3,208Â $5,656Â $6,303Â Net loss$(18,010)$(15,808)$(36,740)$(30,773)Net loss per share attributable to common stockholders, basic and diluted(0.14)(0.13)(0.29)(0.25)Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted125,317,650Â 124,603,181Â 125,226,552Â 124,601,762Â The accompanying notes are an integral part of these condensed consolidated financial statements.2Nautilus Biotechnology, Inc.Condensed Consolidated Statements of Comprehensive LossThree and Six Months Ended June 30, 2024 and 2023 (Unaudited) Three Months Ended June 30,Six Months Ended June 30,(in thousands)20242023202420232023Net loss$(18,010)$(15,808)$(36,740)$(30,773)Other comprehensive income (loss):Unrealized gain (loss) on securities available-for-sale199Â (1,430)(291)(535)Total other comprehensive income (loss)199Â (1,430)(291)(535)Comprehensive loss$(17,811)$(17,238)$(37,031)$(31,308)The accompanying notes are an integral part of these condensed consolidated financial statements.3Nautilus Biotechnology, Inc.Condensed Consolidated Statements of Stockholdersâ€™ EquityThree and Six Months Ended June 30, 2024 and 2023 (Unaudited)Three Months Ended June 30, 2024Additional Paid-in CapitalAccumulated Other Comprehensive LossAccumulated DeficitTotal Stockholdersâ€™ EquityCommon Stock(in thousands, except share amounts)SharesAmountBalances at March 31, 2024125,265,015Â $13Â $471,193Â (745)(220,969)$249,492Â Issuance of common stock upon exercise of vested stock options17,838Â â€”Â 30Â â€”Â â€”Â 30Â Issuance of common stock under employee stock purchase plan123,895Â â€”Â 289Â â€”Â â€”Â 289Â Stock-based compensation expenseâ€”Â â€”Â 3,279Â â€”Â â€”Â 3,279Â Other comprehensive incomeâ€”Â â€”Â â€”Â 199Â â€”Â 199Â Net lossâ€”Â â€”Â â€”Â â€”Â (18,010) (18,010)Balances at JuneÂ 30, 2024125,406,748Â $13Â $474,791Â (546)(238,979)$235,279Â Three Months Ended June 30, 2023Additional Paid-in CapitalAccumulated Other Comprehensive LossAccumulated DeficitTotal Stockholdersâ€™ EquityCommon Stock(in thousands, except share amounts)SharesAmountBalances at March 31, 2023124,866,392Â $12Â $458,191Â (959)(153,529)$303,715Â Issuance of common stock upon exercise of vested stock options5,000Â â€”Â 6Â â€”Â â€”Â 6Â Issuance of common stock under employee stock purchase plan59,507Â â€”Â 92Â â€”Â â€”Â 92Â Stock-based compensation expenseâ€”Â â€”Â 3,098Â â€”Â â€”Â 3,098Â Other comprehensive lossâ€”Â â€”Â â€”Â (1,430)â€”Â (1,430)Net lossâ€”Â â€”Â â€”Â â€”Â (15,808) (15,808)Balances at JuneÂ 30, 2023124,930,899Â $12Â $461,387Â $(2,389)$(169,337)$289,673Â 4Nautilus Biotechnology, Inc.Condensed Consolidated Statements of Stockholdersâ€™ EquityThree and Six Months Ended June 30, 2024 and 2023 (Unaudited)Six Months Ended June 30, 2024Additional Paid-in CapitalAccumulated Other Comprehensive LossAccumulated DeficitTotal Stockholdersâ€™ EquityCommon Stock(in thousands, except share amounts)SharesAmountBalances at December 31, 2023125,068,601Â $13Â $467,834Â (255)(202,239)$265,353Â Issuance of common stock upon exercise of vested stock options214,252Â â€”Â 275Â â€”Â â€”Â 275Â Issuance of common stock under employee stock purchase plan123,895Â â€”Â 289Â â€”Â â€”Â 289Â Stock-based compensation expenseâ€”Â â€”Â 6,393Â â€”Â â€”Â 6,393Â Other comprehensive lossâ€”Â â€”Â â€”Â (291)â€”Â (291)Net lossâ€”Â â€”Â â€”Â â€”Â (36,740) (36,740)Balances at JuneÂ 30, 2024125,406,748Â $13Â $474,791Â (546)(238,979)$235,279Â Six Months Ended June 30, 2023Additional Paid-in CapitalAccumulated Other Comprehensive LossAccumulated DeficitTotal Stockholdersâ€™ EquityCommon Stock(in thousands, except share amounts)SharesAmountBalances at December 31, 2022124,865,485Â $12Â $455,330Â $(1,854)$(138,564)$314,924Â Issuance of common stock upon exercise of vested stock options5,907Â â€”Â 7Â â€”Â â€”Â 7Â Issuance of common stock under employee stock purchase plan59,507Â â€”Â 92Â â€”Â â€”Â 92Â Stock-based compensation expenseâ€”Â â€”Â 5,958Â â€”Â â€”Â 5,958Â Other comprehensive lossâ€”Â â€”Â â€”Â (535)â€”Â (535)Net lossâ€”Â â€”Â â€”Â â€”Â (30,773)(30,773)Balances at JuneÂ 30, 2023124,930,899Â $12Â $461,387Â $(2,389)$(169,337)$289,673Â The accompanying notes are an integral part of these condensed consolidated financial statements.5Nautilus Biotechnology, Inc.Condensed Consolidated Statements of Cash FlowsSix Months Ended June 30, 2024 and 2023 (Unaudited)Six Months Ended June 30,(in thousands)20242023Cash flows from operating activitiesNet loss$(36,740)$(30,773)Adjustments to reconcile net loss to net cash used in operating activitiesStock-based compensation expense6,393Â 5,958Â Amortization of operating lease right-of-use assets2,160Â 1,806Â Depreciation1,028Â 826Â Amortization (accretion) of premium (discount) on securities, net(1,453)(1,412)Changes in operating assets and liabilities:Prepaid expenses and other assets(71)(787)Accounts payable(308)(199)Accrued expenses and other liabilities(706)(117)Operating lease liabilities(2,026)(1,375)Net cash used in operating activities(31,723)(26,073)Cash flows from investing activitiesProceeds from maturities of securities53,500Â 32,249Â Purchases of securities(15,694)(46,844)Purchases of property and equipment(1,159)(1,155)Net cash provided by (used in) investing activities36,647Â (15,750)Cash flows from financing activitiesProceeds from exercise of stock options275Â 7Â Proceeds from issuance of common stock under employee stock purchase plan289Â 92Â Net cash provided by financing activities564Â 99Â Net increase (decrease) in cash, cash equivalents and restricted cash5,488Â (41,724)Cash, cash equivalents and restricted cash at beginning of period20,399Â 115,477Â Cash, cash equivalents and restricted cash at end of period$25,887Â $73,753Â Supplementary cash flow information on non-cash activities:Acquisitions of property and equipment included in accounts payable$444Â $323Â Right-of-use asset obtained in exchange for operating lease liability$â€”Â $7,623Â The accompanying notes are an integral part of these condensed consolidated financial statements6Nautilus Biotechnology, Inc.Notes to Condensed Consolidated Financial Statements(Unaudited)1.Description of Business and Basis of PresentationNautilus Biotechnology, Inc. (the â€œCompanyâ€) is a biotechnology company incorporated in 2016 with corporate headquarters in Seattle, Washington and research and development headquarters in San Carlos, California. Since the Companyâ€™s incorporation in 2016, the Company has devoted substantially all of its resources to research and development activities, including with respect to its proteomics platform, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital and providing general and administrative support for these operations. On June 9, 2021, Nautilus Biotechnology, Inc. a Delaware corporation (f/k/a ARYA Sciences Acquisition Corp. III, a Cayman Islands exempted company and the Companyâ€™s predecessor company (â€œARYAâ€)), consummated the business combination (the â€œBusiness Combinationâ€) pursuant to the terms of that certain Business Combination Agreement, dated as of February 7, 2021 (the â€œBCAâ€), by and among ARYA, Mako Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ARYA (â€œMako Merger Subâ€), and Nautilus Subsidiary, Inc., a Delaware corporation (f/k/a Nautilus Biotechnology, Inc.) (â€œLegacy Nautilusâ€). As a result of the Business Combination, ARYA changed its name to â€œNautilus Biotechnology, Inc.â€ and Mako Merger Sub merged with and into Legacy Nautilus with Legacy Nautilus surviving as the surviving company and becoming a wholly-owned subsidiary of ARYA (the â€œMergerâ€ and, collectively with the other transactions described in the BCA, the â€œReverse Recapitalizationâ€). In addition, in conjunction with the completion of the Business Combination, certain investors (â€œPIPE Investorsâ€) subscribed for the purchase of an aggregate of 20,000,000 shares of common stock of the Company (â€œNew Nautilus Common Stockâ€) at a price of $10.00 per share for aggregate gross proceeds of $200.0Â million (â€œPIPE Financingâ€).Basis of PresentationThe condensed consolidated financial statements and accompanying notes are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) and regulations of the U.S. Securities and Exchange Commission (the â€œSECâ€) for interim financial reporting. All intercompany transactions and balances have been eliminated upon consolidation. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements were prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Companyâ€™s financial position, results of operations, and cash flows for the interim periods. The interim financial results are not necessarily indicative of the results for a full year. These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023 on file with the SEC. The Companyâ€™s reporting currency is the U.S. dollar. Going ConcernThe Companyâ€™s condensed consolidated financial statements have been prepared on the basis of continuity of operations, the realization of assets, and the satisfaction of liabilities in the ordinary course of business. Since inception, the Company has been engaged in developing its technology, raising capital, and recruiting personnel. The Companyâ€™s operating plan may change as a result of many factors currently unknown and there can be no assurance that the current operating plan will be achieved in the time frame anticipated by the Company, and it may need to seek additional funds sooner than planned. If adequate funds are not available to the Company on a timely basis, it may be required to delay, limit, reduce, or terminate certain commercial efforts, or pursue merger or acquisition strategies, all of which could adversely affect the holdings or the rights of the Companyâ€™s stockholders. The Company has incurred net operating losses and negative cash flows from operations in every year since inception and expects this to continue for the foreseeable future. As of JuneÂ 30, 2024, the Company had an accumulated deficit of $239.0Â million.7Nautilus Biotechnology, Inc.Notes to Condensed Consolidated Financial Statementsâ€”(Continued)(Unaudited)The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock and common stock. In June 2021, the Company received gross proceeds of approximately $345.5 million from PIPE Investors and the Business Combination offset by approximately $18.2 million of transaction costs and underwritersâ€™ fees relating to the closing of the Business Combination. The Company had cash, cash equivalents, and short-term investments of $167.4 million as of JuneÂ 30, 2024. As of the date on which these condensed consolidated financial statements were issued, the Company believes that its cash, cash equivalents, and short-term investments will be sufficient to fund its operations for at least the next twelve months following the issuance of the condensed consolidated financial statements. The Companyâ€™s actual results could vary as a result of, and its near and long-term future capital requirements will depend on many factors, including its growth rate and the timing and extent of spending to support its research and development efforts. The Company has based its estimates on assumptions that may prove to be wrong, and it could use its available capital resources sooner than it currently expects. The Company may be required to seek additional equity or debt financing. Future liquidity and cash requirements will depend on numerous factors. In the event that additional financing is required, the Company may not be able to raise it on acceptable terms or at all. If the Company is unable to raise additional capital when desired, or if it cannot expand its operations or otherwise capitalize on its business opportunities because it lacks sufficient capital, its business, operating results, and financial condition would be adversely affected. 2.Significant Accounting PoliciesUse of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determining the estimated lives of property and equipment, stock-based compensation, research and development accruals, loss contingency accruals, and the valuation allowance for deferred tax assets. These estimates and assumptions are based on managementâ€™s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods. As future events and their effects cannot be determined with precision, actual results could materially differ from those estimates and assumptions. Concentrations of Credit Risk and Other Risks and UncertaintiesCredit risk represents the accounting loss that would be recognized as of the reporting date if counterparties failed to perform as contracted. Financial instruments, which potentially subject the Company to concentration of credit risk, consist of cash balances maintained in excess of federal depository insurance limits and investments in marketable debt securities that are not federally insured. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk on cash or investments. The Company relies, and expects to continue to rely, on a number of vendors to provide services, supplies and materials related to its research and development programs. The Company relies on single source suppliers for certain components and materials used in the Nautilus platform. The loss of any of these single source suppliers would require the Company to expend significant time and effort to locate and qualify an alternative source of supply for these components. The

Company also relies, and expects to continue to rely, on third-party manufacturers and, in many cases, single third-party manufacturers for the production of certain reagents and antibodies. These programs could be adversely affected by a significant interruption in these services or the availability of materials.The Company is subject to risks similar to those ofÂ pre-clinicalÂ stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, the impact of negative global and national 8Nautilus Biotechnology, Inc.Notes to Condensed Consolidated Financial Statementsâ€”(Continued)(Unaudited)events and the need to obtain adequate additional financing to fund the development of its products. There can be no assurance that the Companyâ€™s research and development will be successfully completed, that adequate protection for the Companyâ€™s intellectual property will be maintained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Companyâ€™s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.Segment ReportingOperating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker (â€œCODMâ€) in deciding how to allocate resources and in assessing performance. The Companyâ€™s Chief Executive Officer is its CODM. The Companyâ€™s CODM reviews financial information presented on a consolidated basis for the purposes of making operating decisions, allocating resources and evaluating financial performance. As such, the Company has determined that it operates in one operating and one reportable segment. The Companyâ€™s long-lived assets are entirely based in the United States. Cash and Cash Equivalents The Company considers all highly-liquid investments with an original maturity of three months or less as of the date of acquisition to be cash equivalents. InvestmentsThe Company considers investments with an original maturity greater than three months and remaining maturities less than one year to be short-term investments. The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as long-term investments. The Company classifies its marketable debt securities as available for sale and reports them at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For investments sold prior to maturity, the cost of investments sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in other income (expense), net in the condensed consolidated statement of operations. If the estimated fair value of a marketable debt security is below its amortized cost basis, the Company evaluates whether it is more likely than not that the Company will be required to sell the security before its anticipated recovery in market value and whether credit losses exist for the related securities. Credit-related losses are recognized as an allowance for credit losses on the balance sheet with a corresponding adjustment to earnings. Unrealized gains and losses that are unrelated to credit deterioration are reported in accumulated other comprehensive income (loss).Fair Value of Financial InstrumentsFair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and9Nautilus Biotechnology, Inc.Notes to Condensed Consolidated Financial Statementsâ€”(Continued)(Unaudited)Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.The carrying amounts of cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other liabilities approximate their respective fair values due to their short-term nature.LeasesThe Company determines if an arrangement includes a lease at inception by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. Operating leases with a term of more than one year are included in operating lease right-of-use (â€œROUâ€) assets and operating lease liabilities on the Company's condensed consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments. Operating lease ROU assets and liabilities are recognized on the lease commencement date based on the present value of the future minimum lease payments over the lease term. The Company uses the incremental borrowing rate commensurate with the lease term based on the information available at the lease commencement date in determining the present value of the lease payments as the Company's leases generally do not provide an implicit rate. ROU assets initially equal the lease liability, adjusted for any prepaid lease payments and initial direct costs incurred, less any lease incentives received. Certain of the Company's leases include renewal options which allow the Company to, at its election, renew or extend the lease for a fixed or indefinite period of time. These renewal periods are included in the lease terms when the Company is reasonably certain the options will be exercised. Lease expense is recognized on a straight-line basis over the lease term when leases are operating leases. If it is considered a finance lease, expense is recognized over the lease term within interest expense and amortization in the Companyâ€™s condensed consolidated statements of operations. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's facility leases and to account for the lease and non-lease components as a single lease component. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less.Comprehensive Loss Comprehensive loss consists of net loss and other gains or losses affecting stockholdersâ€™ equity that, under U.S. GAAP are excluded from net loss. For the three and six months ended June 30, 2024 and 2023, net unrealized gains and losses on marketable debt securities were included as a component of comprehensive income (loss). Accounting PronouncementsThe Company is provided the option to adopt new or revised accounting guidance as an â€œemerging growth companyâ€ under the Jumpstart Our Business Startups Act of 2012 (the â€œJOBS Actâ€) either (1) within the same periods as those otherwise applicable to public business entities, or (2) within the same time periods as non-public business entities, including early adoption when permissible. With the exception of standards the Company elected to early adopt, when permissible, the Company has elected to adopt new or revised accounting guidance within the same time period as non-public business entities, as indicated below. Recently Issued Accounting PronouncementsIn November 2023, the FASB issued ASU 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,â€ which amends existing guidance on segment reporting to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The ASU is effective for the Company for the fiscal year ending December 31, 2024 and for interim periods beginning after 10Nautilus Biotechnology, Inc.Notes to Condensed Consolidated Financial Statementsâ€”(Continued)(Unaudited)December 31, 2024. The Company is in the process of evaluating the impact of the adoption of this Accounting Standards Update on its consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosures,â€ to enhance the transparency and decision usefulness of income tax disclosures. The ASU is effective for the Company for the fiscal year ending December 31, 2025. The Company is in the process of evaluating the impact of the adoption of this Accounting Standards Update on its consolidated financial statements and related disclosures. The Company does not anticipate adoption to have a material impact on its consolidated financial statements and related disclosures. 3. Â Â Â Â Fair Value MeasurementsThe following table details the assets carried at fair value and measured on a recurring basis within the three levels of fair value as of JuneÂ 30, 2024 and DecemberÂ 31, 2023:(in thousands)Gross UnrealizedReported as:June 30, 2024Amortized CostGainsLossesFair ValueCash equivalentsShort-term investmentsLong-term investmentsLevel 1Mutual funds$1,260Â $â€”Â $â€”Â $1,260Â $1,260Â $â€”Â $â€”Â U.S. treasury securities57,124Â 17Â (129)57,012Â 2,996Â 35,458Â 18,558Â Total Level 158,384Â 17Â (129)58,272Â 4,256Â 35,458Â 18,558Â Level 2Commercial paper20,457Â â€”Â (11)20,446Â 20,446Â â€”Â â€”Â Corporate debt securities4,984Â â€”Â (24)4,960Â â€”Â 4,960Â â€”Â Agency securities149,447Â 18Â (417)149,048Â â€”Â 102,140Â 46,908Â Total Level 2174,888Â 18Â (452)174,454Â 20,446Â 107,100Â 46,908Â Total Level 1 and Level 2$233,272Â $35Â (581)232,726Â $24,702Â $142,558Â $65,466Â (in thousands)Gross UnrealizedReported as:December 31, 2023Amortized CostGainsLossesFair ValueCash equivalentsShort-term investmentsLong-term investmentsLevel 1Mutual funds$590Â $â€”Â $â€”Â $590Â $590Â $â€”Â $â€”Â U.S. treasury securities74,115Â 104Â (247)73,972Â â€”Â 50,638Â 23,334Â Total Level 174,705Â 104Â (247)74,562Â 590Â 50,638Â 23,334Â Level 2Commercial paper18,653Â â€”Â (9)18,644Â 18,644Â â€”Â â€”Â Corporate debt securities6,950Â â€”Â (37)6,913Â â€”Â 6,913Â â€”Â Agency securities163,849Â 358Â (424)163,783Â â€”Â 96,470Â 67,313Â Total Level 2189,452Â 358Â (470)189,340Â 18,644Â 103,383Â 67,313Â Total Level 1 and Level 2$264,157Â $462Â (717)263,902Â $19,234Â $154,021Â $90,647Â Short-term investments have a contractual maturity date that is one year or less from the respective balance sheet date. Long-term investments have a contractual maturity date that is more than one year, but less than two years from the respective balance sheet date. The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are as follows:11Nautilus Biotechnology, Inc.Notes to Condensed Consolidated Financial Statementsâ€”(Continued)(Unaudited)(in thousands)Securities in Unrealized Loss Position Less than 12 monthsSecurities in Unrealized Loss Position Greater than 12 monthsTotalJune 30, 2024Gross Unrealized LossesFair Market ValueGross Unrealized LossesFair Market ValueGross Unrealized LossesFair Market ValueU.S. treasury securities$67Â $26,444Â $62Â $22,754Â $129Â $49,198Â Commercial paper11Â 20,447Â â€”Â â€”Â 11Â 20,447Â Corporate debt securitiesâ€”Â â€”Â 24Â 4,959Â 24Â 4,959Â Agency securities163Â 53,020Â 254Â 85,593Â 417Â 138,613Â Total$241Â $99,911Â $340Â $113,306Â $581Â $213,217Â (in thousands)Securities in Unrealized Loss Position Less than 12 monthsSecurities in Unrealized Loss Position Greater than 12 monthsTotalDecember 31, 2023Gross Unrealized LossesFair Market ValueGross Unrealized LossesFair Market ValueGross Unrealized LossesFair Market ValueU.S. treasury securities$85Â $20,408Â $162Â $30,230Â $247Â $50,638Â Commercial paper9Â 18,644Â â€”Â â€”Â 9Â 18,644Â Corporate debt securities37Â 6,913Â â€”Â â€”Â 37Â 6,913Â Agency securities229Â 85,039Â 195Â 25,704Â 424Â 110,743Â Total$360Â $131,004Â $357Â $55,934Â $717Â $186,938Â The Company reviewed its investment portfolio based on the underlying risk profile of the securities and have a no loss expectation for these investments. The Company reviewed the securities in an unrealized loss position and evaluated the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The Company recognized no credit losses during the three and six months ended June 30, 2024 and 2023, and had no allowance for credit losses as of JuneÂ 30, 2024 and DecemberÂ 31, 2023. 4. Â Â Â Â Composition of Certain Condensed Consolidated Financial Statement Line ItemsProperty and Equipment, Net Property and equipment consisted of the following:(in thousands)June 30,2024December 31,2023Laboratory equipment$6,474Â $6,337Â Leasehold improvements118Â 118Â Computer hardware335Â 222Â Furniture, fixtures and office equipment324Â 324Â Prototype equipment1,476Â 996Â Construction in progress1,601Â 904Â 10,328Â 8,901Â Less: Accumulated depreciation(5,634)(4,634)Total$4,694Â $4,267Â The Company recorded depreciation expense of $0.5 million and $1.0 million for the three and six months ended June 30, 2024, respectively, and $0.4 million and $0.8 million for the three and six months ended June 30, 2023, respectively, which was primarily allocated to research and development expense. 12Nautilus Biotechnology, Inc.Notes to Condensed Consolidated Financial Statementsâ€”(Continued)(Unaudited)Accrued Expenses and Other LiabilitiesAccrued expenses and other liabilities consisted of the following:(in thousands)June 30,2024December 31,2023Employee compensation$2,071Â $2,590Â Accrued research and development342Â 731Â Accrued professional and consulting fees522Â 245Â Other304Â 379Â Total$3,239Â $3,945Â Cash, Cash Equivalents and Restricted CashCash, cash equivalents and restricted cash consisted of the following:(in thousands)June 30,2024December 31,2023Cash and cash equivalents$24,885Â $19,397Â Restricted cash included in other long-term assets (Note 8)1,002Â 1,002Â Total$25,887Â $20,399Â Other long-term assets consisted of $1.0Â million of restricted cash and $0.2Â million of deposits as of JuneÂ 30, 2024 and DecemberÂ 31, 2023. 5. Â Â Â Â Common StockThere were 125,406,748 shares issued and outstanding as of JuneÂ 30, 2024.Common Stock Reserved for Future IssuanceShares of common stock reserved for future issuance on an as-if converted basis, were as follows:June 30,2024December 31,2023Shares available for grant under 2021 Equity Incentive Plan23,449,238Â 20,279,560Â Stock options issued and outstanding17,545,835Â 14,676,335Â Shares available for grant under 2021 Employee Stock Purchase Plan4,631,929Â 3,505,138Â Total shares of common stock reserved45,627,002Â 38,461,033Â 6. Â Â Â Â Income Taxes The Company

accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. For the three and six months ended June 30, 2024 and 2023, no income tax expense or benefit was recognized, due to a full valuation allowance recorded against its deferred tax assets. 7. Â Â Â Â Equity Incentive Plans and Stock-based CompensationOn June 8, 2021, the stockholders of the Company approved the 2021 Equity Incentive Plan (â€œ2021 Planâ€) and the 2021 Employee Stock Purchase Plan (â€œ2021 ESPPâ€). As of JuneÂ 30, 2024, 23,449,238 and 4,631,929 shares were available for grant under the 2021 Plan and 2021 ESPP, respectively. 13Nautilus Biotechnology, Inc.Notes to Condensed Consolidated Financial Statementsâ€”(Continued)(Unaudited)2021 Employee Stock Purchase PlanUnder the 2021 ESPP, participants are permitted to purchase shares of Common Stock, up to the IRS allowable limit, through contributions (in the form of payroll deductions or otherwise to the extent permitted by the administrator of the 2021 ESPP) of up to 15% of their eligible compensation. Participants are permitted to purchase shares of the Companyâ€™s Common Stock at 85% of the lower of the fair market value of the Companyâ€™s Common Stock on the first trading day of an offering period or on the last trading date in each purchase period. The Company offers a six month purchase period. Participants may end their participation at any time during an offering and will be paid their accrued contributions that have not yet been used to purchase shares. Participation ends automatically upon termination of employment with the Company. The number of shares of common stock available for issuance under the 2021 ESPP will be increased on the first day of each fiscal year in an amount equal to the least of (i) 3,734,500 shares of common stock, (ii) a number of shares of common stock equal to one percent (1%) of the total number of shares of all classes of common stock of the Company on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the Administrator no later than the last day of the immediately preceding fiscal year. On January 1, 2024, the number of shares available under the 2021 ESPP increased by 1,250,686 shares pursuant to this feature.2021 Equity Incentive PlanUnder the 2021 Plan, the Company can grant incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to employees, non-employee directors and consultants. Options generally expire ten years after the date of grant. The number of shares available for issuance under the 2021 Plan will be increased on the first day of each fiscal year in an amount equal to the least of (i) 18,672,200 shares, (ii) a number of shares equal to five percent (5%) of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the Administrator no later than the last day of the immediately preceding fiscal year. On January 1, 2024, the number of shares available under the 2021 Plan increased by 6,253,430 shares pursuant to this feature.2017 Equity Incentive PlanAt the time of adoption of the 2021 Plan and the 2021 ESPP, no further awards will be granted under the 2017 Equity Incentive Plan (â€œ2017 Planâ€). Stock-based awards forfeited or cancelled from the 2017 Plan are returned to the pool of shares of Common Stock available for issuance under the 2021 Plan.Grant Date Fair Value of Stock OptionsIn determining the compensation cost of the option awards, the fair value for each option award has been estimated using the Black Scholes model. The significant assumptions used in these calculations are summarized as follows:Three Months Ended June 30,Six Months Ended June 30,20242023202420232023Expected term (in years)5.3 - 6.05.3 - 6.15.3 - 6.05.3 - 6.4Expected volatility99.7% - 101.1%103.1% - 106.5%99.7% - 101.1%102.7% - 107.5%Expected dividend rate0.0Â %0.0Â %0.0Â %0.0Â %Risk free interest rate4.17% - 4.60%3.58% - 3.87%4.01% - 4.60%3.50% - 4.08%Expected term: The expected term of stock options represents the weighted-average period the stock options are expected to remain outstanding. The Company does not have sufficient historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term of options and has opted to use the â€œsimplified method,â€ whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option.14Nautilus Biotechnology, Inc.Notes to Condensed Consolidated Financial Statementsâ€”(Continued)(Unaudited)Expected volatility: Historically, the Company has been a private company and lacked companyâ€‘specific historical and implied volatility information for its common stock. Therefore, the expected volatility of the Companyâ€™s common stock was determined by using an average of historical volatilities of selected industry peers deemed to be comparable to the Companyâ€™s business corresponding to the expected term of the awards and the Company expects to continue to do so until such time as the Company has adequate historical data regarding the volatility of its traded common stock price.Expected dividend yield: The expected dividend rate is zero as the Company has no history or expectation of declaring dividends on its common stock.Risk-free interest rate: The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities corresponding to the expected term of the awards. The following table summarizes option award activity during the six months ended June 30, 2024:Number of Stock Option AwardsWeighted Average Exercise PriceWeighted Average Remaining Contractual Life (Years)Aggregate Intrinsic Value (in thousands)Outstanding as of DecemberÂ 31, 202314,676,335Â $3.63Â Granted3,423,900Â $2.65Â Exercised(214,252)$1.28Â Forfeited(340,148)$3.40Â Outstanding as of JuneÂ 30, 202417,545,835Â $3.47Â 7.8$6,304Â Options vested and expected to vest as of JuneÂ 30, 202417,545,835Â $3.47Â Vested and exercisable at JuneÂ 30, 20249,482,993Â $3.83Â 6.9$5,446Â As of JuneÂ 30, 2024, there was $19.4 million of total unrecognized compensation expense expected to be recognized over a weighted average-period of 2.3 years. Aggregate intrinsic value represents the difference between the fair market value of the common stock and the exercise price of outstanding, in-the-money options. Stock-based Compensation ExpenseThe following sets forth the total stock-based compensation expense included in the Companyâ€™s condensed consolidated statement of operations:Three Months Ended June 30,Six Months Ended June 30,(in thousands)20242023202420232023Research and development$1,146Â $1,048Â $2,242Â $2,023Â General and administrative2,133Â 2,050Â 4,151Â 3,935Â Total stock-based compensation expense$3,279Â $3,098Â $6,393Â $5,958Â 8. Â Â Â Â Commitments and Contingencies Purchase CommitmentsOpen purchase commitments are for the purchase of goods and services related to, but not limited to, research and development, facilities, and professional services under non-cancellable contracts. They were not recorded as liabilities on the condensed consolidated balance sheet as of JuneÂ 30, 2024 as the Company had not yet received the related goods or services. As of JuneÂ 30, 2024, the Company had open purchase commitments for goods and services of $2.3 million, of which $1.7 million are expected to be received through the next 12 months.15Nautilus Biotechnology, Inc.Notes to Condensed Consolidated Financial Statementsâ€”(Continued)(Unaudited)Legal ProceedingsFrom time to time, the Company may become involved in litigation relating to claims arising from the ordinary course of business. The Company may record accruals for loss contingencies associated with legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues. Loss contingency accruals would be included in accrued and other liabilities and general and administrative expenses.U.S. District Court ProceedingsOn December 14, 2023, the Company filed suit in the United States District Court for the Northern District of California against Somalogic (now known as Standard Biotools, Inc.), and the California Institute of Technology seeking declaratory judgment that the Company does not infringe any claims of US Patent No. 7,842,793 related to DNA origami structures, allegedly licensed from the California Institute of Technology through Somalogicâ€™s purchase of Palamedrix, Inc. On March 29, 2024, Somalogic filed a motion to dismiss the suit. On April 19, 2024, the Company filed a First Amended Complaint addressing issues raised in Somalogicâ€™s motion to dismiss. On April 22, 2024, the Court issued an order dismissing Somalogicâ€™s motion to dismiss as moot. On May 16, 2024, the Court granted the partiesâ€™ request for a temporary stay of the proceedings. While the Company believes that it will be able to prevail as to its claims in this litigation, the Company may incur significant expense and management distraction in prosecuting this litigation. Moreover, notwithstanding managementâ€™s belief as to the strength of the Companyâ€™s claims in this matter, litigation generally, and patent litigation in particular, can be unpredictable. As such, management cannot be certain that the Company will prevail in this litigation. LeasesThe Company is obligated under certain non-cancellable operating leases for office space and laboratory space. This space includes operating leases in Seattle, Washington, San Carlos, California, and San Diego, California.The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of JuneÂ 30, 2024:Lease Obligations(in thousands)Six months ending DecemberÂ 31, 2024$2,931Â 20257,182Â 20266,874Â 20276,889Â 20285,816Â 2029 and thereafter13,207Â Total future minimum lease payments42,899Â Less: Imputed interest(10,297)Total operating lease liabilities$32,602Â 16Nautilus Biotechnology, Inc.Notes to Condensed Consolidated Financial Statementsâ€”(Continued)(Unaudited)For the six months ended June 30, 2024 and 2023, cash paid for amounts included in the measurement of operating lease liabilities included in cash flows used in operating activities was $3.5 million and $2.8 million, respectively.The Company has $1.0 million in cash-collateralized letters of credit with one financial institution in lieu of security deposits in connection with the San Carlos and San Diego lease agreements. Indemnification AgreementsIn the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnifications will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by them in any action or proceeding to which any of them are, or are threatened to be, made a party by reason of their service as a director or officer. The Company maintains director and officer insurance coverage that would generally enable it to recover a portion of any future amounts paid. The Company may be subject to indemnification obligation by law with respect to the actions of its employees under certain circumstances and in certain jurisdictions. 9. Â Â Â Â Basic and Diluted Net Loss per ShareThe following tables set forth the computation of the Companyâ€™s basic and diluted net loss per share attributable to common stockholders for the three and six months ended June 30, 2024 and 2023:Three Months Ended June 30,Six Months Ended June 30,(in thousands, except share and per share amounts)20242023202420232023Numerator:Net loss attributable to common stockholders$(18,010)$(15,808)$(36,740)$(30,773)Denominator:Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted125,317,650Â 124,603,181Â 125,226,552Â 124,601,762Â Net loss per share attributable to common stockholders, basic and diluted:(0.14)(0.13)(0.29)(0.25)The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows:Three and Six Months Ended June 30,20242023Options to purchase common stock17,545,83514,699,055Employee stock purchase plan139,86178,003Total potentially dilutive common share equivalents17,685,69614,777,058 17ITEM 2. MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSThe following discussion and analysis provides information that our management believes is relevant to an assessment and understanding of Nautilus Biotechnology, Inc.â€™s (â€œNautilusâ€ or the â€œCompanyâ€) condensed consolidated results of operations and financial condition. The discussion should be read together with the condensed consolidated financial statements and the accompanying notes to those statements that are included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements for the year ended December 31, 2023 and the related notes included in the Companyâ€™s Annual Report on Form 10-K filed with the SEC on February 28, 2024. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. Nautilusâ€™ actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled â€œRisk Factorsâ€ in Part II, Item 1A as set forth in this Quarterly Report on Form 10-Q.Unless otherwise indicated or the context otherwise requires, references in this â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ section to â€œNautilus,â€ â€œwe,â€ â€œus,â€ â€œourâ€ and other similar terms refer to the business and operations of Legacy Nautilus prior to the Business Combination and to New Nautilus and its consolidated subsidiary following the Business Combination.OverviewWe are a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Our mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. We were founded on the belief that incremental advancements of existing technologies are inadequate, and that a bold scientific leap would be required to radically reinvent proteomics and revolutionize precision medicine. Our vision is to integrate our breakthrough innovations in

computer science, engineering, and biochemistry to develop and commercialize a proteomic analysis technology of extreme sensitivity and scale. To accomplish this, we have built a prototype of a proteome analysis system, an instrument to perform massively parallel single protein molecule measurements which will be further developed to deliver the speed, simplicity, accuracy, and versatility that we believe is necessary to establish a new gold standard in the field. Since our incorporation in 2016, we have devoted substantially all of our resources to research and development activities, including with respect to our proteomics platform, or Nautilus platform, business planning, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital and providing general and administrative support for these operations. We do not have any products available for commercial sale, and we have not generated any revenue from our Nautilus platform or other sources since inception. Our ability to generate revenue sufficient to achieve profitability, if ever, will depend on the successful development and eventual commercialization of our Nautilus platform, which we expect, if it ever occurs, will take a number of years. Our Nautilus platform, which includes our end-to-end solution comprised of instruments, consumables, and software analysis, is currently under development and will require significant additional research and development efforts, including extensive testing prior to commercialization. These efforts require significant amounts of additional capital and adequate personnel infrastructure. There can be no assurance that our research and development activities will be successfully completed, or that our Nautilus platform will be commercially viable. In order to commercialize our Nautilus platform in volume, we will need to establish internal manufacturing capacity or to contract with one or more manufacturing partners, or both. Our technology is complex, and the manufacturing process for our products will be similarly complex, involving a large number of unique precision parts in addition to the production of various reagents and antibodies. We may encounter unexpected difficulties in manufacturing our Nautilus platform, instruments, and related consumables. Among other factors, we will need to develop reliable supply chains for the various components in our Nautilus platform, instruments, and consumables to support large-scale commercial production. In connection with our Nautilus platform, we intend to utilize over 300 complex reagents and various antibodies in order to generate deep proteomic information at the speed and scale which we expect our Nautilus platform to perform. Such reagents and antibodies are expected to be more difficult to manufacture and more expensive to procure. There is no assurance that we will be able to build manufacturing or 18consumable production capacity internally or find one or more suitable manufacturing or production partners, or both, to meet the volume and quality requirements necessary to be successful in the proteomics market.Given our stage of development, we have not yet established a commercial organization or distribution capabilities. We do intend to build a commercial infrastructure to support sales of our products. We expect to manage sales, marketing and distribution through both internal resources and third-party relationships. We plan to commercialize our proteomics platform using a three-phase plan that has been shown to be effective and optimal for introducing disruptive products in numerous life sciences technology markets. The first phase is expected to involve collaboration with biopharmaceutical companies and key opinion leaders to validate the performance and utility of Nautilusâ€™ product, during which we do not expect to recognize significant revenue, if any. The second phase will include an early access limited release phase in which we expect to recognize limited revenue. Finally, the third phase is anticipated to include a broader commercial launch. We are currently in the collaboration phase during which we have entered into collaborations with a small number of research customers, including with biopharmaceutical companies and key opinion leaders in proteomics whose assessment and validation of our products can significantly influence other researchers in their respective markets and/or fields. During the early access limited release phase, we plan to leverage our publications to drive awareness and customer demand to pre-sell instruments and reagents to select customers performing large-scale proteomics research. During the second phase, we expect to work closely with early access customers to demonstrate a unique value proposition for our Nautilus platform. During this phase, we plan to provide early access to our partners with broad-scale and targeted analyses and profiling of samples analyzed in our facility and shared via a cloud platform. We anticipate early access engagements in 2025. We do not anticipate that these activities will result in any material revenue. We expect this second phase to lead into the third phase of launch of our proteome analysis platform in 2025 and subsequent broad commercialization thereafter. Voice of customer studies have suggested that there is market demand for a proteomics platform with specifications that are initially lower than what we have previously disclosed, for example, around characteristics such as sample input and proteome coverage. Consequently, as we balance our time to market goals with our evolving view of customer requirements, we are refining our initial launch specifications. We believe that subsequent consumable releases will enable our platform to meet or exceed our previously announced product specifications.We intend to commercialize our Nautilus platform through a direct sales channel in the United States, and through both direct and distributor sales channels in regions outside the United States. Given our stage of development, we currently have limited marketing, sales, commercial product distribution or service and support capabilities. We intend to build the necessary infrastructure for these activities in the United States, European Union, the United Kingdom, and potentially other countries and regions, including Asia-Pacific, as we execute on our three phase commercial launch strategy for our Nautilus platform. On June 9, 2021, Nautilus Biotechnology, Inc., a Delaware corporation (f/k/a ARYA Sciences Acquisition Corp. III, a Cayman Islands exempted company and the Companyâ€™s predecessor company (â€œARYAâ€)), consummated the business combination (the â€œBusiness Combinationâ€) pursuant to the terms of that certain Business Combination Agreement, dated as of February 7, 2021 (the â€œBCAâ€), by and among ARYA, Mako Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ARYA (â€œMako Merger Subâ€), and Nautilus Subsidiary, Inc., a Delaware corporation (f/k/a Nautilus Biotechnology, Inc.) (â€œLegacy Nautilusâ€). As a result of the Business Combination, ARYA changed its name to â€œNautilus Biotechnology, Inc.â€ and Mako Merger Sub merged with and into Legacy Nautilus with Legacy Nautilus surviving as the surviving company and becoming a wholly-owned subsidiary of ARYA (the â€œMergerâ€ and, collectively with the other transactions described in the BCA, the â€œReverse Recapitalizationâ€). In addition, in conjunction with the completion of the Business Combination, certain investors (â€œPIPE Investorsâ€) subscribed for the purchase of an aggregate of 20,000,000 shares of common stock of the Company (â€œNew Nautilus Common Stockâ€) at a price of $10.00 per share for aggregate gross proceeds of $200.0Â million (â€œPIPE Financingâ€).Prior to the Business Combination, we financed our operations primarily through private placements of convertible preferred stock and had raised aggregate net proceeds of $108.4 million from these private placements. In connection with the consummation of the Business Combination and PIPE Financing, we received additional 19gross proceeds of approximately $345.5 million from PIPE Investors and the Business Combination, offset by approximately $18.2 million of transaction costs and underwritersâ€™ fees relating to the closing of the Business Combination. As of JuneÂ 30, 2024, we had cash, cash equivalents and short-term investments of $167.4 million. Based on this, we believe that our existing cash, cash equivalents, and short-term investments will enable us to fund our planned operating expenses and capital expenditures through at least the next 12 months.We have incurred significant losses since the commencement of our operations. Our net loss was $36.7 million during the six months ended June 30, 2024, and we expect to continue to incur significant losses for the foreseeable future as we continue our research and development activities and planned commercialization of our Nautilus platform. As of JuneÂ 30, 2024, we had an accumulated deficit of $239.0Â million. These losses have resulted primarily from costs incurred in connection with research and development activities and to a lesser extent from general and administrative costs associated with our operations. We expect to incur significant and increasing expenses and operating losses for the foreseeable future. Our net losses may fluctuate significantly from period to period, depending on the timing of and expenditures on our planned commercialization and research and development activities.We expect our expenses and capital requirements will increase substantially in connection with our ongoing activities as we:â€¢continue our research and development activities, including with respect to our Nautilus platform;â€¢undertake activities to establish sales, marketing and distribution capabilities for our Nautilus platform;â€¢incur setup costs related to production tooling and required testing;â€¢maintain, protect and expand our intellectual property portfolio, including patents, trade secrets and know how;â€¢implement operational, financial and management information systems;â€¢attract, hire and retain additional management, scientific and administrative personnel; andâ€¢continue to operate as a public company.As a result, we will require substantial additional funding to develop our products and support our continuing operations. Until such time that we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, which could include income from collaborations, strategic partnerships or marketing, distribution or licensing arrangements with third parties or from grants. We may be unable to raise additional funds or to enter into such agreements or arrangements on favorable terms, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the COVIDâ€‘19 pandemic, recent and any potential future financial institution failures, the conflicts in Eastern Europe, the Middle East and in other countries, and otherwise. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of operations or financial condition, and could force us to delay, reduce or eliminate our product development or future commercialization efforts. We may also be required to grant rights to develop and market products that we would otherwise prefer to develop and market ourselves. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our development efforts. We cannot assure you that we will ever be profitable or generate positive cash flow from operating activities.Impact of Negative Global or National EventsBusinesses have been and will continue to be impacted by a number of challenging global and national events and circumstances that continue to evolve, including extreme weather conditions, economic uncertainty, inflation, changing interest rates, recent and any potential future financial institution failures, and conflicts in Eastern Europe, the Middle East and in other countries. The extent of the impact of these events and circumstances on our business, operations and development timelines and plans remains uncertain, and will depend on certain developments, 20including the duration and scope of the events and their impact on our development activities, third-party manufacturers, and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. We have been and continue to actively monitor the potential impacts that these various events and circumstances may have on our business and we take steps, where warranted, to minimize any potential negative impacts on our business resulting from these events and circumstances.We have been and continue to actively monitor our supply chain in light of these challenging global and national events and circumstances, including our third-party materials suppliers. We have, in the past, experienced some supply disruptions due to the COVID-19 pandemic, including closures at certain chip manufacturers, which led to extended lead times for certain chips; diversion of certain lab materials needed to support COVID-19 relief efforts; and lower availability of certain reagents. While certain of these disruptions have been resolved since the start of the COVID-19 pandemic, we are continuing to monitor our supply chain and contingency planning is ongoing with our partners to reduce the possibility of an interruption to our development activities or the availability of necessary materials. The ultimate impact of these global and national events and circumstances, either individually or in aggregate, is highly uncertain and subject to change. In April 2023, President Biden signed legislation that ended the COVID-19 national emergency on May 11, 2023. The full impact of this termination of the national emergency and the wind-down of the public health emergency on FDA and other regulatory policies and operations are unclear. To the extent possible, we are conducting business as usual, with necessary or advisable modifications to mitigate potentially negative impacts to our business. We will continue to actively monitor any developments related to these global and national events, and may take further actions to mitigate potential negative impacts to our business, and that may alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business. At this point, the extent to which these global or national events and circumstances may affect our future business, operations and development timelines and plans, including the resulting impact on our expenditures and capital needs, remains uncertain.Components of Our Results of Operations RevenueTo date, we have not generated any revenue and we may not generate any revenue from the sale of products or from other sources in the near future.Operating ExpensesResearch and Development ExpenseResearch and development expenses account for a significant portion of our operating expenses and consist primarily of salaries, related benefits and stock-based compensation expense of product development personnel, laboratory supplies and equipment, depreciation and amortization, external costs of vendors engaged to conduct research and development activities, and allocated expenses for technology and facilities. We expense research and development expenses in the periods in which they are incurred.We plan to continue to invest in our research and development efforts and to increase our investment in research and development efforts related to our product development. As a result, we expect research and development expenses to increase in absolute dollars as we continue to advance our product development, hire additional personnel and retain existing personnel, purchase supplies and materials and allocate expense to our research and development facilities.General and Administrative ExpensesGeneral and administrative expenses consist of salaries, related benefits, and stock-based compensation expense for personnel in executive, operations, legal, human resources, finance, marketing, commercial, IT personnel and administrative functions, professional fees for legal, patent, consulting, accounting and audit services, directors and

21officers insurance, allocated expenses for technology and facilities, loss contingency accruals, and marketing expenses. We expense general and administrative expenses in the periods in which they are incurred.We expect that our general and administrative expenses will increase substantially over the next several years as we hire additional personnel to support the growth in research and development activities for our products and commercial activities supporting the growth of our business, including sales, marketing, service, support, and distribution infrastructure. We also anticipate that we will incur higher expenses related to accounting, audit, legal, regulatory, insurance, compliance with the rules and regulations of the SEC, Sarbanes-Oxley Act and those of any national securities exchange on which our securities are traded, investor and public relations, and other administrative and professional services.Other Income (Expense)Other income (expense) consists primarily of interest income on our cash, cash equivalents and investments, including accretion and amortization of discounts and premiums on marketable debt securities. Other miscellaneous non-recurring expenses such as gains or losses on disposal of property and equipment are also included.Results of OperationsComparison of the Three Months Ended June 30, 2024 to the Three Months Ended June 30, 2023 The following table shows our condensed consolidated statements of operations for the periods indicated:Three Months Ended June 30,Change($)Change (%)20242023(in thousands)Operating expensesResearch and development$12,436Â $11,912Â $524Â 4Â %General and administrative8,353Â 7,104Â 1,249Â 18Â %Total operating expenses20,789Â 19,016Â 1,773Â 9Â %Other income (expense)Interest income2,798Â 3,222Â (424)(13)%Other expense(19)(14)(5)36Â %Total other income2,779Â 3,208Â (429)(13)%Net loss$(18,010)$(15,808)$(2,202)14Â %Research and Development ExpensesResearch and development expenses were $12.4 million for the three months ended June 30, 2024, compared to $11.9 million for the three months ended June 30, 2023, an increase of $0.5 million, or 4%. The increase was due to a $0.4 million increase in salaries, related benefits, and stock-based compensation, a $0.3 million increase in laboratory supplies and equipment expense. These increases are attributable to increased headcount during the period. These increases were partially offset by a $0.3 million decrease in facilities costs.General and Administrative ExpensesGeneral and administrative expenses were $8.4 million for the three months ended June 30, 2024, compared to $7.1 million for the three months ended June 30, 2023, an increase of $1.2 million, orÂ 18%. The increase was due to a $0.7 million increase in professional services attributable to legal and audit fees, and a $0.4 million increase in salaries, related benefits, and stock-based compensation, attributable to increased hiring during the period. 22Other Income (Expense)Other income (expense) for the three months ended June 30, 2024 decreased compared to the three months ended June 30, 2023. The decrease is attributable to the decrease in interest income as our cash, cash equivalents, and investments balance decreased during the period.Comparison of the Six Months Ended June 30, 2024 to the Six Months Ended June 30, 2023 The following table shows our condensed consolidated statements of operations for the periods indicated:Six Months Ended June 30,Change($)Change (%)20242023(in thousands)Operating expensesResearch and development$25,366Â $22,789Â $2,577Â 11Â %General and administrative17,030Â 14,287Â 2,743Â 19Â %Total operating expenses42,396Â 37,076Â 5,320Â 14Â %Other income (expense)Interest income5,675Â 6,320Â (645)(10)%Other expense(19)(17)(2)12Â %Total other income5,656Â 6,303Â (647)(10)%Net loss$(36,740)$(30,773)$(5,967)19Â %Research and Development ExpensesResearch and development expenses were $25.4 million for the six months ended June 30, 2024, compared to $22.8 million for the six months ended June 30, 2023, an increase of $2.6 million, or 11%. The increase was due to a $1.7 million increase in salaries, related benefits, and stock-based compensation, and a $1.0 million increase in laboratory supplies and equipment expense attributable to increased headcount during the period. Also contributing to the increase was a $0.2 million increase in facilities costs attributable to a new lease that commenced in March 2023, and a $0.2 million increase in depreciation attributable to the growth in laboratory and prototype equipment balances. These increases were partially offset by a $0.5 million decrease in professional services as more development efforts were performed by the Company. General and Administrative ExpensesGeneral and administrative expenses were $17.0 million for the six months ended June 30, 2024, compared to $14.3 million for the six months ended June 30, 2023, an increase of $2.7 million, orÂ 19%. The increase was due to a $1.1 million increase in salaries, related benefits, and stock-based compensation attributable to increased headcount during the period, a $0.5Â million increase in professional services from fees related to the shelf registration statement filed during the period, a $0.9Â million increase in other professional services attributable to legal and audit fees, and a $0.2 million increase in facilities cost . These increases were partially offset by a $0.3 million decrease in insurance costs.Other Income (Expense)Other income (expense) for the six months ended June 30, 2024 decreased compared to the six months ended June 30, 2023. The decrease is attributable to the decrease in interest income as our cash, cash equivalents, and investments balance decreased during the period.23Liquidity and Capital ResourcesSources of LiquiditySince our inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from our operations. Our net loss was $36.7 million for the six months ended June 30, 2024. As of JuneÂ 30, 2024, we had an accumulated deficit of $239.0Â million. Prior to the Business Combination, we funded our operations primarily with proceeds from the sale of convertible preferred stock. Prior to the Business Combination, we had raised net proceeds of $108.4Â million from these private placements of our convertible preferred stock. In June 2021, in conjunction with the consummation of the Business Combination with ARYA, we received additional gross proceeds of approximately $345.5Â million from PIPE Investors and the Business Combination, offset by approximately $18.2Â million of transaction costs and underwritersâ€™ fees relating to the closing of the Business Combination. As of JuneÂ 30, 2024, we had cash, cash equivalents and investments of $232.9Â million.Â Â Â Â Our primary uses of cash to date have been to fund our research and development activities, business planning, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations.In February 2024, we entered into a sales agreement (the â€œSales Agreementâ€) with Cowen and Company, LLC (â€œTD Cowenâ€) under which we may offer and sell up to $125.0 million of shares of our common stock from time to time through an â€œat the marketâ€ offering program under which TD Cowen will act as sales agent. Under the Sales Agreement, we set the parameters for the sale of shares, including the number or dollar amount of shares to be issued, the time period during which sales are requested to be made, limitations on the number or dollar amount of shares that may be sold in any one trading day and any minimum price below which sales may not be made. The Sales Agreement provides that TD Cowen will be entitled to compensation for its services in an amount equal to up to 3.0% of the gross proceeds of all shares of common stock sold through TD Cowen under the Sales Agreement. We have no obligation to sell any shares under the Sales Agreement and may at any time suspend solicitation and offers under the Sales Agreement. During the six months ended June 30, 2024, we did not sell any shares of common stock pursuant to the sales agreement.Funding RequirementsTo date, we have not generated any revenue and we may not generate any revenue from the sale of products or from other sources in the near future. We expect our expenses and capital requirements will increase substantially in connection with our ongoing activities as we:â€¢continue our research and development activities, including with respect to our Nautilus platform;â€¢undertake activities to establish sales, marketing and distribution capabilities for our Nautilus platform;â€¢incur setup costs related to production tooling and required testing;â€¢maintain, protect and expand our intellectual property portfolio, including patents, trade secrets and know how;â€¢implement operational, financial and management information systems;â€¢attract, hire and retain additional management, scientific and administrative personnel; andâ€¢continue to operate as a public company.Based on our planned operations, we expect our current cash, cash equivalents, and short-term investments will be sufficient to fund our operating expenses and capital expenditures for at least the next 12 months. We continue to face challenges and uncertainties and, as a result, our available capital resources may be consumed more rapidly than currently expected due to: delays in execution of our development plans; the scope and timing of our investment in our sales, marketing, and distribution capabilities; changes we may make to the business that affect ongoing 24operating expenses; the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; changes we may make in our business or commercialization strategy; changes we may make in our research and development spending plans; our need to implement additional infrastructure and internal systems; the impact of global and national conflicts or other disruptions; and other items affecting our forecasted level of expenditures and use of cash resources including potential acquisitions.Until such time as we can generate significant revenue from commercialization of our products, if ever, we will continue to require substantial additional capital to develop our Nautilus platform and fund operations for the foreseeable future. We intend to obtain such capital through public or private equity offerings or debt financings (including potential sales under the Sales Agreement), credit or loan facilities or a combination of one or more of these funding sources. We may also seek additional financing opportunistically. We may be unable to raise additional funds on favorable terms or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the COVIDâ€‘19 pandemic, recent and any potential future financial institution failures, the conflicts in Eastern Europe, the Middle East and in other countries, and otherwise. Our failure to raise additional capital, if needed, would have a negative impact on our financial condition and our ability to execute our business plan.Our expected future capital requirements depend on many factors including expansion of our product portfolio and the timing and extent of spending on sales and marketing and the development of our technology. If we raise additional funds by issuing equity securities, including any issuances pursuant to our â€œat the marketâ€ equity offering program under our Sales Agreement with TD Cowen, our stockholders will experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.Historical Cash FlowsFor the Six Months Ended June 30, 2024 and 2023 The following table summarizes our cash flows for the six months ended June 30, 2024 and 2023:Â Six Months Ended June 30,20242023(inÂ thousands)Net cash used in operating activities$(31,723)$(26,073)Net cash provided by (used in) investing activities36,647Â (15,750)Net cash provided by financing activities564Â 99Â Net increase (decrease) in cash, cash equivalents and restricted cash$5,488Â $(41,724)Operating ActivitiesDuring the six months ended June 30, 2024, net cash used in operating activities was $31.7Â million, resulting from our net loss of $36.7Â million and decrease in net changes in assets and liabilities aggregating $3.1Â million. Net cash used in operating activities was partially offset by non-cash charges aggregating $8.1Â million, which included $6.4Â million of stock-based compensation, $2.2Â million of amortization of operating lease right-of-use assets, and $1.0Â million of depreciation. These non-cash charges were partially offset by $1.5Â million of net accretion of discounts on securities.During the six months ended June 30, 2023, net cash used in operating activities was $26.1 million, resulting from our net loss of $30.8 million and decrease in net changes in assets and liabilities aggregating $2.5 million. Net cash used in operating activities was partially offset by non-cash charges aggregating $7.2 million, which included $6.0 million of stock-based compensation, $1.8 million amortization of operating lease right-of-use assets, and $0.8 25million of depreciation. These non-cash charges were partially offset by $1.4 million of net accretion of discounts on securities.Investing ActivitiesDuring the six months ended June 30, 2024, net cash provided by investing activities was $36.6Â million, resulting fromÂ $53.5Â million in proceeds from the maturity of securities, partially offset by $15.7 million in purchases of securities and $1.2Â million in purchases of property and equipment.During the six months ended June 30, 2023, net cash used in investing activities was $15.8 million, resulting from $46.8 million in purchases of securities and $1.2 million in purchases of property and equipment, partially offset by $32.2 million in proceeds from maturities of securities.Financing ActivitiesDuring the six months ended June 30, 2024, cash provided by financing activities was comprised of $0.6 million of proceeds from exercise of stock options and issuance of common stock under the employee stock purchase plan.During the six months ended June 30, 2023, cash provided by financing activities was comprised of $0.1 million of proceeds from exercise of stock options and issuance of common stock under the employee stock purchase plan.Contractual Obligations and CommitmentsFor a discussion of our contractual obligations and commitments, refer to Part I, Item 1, Note 8, â€œCommitments and Contingencies,â€ in our notes to condensed consolidated financial statements in this Quarterly Report on Form 10-Q.Critical Accounting Policies and EstimatesOur discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses. We evaluate our estimates and assumptions on an ongoing basis, and base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for the judgments we make about the carrying value of assets and liabilities that are not readily apparent from other sources. Because these estimates can vary depending on the situation, actual results may differ from these estimates. Making estimates and judgments about future events is inherently unpredictable and is subject to significant uncertainties, some of which are beyond our control. Should any of these estimates and assumptions change or prove to have been incorrect, it could have a material impact on our results of operations, financial position and statement of cash flows.Other than the policies noted in Part I, Item 1, Note 2,

â€œSignificant Accounting Policies,â€ in our notes to condensed consolidated financial statements in this Quarterly Report on Form 10-Q, there have been no material changes to our critical accounting policies and estimates as compared to those disclosed in our audited financial statements as of and for the years ended DecemberÂ 31, 2023 and 2022.Recent Accounting Pronouncements For a description of recent accounting pronouncements, including the expected dates of adoption and estimated effects, if any, on our condensed consolidated financial statements, see Part I, Item 1, Note 2 â€œSignificant Accounting Policiesâ€ in our notes to condensed consolidated financial statements in this Quarterly Report on Form 10-Q. 26Emerging Growth Company Accounting ElectionThe Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an â€œemerging growth companyâ€ such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to use this extended transition period under the JOBS Act until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult.We will cease to be an emerging growth company on the date that is the earliest of (i) the last day of the fiscal year in which we have total annual gross revenue of $1.235 billion or more, (ii) the last day of our fiscal year following the fifth anniversary of the date of the closing of ARYAâ€™s initial public offering, (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission.Further, even after we no longer qualify as an emerging growth company, we may still qualify as a â€œsmaller reporting company,â€ which would allow us to take advantage of many of the same exemptions from disclosure requirements, including reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common shares less attractive because we may rely on these exemptions. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and our share price may be more volatile.27ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKQualitative and Quantitative Disclosures About Market RiskOur market risk exposure is primarily a result of fluctuations in interest rates and inflation. We do not hold or issue financial instruments for trading purposes.Interest Rate RiskWe had cash, cash equivalents and investments of $232.9Â million as of JuneÂ 30, 2024. The primary goals of our investment policy are liquidity and capital preservation. We do not enter into investments for trading or speculative purposes. The carrying amount of our cash equivalents reasonably approximates fair value, due to the short maturities of these instruments. Our investments are exposed to market risk due to a fluctuation in interest rates, which may affect the fair market value of our investments in marketable debt securities. As of JuneÂ 30, 2024, the effect of a hypothetical 1.00% (100 basis point) change in interest rates would have changed the fair value of our marketable debt securities by $1.4 million. Such change would only be realized if we sold the marketable debt securities prior to maturity. Inflation RiskInflation generally affects us by increasing our cost of labor and goods and services. We believe that inflation has had some effect on our financial results during the periods presented. If we experience continued or future inflationary pressure, it may impact the costs of our operations as well as the costs to manufacture, sell and distribute our products and provide our services in the future. We may not be able to fully offset those increased costs through reduced spending or price increases to our products and services. 28ITEM 4. CONTROLS AND PROCEDURESEvaluation of Disclosure Controls and ProceduresWe carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13aâ€“15(e) and 15dâ€“15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of JuneÂ 30, 2024.Changes in Internal Control over Financial ReportingThere has been no change in our internal control over financial reporting during the quarter ended JuneÂ 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. Inherent Limitations on the Effectiveness of ControlsControl systems, no matter how well conceived and operated, are designed to provide a reasonable, but not an absolute, level of assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Because of the inherent limitations in any control system, misstatements due to error or fraud may occur and not be detected.29PART II: OTHER INFORMATIONITEM 1. LEGAL PROCEEDINGSU.S. District Court ProceedingsOn December 14, 2023, we filed suit in the United States District Court for the Northern District of California (the â€œCourtâ€) against Somalogic, Inc. (Somalogic) which recently merged with and is now part of â€œStandard Biotools, Inc.,â€ and the California Institute of Technology. This suit seeks declaratory judgment that Nautilus does not infringe any claims of US Patent No. 7,842,793 related to DNA origami structures (the â€˜793 Patent), which Somalogic has allegedly licensed from the California Institute of Technology through its purchase of Palamedrix, Inc. We have taken this action in response to Somalogicâ€™s allegations that the Nautilus proteome analysis platform infringes the claims of the â€˜793 Patent. We believe that it does not use any technology related to what the â€˜793 Patent purports to claim in any of the products or services that we are developing. Nor do we have any interest or plans to use such technology in any of our future products or services. We intend to vigorously pursue our claims in this litigation. On March 29, 2024, Somalogic filed a motion to dismiss the suit. On April 19, 2024, Nautilus filed a First Amended Complaint addressing issues raised in Somalogicâ€™s motion to dismiss. On April 22, 2024, the Court issued an order dismissing Somalogicâ€™s motion to dismiss as moot. On May 16, 2024, the Court granted the partiesâ€™ request for a temporary stay of the proceedings.Other ProceedingsFrom time to time, we may become involved in various claims and legal proceedings. Regardless of outcome, litigation and other legal and administrative proceedings can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.Item 1A. Risk FactorsÂ You should consider carefully the following information about the risks described below, together with the other information contained in this Quarterly Report on Form 10-Q and in our other public filings, in evaluating our business. If any of the following risks actually occurs, our business, financial condition, results of operations, and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline.Summary Risk FactorsOur business is subject to numerous risks and uncertainties that you should consider before investing in our company, as more fully described below. The principal factors and uncertainties that make investing in our company risky include, among others:Risks Related to Our Businessâ€¢We are a development stage company that has incurred net losses in every period to date, has not yet commercialized any products, and expects to continue to incur significant losses as we develop our business. â€¢Our business is entirely dependent on the successful development and commercialization of our proteomics platform (the â€œNautilus platformâ€), which remains in the development stage and could be subject to delays, technical challenges and market acceptance challenges. â€¢We may not compete successfully with our initial or future products in the highly competitive life sciences technology market.â€¢We are dependent upon third parties for certain aspects of the development and commercialization of the Nautilus platform.30â€¢Our business depends significantly on research and development spending by pharmaceutical companies as well as by academic institutions and other research institutions and any reduction in spending could limit demand for our products.â€¢We may not be able to launch our Nautilus platform successfully and even if it is successful, we may experience material delays in our commercialization program relative to current expectations.â€¢Our operating results may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.â€¢We may need to raise additional capital to fund our development and commercialization plans.Risks Related to Our Intellectual Propertyâ€¢We may be unable to obtain and maintain sufficient intellectual property protection for our products and technology, or if the scope of our intellectual property protection obtained is not sufficiently broad, competitors could develop and commercialize products similar or identical to ours.â€¢We may not be able to protect our intellectual property and proprietary rights throughout the world. Risks Related to Litigationâ€¢We may become involved in litigation to enforce or defend our intellectual property rights, or to defend ourselves from claims that we infringe the intellectual property rights of others.â€¢We may face liability and/or negative publicity for any unknown defects or errors in our products.Risks Related to Regulatory and Legal Compliance Mattersâ€¢Our products may, in the future, be subject to regulation by the FDA or other regulatory authorities.â€¢We are currently subject to, and may in the future become subject to additional, U.S. federal and state laws and regulations, as well as the laws and regulations of other countries, relating to how we collect, store and process personal information.â€¢Future expansion of our development and commercialization activities outside of the United States, may subject us to an increased risk of inadvertently conducting activities in a manner that violates the U.S. Foreign Corrupt Practices Act and similar laws. â€¢Environmental and health safety laws, including any failure to comply with such laws, may result in liabilities, expenses and restrictions on our operations.â€¢Our employees, independent contractors, consultants, commercial partners, distributors and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.Risks Related to our Operations â€¢We may experience a significant disruption in our information technology systems or breaches of data security.â€¢We are highly dependent on our key personnel, and if we are unable to recruit and retain key executives and scientists, we may not be able to achieve our goals.â€¢Our operations and financial results could be adversely impacted by global and national events, such as the COVID-19 pandemic, conflicts in Eastern Europe and the Middle East, and general economic downturns.â€¢Global supply chain interruptions may negatively impact the development and commercialization of our products.31Risks Related to Our Common Stockâ€¢The price of and market for our Common Stock may be volatile, which could result in substantial losses for investors and/or an inability to readily trade in our Common Stock.â€¢We will have broad discretion over the use of the proceeds to us from our â€œat the marketâ€ equity offering program and may apply the proceeds to uses that do not improve our operating results or the value of your securities.General Risk Factorsâ€¢We will continue to incur significant increased costs and management resources as a result of operating as a public company.â€¢Reports published by analysts, including projections in those reports that differ from our actual results, could adversely affect the price and trading volume of our common shares.â€¢Our ability to timely and accurately report our financial results and projections as a public company may be impacted by the effectiveness of our internal controls, and our estimates and judgments relating to critical accounting policies.Our risk factors are not guarantees that no such conditions exist as of the date of this report and should not be interpreted as an affirmative statement that such risks or conditions have not materialized, in whole or in part.Risks Related to Our Business We are a development stage company that has incurred net losses in every period to date, has not yet commercialized any products, and expects to continue to incur significant losses as we develop our business. We may never achieve profitability.We are a development stage company that has incurred net losses in each quarterly and annual period since inception and that has not yet generated any revenue. We expect to incur increasing costs as we continue to devote substantially all of our resources towards the development and anticipated future commercialization of our Nautilus platform, which includes our end-to-end solution comprised of instruments, consumables, and software analysis. We cannot be certain if we will ever generate revenue or if or when we will produce sufficient revenue from operations to support our costs. Even if profitability is achieved, we may not be able to sustain profitability. We incurred net losses of $18.0 million and $36.7 million during the three and six months ended June 30, 2024, respectively and $15.8 million and $30.8 million during the three and six months ended June 30, 2023, respectively. As of JuneÂ 30, 2024, we had an accumulated deficit of $239.0 million. These losses and accumulated deficit were primarily due to the substantial investments we made in the scientific and technological development of our Nautilus platform. We expect to incur substantial losses and negative cash flows for the foreseeable future. In addition, as a public company, we will continue to incur significant legal, accounting, and other expenses. These increased expenses will make it harder for us to achieve and sustain future profitability. We may incur significant losses in the future for a number of reasons, many of which are beyond our control, including the other risks described in this Quarterly Report on Form 10-Q.Our business is entirely dependent on the success of our Nautilus platform, which remains in the development stage and subject to scientific and technical validation. If we are unable to develop and commercialize our Nautilus platform successfully and in a manner that provides currently anticipated functionality and levels of performance, we may never be able to recognize any revenue, and our business, operating results, and financial condition will suffer.Our future success is entirely dependent on our ability to successfully develop and commercialize our Nautilus platform,

which is based on innovative yet complex and unproven technologies and which is anticipated to be used in demanding scientific research that requires substantial levels of accuracy and precision. We are investing substantially all of our management efforts and financial resources in the development and commercialization of our Nautilus platform, which remains in the development stage and subject to scientific and technical validation. Additionally, in developing our platform technology, we currently rely on co-development partners to assist us in the 32development of certain component technologies in our platform. We have experienced difficulties with some of these partners successfully delivering these component technologies on time and to our specifications, and these partners may not be successful in delivering these component technologies on time, to our specifications, or at all, in the future, which could have an adverse impact on our ability to meet our development timelines, and/or our productsâ€™ level of currently anticipated functionality and performance. While our goal is to leverage our Nautilus platform to comprehensively measure the human proteome, the human proteome is dynamic and far more complex and diverse in structure, composition and number of variants than either the genome or transcriptome. If we cannot successfully complete platform development, if we are unable to achieve our goals for mapping the proteome, if our products fail to deliver currently anticipated functionality and levels of performance, if our products are found by a court of law to infringe the intellectual property of another party, or if we are unable to obtain broad scientific and market acceptance of our products and technologies, we may never recognize material revenue and may be unable to continue our operations.We have not yet commercially launched our Nautilus platform. We may not be able to launch our Nautilus platform successfully and even if it is successful, we may experience material delays in our commercialization program relative to current expectations.We anticipate commercializing our Nautilus platform in three phases involving first collaboration with biopharmaceutical companies and key opinion leaders to validate the performance and utility of our product, during which we do not expect to recognize significant revenue, if any; secondly an early access limited release phase in which we expect to recognize limited revenue; and finally a broader commercial launch phase. We are currently in the collaboration phase during which we have entered into collaborations with a small number of research customers, including with biopharmaceutical companies and key opinion leaders in proteomics whose assessment and validation of our products can significantly influence other researchers in their respective markets and/or fields. During the second, early access phase, we expect to work closely with early access customers to demonstrate a unique value proposition for our Nautilus platform. During this phase, we plan to provide early access to our partners with broad-scale and targeted analyses and profiling of samples analyzed in our facility and shared via a cloud platform. We anticipate early access engagements in 2025. We do not anticipate that these activities will result in any material revenue. We expect this second phase to lead into the third phase of launch of our proteome analysis platform in 2025 and subsequent broad commercialization thereafter. Voice of customer studies have suggested that there is market demand for a proteomics platform with specifications that are initially lower than what we have previously disclosed, for example, around characteristics such as sample input and proteome coverage. Consequently, as we balance our time to market goals with our evolving view of customer requirements, we are refining our initial launch specifications. We believe that subsequent consumable releases will enable our platform to meet or exceed our previously announced product specifications. Achieving the scientific and commercial objectives identified above within currently anticipated timelines will require substantial investments in our technologies and in the underlying science. Scientific and technological development of the nature being undertaken by us is extraordinarily complex, and there can be no assurances that any of these phases of commercial development will be successful or that they will be completed within the timelines currently anticipated. Given the scientific and technical complexity of our products, we could experience material delays in product development and commercial launch. If our research and product development efforts do not result in commercially viable products within the anticipated timelines, our business, operating results, and financial condition will be adversely affected.The commercialization of our products will require us to establish relationships and successfully collaborate with leading life science companies and research institutions, initially to test and validate our products and subsequently as we seek to expand the markets for our products. We may be unable to establish sufficient collaborations of this nature, and such collaborations could result in agreements that limit or otherwise impair our flexibility to pursue other strategic opportunities.As noted above, establishing collaborations and partnerships with large pharmaceutical and biotechnology companies and with major research institutions is a material element of our commercialization strategy. While early collaborations are expected to focus on the assessment and validation of our Nautilus platform with a focus in part on publication of results in peer-reviewed scientific journals, we also intend to pursue additional, potentially 33revenue-generating collaborations in areas of biological interest. Among other examples, we may pursue collaborations relating to the development and commercialization of therapeutic product candidates targeting proteins identified by our Nautilus platform.There can be no assurance that we will be successful in developing or maintaining collaborations or that, if established, these collaborations will achieve the desired objectives. Establishing collaborations is difficult and time-consuming. Discussions may not lead to collaborations on favorable terms, if at all, and particularly where we are negotiating against major pharmaceutical companies, we may have relatively less leverage in negotiating favorable terms. To the extent we agree to work exclusively with a party in a given field, our opportunities to collaborate with others in that field would be limited. Certain parties may seek to partner with other companies in addition to us in connection with a project. This, in turn, may limit the commercial potential of any products that are the subject of such collaborations. Potential collaborators may elect not to work with us based upon their assessment of our financial, regulatory, commercial or intellectual property position.Even if we are successful in entering into collaborations, the success of such collaborations will depend heavily on the efforts and activities of our collaborators.Scientific collaborations of the nature we propose to pursue are subject to numerous risks, including that:â€¢collaborators may have significant discretion in determining the efforts and resources that they will apply to a specific project;â€¢collaborators may not pursue development and commercialization of products or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding, or other external factors such as a business combination that diverts resources or creates competing priorities;â€¢collaborators may own intellectual property covering products that result from our collaboration with them, and in such cases, we would not have the right to develop or commercialize such intellectual property;â€¢collaborators may co-own intellectual property covering products that result from our collaboration with them, and in such cases, we would not have the right to exclude others from developing or commercializing such intellectual property;â€¢collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with product candidates that are being developed under the collaboration with us;â€¢a collaborator with marketing, manufacturing, and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;â€¢we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;â€¢collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;â€¢disputes may arise between us and a collaborator that cause the delay or termination of the research, development, or commercialization of products or that result in costly litigation or arbitration that diverts management attention and resources;â€¢collaborations may be terminated, and, if terminated, in addition to reducing our revenue, may reduce exposure to research and clinical trials that facilitate the collection and incorporation of new information into our platform; andâ€¢a collaboratorâ€™s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.34In addition, before obtaining marketing approval from regulatory authorities for the sale of product candidates subject to future collaborations, our collaborators must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates. If clinical trials of product candidates resulting from collaborations are prolonged or delayed, collaborators may be unable to obtain required regulatory approvals and therefore be unable to commercialize product candidates on a timely basis or at all, which may have a material impact on the revenue recognized from such collaborations.Even if we are able to complete development of our Nautilus platform, we may not achieve or maintain significant commercial market acceptance.Even if we are able to complete development of our Nautilus platform, the platform will be subject to market forces and adoption curves common to new technologies. The market for novel proteomics technologies and products like those being developed by us is in the early stages of development. While these technologies present the potential to displace legacy products, changing long-standing scientific workflows with new instruments requiring substantial capital expenditures will require us to invest substantial financial and management resources to educate potential customers on the benefits of our Nautilus platform relative to existing technologies and to validate our Nautilus platformâ€™s ability to meet customer requirements. In that regard, we anticipate that our initial market focus will be pharmaceutical development and associated research, which are characterized by demanding and exacting requirements for product performance and accuracy. If widespread adoption of our Nautilus platform takes longer than anticipated or does not occur, our business will be materially and adversely affected.More specifically, the successful introduction of new technologies in life science markets requires substantial engagement with the scientific community in order to encourage community acceptance of the utility, performance, and cost of the technology relative to its benefits in the applicable field or fields of research. The life sciences scientific community is often led by a small number of early adopters and key opinion leaders who significantly influence the larger community through publications in peer-reviewed journals. In these journal publications, the researchers describe not only their discoveries but also the methods and typically the products used to fuel these discoveries. We expect that references to the use of our Nautilus platform in peer-reviewed journal publications will be critical to our ability to obtain widespread acceptance within the scientific community. In addition, continuing collaborative relationships with key opinion leaders will be vital to maintaining any market acceptance we achieve. If too few researchers describe the use of our products, too many researchers shift to a competing product and publish research outlining their use of that product, or too many researchers negatively describe the use of our products in publications, customers may be less willing to engage with us concerning our products, which could materially delay our commercialization plan and/or substantially extend our sales cycles. Moreover, these customers may ultimately be less willing to purchase our products, which would adversely affect our business and future revenue.Specific, material factors that will influence our ability to achieve market acceptance include the following:â€¢the ability of our marketing and engagement initiatives to increase awareness of the capabilities of our Nautilus platform;â€¢the ability of our Nautilus platform to demonstrate reliable performance in intended use applications, in particular, when the platform is used by customers in their own research;â€¢our ability to demonstrate that the functionality and performance of our Nautilus platform relative to alternative products and technologies justifies the substantial anticipated cost of the platform;â€¢the willingness of prospective customers to adopt new products and workflows;â€¢the ease of use of our Nautilus platform and whether it reliably provides significant advantages over alternative products and technologies;â€¢the rate of adoption of our Nautilus platform by biopharmaceutical companies, laboratories, academic institutions and others;35â€¢the prices at which we will be able to sell our Nautilus platform instruments and consumables;â€¢our ability to develop new products, workflows, and solutions that meet customer requirements;â€¢the introduction or development and commercialization by competitors of new products or enhancements to existing products with functionality and/or performance similar to our Nautilus platform; andâ€¢the impact of our investments in product innovation and commercial growth.We cannot assure you that we will be successful in addressing any of these criteria or any additional criteria that might affect the market acceptance of our products. If we are unsuccessful in achieving and maintaining market acceptance of our Nautilus platform, our business, financial condition and results of operations would be adversely affected.We have no experience in manufacturing our products at commercial scale. If we are unable to establish manufacturing capacity by ourselves or with partners in a timely manner after completing development, commercialization of our Nautilus platform would be delayed, which would result in lost revenue and harm our business.In order for us to commercialize our Nautilus platform in volume, we will need to establish internal manufacturing capacity or to contract with one or more manufacturing partners, or both. Our technology is complex, and the manufacturing process for our products will be similarly complex, involving a large number of unique precision parts in addition to the production of various reagents and antibodies. We may encounter unexpected difficulties in manufacturing our Nautilus platform, including our proteome analysis system and related consumables. Among other factors, we will need to develop reliable supply chains for the various components in our platform instruments and consumables to support large-scale commercial production. In connection with our Nautilus platform, we may utilize long lead time instrument system components, such as cameras and lasers, and as a result, it may impact our ability to consistently source such components. Additionally, we intend to utilize over 300 complex reagents and various antibodies in order to generate deep proteomic information at the speed and scale which we expect our Nautilus platform to perform. Such reagents and antibodies are expected to be more difficult to manufacture and more expensive to procure. There are no assurances that we will be able to build manufacturing or consumable production capacity internally or find one or more suitable manufacturing or production partners, or both, to meet the volume and quality requirements necessary to be successful in the proteomics market. In addition,

in connection with establishing third party relationships or sourcing component supplies, including with respect to instrument components, reagents and antibodies, we may incur costs that are higher than currently expected and that may adversely affect our gross margins and operating results following commercialization. Assuming we complete development of our Nautilus platform, we may experience manufacturing and product quality issues as we increase the scale of our production. Any delay or inability in establishing or expanding our manufacturing capacity could diminish our ability to develop or sell our products, result in increased or unanticipated costs, result in lost revenue, and seriously harm our business, results of operations and financial condition.If we are unable to establish an effective commercial organization, including effective distribution channels and sales and marketing functions, we may not be successful in commercializing our Nautilus platform.We are only beginning to establish an internal organization focused specifically on the commercialization of our Nautilus platform. Our initial hiring has focused on senior commercial leadership, and although this leadership has considerable industry experience, in order to achieve substantial revenue growth and profitability, we will be required to develop sales, marketing, distribution, customer service, and customer support capabilities. Staffing of these functions will frequently require individuals with the requisite technical and scientific expertise to establish and support sales of a sophisticated and complex platform for life sciences experimentation. We will be required to expend substantial financial resources to hire personnel and develop our commercial operations prior to commercial launch of our Nautilus platform. Accordingly, these initiatives will adversely affect our operating expenses prior to us having material off-setting revenue, if any.To develop these functions successfully, we will face a number of additional risks, including:36â€¢our ability to attract, retain, and manage the sales, marketing, customer service, and customer support force necessary to commercialize and gain market acceptance for our technology, with the additional challenge that many of these new hires will require specific scientific and technological expertise that may be more difficult to find; andâ€¢the time and cost of establishing a specialized sales, marketing and customer service and support force.In addition to our internal organization, we may seek to enlist one or more third parties to assist with sales, distribution, and customer service and support globally or in certain regions of the world. In certain markets, we could seek to establish partnerships with larger market participants to provide access to their distribution channels and which could also involve scientific or technological collaboration. There is no guarantee, if we do seek to enter into any of these arrangements, that we will be successful in attracting desirable partners or that we will be able to enter into such arrangements on commercially favorable terms. If our commercialization efforts, or those of any third-party partners, are not successful, our Nautilus platform may not gain market acceptance, which could materially impact our business and results of operations.The size of the markets for our Nautilus platform may be smaller than estimated, and new market opportunities may not develop as quickly as we expect, or at all, limiting our ability to successfully sell our products.The market for proteomics technologies and products is evolving, making it difficult to predict with any accuracy the size of the markets for our current and future products, including our Nautilus platform. Our estimates of the total addressable market for our current and future products, including with respect to the proteomics market, the diagnostic market, and the mass spectrometry market, are based on a number of internal and third-party estimates and assumptions. In particular, our estimates are based on our expectations that researchers in the market for certain life sciences research tools and technologies will view our products as competitive alternatives to, or better options than, existing tools and technologies. We also expect researchers will recognize the ability of our products to complement, enhance and enable new applications of their current tools and technologies. We expect them to recognize the value proposition offered by our products enough to purchase our products in addition to the tools and technologies they already own. Underlying each of these expectations are a number of estimates and assumptions that may be incorrect, including the assumptions that government or other sources of funding will continue to be available to life sciences researchers at times and in amounts necessary to allow them to purchase our products and that researchers have sufficient samples and an unmet need for performing proteomics studies at scale across thousands of samples. In addition, sales of new products into new market opportunities may take years to develop and mature and we cannot be certain that these market opportunities will develop as we expect. New life sciences technology may not be adopted until the consistency and accuracy of such technology, method or device has been proven. As a result, the sizes of the annual total addressable market for new markets and new products are even more difficult to predict. Our product is an innovative new product, and while we draw comparisons between the evolution and growth of the genomics market, the proteomics market may develop more slowly or differently. In addition, our Nautilus platform may not impact the field of proteomics in the same manner or degree, or within the same time frame, that NGS technologies have impacted the field of genomics, or at all. While we believe our assumptions and the data underlying our estimates of the total addressable market for our products are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates, or those underlying the third-party data we have used, may change at any time, thereby reducing the accuracy of our estimates. As a result, our estimates of the total addressable market for our products may be incorrect.The future growth of the market for our current and future products depends on many factors beyond our control, including recognition and acceptance of our products by the scientific community and the growth, prevalence and costs of competing products and solutions. Such recognition and acceptance may not occur in the near term, or at all. If the markets for our current and future products are smaller than estimated or do not develop as we expect, our growth may be limited and our business, financial condition and operational results of operations could be adversely affected.37We are dependent on single source suppliers for some of the components and materials used in our Nautilus platform, and the loss of any of these suppliers could harm our business.We rely on single source suppliers for certain components and materials used in our Nautilus platform, including our click-reagent modified oligos, glass or silicon that is nano-fabricated into our biochips and high-speed stage used in the instrument. The loss of any of these single source suppliers would require us to expend significant time and effort to locate and qualify an alternative source of supply for these components. Though we do not currently have contracts for third parties to provide manufacturing capabilities for each component of our Nautilus platform for which we expect to employ such third party manufacturers, if we are successful in reaching the point of manufacturing our products for commercialization, we may rely on a single company for such manufacturing. Any contractual disputes between us and such manufacturer or loss of manufacturing ability by such manufacturer could similarly require significant time, effort and expense to locate and qualify an alternative source of manufacturing, which could materially harm our business.We also rely, and expect to continue to rely, on third-party manufacturers and, in many cases, single third-party manufacturers for the production of certain reagents and antibodies needed to generate the deep proteomic information at the speed and scale which we expect our Nautilus platform to perform. With respect to any antibodies or reagents that are single sourced, the loss of any suppliers would require significant time and effort to locate and qualify an alternative source of supply. Such reagents and antibodies may also become scarce, more expensive to procure, or not meet quality standards, and we may not be able to obtain favorable terms in agreements with suppliers. Given their complexity, our suppliers may not be able to provide these reagents and antibodies in a cost-effective manner or in a time frame that is consistent with our expected future needs. If our suppliers cease or interrupt production or if suppliers fail to supply materials, products or services to us for any reason, such interruption could delay development, or interrupt the commercial supply, with the potential for additional costs and lost revenue. If this were to occur, we might also need to seek alternative means to fulfill our manufacturing needs. Any such transition would require significant efforts in testing and validation and could result in delays or other issues, which could materially harm our business.The life sciences technology market is highly competitive. If we fail to compete effectively, our business and results of operation will suffer.We face significant competition in the life sciences technology market. We currently compete with technology and diagnostic companies that supply components, products, and services to customers engaged in proteomics analysis. These companies include Agilent Technologies; Becton, Dickinson and Company; Bruker Corporation; Danaher; Luminex; Olink Proteomics; Quanterix; Standard Biotools (formerly known as Somalogic); Quantum-Si; and Thermo Fisher Scientific. We also compete with a number of emerging companies that are developing proteomic products and solutions.Some of our current competitors are large publicly-traded companies, or are divisions of large publicly-traded companies, and enjoy a number of competitive advantages over us, including:â€¢greater name and brand recognition;â€¢greater financial and human resources;â€¢broader product lines;â€¢larger sales forces and more established distributor networks;â€¢substantial intellectual property portfolios;â€¢larger and more established customer bases and relationships; andâ€¢better established, larger scale and lower cost manufacturing capabilities.We cannot assure investors that our products will compete favorably or that we will be successful in the face of increasing competition from products and technologies introduced by our existing or future competitors or by 38companies entering our markets or that are developed by our customers internally. In addition, we cannot assure investors that our competitors do not have or will not develop products or technologies that currently or in the future will enable them to produce competitive products with superior functionality or performance or at lower costs than ours or that are able to run comparable experiments at a lower total experiment cost. Any failure to compete effectively could materially and adversely affect our business, financial condition and operating results.Even if our Nautilus platform is commercialized and achieves broad scientific and market acceptance, if we fail to improve it or introduce compelling new products, our revenue and our prospects could be harmed.The life sciences industry is characterized by rapid and significant technological changes, frequent new product introductions and enhancements and evolving industry standards. Even if we are able to commercialize our Nautilus platform and achieve broad scientific and market acceptance, our ability to attract new customers and increase revenue from existing customers will depend in large part on our ability to enhance and improve our Nautilus platform and to introduce compelling new products. The success of any enhancement to our Nautilus platform or introduction of new products depends on several factors, including timely completion and delivery, competitive pricing, adequate quality testing, integration with existing technologies, freedom from intellectual property encumbrance, appropriately timed and staged introduction and overall market acceptance. Any new product or enhancement to our Nautilus platform that we develop may not be introduced in a timely or cost-effective manner, may contain defects, errors, vulnerabilities or bugs, or may not achieve the market acceptance necessary to generate significant revenue.The typical development cycle of new life sciences products can be lengthy and complicated, and may require new scientific discoveries or advancements, considerable resources and complex technology and engineering. Such developments may involve external suppliers and service providers, making the management of development projects complex and subject to risks and uncertainties regarding timing, timely delivery of required components or services and satisfactory technical performance of such components or assembled products. If we do not achieve the required technical specifications or successfully manage new product development processes, or if development work is not performed according to schedule, then such new technologies or products may be adversely impacted. If we are unable to successfully develop new products, enhance our proteomics product platform to meet customer requirements, compete with alternative products, or otherwise gain and maintain market acceptance, our business, results of operations and financial condition could be harmed.We rely on third parties for development of certain aspects of the Nautilus platform, and any failure of these third parties to perform their respective obligations in a timely manner or to our specifications could negatively impact our timelines, costs or product performance.We are engaged with a number of third party collaborators who assist us in co-development of certain aspects of the Nautilus platform, including, for example, certain affinity reagents and array chip substrates. Our agreements with these third party collaborators include obligations for these third parties to deliver certain aspects of technology to be used in the Nautilus platform in accordance with certain defined timelines, in accordance with defined specifications, and in accordance with certain cost limitations. We have also sought to include redundancy and contingency planning with respect to the efforts of our third party collaborators where practicable. Despite our contractual assurances and contingency planning, it is possible that one or more of our third party collaborators may fail to deliver their respective technologies to us on time or in accordance with our specifications, and such failure could negatively impact the timing of the commercialization of the Nautilus platform, its performance, or its cost.Our business will depend significantly on research and development spending by pharmaceutical companies as well as by academic and other research institutions. Any reduction in spending could limit demand for our products and adversely affect our business, results of operations, financial condition and prospects.We expect that our revenue in the foreseeable future will be derived primarily from sales of our Nautilus platform to biotechnology companies and life science laboratories worldwide, and to a lesser extent, academic institutions and non-profit organizations. Our success will depend upon demand for and use of our products. Accordingly, the spending policies of these customers could have a significant effect on the demand for our technology. These policies may be based on a wide variety of factors, including the resources available to make 39purchases, the spending priorities among various types of equipment, policies regarding spending during recessionary periods and changes in the political climate. In addition, academic, governmental and other research institutions that fund research and development activities may be subject to stringent budgetary constraints that could result in spending reductions, reduced allocations or budget cutbacks, which could jeopardize the ability of these customers to purchase our products. Our operating results may fluctuate substantially due to reductions and delays in research and development expenditures by these customers. For example, reductions in capital expenditures by these customers may result in

lower than expected system sales and, similarly, reductions in operating expenditures by these customers could result in lower than expected sales of our Nautilus platform. These reductions and delays may result from factors that are not within our control, such as:â€¢decreases in government funding of research and development;â€¢changes in economic conditions, including recessionary effects, inflationary pressures and instability in the global financial markets, including with respect to any future financial institution failures;â€¢changes in government programs that provide funding to research institutions and companies, including changes in the amount of funds allocated to different areas of research or changes that have the effect of increasing the length of time of the funding process;â€¢changes in the regulatory environment affecting life science and Ag-Bio companies engaged in research and commercial activities;â€¢differences in budget cycles across various geographies and industries;â€¢market-driven pressures on companies to consolidate operations and reduce costs;â€¢mergers and acquisitions in the life science and Ag-Bio industries; andâ€¢other factors affecting research and development spending.Any decrease in our customersâ€™ budgets or expenditures or in the size, scope or frequency of capital or operating expenditures as a result of the foregoing or other factors could materially and adversely affect our business, results of operations, financial condition, and prospects.Our operating results may fluctuate significantly in the future, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. In the near term, as we devote substantially all of our resources towards the development and anticipated future commercialization of our Nautilus platform, specific factors that may result in fluctuations include, without limitation:â€¢the timing and cost of, and level of investment in, research and development and commercialization activities relating to our Nautilus platform;â€¢our ability to successfully establish and successfully maintain appropriate collaborations and derive revenue from those collaborations; â€¢the impact that economic inflation may have on our costs for manufacturing our products;â€¢any litigation or governmental investigations involving us, our industry or both; andâ€¢our ability to successfully develop and commercialize our Nautilus platform on our anticipated timeline.As we transition from a company with a focus on research and development to a company capable of supporting manufacturing, these fluctuations may also occur due to a variety of other factors, many of which are outside of our control, including, but not limited to:40â€¢the level of demand for any products we are able to commercialize, particularly our Nautilus platform, which may vary significantly from period to period;â€¢our ability to drive adoption of our Nautilus platform in our target markets and our ability to expand into any future target markets;â€¢the impact that economic inflation may have on our costs for manufacturing our products;â€¢the prices at which we will be able to sell our Nautilus platform;â€¢the volume and mix of our sales between consumables, instruments and software, or changes in the manufacturing or sales costs related to our products;â€¢the timing and amount of expenditures that we may incur to develop, commercialize or acquire additional products and technologies or for other purposes, such as the expansion of our facilities;â€¢changes in governmental funding of life sciences research and development or changes that impact budgets and budget cycles;â€¢seasonal spending patterns of our customers;â€¢the timing of when we recognize any revenue;â€¢future accounting pronouncements or changes in our accounting policies;â€¢higher than anticipated service, replacement and warranty costs;â€¢the impact of the COVID-19 pandemic, the conflicts in Eastern Europe and the Middle East, recent and any potential future financial institution failures, and other national and global events on the economy, investment in life sciences and research industries, our business operations, and resources and operations of our customers, suppliers, and distributors; andâ€¢general industry, economic and market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.The cumulative effects of the factors discussed above could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.This variability and unpredictability could also result in us failing to meet the expectations of industry or financial analysts or investors for any period. If we are unable to commercialize products or generate revenue, or if our operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, it could cause the market price of our Common Stock to decline.We have a limited operating history, which may make it difficult to evaluate our current business and the prospects for our future viability, and to predict our future performance.We are a life sciences technology company with a limited operating history. We have not completed development of our Nautilus platform or any other products and have not generated any revenue to date. Our operations to date have been limited to developing our Nautilus platform. Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companies in their early stages of operations. Consequently, predictions about our future success or viability are highly uncertain and may not be as accurate as they could be if we had a longer operating history or a company history of successfully developing and commercializing products.In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown obstacles. We will eventually need to transition from a 41company with a focus on research and development to a company capable of supporting manufacturing and commercial activities as well, and we may not be successful in such a transition. We have encountered in the past, and will encounter in the future, risks and uncertainties frequently experienced by growing companies with limited operating histories in emerging and rapidly changing industries. If our assumptions regarding these risks and uncertainties, which we use to plan and operate our business, are incorrect or change, or if we do not address these risks successfully, our results of operations could differ materially from our expectations, and our business, financial condition and results of operations could be adversely affected.We may need to raise additional capital to fund our development and commercialization plans.Based on our current plans, we believe that our available resources and existing cash, cash equivalents and short-term investments, will be sufficient to meet our anticipated cash requirements for at least 12 months from the date of this Quarterly Report on Form 10-Q. If our available resources and existing cash and cash equivalents and short-term investments are insufficient to satisfy our liquidity requirements, including because of the realization of other risks described in this Quarterly Report on Form 10-Q, we may be required to raise additional capital prior to such time through issuances of equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing.We expect that we will need to raise additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing or acquisition opportunities or for other reasons, including:â€¢funding development and marketing efforts of our Nautilus platform or any other future products;â€¢increasing our sales and marketing and other commercialization efforts to drive market adoption of our Nautilus platform, once commercialized;â€¢expanding our technologies into additional markets;â€¢preparing, filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;â€¢acquiring, licensing or defending against third party intellectual property rights;â€¢acquiring or investing in complementary technologies, businesses or assets; andâ€¢financing capital expenditures and general and administrative expenses.Our present and future funding requirements will depend on many factors, including:â€¢delays in execution of our development plans;â€¢the scope and timing of our investment in our sales, marketing, and distribution capabilities;â€¢changes we may make to our business that affect ongoing operating expenses;â€¢the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;â€¢changes we may make in our business or commercialization strategy;â€¢changes we may make in our research and development spending plans;â€¢the effect of competing technological and market developments;â€¢our need to implement additional infrastructure and internal systems;â€¢the impact of the COVID-19 pandemic, the conflicts in Eastern Europe and the Middle East; and42â€¢other items affecting our forecasted level of expenditures and use of cash resources including potential acquisitions.The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, dilution to our stockholders could result. If we raise funds by issuing debt securities, those debt securities could have rights, preferences and privileges senior to those of holders of our Common Stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations or licensing arrangements, we might be required to relinquish significant rights to our technologies or products or grant licenses on terms that are not favorable to us.We may be unable to raise additional funds or to enter into such agreements or arrangements on favorable terms, or at all. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and the recent disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the COVIDâ€‘19 pandemic, the conflicts in Eastern Europe and the Middle East, and otherwise. If we are unable to obtain adequate financing or financing on terms satisfactory to us, if we require it, our ability to continue to pursue our business objectives and to respond to business opportunities, challenges, or unforeseen circumstances could be significantly limited, and could have a material adverse effect on our business, financial condition, results of operations and prospects.In addition, actual events involving limited liquidity or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, the collapse of Silicon Valley Bank and other financial institutions in March 2023 has caused and could continue to cause instability in the global financial markets.Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect us, the financial institutions with which we have arrangements directly, or the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or failures, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry. These factors could involve financial institutions or financial services industry companies with which we have financial or business relationships, but could also include factors involving financial markets or the financial services industry generally. Credit and banking costs, generally, may also be adversely impacted by these factors, resulting in higher costs for the Company. For example, as part of our efforts to diversify our banking and credit arrangements following the collapse of Silicon Valley Bank, we have incurred higher banking related costs.In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all.Risks Related to Our Intellectual PropertyIf we are unable to obtain and maintain sufficient intellectual property protection for our products and technology, or if the scope of our intellectual property protection obtained is not sufficiently broad, competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our products may be impaired.Our commercial success depends in part on our ability to protect our intellectual property and proprietary technologies. We rely on patent protection, where appropriate and available, as well as a combination of copyright, trade secret and trademark laws, and nondisclosure, confidentiality and other contractual restrictions to protect our proprietary technology. However, these legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If we fail to obtain, maintain and protect our intellectual property, third parties may be able to compete more effectively against us. In addition, we may incur 43substantial costs related to litigation or other patent proceedings in our attempts to recover or restrict use of our intellectual property.To the extent our intellectual property offers inadequate protection, or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property does not provide adequate coverage of our competitorsâ€™ products, our competitive position could be adversely affected, as could our business, financial condition, results of operations and prospects. Both the patent application process and the process of managing patent and other intellectual property disputes are generally unpredictable, time-consuming and expensive.Our success depends in large part on our and any future licensorâ€™s ability to obtain and maintain protection of the intellectual property we may own or license, whether solely or jointly, particularly patents, in the United States and other countries with respect to our products and technologies. We apply for patents to protect our products, technologies and commercial activities, as we deem appropriate. However, obtaining and enforcing patents is costly, time-consuming and complex, and we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, we may not develop additional proprietary products, methods and technologies that are patentable. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents which may be licensed from or to third parties. In connection with any future licensing arrangements with third parties, these patents and applications may not be prosecuted and enforced by such third parties in a manner consistent with the best interests of our business.In

addition, the patent position of life sciences technology companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. Changes in either the patent laws or in interpretations of patent laws in the United States or other jurisdictions may diminish the value of our intellectual property. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. It is possible that none of our pending patent applications will result in issued patents in a timely fashion or at all, and even if issued, the patents may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged, narrowed or invalidated by third parties. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. It is possible that third parties will design around our current or future patents such that we cannot prevent such third parties from using similar technologies and commercializing similar products to compete with us. Some of our owned or any future licensed patents or patent applications may be challenged at a future point in time and we may not be successful in defending any such challenges made against our patents or patent applications. Any successful third-party challenge to our patents could result in diminished or lost rights, for example, due to narrowing, unenforceability or invalidity of such patents and increased competition to our business. The outcome of patent litigation or other proceedings is generally uncertain, and any attempt by us to enforce our patent rights against others or to challenge the patent rights of others may not be successful, or, regardless of success, may take substantial time and result in substantial cost, and may divert our efforts and attention from other aspects of our business. Any of the foregoing events could have a material adverse effect on our business, financial condition and results of operations.The U.S. law relating to the patentability of certain inventions in the life sciences technology industry is uncertain and rapidly changing, which may adversely impact our existing patents or our ability to obtain patents in the future.Changes in either the patent laws or interpretation of the patent laws in the United States or in other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In the last decade, the US Congress made sweeping changes to patent law in passing the America Invents Act (AIA). These changes include, among others, allowing third-party submission of prior art to the United States Patent and Trademark Office (USPTO) during patent prosecution and additional procedures to challenge the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review and derivation proceedings. The changes brought about by the AIA have not been extensively tested, 44and therefore increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.Various courts, including the U.S. Supreme Court, have recently rendered decisions that impact the scope of patentability of certain inventions or discoveries relating to our technology and commercial goals. Specifically, these decisions have substantially increased the probability that patent claims will be ruled patent ineligible for reciting a natural phenomenon, law of nature or abstract idea. Furthermore, in view of these decisions, since December 2014, the USPTO has published and continues to publish revised guidelines for patent examiners to apply when examining claims for patent eligibility. Patent claims relating to software algorithms, biologically-derived reagents, methods for analyzing biological systems and other subject matters that underlies our technology and commercial goals are impacted by these changes.Actions taken by the U.S. Congress, federal courts and USPTO have from time to time narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. Similar changes have been made by authorities in other jurisdictions. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, such changes create uncertainty with respect to the value of patents, once obtained. Depending on decisions by authorities in various jurisdictions, the laws and regulations governing patents could change in unpredictable ways that may have a material adverse effect on our ability to obtain new patents and to defend and enforce our existing patents and patents that we might obtain in the future.We cannot assure you that our patent portfolio will not be negatively impacted by the current uncertain state of the law, new court rulings or changes in guidance or procedures issued by governments or patent offices around the world. From time to time, the U.S. Supreme Court, other federal courts, the U.S. Congress or the USPTO may change the standards of patentability, scope and validity of patents within the life sciences technology and any such changes, or any similar adverse changes in the patent laws of other jurisdictions, could have a negative impact on our business, financial condition, prospects and results of operations.We may not be able to protect our intellectual property rights throughout the world.Filing, prosecuting and defending patents on our Nautilus platform in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States.The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States, and we and any future licensor may encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we and any future licensor may not be able to prevent third parties from practicing our inventions in some or all countries outside the United States, or from selling or importing products made using our or any future licensorâ€™s inventions in and into the United States or other jurisdictions. Competitors and other third parties may be able to use our technologies in jurisdictions where we have not obtained patent protection to develop our own products and technologies and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products. We and any future licensorâ€™s patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. In addition, certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. Furthermore, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of any patents.Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the misappropriation or other violations of our intellectual property rights including infringement of our patents in such countries. The legal systems in certain countries may also favor state-sponsored companies or companies headquartered in particular jurisdictions over our patents and other intellectual property protection. The absence of harmonized intellectual property 45protection laws and effective enforcement makes it difficult to ensure consistent respect for patent, trade secret, and other intellectual property rights on a worldwide basis. As a result, it is possible that we will not be able to enforce our rights against third parties that misappropriate our proprietary technology in those countries.Proceedings to enforce our or any future licensorâ€™s patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our and any future licensorâ€™s patents at risk of being invalidated or interpreted narrowly and our and any future licensorâ€™s patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We and any future licensor may not prevail in any lawsuits that we and any future licensor initiates, or that are initiated against us or any future licensor, and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our products, services and other technologies and the enforcement of intellectual property. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Any of the foregoing events could have a material adverse effect on our business, financial condition, results of operations and prospects.We may become involved in lawsuits to defend against third-party claims of infringement, misappropriation or other violations of intellectual property or to protect or enforce our intellectual property, any of which could be expensive, time consuming and unsuccessful, and may prevent or delay our development and commercialization efforts.Litigation may be necessary for us to enforce our patent and proprietary rights and/or to determine the scope, coverage and validity of othersâ€™ proprietary rights. Litigation on these matters has been prevalent in our industry and we expect that this will continue. To determine the priority of inventions, we may have to initiate and participate in interference proceedings declared by the USPTO that could result in substantial legal fees and could substantially affect the scope of our patent protection. Also, our intellectual property may be subject to significant administrative and litigation proceedings such as invalidity, unenforceability, re-examination and opposition proceedings against our patents. The outcome of any litigation or other proceeding is inherently uncertain and might not be favorable to us, and we might not be able to obtain licenses to technology that we require or a competitor may have already obtained an exclusive license to such technology in all fields. Even if such licenses are obtainable, they may not be available at a reasonable cost. We could therefore incur substantial costs related to royalty payments for licenses obtained from third parties, which could negatively affect our gross margins. In some cases, the outcome of litigation may be to enjoin us from commercializing a patent protected technology. We could encounter delays in product introductions, or interruptions in product sales, as we develop alternative methods or products.In addition, if we resort to legal proceedings to enforce our intellectual property rights or to determine the validity, scope and coverage of the intellectual property or other proprietary rights of others, the proceedings could be burdensome and expensive, even if we were to prevail.Our commercial success may depend in part on our non-infringement of the patents or proprietary rights of third parties. Numerous significant intellectual property issues have been litigated, and will likely continue to be litigated, between existing and new participants in the life sciences market and competitors may assert that our products infringe their intellectual property rights as part of a business strategy to impede our successful entry into those markets. Third parties may assert that we are employing our proprietary technology without authorization. We are aware that there are issued third party patents that are in the general proteomics field. Specifically, we are aware of various U.S. patents and U.S. non-provisional applications assigned to Washington University and the National Institute of Health, with claims directed to characterizing and identifying a polypeptide strand.In addition, our competitors and others may have patents or may in the future obtain patents and may claim that use of our products infringes these patents. For example, we have received and may from time to time in the future receive letters, notices or â€œinvitations to licenseâ€ related to the use of intellectual property in our products or services, or may become the subject of claims that our products and business operations infringe or violate the intellectual property rights of others. For example, on December 14, 2023, we filed suit in the United States District Court for the Northern District of California against Somalogic, Inc. (Somalogic) which recently merged with and is 46now part of â€œStandard Biotools, Inc.â€, and the California Institute of Technology. This suit seeks declaratory judgment that we do not infringe any claims of US Patent No. 7,842,793 related to DNA origami structures (the â€˜793 Patent), which Somalogic has allegedly licensed from the California Institute of Technology through its purchase of Palamedrix, Inc. We took this action in response to Somalogicâ€™s allegations that our proteome analysis platform infringes the claims of the â€˜793 Patent. Notwithstanding our belief as to the strength of our claims, litigation generally, and patent litigation in particular, can be unpredictable. If we do not succeed in establishing that our products or services do not infringe the claims of the â€˜793 Patent, it could negatively impact our business by imposing royalties on our products or services, requiring significant redevelopment of certain aspects of our products and/or preventing us from making, using or selling our products or services. Even if we were to prevail in this or any future litigation, litigation could also result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition.As we move into new markets and applications for our products, incumbent participants in such markets may assert their patents and other proprietary rights against us, alleging that our products or services infringe, misappropriate or otherwise violate their intellectual property rights, including patents and trade secrets, as a means of slowing or preventing our entry into such markets, or as a means to extract substantial license and royalty payments from us. The defense of these matters can be time consuming, costly to defend in litigation, divert managementâ€™s attention and resources, damage our reputation and brand and cause us to incur significant expenses or make substantial payments.Issued patents covering our products could be found invalid or unenforceable if challenged.Our owned and any future licensed patents and patent applications may be subject to validity, enforceability and priority disputes. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of our patents or patent applications may be challenged at a future point in time in opposition, derivation, reexamination, inter partes review, post-grant review or interference or other similar proceedings. Any successful third-party challenge to our patents in this or any other proceeding could result in the unenforceability or invalidity of such patents, which may lead to increased competition to our business, which could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, if we or any future licensor initiates legal proceedings against a third party to enforce a patent covering our products, the defendant could counterclaim that such patent covering our products, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. There are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including, but not limited to, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an

allegation that someone connected with prosecution of the patent withheld relevant information from the relevant patent office, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include ex parte re-examination, inter partes review, post-grant review, derivation and equivalent proceedings in non-U.S. jurisdictions, such as opposition proceedings. Such proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover and protect our products. With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which us, any future licensor, our patent counsel and the patent examiner were unaware during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant or other third party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection for our products and technologies, which could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license intellectual property or develop or commercialize current or future products.We may not be aware of all third-party intellectual property rights potentially relating to our products. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent 47applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO, or other similar proceedings in non-U.S. jurisdictions, that could result in substantial cost to us and the loss of valuable patent protection. The outcome of such proceedings is uncertain. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, changes to the patent laws of the United States in the last decade allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, regardless of the merit of such proceedings and regardless of whether we are successful, we could experience significant costs and our management may be distracted. Any of the foregoing events could have a material adverse effect on our business, financial condition, results of operations and prospects.If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected, and our business could be harmed.We rely heavily on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, including parts of our Nautilus platform, and to maintain our competitive position. However, trade secrets and know-how can be difficult to protect. In particular, we anticipate that with respect to our technologies, these trade secrets and know how will over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, and the movement of personnel between academic and industry scientific positions.In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisers. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors or other third parties will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure, which could adversely impact our ability to establish or maintain a competitive advantage in the market, business, financial condition, results of operations and prospects.Monitoring unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had wrongfully obtained and was using our trade secrets, it would be expensive and time-consuming, it could distract our personnel, and the outcome would be unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets.We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor or other third party, absent patent protection, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. Competitors or third parties could purchase our products and attempt to replicate some or all of the competitive advantages we derive from our development efforts, design around our protected technology, develop their own competitive technologies that fall outside the scope of our intellectual property rights or independently develop our technologies without reference to our trade secrets. If any of our trade secrets were to be disclosed to or independently discovered by a competitor or other third party, it could materially and adversely affect our business, financial condition, results of operations and prospects.48We may be subject to claims challenging the inventorship of our patents and other intellectual property.We or any future licensor may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets or other intellectual property. For example, us or any future licensor may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our products. In addition, counterparties to our consulting, software development, and other agreements may assert that they have an ownership interest in intellectual property developed under such arrangements. Litigation may be necessary to defend against claims challenging ownership or inventorship of our or any future licensorâ€™s ownership of our patents, trade secrets or other intellectual property. If we or any future licensor fails in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our Nautilus platform, including our software, workflows, consumables and reagent kits. In such an event, we may be required to obtain licenses from third parties and such licenses may not be available on commercially reasonable terms or at all or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture or commercialization of our products and technologies. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees, and certain customers or partners may defer engaging with us until the particular dispute is resolved. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.We may not be able to protect and enforce our trademarks and trade names or build name recognition in our markets of interest thereby harming our competitive position.The registered or unregistered trademarks or trade names that we own may be challenged, infringed, circumvented, declared generic, lapsed or determined to be infringing on or dilutive of other marks. We may not be able to protect our rights in these trademarks and trade names, which we need in order to build name recognition. In addition, third parties have filed, and may in the future file, for registration of trademarks similar or identical to our trademarks, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Further, we have and may in the future enter into agreements with owners of such third-party trade names or trademarks to avoid potential trademark litigation which may limit our ability to use our trade names or trademarks in certain fields of business. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business, financial condition, results of operations and prospects may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources. Any of the foregoing events could have a material adverse effect on our business, financial condition and results of operations.Patent terms may be inadequate to protect our competitive position on our Nautilus platform for an adequate amount of time.Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. While extensions may be available, the life of a patent, and the protection it affords, is limited. In the United States, a patentâ€™s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date. Even if patents covering our products are obtained, once the patent life has expired, we may be open to competition from competitive products. If one of our products requires extended development, testing and/or regulatory review, patents protecting such products might expire before or shortly after such products are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours, which could have a material adverse effect on our business, financial condition and results of operations.49Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we may rely on any future licensor to pay these fees due to the U.S. and non-U.S. patent agencies and to take the necessary action to comply with these requirements with respect to any future licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors may be able to enter the market without infringing our patents and this circumstance would have a material adverse effect on our business, financial condition, results of operations and prospects.We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed trade secrets of our former employers.We have employed and expect to employ individuals who were previously employed at universities or other companies, including, for example, our competitors or potential competitors. Although we try to ensure that our employees, consultants, advisors and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that our employees, advisors, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information of their former employers or other third parties, or to claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights and face increased competition to our business. Any such litigation or the threat thereof may adversely affect our ability to hire employees or contract with advisors, contractors and consultants. A loss of key research personnel work product could hamper or prevent our ability to commercialize potential products, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. Some of our competitors may be able to sustain the costs of this type of litigation or proceedings more effectively than we can because of their substantially greater financial resources.In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Furthermore, individuals executing agreements with us may have pre-existing or competing obligations to a third party, such as an academic institution, and thus an agreement with us may be ineffective in perfecting ownership of inventions developed by that individual, which could have a material adverse effect on our

business, financial condition, results of operations, and prospects.Furthermore, we or any future licensor may in the future be subject to claims by former or current employees, consultants or other third parties asserting an ownership right or inventorship in our owned, or any future licensed, patents or patent applications. For example, our Founder and Chief Scientist is employed by Stanford University and a member of the Stanford Cancer Institute. Stanford University and the Stanford Cancer Institute may assert an ownership right in any of our owned patents or patent applications. We may have other consultants that are or have been employed by third parties, which may assert an ownership right in any of our owned patents or patent applications. In addition, we are aware that we might not be able to obtain ownership of or seek a license to any 50intellectual property developed during a research collaboration with a third party. An adverse determination in any such proceeding may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar technology, without payment to us, or could limit the duration of the patent protection covering our technology and products. Such challenges may also result in our inability to develop, manufacture or commercialize our products without infringing third-party patent rights. Any of the foregoing could harm our business, financial condition, results of operations and prospects.If we cannot license rights to use technologies on reasonable terms, we may not be able to commercialize new products in the future.We may identify third-party technology that we may need to license or acquire in order to develop or commercialize our products or technologies, including our Nautilus platform. However, we may be unable to secure such licenses or acquisitions. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources, or greater development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. In return for the use of a third partyâ€™s technology, we may agree to pay the licensor royalties based on sales of our products or services. Royalties are a component of cost of products or technologies and affect the margins on our products. We may also need to negotiate licenses to patents or patent applications before or after introducing a commercial product. We may not be able to obtain necessary licenses to patents or patent applications, and our business may suffer if we are unable to enter into the necessary licenses on acceptable terms or at all, if any necessary licenses are subsequently terminated, if the licensor fails to abide by the terms of the license or fails to prevent infringement by third parties, or if the licensed intellectual property rights are found to be invalid or unenforceable.Our use of open source software and failure to comply with the terms of the underlying open source software licenses could impose limitations on our ability to commercialize our products and provide third parties to our proprietary software.Our products utilize open source software that contain modules licensed for use from third-party authors under open source licenses. In particular, some of the software may be provided under license arrangements that allow use of the software for research or other noncommercial purposes. Use and distribution of open source software may entail greater risks than use of third-party commercial software, as open source software licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the code. Some open source software licenses contain requirements that the licensee make its source code publicly available if the licensee creates modifications or derivative works using the open source software, depending on the type of open source software the licensee uses and how the licensee uses it. If we combine our proprietary software with open source software in a certain manner, we could, under certain open source software licenses, be required to release the source code of our proprietary software to the public for free. This would allow our competitors and other third parties to create similar products with less development effort and time and ultimately could result in a loss of our product sales and revenue, which could have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, some companies that use third-party open source software have faced claims challenging their use of such open source software and their compliance with the terms of the applicable open source license. We may be subject to suits by third parties claiming ownership of what we believe to be open source software or claiming non-compliance with the applicable open source licensing terms. Use of open source software may also present additional security risks because the public availability of such software may make it easier for hackers and other third parties to compromise or attempt to compromise our technology platform and systems.Although we review and monitors our use of open source software to avoid subjecting our proprietary software to conditions we do not intend, the terms of many open source software licenses have not been interpreted by United States courts, and there is a risk that these licenses could be construed in a way that could impose unanticipated 51conditions or restrictions on our ability to commercialize our products and proprietary software. Moreover, we cannot assure investors that our processes for monitoring and controlling our use of open source software in our products will be effective. If we are held to have breached the terms of an open source software license, we could be subject to damages, required to seek licenses from third parties to continue offering our products on terms that are not economically feasible, to re-engineer our products, to discontinue the sale of our products if re-engineering could not be accomplished on a timely basis, or to make generally available, in source code form, our proprietary code, any of which could adversely affect our business, financial condition, results of operations and prospects.Intellectual property rights do not necessarily address all potential threats.The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:â€¢others may be able to make products that are similar to products and technologies we may develop or may be able to utilize similar technologies that are not covered by the claims of the patents that we own or licenses now or in the future;â€¢we, or any future licensor(s), might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future;â€¢we, or any future licensor(s), might not have been the first to file patent applications covering certain of our or their inventions;â€¢others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise violating our owned or future licensed intellectual property rights;â€¢it is possible that our pending patent applications or those that we may license or own in the future will not lead to issued patents;â€¢issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;â€¢our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;â€¢we may not develop additional proprietary technologies that are patentable;â€¢the patents of others may harm our business; andâ€¢we may choose not to file a patent for certain trade secrets or know-how, and a third party may independently derive, use, commercialize, publish or patent such intellectual property.Should any of these events occur, they could materially adversely affect our business, financial condition, results of operations and prospects.Risks Related to LitigationWe may become involved in litigation to enforce or defend our intellectual property rights, or defend ourselves from claims that we infringe the intellectual property rights of others, which litigation could consume significant resources and management time, and in which an adverse result could result in loss of our intellectual property rights, a requirement that we pay significant damages, and could prevent us from selling our products.The life sciences industry is highly competitive, and companies in this industry routinely engage in litigation and governmental proceedings to enforce and defend the intellectual property rights that they believe they possess. We may become involved in litigation or governmental and/or administrative proceedings to enforce or defend our intellectual property rights. Additionally, we have and may continue to become involved in litigation and/or 52governmental or administrative proceedings to defend ourselves from claims that our products or services infringe the intellectual property rights of others, or to challenge the claimed intellectual property rights of others where we believe they may not be entitled to such rights. Such litigation and governmental proceedings are inherently unpredictable and costly, and can require significant time and attention of management. In addition to the costs and distraction of litigation, if we are unsuccessful in enforcing our intellectual property rights, or in defending our intellectual property rights from challenges of others, wit could result in our loss of our ability to exclude others from practicing aspects of our technology which could lead to greater competition for our products and services. Additionally, if we are unable to successfully defend ourselves from claims that we infringe the intellectual property rights of others and are unable to develop non-infringing alternative approaches for our products and services, we may be required to pay significant damages and ongoing royalties, or we may be prohibited from selling our products and services. Our success depends upon our ability to successfully enforce and defend our own intellectual property rights, and to defend ourselves from claims that we infringe the intellectual property rights of others.Our products could have unknown defects or errors, which may give rise to claims against us and adversely affect market adoption of our Nautilus platform.Our Nautilus platform utilizes novel and complex technology applied on a microscopic scale, using key components that are not amenable to full characterization or quality assessment using conventional techniques or instrumentation, and such systems may develop or contain undetected defects or errors. We cannot assure you that material performance problems, defects or errors will not arise, and as we increase the density and integration of our Nautilus platform, these risks may increase. We expect to provide warranties that our Nautilus platform will meet performance expectations or be free from defects. The costs incurred in correcting any defects or errors may be substantial and could adversely affect our operating margins.In manufacturing our Nautilus platform, we depend upon third parties for the supply of various components. Many of these components require a significant degree of technical expertise to produce. If our suppliers fail to produce components to specification, or if the suppliers, or we, use defective materials or workmanship in the manufacturing process, the reliability and performance of our products will be compromised.If our products contain defects, we may experience:â€¢a failure to achieve market acceptance or expansion of our product sales;â€¢loss of customer orders and delay in order fulfillment;â€¢damage to our brand reputation;â€¢increased cost of our warranty program due to product repair or replacement;â€¢product recalls or replacements;â€¢inability to attract new customers;â€¢diversion of resources from our manufacturing and research and development departments into our service department; andâ€¢legal claims against us, including product liability claims, which could be costly and time consuming to defend and result in substantial damages. The occurrence of any one or more of the foregoing could negatively affect our business, financial condition and results of operations.If we are sued for product liability, we could face substantial liabilities that exceed our resources.The marketing, sale and use of our products could lead to the filing of product liability claims were someone to allege that our products identified inaccurate or incomplete information regarding the proteins analyzed or otherwise failed to perform as designed. We may also be subject to liability for errors in, a misunderstanding of or 53inappropriate reliance upon, the information we provide in the ordinary course of our business activities. A product liability claim could result in substantial damages and be costly and time-consuming for us to defend. We maintain product liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability claims. Any product liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could damage our reputation, or cause current customers to terminate existing agreements and potential partners to seek other partners, any of which could adversely impact our business, financial condition and results of operations.Risks Related to Regulatory and Legal Compliance MattersAlthough our products currently are not labeled or intended for any use which would subject us to regulation by the FDA or other regulatory authorities, if we elect to label and promote any of our products as clinical or medical device products, we would be subject to regulation in the future and would be required to obtain prior approval or clearance by the FDA or other regulatory authorities, which could take significant time and expense and could fail to result in FDA clearance or approval for the intended uses we believe are commercially attractive.Our products are currently labeled and promoted, and are, and in the near-future will be, sold primarily to research companies and academic and research institutions as research use only (â€œRUOâ€) products, and are not currently intended to be used, for clinical diagnostic tests or as medical devices. If we elect to label and market our products for use as, or in the performance of, clinical diagnostics in the United States, thereby subjecting them to FDA regulation as medical devices, we would be required to obtain premarket 510(k) clearance or premarket approval from the FDA, unless an exception applies.We may in the future register with the FDA as a medical device manufacturer and list some of our products with the FDA pursuant to an FDA Class I listing for general purpose laboratory equipment. While this regulatory classification is exempt from certain FDA requirements, such as the need to submit a premarket notification commonly known as a 510(k) application, and some of the requirements of the FDAâ€™s Quality System Regulations (the â€œQSRsâ€), we would be subject to ongoing FDA â€œgeneral controls,â€ which include compliance with FDA regulations for labeling, inspections by the FDA, complaint evaluation, corrections and removals reporting, promotional restrictions, reporting adverse events or malfunctions for our products, and general prohibitions against misbranding and adulteration. The FDAâ€™s new Quality Management System Regulation (â€œQMSRâ€), which incorporates by reference certain requirements under ISO 13485, will go into effect on February 2, 2026. In addition, we may in the future submit 510(k) premarket notification applications to the FDA to obtain FDA clearance of certain of our products on a selective basis. It is

possible, in the event we elect to submit 510(k) applications for certain of our products, that the FDA would take the position that a more burdensome premarket application, such as a premarket approval application (â€œPMAâ€) or a de novo application is required for some of our products. If such applications were required, greater time and investment would be required to obtain FDA approval. Even if the FDA agreed that a 510(k) was appropriate, FDA clearance can be expensive and time consuming. It can take a significant amount of time to prepare and submit a 510(k) application, including conducting appropriate testing on our products, and several months to years for the FDA to review a submission. Notwithstanding the effort and expense, FDA clearance or approval could be denied for some or all of our products for which we choose to market as a medical device or a clinical diagnostic device. Even if we were to seek and obtain regulatory approval or clearance, it may not be for the intended uses we request or that we believe are important or commercially attractive. There can be no assurance that future products for which we may seek premarket clearance or approval will be cleared or approved by the FDA or a comparable foreign regulatory authority on a timely basis, if at all, nor can there be assurance that labeling claims will be consistent with our anticipated claims or adequate to support continued adoption of such products. Compliance with FDA or comparable foreign regulatory authority regulations will require substantial costs, and subject us to heightened scrutiny by regulators and substantial penalties for failure to comply with such requirements or the inability to market our products. The lengthy and unpredictable premarket clearance or approval process, as well as the unpredictability of the results of any required clinical studies, may result in our failing to obtain regulatory clearance or approval to market such products, which would significantly harm our business, results of operations, reputation, and prospects.54If we sought and received regulatory clearance or approval for certain of our products, we would be subject to ongoing FDA obligations and continued regulatory oversight and review, including the general controls listed above and the FDAâ€™s QSRs for our development and manufacturing operations. In addition, we may be required to obtain a new 510(k) clearance before we could introduce subsequent modifications or improvements to such products. We could also be subject to additional FDA post-marketing obligations for such products, any or all of which would increase our costs and divert resources away from other projects. If we sought and received regulatory clearance or approval and are not able to maintain regulatory compliance with applicable laws, we could be prohibited from marketing our products for use as, or in the performance of, clinical diagnostics and/or could be subject to enforcement actions, including warning letters and adverse publicity, fines, injunctions, and civil penalties; recall or seizure of products; operating restrictions; and criminal prosecution.In addition, we could decide to seek regulatory clearance or approval for certain of our products in countries outside of the United States. Sales of such products outside the United States will likely be subject to foreign regulatory requirements, which can vary greatly from country to country. As a result, the time required to obtain clearances or approvals outside the United States may differ from that required to obtain FDA clearance or approval and we may not be able to obtain foreign regulatory approvals on a timely basis or at all. Following Brexit, medical device products entering the U.K. market will have to comply with the regulatory requirements of the Medicines and Healthcare products Regulatory Agency (the â€œMHRAâ€), including the new UK Medical Device Regulations, which are scheduled to go into effect by July 2024. In July 2023, MHRA updated its guidance to reflect that the government now aims to delay implementation of the core aspects of the regulations to July 2025. These foreign regulations and any future requirements that may be implemented by regulatory authorities will increase the difficulty of obtaining and maintaining regulatory approvals and compliance in Europe in the future. In addition, the FDA regulates exports of medical devices. Failure to comply with these regulatory requirements or obtain and maintain required approvals, clearances or certifications could impair our ability to commercialize our products for diagnostic use outside of the United States.Our products could become subject to government regulation as medical devices by the FDA and other regulatory agencies even if we do not elect to seek regulatory clearance or approval to market our products for diagnostic purposes, which would adversely impact our ability to market and sell our products and harm our business. If our products become subject to FDA regulation, the regulatory clearance or approval and the maintenance of continued and post-market regulatory compliance for such products will be expensive, time-consuming, and uncertain both in timing and in outcome.We do not currently expect our Nautilus platform to be subject to the clearance or approval of the FDA, as it is not intended to be used for the diagnosis, treatment or prevention of disease. However, as we expand our product line and the applications and uses of our current or products into new fields, certain of our future products could become subject to regulation by the FDA, or comparable international agencies, including requirements for regulatory clearance or approval of such products before they can be marketed. Also, even if our products are labeled, promoted, and intended as RUO, the FDA or comparable agencies of other countries could disagree with our conclusion that our products are intended for research use only or deem our sales, marketing and promotional efforts as being inconsistent with RUO products. For example, our customers may independently elect to use our RUO labeled products in their own laboratory developed tests (â€œLDTsâ€) for clinical diagnostic use. While the FDA has traditionally exercised enforcement discretion with LDTs, the FDA could take the view that our sale of our RUO labeled products were made with the knowledge that the products will be used as medical devices, and could therefore subject our products to government regulation, and the regulatory clearance or approval and maintenance process for such products may be uncertain, expensive, and time-consuming. Regulatory requirements related to marketing, selling, and distribution of RUO products could change or be uncertain, even if clinical uses of our RUO products by our customers were done without our consent. If the FDA or other regulatory authorities assert that any of our RUO products are subject to regulatory clearance or approval, our business, financial condition, or results of operations could be adversely affected.The FDA has historically exercised enforcement discretion in not enforcing the medical device regulations against laboratories offering LDTs. FDA recently issued a final rule that amends FDAâ€™s regulations to make explicit that in vitro diagnostis (â€œIVDsâ€) are devices under the Federal Food, Drug, and Cosmetic Act, including when the manufacturer of the IVD is a laboratory, and phases out its enforcement discretion for LDTs. The American Clinical 55Laboratory Association and a private laboratory have filed a lawsuit challenging this FDA final rule. Further, the U.S. Supreme Court overruled the Chevron doctrine, which gives deference to regulatory agenciesâ€™ statutory interpretations in litigation against federal government agencies, such as the FDA, where the law is ambiguous. This landmark Supreme Court decision may invite more companies and other stakeholders to bring lawsuits against the FDA to challenge FDAâ€™s statutory interpretations, including its decision to regulate LDTs as medical devices. These judicial challenges can lead to uncertainties in the industry. We cannot predict the full impact of the LDT final rule and ongoing litigation against the FDA on us or the industry in general. Any restrictions on LDTs by the FDA, Congress, or regulatory authorities may decrease the demand for our products. The adoption of new restrictions on RUO products, whether by the FDA or Congress, could adversely affect demand for our specialized reagents and instruments. Further, we could be required to obtain premarket clearance or approval before we can sell our products to certain customers.Further, sales of devices for diagnostic purposes may subject us to additional healthcare regulation and enforcement by the applicable government agencies. Such laws include, without limitation, state and federal anti-kickback or anti-referral laws, healthcare fraud and abuse laws, false claims laws, privacy and security laws, the Physician Payments Sunshine Act and related transparency and manufacturer reporting laws, and other laws and regulations applicable to medical device manufacturers. If our operations are found to be in violation of any applicable FDA or healthcare laws and regulations, we may be subject to penalties, monetary damages, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain clearance or approvals from the FDA, fees from regulators, fines, significant settlements or judgments, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, or other restrictions on our operations, any of which could adversely impact our financial results. Any action against us for an alleged or suspected violation by a private party or governmental agency could cause us to incur significant legal expenses, adversely impact our reputation, and could divert our managementâ€™s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.Additionally, on November 25, 2013, the FDA issued Final Guidance â€œDistribution of In Vitro Diagnostic Products Labeled for Research Use Only.â€ This guidance emphasizes that the FDA will review the totality of the circumstances when it comes to evaluating whether equipment and testing components are properly labeled as RUO. This guidance states that merely including a labeling statement that the product is for research purposes only will not necessarily render the device exempt from the FDAâ€™s clearance, approval, and other regulatory requirements if the circumstances surrounding the distribution, marketing and promotional practices indicate that the manufacturer knows its products are, or intends for its products to be, used for clinical diagnostic purposes. These circumstances may include written or verbal sales and marketing claims or links to articles regarding a productâ€™s performance in clinical applications and a manufacturerâ€™s provision of technical support for clinical applications.Even if the FDA does not modify its policy of enforcement discretion, whether due to changes in FDA policy or legislative action, the FDA may disagree with the marketing of our current products in the United States. We may also be required to conduct clinical studies to support our currently marketed products or planned product launches. If we are required to conduct such clinical trials or to obtain regulatory authorization, delays in the commencement of our product launches or our changes to our current marketing strategy could significantly increase our costs and delay our commercialization plans, which could harm our financial prospects.We are currently subject to, and may in the future become subject to additional, U.S. federal and state laws and regulations imposing obligations on how we collect, store and process personal information. Our actual or perceived failure to comply with such obligations could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our future customer base, and thereby decrease our revenue.In the ordinary course of our business, we currently, and, in the future, will, collect, store, transfer, use or process sensitive data, including personally identifiable information of employees, and intellectual property and proprietary business information owned or controlled by us and other parties. The secure processing, storage, maintenance, and transmission of this critical information are vital to our operations and business strategy. We are, and may increasingly become, subject to various laws and regulations, as well as contractual obligations, relating to 56data privacy and security in the jurisdictions in which we operate. The regulatory environment related to data privacy and security is increasingly rigorous, with new and constantly changing requirements applicable to our business, and enforcement practices are likely to remain uncertain for the foreseeable future. These laws and regulations may be interpreted and applied differently over time and from jurisdiction to jurisdiction, and it is possible that they will be interpreted and applied in ways that may have a material adverse effect on our business, financial condition, results of operations and prospects.In the United States, various federal and state regulators, including governmental agencies like the Consumer Financial Protection Bureau and the Federal Trade Commission, have adopted, or are considering adopting, laws and regulations concerning personal information and data security. Certain state laws may be more stringent or broader in scope, or offer greater individual rights, with respect to personal information than federal, international or other state laws, and such laws may differ from each other, all of which may complicate compliance efforts. For example, the California Consumer Privacy Act (the â€œCCPAâ€), which increases privacy rights for California residents and imposes obligations on companies that process their personal information, came into effect on January 1, 2020. Among other things, the CCPA requires covered companies to provide new disclosures to California consumers and provide such consumers new data protection and privacy rights, including the ability to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for certain data breaches that result in the loss of personal information. This private right of action may increase the likelihood of, and risks associated with, data breach litigation. In November 2020, California passed the California Privacy Rights Act (the â€œCPRAâ€), which amended and expanded the CCPA as of January 1, 2023. Although the CCPA includes exemptions for certain clinical trial data, the law may increase our compliance costs and potential liability with respect to other personal information we collect about California customers. It is possible that these consumer, health-related and data protection laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. In addition to the CCPA, numerous other statesâ€™ legislatures are considering or have enacted similar data privacy laws. For example, Virginia, Colorado, Utah and Connecticut have each passed laws similar to but different from the CCPA and CPRA that have taken effect in 2023; Florida, Montana, Oregon and Texas have enacted similar laws that have gone or will go into effect in 2024; Tennessee, Delaware, Iowa, Maryland, Minnesota, New Hampshire, Nebraska, and New Jersey have enacted similar laws that go into effect in 2025; and Indiana and Kentucky have enacted a similar law that will go into effect in 2026. Additionally, certain other state laws govern the privacy and security of health information in certain circumstances, such as Washingtonâ€™s My Health, My Data Act, which contains a private right of action. These new state laws will require ongoing compliance efforts and investment. In addition, laws in all 50 U.S. states require businesses to provide notice to consumers whose personal information has been disclosed as a result of a data breach. State laws are changing rapidly and there is discussion in the U.S. Congress of a new comprehensive federal data privacy law to which we would become subject if it is enacted.Furthermore, regulations promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996 (the â€œHIPAAâ€), establish privacy and security standards that limit the use

and disclosure of certain individually identifiable health information defined in HIPAA as â€œprotected health informationâ€ and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can require complex factual and statistical analyses and may be subject to changing interpretation. Although we take measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached, subject to a security incident, or otherwise compromised or disrupted due to various causes, including employee error, malfeasance or other malicious or inadvertent actions. Any such breach, incident, compromise or disruption could compromise our networks and the information stored there could be accessed by unauthorized parties, manipulated, publicly disclosed, lost, stolen, corrupted, made unavailable, or misused or otherwise processed without authorization. Any such access, breach or other loss of information could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy of personal information, such as the HIPAA, the Health Information Technology for Economic and Clinical Health Act, and regulatory penalties. Notice of breaches must be made to affected individuals, the Secretary of the Department of Health and Human Services, and for extensive breaches, 57notice may need to be made to the media or State Attorneys General. Such a notice could harm our reputation and our ability to compete.We are in the process of evaluating compliance needs but do not currently have in place formal policies and procedures related to the storage, collection and processing of information, and have not conducted any internal or external data privacy audits to fully assess our compliance with all applicable data protection laws and regulations. Additionally, we do not currently have policies and procedures in place for assessing our third-party vendorsâ€™ compliance with applicable data protection laws and regulations. All of these evolving compliance and operational requirements impose significant costs, such as costs related to organizational changes, implementing additional protection technologies, training employees and engaging consultants, which are likely to increase over time. In addition, such requirements may require us to modify our data processing practices and policies, distract management or divert resources from other initiatives and projects, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Any failure or perceived failure by us or our third-party vendors, collaborators, contractors and consultants to comply with any applicable federal, state or similar foreign laws and regulations, contractual obligations or any other actual or asserted obligations relating to data privacy and security could result in damage to our reputation, as well as claims, demands, proceedings or litigation by governmental agencies or other third parties, including class action privacy litigation in certain jurisdictions, which would subject us to significant fines, sanctions, awards, penalties, judgments and other liabilities, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.Our use of artificial intelligence and machine learning technologies may result in reputational harm or liability.We have incorporated and may continue to incorporate additional artificial intelligence and machine learning, or AIML, technologies into our platform, including within our decoding pipelines and otherwise within our business, and these solutions and features are key elements of our technological approach and to our future growth over time. We rely and expect to rely on AIML technologies in our platform, but there can be no assurance that we will realize the desired or anticipated benefits from AIML or any at all. We may also fail to properly implement or utilize AIML technologies. Our competitors, customers, or other third parties may incorporate AIML into their products and services or otherwise within their business more quickly or more successfully than us, which could impair our ability to compete with or serve them effectively, which could adversely affect our results of operations. Additionally, our use of AIML technologies may expose us to additional claims, demands and proceedings by private parties and regulatory authorities and subject us to legal liability as well as brand and reputational harm. For example, if output from AIML technologies or that they assist in producing are or are alleged to be deficient, inaccurate, or biased, or for such output, or such technologies or their development or deployment, including the collection, use, or other processing of data used to train or create such AIML technologies, to alleged to infringe upon or to have misappropriated third-party intellectual property rights or to violate applicable laws, regulations, or other actual or asserted legal obligations to which we are or may become subject, then our business, financial condition, and results of operations may be adversely affected. The legal, regulatory, and policy environments around AIML are evolving rapidly, and we may become subject to new and evolving legal and other obligations. These and other developments may require us to make significant changes to our use of AIML, including by limiting or restricting our use of AIML, and may require us to make significant changes to our policies and practices, which may necessitate expenditure of significant time, expense, and other resources, AIML also presents emerging ethical issues, and if our use of AIML becomes controversial, we may experience brand or reputational harm. If we commercialize our Nautilus platform outside of the United States, our international business could expose us to business, tax, regulatory, political, operational, financial, and economic risks associated with doing business outside of the United States.If we commercialize our Nautilus platform outside of the United States, our international business may be adversely affected by changing economic, political and regulatory conditions in foreign countries. Engaging in international business inherently involves a number of difficulties and risks, including:â€¢required compliance with existing and changing foreign regulatory requirements and laws;58â€¢required compliance with U.S. laws such as the Foreign Corrupt Practices Act, and other U.S. federal laws and regulations established by the office of Foreign Asset Control;â€¢export or import restrictions;â€¢laws and business practices favoring local companies;â€¢foreign currency exchange, longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;â€¢political and economic instability;â€¢changes in social, economic, and political conditions or in laws, regulations and policies governing foreign trade, intellectual property, manufacturing, research and development, and investment both domestically as well as in the other countries and jurisdictions in which we operate and into which we may sell our products including as a result of the separation of the United Kingdom from the European Union (Brexit);â€¢potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements and other trade barriers;â€¢difficulties and costs of staffing and managing foreign operations, including compliance with diverse and complex local employment laws and practices; andâ€¢difficulties protecting, maintaining, enforcing or procuring intellectual property rights.If one or more of these risks occurs, it could require us to dedicate significant resources to remedy such occurrence, and if we are unsuccessful in finding a solution, our financial results will suffer.In addition, if we commercialize our Nautilus platform outside of the United States, we may rely on distributors for sales of our Nautilus platform and related products. To do so we must attract distributors and maintain distributors to maximize the commercial opportunity for our platform. There is no guarantee that we will be successful in attracting or retaining desirable sales and distribution partners or that we will be able to enter into such arrangements on favorable terms. Distributors may not commit the necessary resources to market and sell our Nautilus platform and related products to the level of our expectations or may choose to favor marketing the products of our competitors. If current or future distributors do not perform adequately, or we are unable to enter into effective arrangements with distributors in particular geographic areas, we may not realize long-term international revenue growth and our financial results will suffer.If we expand our development and commercialization activities outside of the United States, we will be subject to an increased risk of conducting activities in a manner that violates the U.S. Foreign Corrupt Practices Act and similar laws. If that occurs, we may be subject to civil or criminal penalties and other adverse consequences which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.We are subject to the U.S. Foreign Corrupt Practices Act, or the FCPA, and similar anti-corruption laws which generally prohibit companies, their employees, agents, representatives, business partners, and third-party intermediaries from authorizing, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. Specifically, the FCPA which prohibits corporations and individuals from paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. We are also subject to the UK Bribery Act, which prohibits both domestic and international bribery, as well as bribery across both public and private sectors.If we choose to establish and expand our commercial operations outside of the United States we will need to comply with non-U.S. regulatory requirements, may need to establish and expand business relationships with various third parties, and we, our employees, agents, representatives, business partners and third-party intermediaries may interact more frequently with foreign officials, including regulatory authorities, and we may be held liable for 59the corrupt or other illegal activities of these employees, agents, representatives, business partners or third-party intermediaries, even if we do not explicitly authorize such activities. Any interactions with any such parties or individuals where improper payments are provided that are found to be in violation of such laws could result in substantial fines and penalties and could materially harm our business. We cannot assure you that all of our employees, agents, representatives, business partners and third-party intermediaries will not take actions in violation of applicable law for which we may ultimately be held responsible.These laws also require that we keep accurate books and records and maintain internal controls and compliance procedures designed to prevent any such actions. While we have policies and procedures to address compliance with such laws, we cannot assure you that none of our employees, agents, representatives, business partners or third-party intermediaries will take actions in violation of our policies and applicable law, for which we may be ultimately held responsible. Further, as we increase our international sales and business, our risks under these laws may increase and expanded programs to maintain compliance with such laws may be costly and may not be effective.Furthermore, any finding of a violation under one countryâ€™s laws may increase the likelihood that we will be prosecuted and be found to have violated another countryâ€™s laws. If our business practices are alleged to be or are found to be in violation of the FCPA, UK Bribery Act or other similar anti-corruption laws, we may be subject to whistleblower complaints, sanctions, settlements, prosecution, enforcement actions, fines, damages, adverse media coverage, investigations, loss of export privileges, significant civil and criminal penalties, or suspension or debarment from government contracts, all of which could have a material adverse effect on our reputation, financial condition and results of operations. Responding to any investigation or action will likely result in materially significant diversion of managementâ€™s attention and resources and significant defense costs and other professional fees.Environmental and health safety laws may result in liabilities, expenses and restrictions on our operations. Failure to comply with environmental laws and regulations could subject us to significant liability.Federal, state, local and foreign laws regarding environmental protection, hazardous substances and human health and safety may adversely affect our business. Our research and development operations involve the use of hazardous substances and are subject to a variety of federal, state, local and foreign environmental laws and regulations relating to the storage, use, discharge, disposal, remediation of, and human exposure to, hazardous substances and the sale, labeling, collection, recycling, treatment and disposal of products containing hazardous substances. These operations are permitted by regulatory authorities, and the resultant waste materials are disposed of in material compliance with environmental laws and regulations. Using hazardous substances in our operations exposes us to the risk of accidental injury, contamination or other liability from the use, storage, importation, handling or disposal of hazardous materials. If we or our suppliersâ€™ operations result in the contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and fines, and any liability could significantly exceed our insurance coverage and have a material adverse effect on our business, financial condition and results of operations. Liability under environmental laws and regulations can be joint and several and without regard to fault or negligence. Compliance with environmental laws and regulations may be expensive and noncompliance could result in substantial liabilities, fines and penalties, personal injury and third-party property damage claims and substantial investigation and remediation costs. Environmental laws and regulations could become more stringent over time, imposing greater compliance costs and increasing risks and penalties associated with violations. We cannot assure you that violations of these laws and regulations will not occur in the future or have not occurred in the past as a result of human error, accidents, equipment failure or other causes. The expense associated with environmental regulation and remediation could harm our financial condition and operating results.Our employees, independent contractors, consultants, commercial partners, distributors and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, distributors, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with applicable FDA regulations, provide accurate information to the FDA, 60comply with federal and state health care fraud and abuse laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct

by these parties, and the precautions we take to detect and prevent such misconduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending our self or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.Demand for our technology could be reduced by legal, social and ethical concerns surrounding the use of genetic information and biological materials.Our products may be used to provide genetic information or analyze biological materials from humans and other living organisms. The information obtained from our products could be used in a variety of applications, which may have underlying legal, social and ethical concerns, including the genetic engineering or modification of agricultural products, testing for genetic predisposition for certain medical conditions and stem cell research. Governmental authorities could, for safety, social or other purposes, call for limits on or impose regulations on the use of genetic testing or the use of certain biological materials. Such concerns or governmental restrictions could limit the use of our products, which could have a material adverse effect on our business, financial condition and results of operations.Risks Related to our Operations If we experience a significant disruption in our information technology systems or breaches of data security, our business could be adversely affected.We rely on information technology systems to keep financial records, facilitate our research and development initiatives, manage our manufacturing operations, maintain quality control, fulfill customer orders, process customer data and information, maintain corporate records, communicate with staff and external parties and operate other critical functions. Our information technology systems and those of our vendors and partners are potentially vulnerable to disruption, failure and compromise due to breakdown, malicious intrusion and computer viruses, ransomware or other malicious software, or other disruptive events, including, but not limited to, natural disasters and catastrophes. Like other life sciences technology companies, we have experienced cybersecurity incidents in the past, and we may experience them again in the future. For example, in January 2024, we experienced an incident involving unauthorized access to an employee account. The Company has worked, and continues to work with external cybersecurity experts, in detecting, blocking, containing, remediating, and investigating any cyber security incidents and risks, and in further enhancing our cybersecurity safeguards. This incident did not, and other incidents have not impacted the availability of our systems, materially disrupted our operations, or had any material impact on our financial or operating results. Cybersecurity risks are constantly evolving, and as such, we anticipate additional work and expense in the future as we continue to further enhance our security processes and initiatives to meet the changing landscape of cyber security risks. While cyber insurance may be available for companies, any available insurance for cyber events, may be limited in amount, subject to deductibles, and may not be adequate to cover us for all costs arising from cyber security incidents. Given increasing cyber security risks, cyber insurance may not be available to us in the future, or may not be available on commercially reasonable terms.Cyberattacks and other malicious internet-based activity continue to increase and cloud-based platform providers of services have been and are expected to continue to be targeted. Furthermore, there may be a heightened 61risk of potential cyberattacks by state actors or others since the escalation of the conflicts in Eastern Europe and intensified conflicts in the Middle East. Methods of attacks on information technology systems and attempting or effecting data security breaches and incidents change frequently, are increasingly complex and sophisticated, including social engineering and phishing scams, and can originate from a wide variety of sources. In addition to traditional computer â€œhackers,â€ malicious code, such as viruses and worms, employee theft or misuse, denial-of-service attacks and sophisticated nation-state and nation-state supported actors now engage in attacks, including advanced persistent threat intrusions. Despite our efforts to create security barriers to such threats, it is virtually impossible for us to entirely mitigate these risks. Despite any of our current or future efforts to protect against cybersecurity attacks and data security breaches, there is no guarantee that our efforts are adequate to safeguard against all such attacks and breaches. Moreover, it is possible that we may not be able to anticipate, detect, appropriately react and respond to, or implement effective preventative measures against, all cybersecurity incidents.If our security measures, or those of our vendors and partners, are compromised due to cybersecurity attacks or security breaches or incidents, including as a result of third-party action, employee or customer error, malfeasance, stolen or fraudulently obtained log-in credentials or otherwise, or if any of these events is perceived to have occurred, our reputation could be damaged, our business and reputation may be harmed, we could become subject to claims, demands and litigation by private parties, and regulatory investigations and other proceedings, and we could incur significant liability. If we were to experience a prolonged system disruption in our information technology systems or those of certain of our vendors and partners, it could negatively impact our ability to serve our customers, which could adversely impact our business, financial condition, results of operations and prospects. If operations at our facilities were disrupted, it may cause a material disruption in our business if we are not capable of restoring functionality on an acceptable timeframe. In addition, our information technology systems, and those of our vendors and partners, are potentially vulnerable to data security breaches and incidents, whether by internal bad actors, such as employees or other third parties with legitimate access to our or our third-party providersâ€™ systems, or external bad actors, which could lead to the exposure of personal data, sensitive data and confidential information to unauthorized persons. Any such data security breaches or incidents could lead to the loss of trade secrets or other intellectual property, or could lead to the loss, unavailability, exposure, unauthorized modification, alteration or other processing of personal information, including sensitive personal information, of our employees, customers and others, any of which could have a material adverse effect on our business, reputation, financial condition and results of operations.In addition, any such access, disclosure or other loss or unauthorized use of information or data could result in legal claims or proceedings, regulatory investigations or actions, and other types of liability under laws that protect the privacy and security of personal information, including federal, state and foreign data protection and privacy regulations, violations of which could result in significant penalties and fines. Furthermore, defending a suit, regardless of its merit, could be costly, divert managementâ€™s attention and harm our reputation. In addition, although we seek to detect and investigate data security incidents, security breaches and other incidents of unauthorized access to our information technology systems and data can be difficult to detect and any delay in identifying such breaches or incidents may lead to increased harm and legal exposure of the type described above. Moreover, there could be public announcements regarding any actual or perceived cybersecurity incidents and any steps we take to respond to or remediate such incidents, and if securities analysts or investors perceive these announcements to be negative, it could, among other things, have a material adverse effect on the price of our Common Stock.The cost of protecting against, investigating, mitigating and responding to potential breaches of our information technology systems and data security breaches and incidents and complying with applicable breach notification obligations to individuals, regulators, partners and others can be significant. As cybersecurity incidents continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities. The inability to implement, maintain and upgrade adequate safeguards could have a material adverse effect on our business, financial condition, results of operations and prospects.We may be unable to manage our anticipated growth effectively.Our anticipated growth will place significant strains on our management, operational and manufacturing systems and processes, sales and marketing team, financial systems and internal controls and other aspects of our 62business. We must upgrade our internal business processes and capabilities to create the scalability that a growing business demands. As of JuneÂ 30, 2024, we had 164 employees. To execute our anticipated growth successfully, we must continue to attract and retain qualified personnel and manage and train them effectively. Developing and commercializing our Nautilus platform will require us to hire and retain scientific, sales and marketing, software, manufacturing, customer service, distribution and quality assurance personnel. In addition, we expect that we will need to hire additional accounting, finance and other personnel as a public company. As a public company, our management and other personnel will need to devote a substantial amount of time towards maintaining compliance with these requirements and effectively manage these growth activities. We may face challenges integrating, developing and motivating our rapidly growing employee base.Further, our anticipated growth will place additional strain on our suppliers and manufacturing facilities, resulting in an increased need for us to carefully monitor quality assurance. Any failure by us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization goals.Our ability to successfully manage our expected growth is uncertain given the fact that we have been in operation only since 2016. As we continue to grow, we will be required to implement more complex organizational management structures and may find it increasingly difficult to maintain the benefits of our corporate culture, including our ability to quickly develop and launch new and innovative products. If we do not successfully manage our anticipated growth, our business, results of operations, financial condition and prospects will be harmed.If we are unable to recruit and retain key executives and scientists, we may be unable to achieve our goals.Our performance is substantially dependent on the performance of our senior management and key scientific and technical personnel, particularly Sujal Patel, one of our founders and our Chief Executive Officer, and Parag Mallick, one of our founders and our Chief Scientist.The loss of the services of any member of our senior management or our scientific or technical staff might significantly delay or prevent the development of our products or achievement of other business objectives by diverting managementâ€™s attention to transition matters and identification of suitable replacements, if any, and could have a material adverse effect on our business. We do not maintain fixed term employment contracts with any of our employees and do not maintain key man life insurance on any of our employees.In addition, our research and product development efforts could be delayed or curtailed if we are unable to attract, train and retain highly skilled employees, particularly, senior scientists and engineers. To expand our research and product development efforts, we need additional people skilled in areas such as molecular and cellular biology, biochemistry, surface chemistry, software, bioinformatics, assay development, mechanical engineering, electrical engineering, optics, fluidics and manufacturing. Competition for these people is intense. Because of the complex and technical nature of our system and the dynamic market in which we compete, any failure to attract and retain a sufficient number of qualified employees could materially harm our ability to develop and commercialize our technology. As part of our retention and incentive efforts, in addition to salary and cash incentives, we have issued stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by decreases in our stock price (whether or not related to or proportional to our operating performance) and may at any time be insufficient to counteract more lucrative offers from other companies. We may face challenges in retaining and recruiting such individuals due to sustained declines in our stock price that could reduce the retention value of equity awards.We may acquire other companies or technologies, which could divert our managementâ€™s attention, result in additional dilution to our stockholders and otherwise disrupt our operations and harm our operating results.We may in the future seek to acquire or invest in businesses, applications or technologies that we believe could complement or expand our Nautilus platform or future products, enhance our technical capabilities or otherwise offer growth opportunities. The pursuit of potential acquisitions may divert the attention of our management and cause us to incur various costs and expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. We may not be able to identify desirable acquisition targets or be successful in entering into an agreement with any particular target or obtain the expected benefits of any acquisition or investment.63We have limited experience in acquiring other businesses or technologies. We may not be able to successfully integrate acquired personnel, operations and technologies, or effectively manage the combined business following an acquisition. Acquisitions could also result in dilutive issuances of equity securities, the use of our available cash, or the incurrence of debt, which could harm our operating results. In addition, if an acquired business fails to meet our expectations, our operating results, business and financial condition may suffer.Unfavorable U.S. or global economic conditions as a result of multiple global events, including the COVID-19 pandemic, the conflicts in Eastern Europe and the Middle East, changing interest rates, instability in the global financial markets, and general economic downturns, could adversely affect our ability to raise capital and our business, results of operations and financial condition.While the potential economic impact brought by multiple adverse global circumstances, such as the COVID-19 pandemic, conflicts in Eastern Europe and the Middle East, potential uncertainty related to Taiwan and its relationship with China, changing interest rates and general economic downturns, and the collapse of Silicon Valley Bank and other financial institutions in March 2023, and related instability in the global financial markets, are difficult to assess or predict, both as to magnitude and duration, these events have resulted in, and may continue to result in, extreme volatility and disruptions in the capital and credit markets, reducing our ability to raise additional capital through equity, equity-linked or debt financings, which could negatively impact our short-term and long-term liquidity and our ability to operate in accordance with our operating plan, or at all. Additionally, these events have resulted, and in the future may result, in disruptions in our supply chains or the supply chains of those entities providing services or products to us, restrictions in our ability to deploy our workforce in our own facilities, locally, nationally or internationally, restrictions on the operating capacity of the

laboratories or research facilities of our customers, decreases in government funding of research and development, or changes to programs that provide funding to research laboratories that may have the impact of redirecting funding to other areas of research, or prolonging or delaying funding cycles, any of which could adversely impact our ability to manufacture and sell our products. Moreover, our results of operations could be adversely affected by general conditions in the global economy and financial markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for our Nautilus platform and our ability to raise additional capital when needed on favorable terms, if at all. A weak or declining economy could strain our customersâ€™ budgets or cause delays in their payments to us. As a result of such events, we or our contractors, partners and/or suppliers could experience shortages, business disruptions or delays for materials sourced or manufactured in countries affected by such events, and their ability to supply us with services or components may be adversely affected. In addition, our contractors and suppliers have raised and may continue to raise prices for goods and services we employ in our research and development efforts and for components or materials used in our Nautilus platform. Additionally, there is ongoing uncertainty regarding the federal budget and federal spending levels, including the possible impacts of a failure to increase the â€œdebt ceiling.â€ Any U.S. government default on its debt could have broad macroeconomic effects that could, among other things, disrupt access to capital markets and deepen recessionary conditions. Further, as of JuneÂ 30, 2024, we had cash, cash equivalents and investments of $232.9 million, consisting of U.S. treasury securities, mutual funds, commercial paper, corporate debt securities, and agency securities. Any default by the U.S. government or credit downgrade of the securities we hold could impact the liquidity or valuation of our investments.Any of the foregoing could harm our business, financial condition and results of operations, and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our ability to raise capital, business, results of operations and financial condition.Global supply chain interruptions could adversely affect our ability to develop and commercialize our products.We may be subject to supply chain interruptions. Current or future supply chain interruptions that could be exacerbated by global political tensions, such as the situation in Eastern Europe, increased conflict in the Middle East, uncertainty related to Taiwan and its relationship with China, and resurgent or new global pandemics could negatively impact our ability to further develop our products or to manufacture and deliver our products or services, which could negatively impact our timelines and business results. For example, we have experienced some supply 64disruptions due to the COVID-19 pandemic, including closures at certain chip manufacturers, which led to extended lead times for certain chips; diversion of certain lab materials needed to support COVID-19 relief efforts; and lower availability of certain reagents, and delays similar to those we experienced during the COVID-19 pandemic could impact us if they recur or are exacerbated due to the situations in Eastern Europe and/or the Middle East. Further, there is currently significant uncertainty about the future relationship between the United States and various other countries, most significantly China, with respect to trade policies, treaties, tariffs, taxes, and other limitations on cross-border operations. The U.S. government has made and continues to make significant additional changes in U.S. trade policy and may continue to take future actions that could negatively impact U.S. trade. For example, legislation has been introduced in Congress to limit certain U.S. biotechnology companies from using equipment or services produced or provided by select Chinese biotechnology companies, and others in Congress have advocated for the use of existing executive branch authorities to limit those Chinese service providersâ€™ ability to engage in business in the U.S. We cannot predict what actions may ultimately be taken with respect to trade relations between the United States and China or other countries, what products and services may be subject to such actions or what actions may be taken by the other countries in retaliation. If we are unable to obtain or use services from existing service providers or become unable to export or sell our products to any of our customers or service providers, our business, liquidity, financial condition, and/or results of operations would be materially and adversely affected.If our facilities become unavailable or inoperable, our research and development program and commercialization launch plan could be adversely impacted and manufacturing of our instruments and consumables could be interrupted.Our Seattle, Washington, facility primarily houses our corporate executive team and our software development operations, while our facilities in San Carlos and San Diego, California primarily house our research and development teams.Our facilities in Seattle, San Carlos and San Diego are vulnerable to natural disasters, public health crises, including the impact of the COVID-19 pandemic, and other catastrophic events. For example, our San Carlos and San Diego facilities are located near earthquake fault zones and are vulnerable to damage from earthquakes as well as other types of disasters, including fires, floods, power loss, communications failures and similar events. If any disaster, public health crisis or catastrophic event were to occur, our ability to operate our business would be seriously, or potentially completely, impaired. If our facilities become unavailable for any reason, we cannot provide assurances that we will be able to secure alternative facilities with the necessary capabilities and equipment on acceptable terms, if at all. We may encounter particular difficulties in replacing our San Carlos facilities given the specialized equipment housed within it. The inability to manufacture our instruments or consumables, combined with our limited inventory of manufactured instruments and consumables, may result in the loss of future customers or harm our reputation, and we may be unable to re-establish relationships with those customers in the future.If our research and development program or planned commercialization program were disrupted by a disaster or catastrophe, the launch of new products, including our Nautilus platform, and the timing of improvements to our products could be significantly delayed and could adversely impact our ability to compete with other available products and solutions. If our capabilities are impaired, we may not be able to manufacture and ship our products in a timely manner, which would adversely impact our business. Although we possess insurance for damage to our property and the disruption of our business, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all.We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.Our research and development processes involve the controlled use of hazardous materials, including select chemicals that may be flammables, toxic or corrosives, as well as potential biohazard materials. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. In addition, our Nautilus platform involves the use of a high-powered laser system, which could result in injury. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials. We do not 65currently maintain separate environmental liability coverage and any such contamination or discharge could result in significant cost to us in penalties, damages and suspension of our operations.Risks Related to Our Common StockAn active trading market for our Common Stock may never develop or be sustained.Prior to the Business Combination, there was no public trading market for Legacy Nautilusâ€™ Common Stock. Although our Common Stock is listed on the Nasdaq Global Select Market, the market for our shares has demonstrated varying levels of trading activity. If an active trading market does not develop, or develops but is not maintained, you may have difficulty selling any of our Common Stock due to the limited public float. We cannot predict the prices at which our Common Stock will trade. It is possible that in one or more future periods our results of operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our Common Stock may fall. Accordingly, we cannot assure you of your ability to sell your shares of our Common Stock when desired or at prices at or above the price you paid for your shares or at all.The market price of our Common Stock has been and may continue to be volatile, which could result in substantial losses for investors.The market price of our Common Stock has been and may continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. The market price of our Common Stock may fluctuate due to a variety of factors, including:â€¢the timing of the launch and commercialization of our products and degree to which such launch and commercialization meets the expectations of securities analysts and investors;â€¢actual or anticipated fluctuations in our operating results, including fluctuations in our quarterly and annual results;â€¢operating expenses being more than anticipated;â€¢the failure or discontinuation of any of our product development and research programs;â€¢changes in the structure or funding of research at academic and research laboratories and institutions, including changes that would affect their ability to purchase our instruments or consumables;â€¢the success of existing or new competitive businesses or technologies;â€¢announcements about new research programs or products of our competitors;â€¢developments or disputes concerning patent applications, issued patents or other proprietary rights;â€¢the recruitment or departure of key personnel;â€¢litigation and governmental investigations involving us, our industry or both;â€¢regulatory or legal developments in the United States and other countries;â€¢volatility and variations in market conditions in the life sciences technology sector generally, or the proteomics or genomics sectors specifically;â€¢investor perceptions of us or our industry;â€¢the level of expenses related to any of our research and development programs or products;â€¢actual or anticipated changes in our estimates as to our financial results or development timelines, variations in our financial results or those of companies that are perceived to be similar to us or changes in estimates 66or recommendations by securities analysts, if any, that cover our Common Stock or companies that are perceived to be similar to us;â€¢whether our financial results meet the expectations of securities analysts or investors;â€¢the announcement or expectation of additional financing efforts;â€¢sales of our Common Stock by us or by our insiders or other stockholders;â€¢general economic, industry and market conditions; andâ€¢the COVID-19 pandemic, natural disasters or major catastrophic events.Recently, stock markets in general, and the market for life sciences technology companies in particular, have experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations, particularly in light of the COVID-19 pandemic. Broad market and industry factors may seriously affect the market price of our Common Stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for our Common Stock. Following periods of such volatility in the market price of a companyâ€™s securities, securities class action litigation has often been brought against that company. Because of the potential volatility of our Common Stock price, we may become the target of securities litigation in the future. Securities litigation could result in substantial costs and divert managementâ€™s attention and resources from our business.There can be no assurance that we will be able to comply with the continued listing standards of Nasdaq.If Nasdaq delists our shares of Common Stock from trading on its exchange for failure to meet Nasdaqâ€™s listing standards, we and our stockholders could face significant material adverse consequences including: â€¢a limited availability of market quotations for our securities; â€¢reduced liquidity for our securities; â€¢a determination that our Common Stock is a â€œpenny stockâ€ which will require brokers trading in our Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities; â€¢a limited amount of new and analyst coverage; and â€¢a decreased ability to issue additional securities or obtain additional financing in the future. Our principal stockholders and management own a significant percentage of our Common Stock and will be able to exercise significant influence over matters subject to stockholder approval.As of JuneÂ 30, 2024, our directors, executive officers, holders of more than 5% of our outstanding shares of Common Stock and their respective affiliates beneficially owned, collectively, approximately 68.8% of the outstanding shares of Common Stock. As a result, these stockholders, if they act together, may significantly influence all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of our company that our other stockholders may believe is in their best interests. This in turn could have a material adverse effect on our stock price and may prevent attempts by our stockholders to replace or remove the board of directors or management.67The sale or the perception of future sales of a substantial number of shares of our Common Stock could cause the market price of our Common Stock to drop significantly, even if our business is doing well.Sales of a substantial number of shares of our Common Stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our Common Stock.Pursuant to the Amended and Restated Registration Rights and Lock-Up Agreement (the â€œRegistration Rights and Lock-Up Agreementâ€) and the Subscription Agreements entered into in connection with the PIPE Financing, we have filed resale registration statements to provide for the resale of the shares issued in the PIPE Financing and the shares of our Common Stock held by the parties to the Registration Rights and Lock-Up Agreement. The market price of our Common Stock could decline if the holders whose shares are registered under such registration statements sell their shares or are perceived by the market as intending to sell their shares.We will have broad discretion over the use of the proceeds to us from our â€œat the marketâ€ equity offering program and may apply the proceeds to uses that do not improve our operating results or the value of your securities.We will have broad discretion to use the net proceeds to us from our â€œat the marketâ€ equity offering program, and investors will be relying solely on the judgment of our board of directors and management regarding the application of these proceeds. Although we expect to use the net proceeds from our â€œat the marketâ€ equity offering program for general corporate purposes and working capital, including for continued product development of our Nautilus platform other research and development activities, and commercialization of our Nautilus platform, we have not allocated these net proceeds for specific purposes. Investors will not have the opportunity, as part of their investment decision, to assess whether the proceeds are being used appropriately. Our use of the proceeds may not improve our operating results or increase the value of the securities

offered pursuant to the â€œat the marketâ€ equity offering program.We do not expect to pay any dividends for the foreseeable future. Investors may never obtain a return on their investment.You should not rely on an investment in our Common Stock to provide dividend income. We do not anticipate that we will pay any dividends to holders of our Common Stock in the foreseeable future. Instead, we plan to retain any earnings to maintain and expand our existing operations, fund our research and development programs and continue to invest in our commercial infrastructure. In addition, any future credit facility or financing we obtain may contain terms prohibiting or limiting the amount of dividends that may be declared or paid on our Common Stock. Accordingly, investors must rely on sales of our Common Stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our Common Stock.Our bylaws designate a state or federal court located within the State of Delaware as the exclusive forum for substantially all disputes between us and our stockholders, and also provide that the federal district courts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, each of which could limit our stockholdersâ€™ ability to choose the judicial forum for disputes with us or our directors, officers, stockholders, or employees.Our bylaws provide that, unless we consent in writing to the selection of an alternative forum (an â€œAlternative Forum Consentâ€), the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state court in Delaware or the federal district court for the District of Delaware) will, to the fullest extent permitted by law, be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, stockholders or other employees to us or our stockholders, (iii) any action arising pursuant to any provision of the Delaware General Corporation Law or our certificate of incorporation or bylaws (each, as may be amended from time to time), or (iv) any action asserting a claim governed by the internal affairs doctrine of the State of Delaware, except for any claim as to which the court does not have jurisdiction over an indispensable party to that claim. The foregoing shall not apply to any claims under the Exchange Act or the Securities Act of 1933, as amended (the 68â€œSecurities Actâ€). In addition, unless we give an Alternative Forum Consent, the federal district courts of the United States shall be the sole and exclusive forum for resolving any action asserting a claim arising under the Securities Act against any person in connection with any offering of the Companyâ€™s securities, including any auditor, underwriter, expert, control person or other defendant.Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our bylaws also provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act.Any person or entity purchasing or otherwise acquiring or holding or owning (or continuing to hold or own) any interest in any of our securities shall be deemed to have notice of and consented to the foregoing bylaw provisions. Although we believe these exclusive forum provisions benefit us by providing increased consistency in the application of Delaware law and federal securities laws in the types of lawsuits to which each applies, the exclusive forum provisions may limit a stockholderâ€™s ability to bring a claim in a judicial forum of its choosing for disputes with us or any of our directors, officers, stockholders, or other employees, which may discourage lawsuits with respect to such claims against us and our current and former directors, officers, stockholders, or other employees. In addition, a stockholder that is unable to bring a claim in the judicial forum of its choosing may be required to incur additional costs in the pursuit of actions which are subject to the exclusive forum provisions described above. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder as a result of our exclusive forum provisions. Further, in the event a court finds either exclusive forum provision contained in our bylaws to be unenforceable or inapplicable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our results of operations.Delaware law and provisions in our certificate of incorporation and bylaws might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our Common Stock.Our status as a Delaware corporation and the anti-takeover provisions of the Delaware General Corporation Law may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder without the approval of holders of 66 2/3% of the voting power of our stockholders other than the interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our certificate of incorporation and bylaws contain provisions that may make the acquisition of our company more difficult, including the following:â€¢our board of directors is classified into three classes of directors with staggered three-year terms and directors are only able to be removed from office for cause by the affirmative vote of holders of at least two-thirds of the voting power of our then outstanding capital stock;â€¢certain amendments to our certificate of incorporation require the approval of stockholders holding two-thirds of the voting power of our then outstanding capital stock;â€¢any stockholder-proposed amendment to certain provisions of our bylaws require the approval of stockholders holding two-thirds of the voting power of our then outstanding capital stock;â€¢our stockholders are only able to take action at a meeting of stockholders and are not able to take action by written consent for any matter;â€¢vacancies on our board of directors are able to be filled only by our board of directors and not by stockholders;69â€¢only the chair of our board of directors, our chief executive officer, our president or a majority of our board of directors are authorized to call a special meeting of stockholders;â€¢certain litigation against us can only be brought in Delaware;â€¢our certificate of incorporation authorizes undesignated preferred stock, the terms of which may be established by our Board and shares of which may be issued, without the approval of the holders of our capital stock; andâ€¢advance notice procedures apply for stockholders to nominate candidates for election as directors or to bring matters before an annual meeting of stockholders.These anti-takeover defenses could discourage, delay, or prevent a transaction involving our change in control. These provisions could also discourage proxy contests and make it more difficult for stockholders to elect directors of their choosing and to cause us to take other corporate actions they desire, any of which, under certain circumstances, could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock.General Risk FactorsWe will continue to incur significant increased costs and management resources as a result of operating as a public company.As a public company, we will continue to incur significant legal, accounting, compliance and other expenses that we did not incur as a private company and these expenses may increase even more after we are no longer an â€œemerging growth company.â€ Our management and other personnel will need to devote a substantial amount of time and incur significant expense in connection with compliance initiatives. As a public company, we will continue to bear all of the internal and external costs of preparing and distributing periodic public reports in compliance with our obligations under the securities laws.In addition, regulations and standards relating to corporate governance and public disclosure, including the SOX, and the related rules and regulations implemented by the SEC and The Nasdaq Stock Market LLC, have increased legal and financial compliance costs and will make some compliance activities more time-consuming. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and may divert managementâ€™s time and attention from our other business activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us, and our business may be harmed. In the future, it may be more expensive or more difficult for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members for our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers.We have broad discretion in the use of the net proceeds from the Business Combination and the PIPE Financing and may not use them effectively.We cannot specify with certainty the particular uses of the net proceeds we received from the Business Combination and the PIPE Financing. Our management will have broad discretion in the application of the net proceeds. Our management may spend a portion or all of the net proceeds in ways that our stockholders may not desire or that may not yield a favorable return. The failure by our management to apply these funds effectively could harm our business, financial condition, results of operations and prospects. Pending their use, we may invest the net proceeds from the Business Combination and the PIPE Financing in a manner that does not produce income or that loses value.70Our ability to use net operating losses and certain other tax attributes to offset future taxable income may be subject to certain limitations.Our U.S. federal and state net operating loss carryforwards, or NOLs, may be unavailable to offset future taxable income because of restrictions under U.S. federal and/or state law. U.S. federal NOLs that arose in tax years ending on or prior to December 31, 2017, are only permitted to be carried forward for 20 years. U.S. federal NOLs that arose in tax years beginning after December 31, 2017, may be carried forward indefinitely, but for taxable years beginning after December 31, 2020, the deductibility of such U.S. federal NOLs will be limited to 80% of our current year taxable income. State NOLs may be subject to similar or different limitations. As of DecemberÂ 31, 2023, we had U.S. federal NOLs of $71.2 million, of which $70.6 million do not expire, and state NOLs of $95.5 million that will begin to expire in 2037. In addition, Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, may limit the NOLs we may use in any year for U.S. federal income tax purposes in the event of certain changes in our ownership. A Code Section 382 â€œownership changeâ€ generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a companyâ€™s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Similar rules may apply under state tax laws. We have not conducted a Code Section 382 study to determine whether the use of our NOLs is impaired. We may have previously undergone an â€œownership change.â€ In addition, future issuances or sales of our stock, including certain transactions involving our stock that are outside of our control, could result in future â€œownership changes.â€ â€œOwnership changesâ€ that have occurred in the past or that may occur in the future could result in the imposition of an annual limit on the amount of pre-ownership change NOLs and other tax attributes we can use to reduce our taxable income, potentially increasing and accelerating our liability for income taxes, and also potentially causing those tax attributes to expire unused. States may impose other limitations on the use of our NOLs and other tax attributes. Any limitation on using NOLs could, depending on the extent of such limitations and the NOLs previously used, result in our retaining less cash after payment of U.S. federal and state income taxes during any year in which we have taxable income, rather than losses, than we would be entitled to retain if such NOLs were available as an offset against such taxable income for U.S. federal and state income tax reporting purposes, which could adversely impact our operating results.Changes in tax laws could have a material adverse effect on our future business, cash flows, results of operations or financial condition.We may in the future be subject to the tax laws, regulations, and policies of several taxing jurisdictions. Changes in tax laws, as well as other factors, could cause us to experience fluctuations in our tax obligations and effective tax rates and otherwise adversely affect our tax positions and/or our tax liabilities. For example, many countries and local jurisdictions and organizations such as the Organisation for Economic Co-operation and Development have proposed or implemented new tax laws or changes to existing tax laws, including additional taxes on payroll or employees and a proposed 15% global minimum tax (Pillar 2) that is being adopted by several countries with implementation beginning in 2024. Any new or changes to tax laws could adversely affect our future effective tax rate, operating results, tax credits or incentives or tax payments, which could have a material adverse effect on our future business, cash flows, results of operations or financial condition if we expand internationally. For example, the United States recently enacted the Inflation Reduction Act of 2022, which implements, among other changes, a 1% non-deductible excise tax on certain stock buybacks effective January 1, 2023. Further, on January 1, 2022, a provision of the Tax Cuts and Jobs Act of 2017 went into effect that eliminates the option to deduct research and development costs in the year incurred and instead requires taxpayers to amortize such costs over five years for domestic and 15 years for foreign costs. Such changes, among others, may adversely affect our future effective tax rate, business, cash flows, results of operations and financial condition.If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results in a timely manner or prevent fraud, which would harm our business.Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet 71our reporting obligations in a timely manner, or at all. In addition, any testing by us conducted in connection with Section 404(a) of the Sarbanes-Oxley Act of 2002 (â€œSOXâ€) or any subsequent testing by our independent registered public accounting firm in connection with Section 404(b) of SOX, may reveal deficiencies in our internal controls over financial reporting that are deemed to be significant deficiencies or material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Ineffective internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our Common Stock.We will be required to disclose material changes made in our internal controls over financing reporting and procedures on a quarterly basis and our

management will be required to assess the effectiveness of these controls annually. We will be required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an â€œemerging growth companyâ€ under the Jumpstart Our Business Startups Act of 2012 (the â€œJOBS Actâ€) or a â€œsmaller reporting company,â€ as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), we will be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, for as long as we are an â€œemerging growth companyâ€ or a â€œsmaller reporting company,â€ our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404(b) of SOX.To achieve compliance with Section 404(a) of SOX within the prescribed period, we have engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively and implement a continuous reporting and improvement process for internal control over financial reporting.An independent assessment of the effectiveness of our internal controls could detect problems that our managementâ€™s assessment might not identify. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our results of operation could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock.The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience and estimates and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, and expenses that are not readily apparent from other sources. For example, in connection with the implementation of the new revenue accounting standard if and when we have product sales, management makes judgments and assumptions based on our interpretation of the new standard. The new revenue standard is principle-based, and interpretation of those principles may vary from company to company based on their unique circumstances. It is possible that interpretation, industry practice and guidance may evolve as we apply the new standard. If our assumptions underlying our estimates and judgements relating to our critical accounting policies change or if actual circumstances differ from our assumptions, estimates or judgements, our operating results may be adversely affected and could fall below our publicly announced guidance or the expectations of securities analysts and investors, resulting in a decline in the market price of our Common Stock.We are an â€œemerging growth companyâ€ and a â€œsmaller reporting companyâ€ and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our Common Stock less attractive to investors.We are an â€œemerging growth company,â€ as defined in the JOBS Act. For so long as we remain an emerging growth company, we are permitted by SEC rules and plan to rely on exemptions from certain disclosure requirements that are applicable to other SEC registered public companies that are not emerging growth companies. 72These exemptions include not being required to comply with the auditor attestation requirements of Section 404 of SOX, not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditorâ€™s report providing additional information about the audit and the financial statements, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result, the information we provide stockholders will be different than the information that is available with respect to other public companies that are not emerging growth companies. To the extent that we continue to qualify as a â€œsmaller reporting company,â€ as such term is defined in Rule 12b-2 under the Exchange Act, after we cease to qualify as an emerging growth company, we will continue to be permitted to make certain reduced disclosures in our periodic reports and other documents that we file with the SEC and will not be required to comply with the auditor attestation requirements of Section 404 of SOX. We cannot predict whether investors will find our Common Stock less attractive if we rely on these exemptions. If some investors find our Common Stock less attractive as a result, there may be a less active trading market for our Common Stock and our stock price may be more volatile.In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.Reports published by analysts, including projections in those reports that differ from our actual results, could adversely affect the price and trading volume of our common shares.Securities research analysts may establish and publish their own periodic projections for us. These projections may vary widely and may not accurately predict the results we actually achieve. The share price of our Common Stock may decline if our actual results do not match the projections of these securities research analysts. Similarly, if one or more of the analysts who write reports on us downgrades our stock or publishes inaccurate or unfavorable research about our business, the share price of our Common Stock could decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, the share price or trading volume of our Common Stock could decline. Increased scrutiny of our environmental, social or governance responsibilities may result in additional costs and risks, and may adversely impact our reputation, employee retention, and willingness of customers and suppliers to do business with us.Investor advocacy groups, proxy advisory services, investment funds, institutional investors, stockholders, and customers are increasingly focused on environmental, social, and governance (â€œESGâ€) practices of companies. Additionally, public interest and legislative pressure related to public companiesâ€™ ESG practices continues to grow. For example, the SEC recently adopted final rules regarding climate-related disclosures in public companiesâ€™ periodic reporting. If our ESG practices fail to meet regulatory requirements or investor or other industry stakeholders' evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, support for local communities, board and employee diversity, human capital management, employee health and safety practices, product quality, supply chain management, corporate governance and transparency, and employing ESG strategies in our operations, our brand, reputation and employee retention may be negatively impacted and customers and suppliers may be unwilling to do business with us. In addition, ESG reporting and disclosure may result in additional costs and require additional resources as well as additional attention from our board of directors and management. If we fail to adopt ESG standards or practices as quickly as stakeholders desire, report on our ESG efforts or practices accurately, or satisfy the expectations of stakeholders, or comply with applicable regulatory requirements, our reputation, business, financial performance, and growth may be adversely impacted.73ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSNone.ITEM 3. DEFAULTS UPON SENIOR SECURITIESNone.ITEM 4. MINE SAFETY DISCLOSURESNone.ITEM 5. OTHER INFORMATIONSecurities Trading Plans of Directors and Executive OfficersDuring our last fiscal quarter, none of our directors or officers, as defined in Rule 16a-1(f), adopted and/or terminated a â€œRule 10b5-1 trading arrangementâ€ or a â€œnon-Rule 10b5-1 trading arrangement,â€ as defined in Regulation S-K Item 408. 74ITEM 6. EXHIBITSExhibitNumberDescription3.1Certificate of Incorporation of Nautilus Biotechnology, Inc. (incorporated by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on June 10, 2021)3.2Amended and Restated Bylaws of Nautilus Biotechnology, Inc. (incorporated by reference to Exhibit 3.2 to the Companyâ€™s Quarterly Report on Form 10-Q filed with the SEC on August 2, 2023)31.1*Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 200231.2*Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 200232.1*â€ Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 200232.2*â€ Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002101.INSInline XBRL Instance Document â€“ the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document101.SCHInline XBRL Taxonomy Extension Schema Document101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document101.LABInline XBRL Taxonomy Extension Label Linkbase Document101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document104Cover page Interactive Data File (embedded with the Inline XBRL document)_____* Filed herewith.â€ The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Nautilus Biotechnology, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.75SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.NAUTILUS BIOTECHNOLOGY, INC.Date: JulyÂ 30, 2024By:/s/ Sujal Patel Sujal PatelChief Executive Officer (Principal Executive Officer)Date: JulyÂ 30, 2024By:/s/ Anna MowryAnna MowryChief Financial Officer (Principal Financial and Accounting Officer)76 EX-31.1 2 exhibit311-q224.htm EX-31.1 DocumentExhibit 31.1CERTIFICATION PURSUANT TORULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Sujal Patel, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Nautilus Biotechnology, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date: JulyÂ 30, 2024By:/s/ Sujal Patel Sujal PatelPresident and Chief Executive Officer(Principal Executive Officer) EX-31.2 3 exhibit312-q224.htm EX-31.2 DocumentExhibit 31.2CERTIFICATION PURSUANT TORULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Anna Mowry, certify that:1.I have reviewed this Quarterly Report on Form 10-Q of Nautilus Biotechnology, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in

this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; andb.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.Date: JulyÂ 30, 2024By:/s/ Anna MowryAnna MowryChief Financial Officer(Principal Financial and Accounting Officer) EX-32.1 4 exhibit321-q224.htm EX-32.1 DocumentExhibit 32.1CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Quarterly Report of Nautilus Biotechnology, Inc. (the â€œCompanyâ€) on Form 10-Q for the period ended JuneÂ 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Sujal Patel, hereby certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that:1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date: JulyÂ 30, 2024By:/s/ Sujal Patel Sujal PatelPresident and Chief Executive Officer(Principal Executive Officer) EX-32.2 5 exhibit322-q224.htm EX-32.2 DocumentExhibit 32.2CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the Quarterly Report of Nautilus Biotechnology, Inc. (the â€œCompanyâ€) on Form 10-Q for the period ended JuneÂ 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Anna Mowry, hereby certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that:1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.Date: JulyÂ 30, 2024By:/s/ Anna MowryAnna MowryChief Financial Officer(Principal Financial and Accounting Officer) EX-101.SCH 6 naut-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Stockholdersâ€™ Equity link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - Description of Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Equity Incentive Plans and Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Basic and Diluted Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Equity Incentive Plans and Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Commitment and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Basic and Diluted Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Description of Business and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Fair Value Measurements - Assets Carried at Fair Value and Measured on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Fair Value Measurements - Unrealized Losses and Fair Values of Available-for-Sale Securities in an Unrealized Loss Position (Details) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items - Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items - Accrued Expenses and Other Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items - Cash, Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items - Other Long-term Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Common Stock - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Common Stock - Common Stock Reserved for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Equity Incentive Plans and Stock-based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Equity Incentive Plans and Stock-based Compensation - Significant Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Equity Incentive Plans and Stock-based Compensation - Option Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Equity Incentive Plans and Stock-based Compensation - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Commitment and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Commitment and Contingencies - Future Principal Contractual Obligations for Operating Lease Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Commitment and Contingencies - Future Principal Contractual Obligations for Operating Lease Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Basic and Diluted Net Loss per Share - Basic and Diluted Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Basic and Diluted Net Loss per Share - Potential Shares of Common Stock Excluded from the Computation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 naut-20240630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 naut-20240630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 naut-20240630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Purchase shares of common stock contribution percent Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Adjustments to reconcile net loss to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Cover [Abstract] Cover [Abstract] Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Summary of Future Principal Contractual Obligations for Operating Lease Commitments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Mutual funds Mutual Fund [Member] Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Short-term investments Short-Term Investments [Member] Proceeds from sale of stock and reverse recapitalization transaction Proceeds From Sale Of Stock And Reverse Recapitalization Transaction Proceeds From Sale Of Stock And Reverse Recapitalization Transaction Operating lease liabilities Increase (Decrease) in Operating Lease Liability 2021 Equity Incentive Plan 2021 Equity Incentive Plan [Member] 2021 Equity Incentive Plan Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Fair Value Measurements Fair Value Disclosures [Text Block] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount Commitments and Contingencies Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Shares available for grant under equity plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Segment Reporting Segment Reporting, Policy [Policy Text Block] Plan Name [Domain] Plan Name [Domain] Price per share (in dollars per share) Sale of Stock, Price Per Share Other long-term assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Consideration received on transaction Sale of Stock, Consideration Received on Transaction Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] U.S. treasury securities US Treasury Securities [Member] Plan Name [Axis] Plan Name [Axis] Equity Components [Axis] Equity Components [Axis] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Vested and exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Fair Value Debt Securities, Available-for-Sale Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Use of Estimates Use of Estimates, Policy [Policy Text Block] Adjustment to Compensation, Amount Adjustment to Compensation Amount Options outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Unrealized gain (loss) on securities available-for-sale Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected

Measure Amount Tabular List, Table Tabular List [Table Text Block] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Schedule of Option Award Activity Schedule of Stock Options Roll Forward [Table Text Block] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Issuance of common stock under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Total potentially dilutive common share equivalents Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Employee stock purchase plan Employee Stock Purchase Plan [Member] Employee Stock Purchase Plan Total Debt Securities, Available-for-Sale, Unrealized Loss Position Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Amortization (accretion) of premium (discount) on securities, net Accretion (Amortization) of Discounts and Premiums, Investments Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Current assets: Assets, Current [Abstract] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Accrued research and development Accrued Research and Development Accrued Research and Development Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Options Options to purchase common stock Share-Based Payment Arrangement, Option [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Depreciation Depreciation 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Payments of transaction costs Payments of Reverse Recapitalization Transaction Costs Payments of Reverse Recapitalization Transaction Costs Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Award Type [Axis] Award Type [Axis] Corporate debt securities Corporate Debt Securities [Member] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Property and equipment, net Total Property, Plant and Equipment, Net Total liabilities Liabilities Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Gross Unrealized Losses Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Unrealized Losses and Fair Values of Available-for-Sale Securities in an Unrealized Loss Position Debt Securities, Available-for-Sale [Table Text Block] Research and development Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Current portion of operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Computer hardware Computer Equipment [Member] Total Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, gross Property, Plant and Equipment, Gross Issuance of common stock upon exercise of vested stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development Research and Development Expense [Member] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) Weighted average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Purchase commitment, next 12 months Purchase Obligation, to be Paid, Year One Total stockholdersâ€™ equity Beginning balance Ending balance Equity, Attributable to Parent Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Letters of credit Letters of Credit Outstanding, Amount Total other comprehensive income (loss) Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Fair Value, Recurring Fair Value, Recurring [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Securities in Unrealized Loss Position Greater than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Sale of Stock [Domain] Sale of Stock [Domain] Acquisitions of property and equipment included in accounts payable Noncash or Part Noncash Acquisition, Fixed Assets Acquired Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Options outstanding, weighted average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Assets Assets [Abstract] Expected dividend rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Commercial paper Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Other income (expense) Other Income and Expenses [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Maximum Maximum [Member] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Leasehold improvements Leasehold Improvements [Member] Schedule of Significant Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Open purchase commitment Long-Term Purchase Commitment, Amount Schedule of Potential Shares of Common Stock Excluded from the Computation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] 2021 Employee Stock Purchase Plan 2021 Employee Stock Purchase Plan [Member] 2021 Employee Stock Purchase Plan Award Timing Predetermined Award Timing Predetermined [Flag] Class of Stock [Line Items] Class of Stock [Line Items] Restricted cash Restricted Cash, Noncurrent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Net loss per share attributable to common stockholders, diluted (in dollars per share) Earnings Per Share, Diluted Amortization of operating lease right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Vested and exercisable, weighted average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Cash, cash equivalents, and short-term investments Cash, Cash Equivalents, and Short-Term Investments Number of operating segments Number of Operating Segments Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Income tax expense Income Tax Expense (Benefit) Short-term investments Debt Securities, Available-for-Sale, Current Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment Net loss attributable to common stockholders, diluted Net Income (Loss) Available to Common Stockholders, Diluted Unrecognized compensation expense, period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total other income Nonoperating Income (Expense) Statement of Comprehensive Income [Abstract] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Number of reportable segments Number of Reportable Segments Total liabilities and stockholders' equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Employee compensation Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Additional paid-in capital Additional Paid in Capital Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest income Interest Income (Expense), Nonoperating Right-of-use asset obtained in exchange for operating lease liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expected term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Agency securities US Government Agencies Debt Securities [Member] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses Operating Expenses [Abstract] Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Credit losses during period Debt Securities, Available-for-Sale, Allowance for Credit Loss, Period Increase (Decrease) Increase in shares available for grant under equity plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Increase in Number of Shares Available for Grant Share-based Compensation Arrangement by Share-based Payment Award, Increase in Number of Shares Available for Grant Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Options vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Long-term investments Debt Securities, Available-for-Sale, Noncurrent Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Offering purchase period Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Purchase Period Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Purchase Period Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Outstanding beginning balance (in dollars per share) Outstanding ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Stock options issued and outstanding (in shares) Outstanding beginning balance (in shares) Outstanding ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Exercise Price Award Exercise Price Basic and Diluted Net Loss per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Issuance of common stock under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock upon exercise of vested stock options Stock Issued During Period, Value, Stock Options Exercised 2029 and thereafter Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Lessee, Operating Lease, Liability, to be Paid, Due after Year Four Stockholders' equity: Equity, Attributable to Parent [Abstract] Securities in Unrealized Loss

Position Less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] Furniture, fixtures and office equipment Furniture, Fixtures And Office Equipment [Member] Furniture, Fixtures And Office Equipment PEO PEO [Member] Income Taxes [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Vested and exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Long-term investments Long Term Investments [Member] Long Term Investments Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total shares of common stock reserved (in shares) Common Stock, Capital Shares Reserved for Future Issuance Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Risk free interest rate, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss PEO Total Compensation Amount PEO Total Compensation Amount Purchase price of common stock, percent Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Entity Ex Transition Period Entity Ex Transition Period Options vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Proceeds from maturities of securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common Stock Common Stock [Member] Measure: Measure [Axis] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Entity Emerging Growth Company Entity Emerging Growth Company Other Other Sundry Liabilities, Current Entity Central Index Key Entity Central Index Key General and administrative General and Administrative Expense [Member] Prototype equipment Prototype Equipment [Member] Prototype Equipment Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Expected volatility, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Common Stock Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Financial Instrument [Axis] Financial Instrument [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] Measurement Frequency [Domain] Measurement Frequency [Domain] Significant Accounting Policies Significant Accounting Policies [Text Block] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Income Taxes Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Earnings Per Share [Abstract] Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Supplementary cash flow information on non-cash activities: Supplemental Cash Flow Elements [Abstract] General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Total operating lease liabilities Operating Lease, Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Fair Value as of Grant Date Award Grant Date Fair Value Level 2 Fair Value, Inputs, Level 2 [Member] Shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Common stock, $0.0001 par value, 1,000,000,000 shares authorized as of JuneÂ 30, 2024 and DecemberÂ 31, 2023; 125,406,748 and 125,068,601 shares issued and outstanding as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively Common Stock, Value, Issued Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accrued expenses and other liabilities Total Accrued Liabilities and Other Liabilities, Current Accrued Liabilities and Other Liabilities, Current Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Preferred stock, $0.0001 par value, 200,000,000 authorized as of JuneÂ 30, 2024 and DecemberÂ 31, 2023; 0 shares issued and outstanding as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 Preferred Stock, Value, Issued Number of Stock Option Awards Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Employee Stock Employee Stock [Member] Net loss per share attributable to common stockholders, basic (in dollars per share) Net loss per share attributable to common stockholders, basic (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Proceeds from issuance of common stock under employee stock purchase plan Proceeds from Stock Plans Cash paid for lease liabilities included in operating activities Operating Lease, Payments Deposits Deposits Assets, Noncurrent Cash equivalents Cash and Cash Equivalents [Member] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Award expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Net loss attributable to common stockholders, basic Net Income (Loss) Available to Common Stockholders, Basic Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Total assets Assets Concentrations of Credit Risk and Other Risks and Uncertainties Concentration Risk, Credit Risk, Policy [Policy Text Block] Schedule of Assets Carried at Fair Value and Measured on a Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Percentage of outstanding stock maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 8) Commitments and Contingencies Risk free interest rate, minimum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Termination Date Trading Arrangement Termination Date Expected volatility, maximum Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Description of Business and Basis of Presentation Business Description and Basis of Presentation [Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Equity Incentive Plans and Stock-based Compensation Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Leases Lessee, Leases [Policy Text Block] Total stock-based compensation expense Share-Based Payment Arrangement, Expense Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Document Fiscal Year Focus Document Fiscal Year Focus Other expense Other Nonoperating Expense Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Name Forgone Recovery, Individual Name Six months ending DecemberÂ 31, 2024 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Vested and exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Investments Investment, Policy [Policy Text Block] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Schedule of Common Stock Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Schedule Of Common Stock Reserved For Future Issuance Insider Trading Arrangements [Line Items] Fair Market Value Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value [Abstract] Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value Composition of Certain Condensed Consolidated Financial Statement Line Items Supplemental Balance Sheet Disclosures [Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated Deficit Retained Earnings [Member] Restricted cash included in other long-term assets Restricted Cash and Cash Equivalents Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares) Weighted average shares used in computing net loss per share attributable to common stockholders, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Securities in Unrealized Loss Position Greater than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Accrued professional and consulting fees Accrued Professional Fees, Current Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Construction in progress Construction in Progress [Member] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Securities in Unrealized Loss Position Less than 12 months Debt

Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Entity Filer Category Entity Filer Category Schedule of Other Liabilities Other Current Liabilities [Table Text Block] Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Purchases of securities Payments to Acquire Debt Securities, Available-for-Sale Company Selected Measure Name Company Selected Measure Name Private Placement Private Placement [Member] EX-101.PRE 10 naut-20240630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.2 Cover - shares 6 Months Ended Jun. 30, 2024 Jul. 25, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Jun. 30, 2024 Â Document Transition Report false Â Entity File Number 001-39434 Â Entity Registrant Name NAUTILUS BIOTECHNOLOGY, INC. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 98-1541723 Â Entity Address, Address Line One 2701 Eastlake Avenue East Â Entity Address, City or Town Seattle Â Entity Address, State or Province WA Â Entity Address, Postal Zip Code 98102 Â City Area Code 206 Â Local Phone Number 333-2001 Â Title of 12(b) Security Common Stock, par value $0.0001 per share Â Trading Symbol NAUT Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company true Â Entity Ex Transition Period false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 125,411,248 Entity Central Index Key 0001808805 Â Amendment Flag false Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q2 Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 7A -Section B -Subsection 2 + Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.2 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 24,885 $ 19,397 Short-term investments 142,558 154,021 Prepaid expenses and other current assets 3,490 3,419 Total current assets 170,933 176,837 Property and equipment, net 4,694 4,267 Operating lease right-of-use assets 30,474 32,634 Long-term investments 65,466 90,647 Other long-term assets 1,180 1,180 Total assets 272,747 305,565 Current liabilities: Â Â Accounts payable 1,627 1,639 Accrued expenses and other liabilities 3,239 3,945 Current portion of operating lease liabilities 3,815 3,538 Total current liabilities 8,681 9,122 Operating lease liabilities, net of current portion 28,787 31,090 Total liabilities 37,468 40,212 Commitments and contingencies (Note 8) Stockholders' equity: Â Â Preferred stock, $0.0001 par value, 200,000,000 authorized as of JuneÂ 30, 2024 and DecemberÂ 31, 2023; 0 shares issued and outstanding as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 0 0 Common stock, $0.0001 par value, 1,000,000,000 shares authorized as of JuneÂ 30, 2024 and DecemberÂ 31, 2023; 125,406,748 and 125,068,601 shares issued and outstanding as of JuneÂ 30, 2024 and DecemberÂ 31, 2023, respectively 13 13 Additional paid-in capital 474,791 467,834 Accumulated other comprehensive income (loss) (546) (255) Accumulated deficit (238,979) (202,239) Total stockholdersâ€™ equity 235,279 265,353 Total liabilities and stockholders' equity $ 272,747 $ 305,565 X - DefinitionAccrued Liabilities and Other Liabilities, Current + ReferencesNo definition available. + Details Name: naut_AccruedLiabilitiesAndOtherLiabilitiesCurrent Namespace Prefix: naut_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and

other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -

Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-

210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.2 Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares Jun. 30, 2024 Dec. 31, 2023 Statement of Financial Position [Abstract] Â Â Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Preferred stock, shares authorized (in shares) 200,000,000 200,000,000 Preferred stock, shares issued (in shares) 0 0 Preferred stock, shares outstanding (in shares) 0 0 Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Common stock, shares authorized (in shares) 1,000,000,000 1,000,000,000 Common stock, shares issued (in shares) 125,406,748 125,068,601 Common stock, shares outstanding (in shares) 125,406,748 125,068,601 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2 Condensed Consolidated Statements of Operations - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Operating expenses Â Â Â Â Research and development $ 12,436 $ 11,912 $ 25,366 $ 22,789 General and administrative 8,353 7,104 17,030 14,287 Total operating expenses 20,789 19,016 42,396 37,076 Other income (expense) Â Â Â Â Interest income 2,798 3,222 5,675 6,320 Other expense (19) (14) (19) (17) Total other income 2,779 3,208 5,656 6,303 Net loss $ (18,010) $ (15,808) $ (36,740) $ (30,773) Net loss per share attributable to common stockholders, basic (in dollars per share) $ (0.14) $ (0.13) $ (0.29) $ (0.25) Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.14) $ (0.13) $ (0.29) $ (0.25) Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares) 125,317,650 124,603,181 125,226,552 124,601,762 Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) 125,317,650 124,603,181 125,226,552 124,601,762 X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16:

http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_GeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest income (expense) classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-

1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherIncomeAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.2 Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net loss $ (18,010) $ (15,808) $ (36,740) $ (30,773) Other comprehensive income (loss): Â Â Â Â Unrealized gain (loss) on securities available-for-sale 199 (1,430) (291) (535) Total other comprehensive income (loss) 199 (1,430) (291) (535) Comprehensive loss $ (17,811) $ (17,238) $ (37,031) $ (31,308) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.2 Condensed Consolidated Statements of Stockholdersâ€™ Equity - USD ($) $ in Thousands Total Common Stock Additional Paid-in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Beginning balance (in shares) at Dec. 31, 2022 Â 124,865,485 Â Â Â Beginning balance at Dec. 31, 2022 $ 314,924 $ 12 $ 455,330 $ (1,854) $ (138,564) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Issuance of common stock upon exercise of vested stock options (in shares) Â 5,907 Â Â Â Issuance of common stock upon exercise of vested stock options 7 Â 7 Â Â Issuance of common stock under employee stock purchase plan (in shares) Â 59,507 Â Â Â Issuance of common stock under employee stock purchase plan 92 Â 92 Â Â Stock-based compensation expense 5,958 Â 5,958 Â Â Other comprehensive income (loss) (535) Â Â (535) Â Net loss (30,773) Â Â Â (30,773) Ending balance (in shares) at Jun. 30, 2023 Â 124,930,899 Â Â Â Ending balance at Jun. 30, 2023 289,673 $ 12 461,387 (2,389) (169,337) Beginning balance (in shares) at Mar. 31, 2023 Â 124,866,392 Â Â Â Beginning balance at Mar. 31, 2023 303,715 $ 12 458,191 (959) (153,529) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Issuance of common stock upon exercise of vested stock options (in shares) Â 5,000 Â Â Â Issuance of common stock upon exercise of vested stock options 6 Â 6 Â Â Issuance of common stock under employee stock purchase plan (in shares) Â 59,507 Â Â Â Issuance of common stock under employee stock purchase plan 92 Â 92 Â Â Stock-based compensation expense 3,098 Â 3,098 Â Â Other comprehensive income (loss) (1,430) Â Â (1,430) Â Net loss (15,808) Â Â Â (15,808) Ending balance (in shares) at Jun. 30, 2023 Â 124,930,899 Â Â Â Ending balance at Jun. 30, 2023 $ 289,673 $ 12 461,387 (2,389) (169,337) Beginning balance (in shares) at Dec. 31, 2023 125,068,601 125,068,601 Â Â Â Beginning balance at Dec. 31, 2023 $ 265,353 $ 13 467,834 (255) (202,239) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Issuance of common stock upon exercise of vested stock options (in shares) 214,252 214,252 Â Â Â Issuance of common stock upon exercise of vested stock options $ 275 Â 275 Â Â Issuance of common stock under employee stock purchase plan (in shares) Â 123,895 Â Â Â Issuance of common stock under employee stock purchase plan 289 Â 289 Â Â Stock-based compensation expense 6,393 Â 6,393 Â Â Other comprehensive income (loss) (291) Â Â (291) Â Net loss $ (36,740) Â Â Â (36,740) Ending balance (in shares) at Jun. 30, 2024 125,406,748 125,406,748 Â Â Â Ending balance at Jun. 30, 2024 $ 235,279 $ 13 474,791 (546) (238,979) Beginning balance (in shares) at Mar. 31, 2024 Â 125,265,015 Â Â Â Beginning balance at Mar. 31, 2024 249,492 $ 13 471,193 (745) (220,969) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Issuance of common stock upon exercise of vested stock options (in shares) Â 17,838 Â Â Â Issuance of common stock upon exercise of vested stock options 30 Â 30 Â Â Issuance of common stock under employee stock purchase plan (in shares) Â 123,895 Â Â Â Issuance of common stock under employee stock purchase plan 289 Â 289 Â Â Stock-based compensation expense 3,279 Â 3,279 Â Â Other comprehensive income (loss) 199 Â Â 199 Â Net loss $ (18,010) Â Â Â (18,010) Ending balance (in shares) at Jun. 30, 2024 125,406,748 125,406,748 Â Â Â Ending balance at Jun. 30, 2024 $ 235,279 $ 13 $ 474,791 $ (546) $ (238,979) X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher

FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -

Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.2 Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Cash flows from operating activities Â Â Net loss $ (36,740) $ (30,773) Adjustments to reconcile net loss to net cash used in operating activities Â Â Stock-based compensation expense 6,393 5,958 Amortization of operating lease right-of-use assets 2,160 1,806 Depreciation 1,028 826 Amortization (accretion) of premium (discount) on securities, net (1,453) (1,412) Changes in operating assets and liabilities: Â Â Prepaid expenses and other assets (71) (787) Accounts payable (308) (199) Accrued expenses and other liabilities (706) (117) Operating lease liabilities (2,026) (1,375) Net cash used in operating activities (31,723) (26,073) Cash flows from investing activities Â Â Proceeds from maturities of securities 53,500 32,249 Purchases of securities (15,694) (46,844) Purchases of property and equipment (1,159) (1,155) Net cash provided by (used in) investing activities 36,647 (15,750) Cash flows from financing activities Â Â Proceeds from exercise of stock options 275 7 Proceeds from issuance of common stock under employee stock purchase plan 289 92 Net cash provided by financing activities 564 99 Net increase (decrease) in cash, cash equivalents and restricted cash 5,488 (41,724) Cash, cash equivalents and restricted cash at beginning of period 20,399 115,477 Cash, cash equivalents and restricted cash at end of period 25,887 73,753 Supplementary cash flow information on non-cash activities: Â Â Acquisitions of property and equipment included in accounts payable 444 323 Right-of-use asset obtained in exchange for operating lease liability $ 0 $ 7,623 X - DefinitionThe sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in accrued expenses, and obligations classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the stock plan during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromStockPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.2 Description of Business and Basis of Presentation 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Description of Business and Basis of Presentation Description of Business and Basis of PresentationNautilus Biotechnology, Inc. (the â€œCompanyâ€) is a biotechnology company incorporated in 2016 with corporate headquarters in Seattle, Washington and research and development headquarters in San Carlos, California. Since the Companyâ€™s incorporation in 2016, the Company has devoted substantially all of its resources to research and development activities, including with respect to its proteomics platform, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital and providing general and administrative support for these operations. On June 9, 2021, Nautilus Biotechnology, Inc. a Delaware corporation (f/k/a ARYA Sciences Acquisition Corp. III, a Cayman Islands exempted company and the Companyâ€™s predecessor company (â€œARYAâ€)), consummated the business combination (the â€œBusiness Combinationâ€) pursuant to the terms of that certain Business Combination Agreement, dated as of February 7, 2021 (the â€œBCAâ€), by and among ARYA, Mako Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ARYA (â€œMako Merger Subâ€), and Nautilus Subsidiary, Inc., a Delaware corporation (f/k/a Nautilus Biotechnology, Inc.) (â€œLegacy Nautilusâ€). As a result of the Business

Combination, ARYA changed its name to â€œNautilus Biotechnology, Inc.â€ and Mako Merger Sub merged with and into Legacy Nautilus with Legacy Nautilus surviving as the surviving company and becoming a wholly-owned subsidiary of ARYA (the â€œMergerâ€ and, collectively with the other transactions described in the BCA, the â€œReverse Recapitalizationâ€). In addition, in conjunction with the completion of the Business Combination, certain investors (â€œPIPE Investorsâ€) subscribed for the purchase of an aggregate of 20,000,000 shares of common stock of the Company (â€œNew Nautilus Common Stockâ€) at a price of $10.00 per share for aggregate gross proceeds of $200.0Â million (â€œPIPE Financingâ€).Basis of PresentationThe condensed consolidated financial statements and accompanying notes are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) and regulations of the U.S. Securities and Exchange Commission (the â€œSECâ€) for interim financial reporting. All intercompany transactions and balances have been eliminated upon consolidation. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements were prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Companyâ€™s financial position, results of operations, and cash flows for the interim periods. The interim financial results are not necessarily indicative of the results for a full year. These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023 on file with the SEC. The Companyâ€™s reporting currency is the U.S. dollar. Going ConcernThe Companyâ€™s condensed consolidated financial statements have been prepared on the basis of continuity of operations, the realization of assets, and the satisfaction of liabilities in the ordinary course of business. Since inception, the Company has been engaged in developing its technology, raising capital, and recruiting personnel. The Companyâ€™s operating plan may change as a result of many factors currently unknown and there can be no assurance that the current operating plan will be achieved in the time frame anticipated by the Company, and it may need to seek additional funds sooner than planned. If adequate funds are not available to the Company on a timely basis, it may be required to delay, limit, reduce, or terminate certain commercial efforts, or pursue merger or acquisition strategies, all of which could adversely affect the holdings or the rights of the Companyâ€™s stockholders. The Company has incurred net operating losses and negative cash flows from operations in every year since inception and expects this to continue for the foreseeable future. As of JuneÂ 30, 2024, the Company had an accumulated deficit of $239.0Â million.The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock and common stock. In June 2021, the Company received gross proceeds of approximately $345.5 million from PIPE Investors and the Business Combination offset by approximately $18.2 million of transaction costs and underwritersâ€™ fees relating to the closing of the Business Combination. The Company had cash, cash equivalents, and short-term investments of $167.4 million as of JuneÂ 30, 2024. As of the date on which these condensed consolidated financial statements were issued, the Company believes that its cash, cash equivalents, and short-term investments will be sufficient to fund its operations for at least the next twelve months following the issuance of the condensed consolidated financial statements. The Companyâ€™s actual results could vary as a result of, and its near and long-term future capital requirements will depend on many factors, including its growth rate and the timing and extent of spending to support its research and development efforts. The Company has based its estimates on assumptions that may prove to be wrong, and it could use its available capital resources sooner than it currently expects. The Company may be required to seek additional equity or debt financing. Future liquidity and cash requirements will depend on numerous factors. In the event that additional financing is required, the Company may not be able to raise it on acceptable terms or at all. If the Company is unable to raise additional capital when desired, or if it cannot expand its operations or otherwise capitalize on its business opportunities because it lacks sufficient capital, its business, operating results, and financial condition would be adversely affected. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.2 Significant Accounting Policies 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Significant Accounting Policies Significant Accounting PoliciesUse of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determining the estimated lives of property and equipment, stock-based compensation, research and development accruals, loss contingency accruals, and the valuation allowance for deferred tax assets. These estimates and assumptions are based on managementâ€™s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods. As future events and their effects cannot be determined with precision, actual results could materially differ from those estimates and assumptions. Concentrations of Credit Risk and Other Risks and UncertaintiesCredit risk represents the accounting loss that would be recognized as of the reporting date if counterparties failed to perform as contracted. Financial instruments, which potentially subject the Company to concentration of credit risk, consist of cash balances maintained in excess of federal depository insurance limits and investments in marketable debt securities that are not federally insured. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk on cash or investments. The Company relies, and expects to continue to rely, on a number of vendors to provide services, supplies and materials related to its research and development programs. The Company relies on single source suppliers for certain components and materials used in the Nautilus platform. The loss of any of these single source suppliers would require the Company to expend significant time and effort to locate and qualify an alternative source of supply for these components. The Company also relies, and expects to continue to rely, on third-party manufacturers and, in many cases, single third-party manufacturers for the production of certain reagents and antibodies. These programs could be adversely affected by a significant interruption in these services or the availability of materials.The Company is subject to risks similar to those ofÂ pre-clinicalÂ stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, the impact of negative global and national events and the need to obtain adequate additional financing to fund the development of its products. There can be no assurance that the Companyâ€™s research and development will be successfully completed, that adequate protection for the Companyâ€™s intellectual property will be maintained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Companyâ€™s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products.Segment ReportingOperating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker (â€œCODMâ€) in deciding how to allocate resources and in assessing performance. The Companyâ€™s Chief Executive Officer is its CODM. The Companyâ€™s CODM reviews financial information presented on a consolidated basis for the purposes of making operating decisions, allocating resources and evaluating financial performance. As such, the Company has determined that it operates in one operating and one reportable segment. The Companyâ€™s long-lived assets are entirely based in the United States. Cash and Cash Equivalents The Company considers all highly-liquid investments with an original maturity of three months or less as of the date of acquisition to be cash equivalents. InvestmentsThe Company considers investments with an original maturity greater than three months and remaining maturities less than one year to be short-term investments. The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as long-term investments. The Company classifies its marketable debt securities as available for sale and reports them at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For investments sold prior to maturity, the cost of investments sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in other income (expense), net in the condensed consolidated statement of operations. If the estimated fair value of a marketable debt security is below its amortized cost basis, the Company evaluates whether it is more likely than not that the Company will be required to sell the security before its anticipated recovery in market value and whether credit losses exist for the related securities. Credit-related losses are recognized as an allowance for credit losses on the balance sheet with a corresponding adjustment to earnings. Unrealized gains and losses that are unrelated to credit deterioration are reported in accumulated other comprehensive income (loss).Fair Value of Financial InstrumentsFair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; andLevel 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.The carrying amounts of cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other liabilities approximate their respective fair values due to their short-term nature.LeasesThe Company determines if an arrangement includes a lease at inception by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. Operating leases with a term of more than one year are included in operating lease right-of-use (â€œROUâ€) assets and operating lease liabilities on the Company's condensed consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments. Operating lease ROU assets and liabilities are recognized on the lease commencement date based on the present value of the future minimum lease payments over the lease term. The Company uses the incremental borrowing rate commensurate with the lease term based on the information available at the lease commencement date in determining the present value of the lease payments as the Company's leases generally do not provide an implicit rate. ROU assets initially equal the lease liability, adjusted for any prepaid lease payments and initial direct costs incurred, less any lease incentives received. Certain of the Company's leases include renewal options which allow the Company to, at its election, renew or extend the lease for a fixed or indefinite period of time. These renewal periods are included in the lease terms when the Company is reasonably certain the options will be exercised. Lease expense is recognized on a straight-line basis over the lease term when leases are operating leases. If it is considered a finance lease, expense is recognized over the lease term within interest expense and amortization in the Companyâ€™s condensed consolidated statements of operations. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's facility leases and to account for the lease and non-lease components as a single lease component. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets

and lease liabilities are not recognized for leases with terms of 12 months or less.Comprehensive Loss Comprehensive loss consists of net loss and other gains or losses affecting stockholdersâ€™ equity that, under U.S. GAAP are excluded from net loss. For the three and six months ended June 30, 2024 and 2023, net unrealized gains and losses on marketable debt securities were included as a component of comprehensive income (loss). Accounting PronouncementsThe Company is provided the option to adopt new or revised accounting guidance as an â€œemerging growth companyâ€ under the Jumpstart Our Business Startups Act of 2012 (the â€œJOBS Actâ€) either (1) within the same periods as those otherwise applicable to public business entities, or (2) within the same time periods as non-public business entities, including early adoption when permissible. With the exception of standards the Company elected to early adopt, when permissible, the Company has elected to adopt new or revised accounting guidance within the same time period as non-public business entities, as indicated below. Recently Issued Accounting PronouncementsIn November 2023, the FASB issued ASU 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,â€ which amends existing guidance on segment reporting to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The ASU is effective for the Company for the fiscal year ending December 31, 2024 and for interim periods beginning after December 31, 2024. The Company is in the process of evaluating the impact of the adoption of this Accounting Standards Update on its consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosures,â€ to enhance the transparency and decision usefulness of income tax disclosures. The ASU is effective for the Company for the fiscal year ending December 31, 2025. The Company is in the process of evaluating the impact of the adoption of this Accounting Standards Update on its consolidated financial statements and related disclosures. The Company does not anticipate adoption to have a material impact on its consolidated financial statements and related disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.2 Fair Value Measurements 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements Fair Value MeasurementsThe following table details the assets carried at fair value and measured on a recurring basis within the three levels of fair value as of JuneÂ 30, 2024 and DecemberÂ 31, 2023:(in thousands)Gross UnrealizedReported as:June 30, 2024Amortized CostGainsLossesFair ValueCash equivalentsShort-term investmentsLong-term investmentsLevel 1Mutual funds$1,260Â $â€”Â $â€”Â $1,260Â $1,260Â $â€”Â $â€”Â U.S. treasury securities57,124Â 17Â (129)57,012Â 2,996Â 35,458Â 18,558Â Total Level 158,384Â 17Â (129)58,272Â 4,256Â 35,458Â 18,558Â Level 2Commercial paper20,457Â â€”Â (11)20,446Â 20,446Â â€”Â â€”Â Corporate debt securities4,984Â â€”Â (24)4,960Â â€”Â 4,960Â â€”Â Agency securities149,447Â 18Â (417)149,048Â â€”Â 102,140Â 46,908Â Total Level 2174,888Â 18Â (452)174,454Â 20,446Â 107,100Â 46,908Â Total Level 1 and Level 2$233,272Â $35Â (581)232,726Â $24,702Â $142,558Â $65,466Â (in thousands)Gross UnrealizedReported as:December 31, 2023Amortized CostGainsLossesFair ValueCash equivalentsShort-term investmentsLong-term investmentsLevel 1Mutual funds$590Â $â€”Â $â€”Â $590Â $590Â $â€”Â $â€”Â U.S. treasury securities74,115Â 104Â (247)73,972Â â€”Â 50,638Â 23,334Â Total Level 174,705Â 104Â (247)74,562Â 590Â 50,638Â 23,334Â Level 2Commercial paper18,653Â â€”Â (9)18,644Â 18,644Â â€”Â â€”Â Corporate debt securities6,950Â â€”Â (37)6,913Â â€”Â 6,913Â â€”Â Agency securities163,849Â 358Â (424)163,783Â â€”Â 96,470Â 67,313Â Total Level 2189,452Â 358Â (470)189,340Â 18,644Â 103,383Â 67,313Â Total Level 1 and Level 2$264,157Â $462Â (717)263,902Â $19,234Â $154,021Â $90,647Â Short-term investments have a contractual maturity date that is one year or less from the respective balance sheet date. Long-term investments have a contractual maturity date that is more than one year, but less than two years from the respective balance sheet date. The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are as follows:(in thousands)Securities in Unrealized Loss Position Less than 12 monthsSecurities in Unrealized Loss Position Greater than 12 monthsTotalJune 30, 2024Gross Unrealized LossesFair Market ValueGross Unrealized LossesFair Market ValueGross Unrealized LossesFair Market ValueU.S. treasury securities$67Â $26,444Â $62Â $22,754Â $129Â $49,198Â Commercial paper11Â 20,447Â â€”Â â€”Â 11Â 20,447Â Corporate debt securitiesâ€”Â â€”Â 24Â 4,959Â 24Â 4,959Â Agency securities163Â 53,020Â 254Â 85,593Â 417Â 138,613Â Total$241Â $99,911Â $340Â $113,306Â $581Â $213,217Â (in thousands)Securities in Unrealized Loss Position Less than 12 monthsSecurities in Unrealized Loss Position Greater than 12 monthsTotalDecember 31, 2023Gross Unrealized LossesFair Market ValueGross Unrealized LossesFair Market ValueGross Unrealized LossesFair Market ValueU.S. treasury securities$85Â $20,408Â $162Â $30,230Â $247Â $50,638Â Commercial paper9Â 18,644Â â€”Â â€”Â 9Â 18,644Â Corporate debt securities37Â 6,913Â â€”Â â€”Â 37Â 6,913Â Agency securities229Â 85,039Â 195Â 25,704Â 424Â 110,743Â Total$360Â $131,004Â $357Â $55,934Â $717Â $186,938Â The Company reviewed its investment portfolio based on the underlying risk profile of the securities and have a no loss expectation for these investments. The Company reviewed the securities in an unrealized loss position and evaluated the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The Company recognized no credit losses during the three and six months ended June 30, 2024 and 2023, and had no allowance for credit losses as of JuneÂ 30, 2024 and DecemberÂ 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.2 Composition of Certain Condensed Consolidated Financial Statement Line Items 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Composition of Certain Condensed Consolidated Financial Statement Line Items Composition of Certain Condensed Consolidated Financial Statement Line ItemsProperty and Equipment, Net Property and equipment consisted of the following:(in thousands)June 30,2024December 31,2023Laboratory equipment$6,474Â $6,337Â Leasehold improvements118Â 118Â Computer hardware335Â 222Â Furniture, fixtures and office equipment324Â 324Â Prototype equipment1,476Â 996Â Construction in progress1,601Â 904Â 10,328Â 8,901Â Less: Accumulated depreciation(5,634)(4,634)Total$4,694Â $4,267Â The Company recorded depreciation expense of $0.5 million and $1.0 million for the three and six months ended June 30, 2024, respectively, and $0.4 million and $0.8 million for the three and six months ended June 30, 2023, respectively, which was primarily allocated to research and development expense. Accrued Expenses and Other LiabilitiesAccrued expenses and other liabilities consisted of the following:(in thousands)June 30,2024December 31,2023Employee compensation$2,071Â $2,590Â Accrued research and development342Â 731Â Accrued professional and consulting fees522Â 245Â Other304Â 379Â Total$3,239Â $3,945Â Cash, Cash Equivalents and Restricted CashCash, cash equivalents and restricted cash consisted of the following:(in thousands)June 30,2024December 31,2023Cash and cash equivalents$24,885Â $19,397Â Restricted cash included in other long-term assets (Note 8)1,002Â 1,002Â Total$25,887Â $20,399Â Other long-term assets consisted of $1.0Â million of restricted cash and $0.2Â million of deposits as of JuneÂ 30, 2024 and DecemberÂ 31, 2023. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/210/tableOfContent + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.2 Common Stock 6 Months Ended Jun. 30, 2024 Equity [Abstract] Â Common Stock Common StockThere were 125,406,748 shares issued and outstanding as of JuneÂ 30, 2024.Common Stock Reserved for Future IssuanceShares of common stock reserved for future issuance on an as-if converted basis, were as follows:June 30,2024December 31,2023Shares available for grant under 2021 Equity Incentive Plan23,449,238Â 20,279,560Â Stock options issued and outstanding17,545,835Â 14,676,335Â Shares available for grant under 2021 Employee Stock Purchase Plan4,631,929Â 3,505,138Â Total shares of common stock reserved45,627,002Â 38,461,033Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.2 Income Taxes 6 Months Ended Jun. 30, 2024 Income Tax Disclosure [Abstract] Â Income Taxes Income Taxes The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. For the three and six months ended June 30, 2024 and 2023, no income tax expense or benefit was recognized, due to a full valuation allowance recorded against its deferred tax assets. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.2 Equity Incentive Plans and Stock-based Compensation 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Equity Incentive Plans and Stock-based Compensation Equity Incentive Plans and Stock-based CompensationOn June 8, 2021, the stockholders of the Company approved the 2021 Equity Incentive Plan (â€œ2021 Planâ€) and the 2021 Employee Stock Purchase Plan (â€œ2021 ESPPâ€). As of JuneÂ 30, 2024, 23,449,238 and 4,631,929 shares were available for grant under the 2021 Plan and 2021 ESPP, respectively. 2021 Employee Stock Purchase PlanUnder the 2021 ESPP, participants are permitted to purchase shares of Common Stock, up to the IRS allowable limit, through contributions (in the form of payroll deductions or otherwise to the extent permitted by the administrator of the 2021 ESPP) of up to 15% of their eligible compensation. Participants are permitted to purchase shares of the Companyâ€™s Common Stock at 85% of the lower of the fair market value of the Companyâ€™s Common Stock on the first trading day of an offering period or on the last trading date in each purchase period. The Company offers a six month purchase period. Participants may end their participation at any time during an offering and will be paid their accrued contributions that have not yet been used to purchase shares. Participation ends automatically upon termination of employment with the Company. The number of shares of common stock available for issuance under the 2021 ESPP will be increased on the first day of each fiscal year in an amount equal to the least of (i) 3,734,500 shares of common stock, (ii) a number of shares of common stock equal to one percent (1%) of the total number of shares of all classes of common stock of the Company on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the Administrator no later than the last day of the immediately preceding fiscal year. On January 1, 2024, the number of shares available under the 2021 ESPP increased by 1,250,686 shares pursuant to this feature.2021 Equity Incentive PlanUnder the 2021 Plan, the Company can grant incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to employees, non-employee directors and consultants. Options generally expire ten years after the date of grant. The number of shares available for issuance under the 2021 Plan will be increased on the first day of each fiscal year in an amount equal to the least of (i) 18,672,200 shares, (ii) a number of shares equal to five percent (5%) of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the Administrator no later than the last day of the immediately preceding fiscal year. On January 1, 2024, the number of shares available under the 2021 Plan increased by 6,253,430 shares pursuant to this feature.2017 Equity Incentive PlanAt the time of adoption of the 2021 Plan and the 2021 ESPP, no further awards will be granted under the 2017 Equity Incentive Plan (â€œ2017 Planâ€). Stock-based awards forfeited or cancelled from the 2017 Plan are returned to the pool of shares of Common Stock available for issuance under the 2021 Plan.Grant Date Fair Value of Stock OptionsIn determining the compensation cost of the option awards, the fair value for each option award has been estimated using the Black Scholes model. The significant assumptions used in these calculations are summarized as follows:Three Months Ended June 30,Six Months Ended June 30,20242023202420232023Expected term (in years)5.3 - 6.05.3 - 6.15.3 - 6.05.3 - 6.4Expected volatility99.7% - 101.1%103.1% - 106.5%99.7% - 101.1%102.7% - 107.5%Expected dividend rate0.0Â %0.0Â %0.0Â %0.0Â %Risk free interest rate4.17% - 4.60%3.58% - 3.87%4.01% - 4.60%3.50% - 4.08%Expected term: The expected term of stock options represents the weighted-average period the stock options are expected to remain outstanding. The Company does not have sufficient historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term of options and has opted to use the â€œsimplified method,â€ whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option.Expected volatility: Historically, the Company has been a private company and lacked companyâ€‘specific historical and implied volatility information for its common stock. Therefore, the expected volatility of the Companyâ€™s common stock was determined by using an average of historical volatilities of selected industry peers deemed to be comparable to the Companyâ€™s business corresponding to the expected term of the awards and the Company expects to continue to do so until such time as the Company has adequate historical data regarding the volatility of its traded common stock price.Expected dividend yield: The expected dividend rate is zero as the Company has no history or expectation of declaring dividends on its common stock.Risk-free interest rate: The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities corresponding to the expected term of the awards. The following table summarizes option award activity during the six months ended June 30, 2024:Number of Stock Option AwardsWeighted Average Exercise PriceWeighted Average Remaining Contractual Life (Years)Aggregate Intrinsic Value (in thousands)Outstanding as of DecemberÂ 31, 202314,676,335Â $3.63Â Granted3,423,900Â $2.65Â Exercised(214,252)$1.28Â Forfeited(340,148)$3.40Â Outstanding as of JuneÂ 30, 202417,545,835Â $3.47Â 7.8$6,304Â Options vested and expected to vest as of JuneÂ 30, 202417,545,835Â $3.47Â Vested and exercisable at JuneÂ 30, 20249,482,993Â $3.83Â 6.9$5,446Â As of JuneÂ 30, 2024, there was $19.4 million of total unrecognized compensation expense expected to be recognized over a weighted average-period of 2.3 years. Aggregate intrinsic value represents the difference between the fair market value of the common stock and the exercise price of outstanding, in-the-money options. Stock-based Compensation ExpenseThe following sets forth the total stock-based compensation expense included in the Companyâ€™s condensed consolidated statement of operations:Three Months Ended June 30,Six Months Ended June 30,(in thousands)2024202320242023Research and development$1,146Â $1,048Â $2,242Â $2,023Â General and administrative2,133Â 2,050Â 4,151Â 3,935Â Total stock-based compensation expense$3,279Â $3,098Â $6,393Â $5,958Â X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards

Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.2 Commitment and Contingencies 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies Commitments and Contingencies Purchase CommitmentsOpen purchase commitments are for the purchase of goods and services related to, but not limited to, research and development, facilities, and professional services under non-cancellable contracts. They were not recorded as liabilities on the condensed consolidated balance sheet as of JuneÂ 30, 2024 as the Company had not yet received the related goods or services. As of JuneÂ 30, 2024, the Company had open purchase commitments for goods and services of $2.3 million, of which $1.7 million are expected to be received through the next 12 months.Legal ProceedingsFrom time to time, the Company may become involved in litigation relating to claims arising from the ordinary course of business. The Company may record accruals for loss contingencies associated with legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues. Loss contingency accruals would be included in accrued and other liabilities and general and administrative expenses.U.S. District Court ProceedingsOn December 14, 2023, the Company filed suit in the United States District Court for the Northern District of California against Somalogic (now known as Standard Biotools, Inc.), and the California Institute of Technology seeking declaratory judgment that the Company does not infringe any claims of US Patent No. 7,842,793 related to DNA origami structures, allegedly licensed from the California Institute of Technology through Somalogicâ€™s purchase of Palamedrix, Inc. On March 29, 2024, Somalogic filed a motion to dismiss the suit. On April 19, 2024, the Company filed a First Amended Complaint addressing issues raised in Somalogicâ€™s motion to dismiss. On April 22, 2024, the Court issued an order dismissing Somalogicâ€™s motion to dismiss as moot. On May 16, 2024, the Court granted the partiesâ€™ request for a temporary stay of the proceedings. While the Company believes that it will be able to prevail as to its claims in this litigation, the Company may incur significant expense and management distraction in prosecuting this litigation. Moreover, notwithstanding managementâ€™s belief as to the strength of the Companyâ€™s claims in this matter, litigation generally, and patent litigation in particular, can be unpredictable. As such, management cannot be certain that the Company will prevail in this litigation. LeasesThe Company is obligated under certain non-cancellable operating leases for office space and laboratory space. This space includes operating leases in Seattle, Washington, San Carlos, California, and San Diego, California.The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of JuneÂ 30, 2024:Lease Obligations(in thousands)Six months ending DecemberÂ 31, 2024$2,931Â 20257,182Â 20266,874Â 20276,889Â 20285,816Â 2029 and thereafter13,207Â Total future minimum lease payments42,899Â Less: Imputed interest(10,297)Total operating lease liabilities$32,602Â For the six months ended June 30, 2024 and 2023, cash paid for amounts included in the measurement of operating lease liabilities included in cash flows used in operating activities was $3.5 million and $2.8 million, respectively.The Company has $1.0 million in cash-collateralized letters of credit with one financial institution in lieu of security deposits in connection with the San Carlos and San Diego lease agreements. Indemnification AgreementsIn the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnifications will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by them in any action or proceeding to which any of them are, or are threatened to be, made a party by reason of their service as a director or officer. The Company maintains director and officer insurance coverage that would generally enable it to recover a portion of any future amounts paid. The Company may be subject to indemnification obligation by law with respect to the actions of its employees under certain circumstances and in certain jurisdictions. Commitments and Contingencies Commitments and Contingencies Purchase CommitmentsOpen purchase commitments are for the purchase of goods and services related to, but not limited to, research and development, facilities, and professional services under non-cancellable contracts. They were not recorded as liabilities on the condensed consolidated balance sheet as of JuneÂ 30, 2024 as the Company had not yet received the related goods or services. As of JuneÂ 30, 2024, the Company had open purchase commitments for goods and services of $2.3 million, of which $1.7 million are expected to be received through the next 12 months.Legal ProceedingsFrom time to time, the Company may become involved in litigation relating to claims arising from the ordinary course of business. The Company may record accruals for loss contingencies associated with legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues. Loss contingency accruals would be included in accrued and other liabilities and general and administrative expenses.U.S. District Court ProceedingsOn December 14, 2023, the Company filed suit in the United States District Court for the Northern District of California against Somalogic (now known as Standard Biotools, Inc.), and the California Institute of Technology seeking declaratory judgment that the Company does not infringe any claims of US Patent No. 7,842,793 related to DNA origami structures, allegedly licensed from the California Institute of Technology through Somalogicâ€™s purchase of Palamedrix, Inc. On March 29, 2024, Somalogic filed a motion to dismiss the suit. On April 19, 2024, the Company filed a First Amended Complaint addressing issues raised in Somalogicâ€™s motion to dismiss. On April 22, 2024, the Court issued an order dismissing Somalogicâ€™s motion to dismiss as moot. On May 16, 2024, the Court granted the partiesâ€™ request for a temporary stay of the proceedings. While the Company believes that it will be able to prevail as to its claims in this litigation, the Company may incur significant expense and management distraction in prosecuting this litigation. Moreover, notwithstanding managementâ€™s belief as to the strength of the Companyâ€™s claims in this matter, litigation generally, and patent litigation in particular, can be unpredictable. As such, management cannot be certain that the Company will prevail in this litigation. LeasesThe Company is obligated under certain non-cancellable operating leases for office space and laboratory space. This space includes operating leases in Seattle, Washington, San Carlos, California, and San Diego, California.The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of JuneÂ 30, 2024:Lease Obligations(in thousands)Six months ending DecemberÂ 31, 2024$2,931Â 20257,182Â 20266,874Â 20276,889Â 20285,816Â 2029 and thereafter13,207Â Total future minimum lease payments42,899Â Less: Imputed interest(10,297)Total operating lease liabilities$32,602Â For the six months ended June 30, 2024 and 2023, cash paid for amounts included in the measurement of operating lease liabilities included in cash flows used in operating activities was $3.5 million and $2.8 million, respectively.The Company has $1.0 million in cash-collateralized letters of credit with one financial institution in lieu of security deposits in connection with the San Carlos and San Diego lease agreements. Indemnification AgreementsIn the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnifications will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by them in any action or proceeding to which any of them are, or are threatened to be, made a party by reason of their service as a director or officer. The Company maintains director and officer insurance coverage that would generally enable it to recover a portion of any future amounts paid. The Company may be subject to indemnification obligation by law with respect to the actions of its employees under certain circumstances and in certain jurisdictions. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.2 Basic and Diluted Net Loss per Share 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Basic and Diluted Net Loss per Share Basic and Diluted Net Loss per ShareThe following tables set forth the computation of the Companyâ€™s basic and diluted net loss per share attributable to common stockholders for the three and six months ended June 30, 2024 and 2023:Three Months Ended June 30,Six Months Ended June 30,(in thousands, except share and per share amounts)2024202320242023Numerator:Net loss attributable to common stockholders$(18,010)$(15,808)$(36,740)$(30,773)Denominator:Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted125,317,650Â 124,603,181Â 125,226,552Â 124,601,762Â Net loss per share attributable to common stockholders, basic and diluted:(0.14)(0.13)(0.29)(0.25)The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows:Three and Six Months Ended June 30,20242023Options to purchase common stock17,545,83514,699,055Employee stock purchase plan139,86178,003Total potentially dilutive common share equivalents17,685,69614,777,058 X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.2 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net loss $ (18,010) $ (15,808) $ (36,740) $ (30,773) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.2 Insider Trading Arrangements 3 Months Ended Jun. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.2 Significant Accounting Policies (Policies) 6 Months Ended Jun. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation The condensed consolidated financial statements and accompanying notes are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€) and regulations of the U.S. Securities and Exchange Commission (the â€œSECâ€) for interim financial reporting. All intercompany transactions and balances have been eliminated upon consolidation. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements were prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Companyâ€™s financial position, results of operations, and cash flows for the interim periods. The interim financial results are not necessarily indicative of the results for a full year. These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended DecemberÂ 31, 2023 on file with the SEC. The Companyâ€™s reporting currency is the U.S. dollar. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determining the estimated lives of property and equipment, stock-based compensation, research and development accruals, loss contingency accruals, and the valuation allowance for deferred tax assets. These estimates and assumptions are based on managementâ€™s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods. As future events and their effects cannot be determined with precision, actual results could materially differ from those estimates and assumptions. Concentrations of Credit Risk and Other Risks and Uncertainties Credit risk represents the accounting loss that would be recognized as of the reporting date if counterparties failed to perform as contracted. Financial instruments, which potentially subject the Company to concentration of credit risk, consist of cash balances maintained in excess of federal depository insurance limits and investments in marketable debt

securities that are not federally insured. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk on cash or investments. The Company relies, and expects to continue to rely, on a number of vendors to provide services, supplies and materials related to its research and development programs. The Company relies on single source suppliers for certain components and materials used in the Nautilus platform. The loss of any of these single source suppliers would require the Company to expend significant time and effort to locate and qualify an alternative source of supply for these components. The Company also relies, and expects to continue to rely, on third-party manufacturers and, in many cases, single third-party manufacturers for the production of certain reagents and antibodies. These programs could be adversely affected by a significant interruption in these services or the availability of materials.The Company is subject to risks similar to those ofÂ pre-clinicalÂ stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, the impact of negative global and national events and the need to obtain adequate additional financing to fund the development of its products. There can be no assurance that the Companyâ€™s research and development will be successfully completed, that adequate protection for the Companyâ€™s intellectual property will be maintained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Companyâ€™s development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products. Segment Reporting Operating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker (â€œCODMâ€) in deciding how to allocate resources and in assessing performance. The Companyâ€™s Chief Executive Officer is its CODM. The Companyâ€™s CODM reviews financial information presented on a consolidated basis for the purposes of making operating decisions, allocating resources and evaluating financial performance. As such, the Company has determined that it operates in one operating and one reportable segment. The Companyâ€™s long-lived assets are entirely based in the United States. Cash and Cash Equivalents The Company considers all highly-liquid investments with an original maturity of three months or less as of the date of acquisition to be cash equivalents. Investments The Company considers investments with an original maturity greater than three months and remaining maturities less than one year to be short-term investments. The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as long-term investments. The Company classifies its marketable debt securities as available for sale and reports them at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For investments sold prior to maturity, the cost of investments sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in other income (expense), net in the condensed consolidated statement of operations. If the estimated fair value of a marketable debt security is below its amortized cost basis, the Company evaluates whether it is more likely than not that the Company will be required to sell the security before its anticipated recovery in market value and whether credit losses exist for the related securities. Credit-related losses are recognized as an allowance for credit losses on the balance sheet with a corresponding adjustment to earnings. Unrealized gains and losses that are unrelated to credit deterioration are reported in accumulated other comprehensive income (loss). Fair Value of Financial Instruments Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets;Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; andLevel 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.The carrying amounts of cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other liabilities approximate their respective fair values due to their short-term nature. Leases The Company determines if an arrangement includes a lease at inception by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. Operating leases with a term of more than one year are included in operating lease right-of-use (â€œROUâ€) assets and operating lease liabilities on the Company's condensed consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments. Operating lease ROU assets and liabilities are recognized on the lease commencement date based on the present value of the future minimum lease payments over the lease term. The Company uses the incremental borrowing rate commensurate with the lease term based on the information available at the lease commencement date in determining the present value of the lease payments as the Company's leases generally do not provide an implicit rate. ROU assets initially equal the lease liability, adjusted for any prepaid lease payments and initial direct costs incurred, less any lease incentives received. Certain of the Company's leases include renewal options which allow the Company to, at its election, renew or extend the lease for a fixed or indefinite period of time. These renewal periods are included in the lease terms when the Company is reasonably certain the options will be exercised. Lease expense is recognized on a straight-line basis over the lease term when leases are operating leases. If it is considered a finance lease, expense is recognized over the lease term within interest expense and amortization in the Companyâ€™s condensed consolidated statements of operations. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's facility leases and to account for the lease and non-lease components as a single lease component. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less. Comprehensive Loss Comprehensive loss consists of net loss and other gains or losses affecting stockholdersâ€™ equity that, under U.S. GAAP are excluded from net loss. For the three and six months ended June 30, 2024 and 2023, net unrealized gains and losses on marketable debt securities were included as a component of comprehensive income (loss). Accounting Pronouncements The Company is provided the option to adopt new or revised accounting guidance as an â€œemerging growth companyâ€ under the Jumpstart Our Business Startups Act of 2012 (the â€œJOBS Actâ€) either (1) within the same periods as those otherwise applicable to public business entities, or (2) within the same time periods as non-public business entities, including early adoption when permissible. With the exception of standards the Company elected to early adopt, when permissible, the Company has elected to adopt new or revised accounting guidance within the same time period as non-public business entities, as indicated below. Recently Issued Accounting PronouncementsIn November 2023, the FASB issued ASU 2023-07, â€œSegment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,â€ which amends existing guidance on segment reporting to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The ASU is effective for the Company for the fiscal year ending December 31, 2024 and for interim periods beginning after December 31, 2024. The Company is in the process of evaluating the impact of the adoption of this Accounting Standards Update on its consolidated financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09, â€œIncome Taxes (Topic 740): Improvements to Income Tax Disclosures,â€ to enhance the transparency and decision usefulness of income tax disclosures. The ASU is effective for the Company for the fiscal year ending December 31, 2025. The Company is in the process of evaluating the impact of the adoption of this Accounting Standards Update on its consolidated financial statements and related disclosures. The Company does not anticipate adoption to have a material impact on its consolidated financial statements and related disclosures. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for comprehensive income. + ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining the fair value of financial instruments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1 + Details Name: us-gaap_FairValueOfFinancialInstrumentsPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for investment in financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19 + Details Name: us-gaap_InvestmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1 + Details Name: us-gaap_LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for segment reporting. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 36 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29 + Details Name: us-gaap_SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.2 Fair Value Measurements (Tables) 6 Months Ended Jun. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of Assets Carried at Fair Value and Measured on a Recurring Basis The following table details the assets carried at fair value and measured on a recurring basis within the three levels of fair value as of JuneÂ 30, 2024 and DecemberÂ 31, 2023:(in thousands)Gross UnrealizedReported as:June 30, 2024Amortized CostGainsLossesFair ValueCash equivalentsShort-term investmentsLong-term investmentsLevel 1Mutual funds$1,260Â $â€”Â $â€”Â $1,260Â $1,260Â $â€”Â $â€”Â U.S. treasury securities57,124Â 17Â (129)57,012Â 2,996Â 35,458Â 18,558Â Total Level 158,384Â 17Â (129)58,272Â 4,256Â 35,458Â 18,558Â Level 2Commercial paper20,457Â â€”Â (11)20,446Â 20,446Â â€”Â â€”Â Corporate debt securities4,984Â â€”Â (24)4,960Â â€”Â 4,960Â â€”Â Agency securities149,447Â 18Â (417)149,048Â â€”Â 102,140Â 46,908Â Total Level 2174,888Â 18Â (452)174,454Â 20,446Â 107,100Â 46,908Â Total Level 1 and Level 2$233,272Â $35Â (581)232,726Â $24,702Â $142,558Â $65,466Â (in thousands)Gross UnrealizedReported as:December 31, 2023Amortized CostGainsLossesFair ValueCash equivalentsShort-term investmentsLong-term investmentsLevel 1Mutual funds$590Â $â€”Â $â€”Â $590Â $590Â $â€”Â $â€”Â U.S. treasury securities74,115Â 104Â (247)73,972Â â€”Â 50,638Â 23,334Â Total Level 174,705Â 104Â (247)74,562Â 590Â 50,638Â 23,334Â Level 2Commercial paper18,653Â â€”Â (9)18,644Â 18,644Â â€”Â â€”Â Corporate debt securities6,950Â â€”Â (37)6,913Â â€”Â 6,913Â â€”Â Agency securities163,849Â 358Â (424)163,783Â â€”Â 96,470Â 67,313Â Total Level 2189,452Â 358Â (470)189,340Â 18,644Â 103,383Â 67,313Â Total Level 1 and Level 2$264,157Â $462Â (717)263,902Â $19,234Â $154,021Â $90,647Â Schedule of Unrealized Losses and Fair Values of Available-for-Sale Securities in an Unrealized Loss Position The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of JuneÂ 30, 2024 and DecemberÂ 31, 2023 are as follows:(in thousands)Securities in Unrealized Loss Position Less than 12 monthsSecurities in Unrealized Loss Position Greater than 12 monthsTotalJune 30, 2024Gross Unrealized LossesFair Market ValueGross Unrealized LossesFair Market ValueGross Unrealized LossesFair Market ValueU.S. treasury securities$67Â $26,444Â $62Â $22,754Â $129Â $49,198Â Commercial paper11Â 20,447Â â€”Â â€”Â 11Â 20,447Â Corporate debt securitiesâ€”Â â€”Â 24Â 4,959Â 24Â 4,959Â Agency securities163Â 53,020Â 254Â 85,593Â 417Â 138,613Â Total$241Â $99,911Â $340Â $113,306Â $581Â $213,217Â (in thousands)Securities in Unrealized Loss Position Less than 12 monthsSecurities in Unrealized Loss Position Greater than 12 monthsTotalDecember 31, 2023Gross Unrealized LossesFair Market ValueGross Unrealized LossesFair Market ValueGross Unrealized LossesFair Market ValueU.S. treasury securities$85Â $20,408Â $162Â $30,230Â $247Â $50,638Â Commercial paper9Â 18,644Â â€”Â â€”Â 9Â 18,644Â Corporate debt securities37Â 6,913Â â€”Â â€”Â 37Â 6,913Â Agency securities229Â 85,039Â 195Â 25,704Â 424Â 110,743Â Total$360Â $131,004Â $357Â $55,934Â $717Â $186,938Â X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.2 Composition of Certain Condensed Consolidated Financial Statement Line Items (Tables) 6 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Schedule of Property and Equipment, Net Property and equipment consisted of the following:(in thousands)June 30,2024December 31,2023Laboratory equipment$6,474Â $6,337Â Leasehold improvements118Â 118Â Computer hardware335Â 222Â Furniture, fixtures and office equipment324Â 324Â Prototype equipment1,476Â 996Â Construction in progress1,601Â 904Â 10,328Â 8,901Â Less: Accumulated depreciation(5,634)(4,634)Total$4,694Â $4,267Â Schedule of Accrued Expenses Accrued expenses and other liabilities consisted of the following:(in thousands)June 30,2024December 31,2023Employee compensation$2,071Â $2,590Â Accrued research and development342Â 731Â Accrued professional and consulting fees522Â 245Â Other304Â 379Â Total$3,239Â $3,945Â Schedule of Other Liabilities Accrued expenses and other liabilities consisted of the following:(in thousands)June 30,2024December 31,2023Employee compensation$2,071Â $2,590Â Accrued research and development342Â 731Â Accrued professional and consulting fees522Â 245Â Other304Â 379Â Total$3,239Â $3,945Â Schedule of Cash and Cash Equivalents Cash, cash equivalents and restricted cash consisted of the following:(in thousands)June 30,2024December 31,2023Cash and cash equivalents$24,885Â $19,397Â Restricted cash included in other long-term assets (Note 8)1,002Â 1,002Â Total$25,887Â $20,399Â Schedule of Restricted Cash Cash, cash equivalents and restricted cash consisted of the following:(in thousands)June 30,2024December 31,2023Cash and cash equivalents$24,885Â $19,397Â Restricted cash included in other long-term assets (Note 8)1,002Â 1,002Â Total$25,887Â $20,399Â X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of other current liabilities. + ReferencesNo definition available. + Details Name: us-gaap_OtherCurrentLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1:

http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of cash and cash equivalents. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cash and cash equivalents restricted as to withdrawal or usage. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 8 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.2 Common Stock (Tables) 6 Months Ended Jun. 30, 2024 Equity [Abstract] Â Schedule of Common Stock Reserved for Future Issuance Shares of common stock reserved for future issuance on an as-if converted basis, were as follows:June 30,2024December 31,2023Shares available for grant under 2021 Equity Incentive Plan23,449,238Â 20,279,560Â Stock options issued and outstanding17,545,835Â 14,676,335Â Shares available for grant under 2021 Employee Stock Purchase Plan4,631,929Â 3,505,138Â Total shares of common stock reserved45,627,002Â 38,461,033Â X - DefinitionSchedule Of Common Stock Reserved For Future Issuance + ReferencesNo definition available. + Details Name: naut_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock Namespace Prefix: naut_ Data Type: dtr-types1:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.2 Equity Incentive Plans and Stock-based Compensation (Tables) 6 Months Ended Jun. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Schedule of Significant Assumptions The significant assumptions used in these calculations are summarized as follows:Three Months Ended June 30,Six Months Ended June 30,2024202320242023Expected term (in years)5.3 - 6.05.3 - 6.15.3 - 6.05.3 - 6.4Expected volatility99.7% - 101.1%103.1% - 106.5%99.7% - 101.1%102.7% - 107.5%Expected dividend rate0.0Â %0.0Â %0.0Â %0.0Â %Risk free interest rate4.17% - 4.60%3.58% - 3.87%4.01% - 4.60%3.50% - 4.08% Schedule of Option Award Activity The following table summarizes option award activity during the six months ended June 30, 2024:Number of Stock Option AwardsWeighted Average Exercise PriceWeighted Average Remaining Contractual Life (Years)Aggregate Intrinsic Value (in thousands)Outstanding as of DecemberÂ 31, 202314,676,335Â $3.63Â Granted3,423,900Â $2.65Â Exercised(214,252)$1.28Â Forfeited(340,148)$3.40Â Outstanding as of JuneÂ 30, 202417,545,835Â $3.47Â 7.8$6,304Â Options vested and expected to vest as of JuneÂ 30, 202417,545,835Â $3.47Â Vested and exercisable at JuneÂ 30, 20249,482,993Â $3.83Â 6.9$5,446Â Schedule of Stock-Based Compensation Expense The following sets forth the total stock-based compensation expense included in the Companyâ€™s condensed consolidated statement of operations:Three Months Ended June 30,Six Months Ended June 30,(in thousands)2024202320242023Research and development$1,146Â $1,048Â $2,242Â $2,023Â General and administrative2,133Â 2,050Â 4,151Â 3,935Â Total stock-based compensation expense$3,279Â $3,098Â $6,393Â $5,958Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the change in stock options. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2 Commitment and Contingencies (Tables) 6 Months Ended Jun. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Summary of Future Principal Contractual Obligations for Operating Lease Commitments The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of JuneÂ 30, 2024:Lease Obligations(in thousands)Six months ending DecemberÂ 31, 2024$2,931Â 20257,182Â 20266,874Â 20276,889Â 20285,816Â 2029 and thereafter13,207Â Total future minimum lease payments42,899Â Less: Imputed interest(10,297)Total operating lease liabilities$32,602Â X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.2 Basic and Diluted Net Loss per Share (Tables) 6 Months Ended Jun. 30, 2024 Earnings Per Share [Abstract] Â Schedule of Basic and Diluted Net Loss Per Share The following tables set forth the computation of the Companyâ€™s basic and diluted net loss per share attributable to common stockholders for the three and six months ended June 30, 2024 and 2023:Three Months Ended June 30,Six Months Ended June 30,(in thousands, except share and per share amounts)2024202320242023Numerator:Net loss attributable to common stockholders$(18,010)$(15,808)$(36,740)$(30,773)Denominator:Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted125,317,650Â 124,603,181Â 125,226,552Â 124,601,762Â Net loss per share attributable to common stockholders, basic and diluted:(0.14)(0.13)(0.29)(0.25) Schedule of Potential Shares of Common Stock Excluded from the Computation of Diluted Net Loss Per Share The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows:Three and Six Months Ended June 30,20242023Options to purchase common stock17,545,83514,699,055Employee stock purchase plan139,86178,003Total potentially dilutive common share equivalents17,685,69614,777,058 X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.2 Description of Business and Basis of Presentation (Details) - USD ($) 1 Months Ended Jun. 09, 2021 Jun. 30, 2021 Jun. 30, 2024 Dec. 31, 2023 Subsidiary, Sale of Stock [Line Items] Â Â Â Â Accumulated deficit Â Â $ 238,979,000 $ 202,239,000 Proceeds from sale of stock and reverse recapitalization transaction Â $ 345,500,000 Â Â Payments of transaction costs Â $ 18,200,000 Â Â Cash, cash equivalents, and short-term investments Â Â $ 167,400,000 Â Private Placement Â Â Â Â Subsidiary, Sale of Stock [Line Items] Â Â Â Â Shares issued in transaction (in shares) 20,000,000 Â Â Â Price per share (in dollars per share) $ 10.00 Â Â Â Consideration received on transaction $ 200,000,000 Â Â Â X - DefinitionPayments of Reverse Recapitalization Transaction Costs + ReferencesNo definition available. + Details Name: naut_PaymentsOfReverseRecapitalizationTransactionCosts Namespace Prefix: naut_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds From Sale Of Stock And Reverse Recapitalization Transaction + ReferencesNo definition available. + Details Name: naut_ProceedsFromSaleOfStockAndReverseRecapitalizationTransaction Namespace Prefix: naut_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CashCashEquivalentsAndShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-

2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash received on stock transaction after deduction of issuance costs. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockConsiderationReceivedOnTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SubsidiarySaleOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.2 Significant Accounting Policies (Details) 3 Months Ended 6 Months Ended Jun. 30, 2024 USD ($) Jun. 30, 2023 USD ($) Jun. 30, 2024 USD ($) segment Jun. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Accounting Policies [Abstract] Â Â Â Â Â Number of operating segments | segment Â Â 1 Â Â Number of reportable segments | segment Â Â 1 Â Â Credit losses during period | $ $ 0 $ 0 $ 0 $ 0 Â Allowance for credit losses | $ $ 0 Â $ 0 Â $ 0 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.2 Fair Value Measurements - Assets Carried at Fair Value and Measured on a Recurring Basis (Details) - Fair Value, Recurring - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Amortized Cost $ 233,272 $ 264,157 Gains 35 462 Losses (581) (717) Fair Value 232,726 263,902 Cash equivalents Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 24,702 19,234 Short-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 142,558 154,021 Long-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 65,466 90,647 Level 1 Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Amortized Cost 58,384 74,705 Gains 17 104 Losses (129) (247) Fair Value 58,272 74,562 Level 1 | Cash equivalents Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 4,256 590 Level 1 | Short-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 35,458 50,638 Level 1 | Long-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 18,558 23,334 Level 1 | Mutual funds Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Amortized Cost 1,260 590 Gains 0 0 Losses 0 0 Fair Value 1,260 590 Level 1 | Mutual funds | Cash equivalents Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 1,260 590 Level 1 | Mutual funds | Short-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 0 0 Level 1 | Mutual funds | Long-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 0 0 Level 1 | U.S. treasury securities Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Amortized Cost 57,124 74,115 Gains 17 104 Losses (129) (247) Fair Value 57,012 73,972 Level 1 | U.S. treasury securities | Cash equivalents Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 2,996 0 Level 1 | U.S. treasury securities | Short-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 35,458 50,638 Level 1 | U.S. treasury securities | Long-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 18,558 23,334 Level 2 Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Amortized Cost 174,888 189,452 Gains 18 358 Losses (452) (470) Fair Value 174,454 189,340 Level 2 | Cash equivalents Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 20,446 18,644 Level 2 | Short-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 107,100 103,383 Level 2 | Long-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 46,908 67,313 Level 2 | Commercial paper Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Amortized Cost 20,457 18,653 Gains 0 0 Losses (11) (9) Fair Value 20,446 18,644 Level 2 | Commercial paper | Cash equivalents Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 20,446 18,644 Level 2 | Commercial paper | Short-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 0 0 Level 2 | Commercial paper | Long-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 0 0 Level 2 | Corporate debt securities Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Amortized Cost 4,984 6,950 Gains 0 0 Losses (24) (37) Fair Value 4,960 6,913 Level 2 | Corporate debt securities | Cash equivalents Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 0 0 Level 2 | Corporate debt securities | Short-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 4,960 6,913 Level 2 | Corporate debt securities | Long-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 0 0 Level 2 | Agency securities Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Amortized Cost 149,447 163,849 Gains 18 358 Losses (417) (424) Fair Value 149,048 163,783 Level 2 | Agency securities | Cash equivalents Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 0 0 Level 2 | Agency securities | Short-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value 102,140 96,470 Level 2 | Agency securities | Long-term investments Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Fair Value $ 46,908 $ 67,313 X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). +

ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=naut_LongTermInvestmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.2 Fair Value Measurements - Unrealized Losses and Fair Values of Available-for-Sale Securities in an Unrealized Loss Position (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Gross Unrealized Losses Â Â Securities in Unrealized Loss Position Less than 12 months $ 241 $ 360 Securities in Unrealized Loss Position Greater than 12 months 340 357 Total 581 717 Fair Market Value Â Â Securities in Unrealized Loss Position Less than 12 months 99,911 131,004 Securities in Unrealized Loss Position Greater than 12 months 113,306 55,934 Total 213,217 186,938 U.S. treasury securities Â Â Gross Unrealized Losses Â Â Securities in Unrealized Loss Position Less than 12 months 67 85 Securities in Unrealized Loss Position Greater than 12 months 62 162 Total 129 247 Fair Market Value Â Â Securities in Unrealized Loss Position Less than 12 months 26,444 20,408 Securities in Unrealized Loss Position Greater than 12 months 22,754 30,230 Total 49,198 50,638 Commercial paper Â Â Gross Unrealized Losses Â Â Securities in Unrealized Loss Position Less than 12 months 11 9 Securities in Unrealized Loss Position Greater than 12 months 0 0 Total 11 9 Fair Market Value Â Â Securities in Unrealized Loss Position Less than 12 months 20,447 18,644 Securities in Unrealized Loss Position Greater than 12 months 0 0 Total 20,447 18,644 Corporate debt securities Â Â Gross Unrealized Losses Â Â Securities in Unrealized Loss Position Less than 12 months 0 37 Securities in Unrealized Loss Position Greater than 12 months 24 0 Total 24 37 Fair Market Value Â Â Securities in Unrealized Loss Position Less than 12 months 0 6,913 Securities in Unrealized Loss Position Greater than 12 months 4,959 0 Total 4,959 6,913 Agency securities Â Â Gross Unrealized Losses Â Â Securities in Unrealized Loss Position Less than 12 months 163 229 Securities in Unrealized Loss Position Greater than 12 months 254 195 Total 417 424 Fair Market Value Â Â Securities in Unrealized Loss Position Less than 12 months 53,020 85,039 Securities in Unrealized Loss Position Greater than 12 months 85,593 25,704 Total $ 138,613 $ 110,743 X - DefinitionDebt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value + ReferencesNo definition available. + Details Name: naut_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract Namespace Prefix: naut_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.2 Fair Value Measurements - Narrative (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Fair Value Disclosures [Abstract] Â Â Â Â Â Â Credit losses during period $ 0 $ 0 $ 0 $ 0 Â Allowance for credit losses $ 0 Â $ 0 Â $ 0 X - DefinitionAmount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.2 Composition of Certain Condensed Consolidated Financial Statement Line Items - Property and Equipment, Net (Details) - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Dec. 31, 2023 Property, Plant and Equipment [Line Items] Â Â Â Â Â Property, plant and equipment, gross $ 10,328 Â $ 10,328 Â $ 8,901 Less: Accumulated depreciation (5,634) Â (5,634) Â (4,634) Total 4,694 Â 4,694 Â 4,267 Depreciation 500 $ 400 1,028 $ 826 Â Laboratory equipment Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Property, plant and equipment, gross 6,474 Â 6,474 Â 6,337 Leasehold improvements Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Property, plant and equipment, gross 118 Â 118 Â 118 Computer hardware Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Property, plant and equipment, gross 335 Â 335 Â 222 Furniture, fixtures and office equipment Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Property, plant and equipment, gross 324 Â 324 Â 324 Prototype equipment Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Property, plant and equipment, gross 1,476 Â 1,476 Â 996 Construction in progress Â Â Â Â Â Property, Plant and Equipment [Line Items] Â Â Â Â Â Property, plant and equipment, gross $ 1,601 Â $ 1,601 Â $ 904 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=naut_LaboratoryEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=naut_FurnitureFixturesAndOfficeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=naut_PrototypeEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.2 Composition of Certain Condensed Consolidated Financial Statement Line Items - Accrued Expenses and Other Liabilities (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Employee compensation $ 2,071 $ 2,590 Accrued research and development 342 731 Accrued professional and consulting fees 522 245 Other 304 379 Total $ 3,239 $ 3,945 X - DefinitionAccrued Liabilities and Other Liabilities, Current + ReferencesNo definition available. + Details Name: naut_AccruedLiabilitiesAndOtherLiabilitiesCurrent Namespace Prefix: naut_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAccrued Research and Development + ReferencesNo definition available. + Details Name: naut_AccruedResearchAndDevelopment Namespace Prefix: naut_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionObligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481573/470-10-45-10 + Details Name: us-gaap_OtherSundryLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.2 Composition of Certain Condensed Consolidated Financial Statement Line Items - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands Jun. 30, 2024 Dec. 31, 2023 Jun. 30, 2023 Dec. 31, 2022 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Â Â Cash and cash equivalents $ 24,885 $ 19,397 Â Â Restricted cash included in other long-term assets 1,002 1,002 Â Â Total $ 25,887 $ 20,399 $ 73,753 $ 115,477 X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards

Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_RestrictedCashAndCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.2 Composition of Certain Condensed Consolidated Financial Statement Line Items - Other Long-term Assets (Details) - USD ($) $ in Millions Jun. 30, 2024 Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Â Restricted cash $ 1.0 $ 1.0 Deposits $ 0.2 $ 0.2 X - DefinitionCarrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DepositsAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 210 -Topic 954 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.2 Common Stock - Narrative (Details) - shares Jun. 30, 2024 Dec. 31, 2023 Equity [Abstract] Â Â Common stock, shares issued (in shares) 125,406,748 125,068,601 Common stock, shares outstanding (in shares) 125,406,748 125,068,601 X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.2 Common Stock - Common Stock Reserved for Future Issuance (Details) - shares Jun. 30, 2024 Dec. 31, 2023 Class of Stock [Line Items] Â Â Stock options issued and outstanding (in shares) 17,545,835 14,676,335 Total shares of common stock reserved (in shares) 45,627,002 38,461,033 2021 Equity Incentive Plan Â Â Class of Stock [Line Items] Â Â Shares available for grant under equity plan (in shares) 23,449,238 20,279,560 2021 Employee Stock Purchase Plan Â Â Class of Stock [Line Items] Â Â Shares available for grant under equity plan (in shares) 4,631,929 3,505,138 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PlanNameAxis=naut_A2021EquityIncentivePlanMember Namespace Prefix: Data Type: na Balance

Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=naut_A2021EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.2 Income Taxes - Narrative (Details) - USD ($) 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Income Tax Disclosure [Abstract] Â Â Â Â Income tax expense $ 0 $ 0 $ 0 $ 0 X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.2 Equity Incentive Plans and Stock-based Compensation - Narrative (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Jan. 01, 2024 Dec. 31, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Unrecognized compensation expense $ 19.4 Â $ 19.4 Â Â Â Unrecognized compensation expense, period for recognition Â Â 2 years 3 months 18 days Â Â Â 2021 Equity Incentive Plan Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Shares available for grant under equity plan (in shares) 23,449,238 Â 23,449,238 Â Â 20,279,560 Number of additional shares authorized (in shares) Â Â 18,672,200 Â Â Â Percentage of outstanding stock maximum Â Â 5.00% Â Â Â Increase in shares available for grant under equity plan (in shares) Â Â Â Â 6,253,430 Â Award expiration period Â Â 10 years Â Â Â 2021 Employee Stock Purchase Plan Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Shares available for grant under equity plan (in shares) 4,631,929 Â 4,631,929 Â Â 3,505,138 Offering purchase period Â Â 6 months Â Â Â Number of additional shares authorized (in shares) Â Â 3,734,500 Â Â Â Percentage of outstanding stock maximum Â Â 1.00% Â Â Â Increase in shares available for grant under equity plan (in shares) Â Â Â Â 1,250,686 Â Employee Stock | 2021 Employee Stock Purchase Plan Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Purchase shares of common stock contribution percent 15.00% Â 15.00% Â Â Â Purchase price of common stock, percent Â Â 85.00% Â Â Â Options Â Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Â Expected dividend rate 0.00% 0.00% 0.00% 0.00% Â Â X - DefinitionShare-based Compensation Arrangement by Share-based Payment Award, Increase in Number of Shares Available for Grant + ReferencesNo definition available. + Details Name: naut_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant Namespace Prefix: naut_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionShare-Based Compensation Arrangement By Share-Based Payment Award, Offering Purchase Period + ReferencesNo definition available. + Details Name: naut_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPurchasePeriod Namespace Prefix: naut_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe highest percentage of annual salary that an employee is permitted to utilize with respect to the plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionMaximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPurchase price of common stock expressed as a percentage of its fair value. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=naut_A2021EquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=naut_A2021EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.2 Equity Incentive Plans and Stock-based Compensation - Significant Assumptions (Details) - Options 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Expected volatility, minimum 99.70% 103.10% 99.70% 102.70% Expected volatility, maximum 101.10% 106.50% 101.10% 107.50% Expected dividend rate 0.00% 0.00% 0.00% 0.00% Risk free interest rate, minimum 4.17% 3.58% 4.01% 3.50% Risk free interest rate, maximum 4.60% 3.87% 4.60% 4.08% Minimum Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Expected term (in years) 5 years 3 months 18 days 5 years 3 months 18 days 5 years 3 months 18 days 5 years 3 months 18 days Maximum Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Expected term (in years) 6 years 6 years 1 month 6 days 6 years 6 years 4 months 24 days X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe maximum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type:

xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.2 Equity Incentive Plans and Stock-based Compensation - Option Award Activity (Details) - USD ($) $ / shares in Units, $ in Thousands 6 Months Ended Jun. 30, 2024 Number of Stock Option Awards Â Outstanding beginning balance (in shares) 14,676,335 Granted (in shares) 3,423,900 Exercised (in shares) (214,252) Forfeited (in shares) (340,148) Outstanding ending balance (in shares) 17,545,835 Options vested and expected to vest (in shares) 17,545,835 Vested and exercisable (in shares) 9,482,993 Weighted Average Exercise Price Â Outstanding beginning balance (in dollars per share) $ 3.63 Granted (in dollars per share) 2.65 Exercised (in dollars per share) 1.28 Forfeited (in dollars per share) 3.40 Outstanding ending balance (in dollars per share) 3.47 Options vested and expected to vest (in dollars per share) 3.47 Vested and exercisable (in dollars per share) $ 3.83 Options outstanding, weighted average remaining contractual life 7 years 9 months 18 days Vested and exercisable, weighted average remaining contractual life 6 years 10 months 24 days Options outstanding, aggregate intrinsic value $ 6,304 Vested and exercisable, aggregate intrinsic value $ 5,446 X - DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef - Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.2 Equity Incentive Plans and Stock-based Compensation - Stock-Based Compensation Expense (Details) - Options - USD ($) $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30,

2024 Jun. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Total stock-based compensation expense $ 3,279 $ 3,098 $ 6,393 $ 5,958 Research and development Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Total stock-based compensation expense 1,146 1,048 2,242 2,023 General and administrative Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Total stock-based compensation expense $ 2,133 $ 2,050 $ 4,151 $ 3,935 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.2 Commitment and Contingencies - Narrative (Details) - USD ($) $ in Millions 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Commitments and Contingencies Disclosure [Abstract] Â Â Open purchase commitment $ 2.3 Â Purchase commitment, next 12 months 1.7 Â Cash paid for lease liabilities included in operating activities 3.5 $ 2.8 Letters of credit $ 1.0 Â X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe total amount of the contingent obligation under letters of credit outstanding as of the reporting date. + ReferencesNo definition available. + Details Name: us-gaap_LettersOfCreditOutstandingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe minimum amount the entity agreed to spend under the long-term purchase commitment. + ReferencesNo definition available. + Details Name: us-gaap_LongTermPurchaseCommitmentAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligationDueInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.2 Commitment and Contingencies - Future Principal Contractual Obligations for Operating Lease Commitments (Details) $ in Thousands Jun. 30, 2024 USD ($) Commitments and Contingencies Disclosure [Abstract] Â Six months ending DecemberÂ 31, 2024 $ 2,931 2025 7,182 2026 6,874 2027 6,889 2028 5,816 2029 and thereafter 13,207 Total future minimum lease payments 42,899 Less: Imputed interest (10,297) Total operating lease liabilities $ 32,602 X - DefinitionLessee, Operating Lease, Liability, to be Paid, Due after Year Four + ReferencesNo definition available. + Details Name: naut_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour Namespace Prefix: naut_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating

lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.2 Basic and Diluted Net Loss per Share - Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Earnings Per Share [Abstract] Â Â Â Â Net loss attributable to common stockholders, basic $ (18,010) $ (15,808) $ (36,740) $ (30,773) Net loss attributable to common stockholders, diluted $ (18,010) $ (15,808) $ (36,740) $ (30,773) Weighted average shares used in computing net loss per share attributable to common stockholders, basic (in shares) 125,317,650 124,603,181 125,226,552 124,601,762 Weighted average shares used in computing net loss per share attributable to common stockholders, diluted (in shares) 125,317,650 124,603,181 125,226,552 124,601,762 Net loss per share attributable to common stockholders, basic (in dollars per share) $ (0.14) $ (0.13) $ (0.29) $ (0.25) Net loss per share attributable to common stockholders, diluted (in dollars per share) $ (0.14) $ (0.13) $ (0.29) $ (0.25) X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -

Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.2 Basic and Diluted Net Loss per Share - Potential Shares of Common Stock Excluded from the Computation of Diluted Net Loss Per Share (Details) - shares 3 Months Ended 6 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Total potentially dilutive common share equivalents 17,685,696 14,777,058 17,685,696 14,777,058 Options to purchase common stock Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Total potentially dilutive common share equivalents 17,545,835 14,699,055 17,545,835 14,699,055 Employee stock purchase plan Â Â Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Â Â Total potentially dilutive common share equivalents 139,861 78,003 139,861 78,003 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=naut_EmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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x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{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Ÿ?*.C(OQ;F8QA9B/6F]_1TT3UMI&A!M M)35W9QYK#*A:..N@*&%1.U9L3@:@Q*3;54T@SDQAF:I8-L)$;#XS@)S0$W@&98M&B(2*Q/Q2UQ4TSB1+]- M6<)0F! 2G>GZDF@@YY+Y,L7[.:N/",C>;* 0& %=RQ$@R)X[^>A.88$)ON_K MPP\4)H"J,2@UU6S)$]"U0.%:P(?,17ZHWS)!H<+EA"EH0@:EIEHFN0)R@X5G MY'SNS*,'IQ4N&*0/-&D*JL:@U-3/E"6MP&Y: 8S[L$D!#-[GKM'8L3D@8PJ:MD4&IJ8Y)AH'=#.,:ZH?-E3SQ$QW[N1./-F9(SA0T)X-24ZTYV:'AYAI7H3]L M\H;N=L X< /X]!' M>LL-#EVXJSVZ:X.B"B@UU3*)*K ;55SW*3)[=QB0P.C=9APBNCDF@*!AM%!.]JVXS;2Y/,3E#]K!GH.J+4#54E U!J6F=@)) M#O"UY ""[&%SN8\1Q8&QPAP6MW!?S&@C0;D E)JZ.5ER 7(M%[B6VAT2*O?$ M2/^HPUVKL0.5F&S2)F"IF10:JIM$@X0-QQX1G+GSCSVCDQ,.H"ZN9C^Y0'0 MK"FH&H-24[%6M(&X:0,PNB/F(A[K<^.YNTJCQ^> E"EH2@:EIGIV\J4/-X.X M!MX1DD2?2KH3CW9F2,X4-">#4E.MD5R"N+G$5?".F/Q@BO4/W>?NS*.] M 041@ZZ 0>54O9& @;@!@PO=$9,03$D841V@NE.,-@'TVQR@:HQ8 (;:(JH- MDE\0-[\8CNZHU2DKD:"^J)K.68>'+MQU'NT$*+R 4E/]DO""N.&%F\O9/;*0 M"Q+@R)@(#" 7Q$(N(AH9>Y(L<=. AOHMR$8NQ(PQ.D,NB"07Q+U#8=2>/'NK M@=(*8FXW$)T?AX&OPU;@"9.0=48E)KJJD01Q(TB+N[)LSMI00BTY@*!WD%2C.X4%'D0QT6<&H$E34#4&I::Z+=D!O98=7(OWJ+F6 M-_8PN"LU>C!?SIB"9F10:JII$AY0-SQX1KCGSCQZ?)KTP KW0+.FH&H,2DWU M^N27+]PT ACN47.5;\(]=Y5&#\\!*5/0E Q*3?5,4@KJIA37P#UJ^0Z(N=IR M)Q[MS)"<*6A.!J6F6B/)!763BZO@'K5 "'U;T-R=>+0UH#!CR 4PJ)2J,Y)1 M4#>C<*$]:D*&*8I]9,PK(+\OL0!52T'5&+5 $+5%5!LD Z%N!O(/T1ZU(@LK MVAL>NG#7>;03H'0#2DWU2](-ZJ8;5Z]:B(+*]JSQ!EHPQ)C17N6. O:LT59 MT=[LY%<3NU_1_#FK'W*Q^BSXO2CIOXQ$KZKW/TRY/VFK;?]#BA^JMJTV_>&: M9V(&U06(]^^KJOURTOTVX_'G0>_^#U!+ P04 "!3@?Y8(/2=,E<& "8 M&@ & 'AL+W=OS79*E1>+A4QV-"?R R]I ;]LN;VC&'Z]F[NSEQ1=VOU/Z MQ6)U69)[>D?5U_)6P-.BU9*RG!:2\0()NKV:7;L7:_1XS7XP^RKTQTJ9L M./^F'WY-KV:.1D0SFBBM@L"_![JF6:8U 8[OC=)9^TT]<7_\HOV3,1Z,V1!)MUSS[FZ5J=S6+9RBE6U)EZ@M__(4V!@5:7\(S:?ZBQUHV"F8HJ:3B>3,9$.2L MJ/^3I\81>Q/[A3\@V@IB?@6K8G^7*(/O-"[23Z&1"D MA_,78$5K"GXQY09/*ORM*CX@SSE'V,&^!<_Z^.G>!!RO]:QG]'ECGM5.VQJG M;07/$62>((H5]_7298I1J]=JK;Y=J\[J"UF2A%[-(&TE%0]TMOKQ!S=T?K*9 M?")E!P[P6P?X4]I7OT,1RKBT&EG/#,U,76D>5G,OC'SGNF<#)^=XHGW^:Z1J8HX3D0AR2F]-(G/:8VXVN-P5[0F_I]:(Z% J6 M06R/:=2"C2;!7N=<*/9O#1!*5A>MC((%2.AR/N?;.803$2FIL@8O&D##X,T> M_J&0&SNA'7_\"&0C$>P;5L<2V/]^L921)! M]?"]]C$@SEF5H[.4R817A8*W!9(TJ83)CG.=1#9CE@.<<],UV7=Z2XI[*7TF9%(& RE#&R89DQX,+*:LXI$_Q4V@Z=LRO+"MNS>&ROKC2P+5*N.^;7CJO= M:;+^HUL\W [3G7#-W6%K'B@\AC@DUS]YJIS(FV'3NBXVITFZUO!$TK3Q@6P%VL(M0Y-*1Q]6-PRY-_ "I_0%C$/8W\LN3N2=J=9^K82R8[(HY .R7CN!N'2[T.U MR/EA[/LC6#OB=J>9^P!K*72&J&=3C>CWBH$J_;7BMM&N&RS[L.UB(YF-.W;& MDX37938@?F"P,42;9W36I/G[H].E^MQZ_S/"M@SZ&]>I;2>J3+@+'FO+9)U[,'DIG]O*YOL):58(D^Q]*_6TT:\GO@ MQ_T6T2(U]Z%;&*G-N.L"\/36>GTT>$04VM![5A0Z3KJ24\%X:K5IN*_&CK<<MK*^A&!1N/QI+G8[5\32KO\THJMOB27,L>_$@C@7@DVE[7=GC3;<>7 MP?$0XAM%0,J@IT^).35 $/O!T=++5NG9>IKK#(XP^\VJ120*!R8M]L[X1JW^ U!+ P04 " !3M@?Y8"9*C@%) !S%P & 'AL+W=O0J MLOAEY7RI(Q[]>APJ3SH7HK(83R>35^-2&SNX/)=W-_[RW-6Q,)9NO IU66J_ MNZ+";2\&)X/VQ:U9;R*_&%^>5WI-"XJ?JAN/IW")3=KJ?#5]EN'?:SM2IY.AFDZF M9_P.^U\<"K\3I_@[-?:VO^)^8-U=S9X J3ZY0U\$/??';'!V.US8PNU (O M"2D:@_K/;!FB1Y+]JYB'D@)GQQ7@PGL3*IW1Q:!B6?Z>!I???'7R:O+V&?/. M.O/.GN/^UX3X+Q:A?M)U-$4=U)5QD;*-=85;[X;JVF8C]2)N2'WSU??3Z>3M MW)65MCMY.GG[4H&75LL^DZ%5QH'_/0%LUU[YP :FC"P.<MM$:/U +:D&)#>A:FJR(QH]A_VC:J,#"W5L2*B16-I&Y%NQ4_A@7QID M'%1TM<\HJ.B>UE=@ST1#T ^2BSJ'E:XT&;X6.C+@#]6R M#25>60O2H2*HLRR,NO,?9'_/$S,\(34!:<:Y0(N%;DXT[!8O LC!NJC?%\ M%N^#LY:*H?+:!'Z5Z+$M6&D?K8*8$'J!\&*D^'S::?5.RKT5GM2_0B]6(WOQEK-;O\]4XO,D&67 MS[+/-526 W,<'JGKZ^LA6,SUKD1*7 ?X*P^*'JBL.(QMDK-(Q[("A9\3. <8 MTIY]T=0 BVX+X.40/UOIHE3(3KU.;G^LR[PS!=F5M_*%+ARBSE4/U4=\Y]9\'FKQ:U,L4FN%3L6'J[<:A,KYU6]M4"Y*&I4,3B5GK MQ0/.>RV829<8BX[!'XANTN*YC'K9R?XGK76VZPZWLD=JQG"&0L00D7Q.1UT]M3*9D&VW7#&ZH,JM+XI@U$I[3HQ$GAAYX097\-4^ P+^C>)TZ4#?]>O@RU/X> MT,(@$$3Q_8M^LB\)3W+JCR/5RY.D8D]SSGM!%90]@%!4XO,.'ZA]KVW0,NDQM='([6J8N("Z=SQ+ -LQO 9 >6'%+#> TW7\?EVOD5IZ;Y'MP0$/I M-6IOS1T-S]/)<#*1/Q4VR%.I0BB'LE)@G-VUZLT/@.4G3,U=/.>)8,$$G2: M UL,ID(^OID,H(0(&P2)-KM55E[%Z2/9$2Y*/$UEH/1!(-K44C-],UNQBB[MWGO]^*SPB[@:PZ,- J3M?,;>Z4:QL!_%!%*R)@6A[$K?D+*,J[I/MD04! M,AN*,3/4F,ET9_VGT6*D?IS-;O9>EHEC71>I<;7ADH,+RFHO#5R.O7]((#A M,B$<8OWB_;QCR]A9NQ-V?,43$7'A#E 'TP3A2'@0&Z*5D= .0 M;>X]E;7#-H5J6 U4H;O]?E "VZ$66O=N5" XVI=4G&[@>OU%(S3-1J MA:T_="#6)B-.&I*#";2J3=P=YE**<=>CI0&& M0+%)LU1JT815PBW^O3!Z:8H$FFU)>:P2G/$ /H#U\$J,VS0)?.P[='65\$,B+\M\U4Q^#2']4+%DW MMIGGB13+B/JH[9W%@-6ZAH=6L%ER(;';;J_37HK&+JF<" _%;M&PF4AG&P-3 MN]X6#3!MY1G9>"5%+Y2@8X[O>2R9;*(H;XFW%, MT5TW4B$[5C6O1\$YR],;M+$P;)N68O1#@G+!DHUFD8RT0Z'MM"BR?U"XK;8RXQXAR\("DU+"5+[6,7H- 9.95IA6+DA,-!Z2&4YF;/+W1O M%92]E-:R;3>K>L+F3(!%YS)W\M"P6LGJ#1LP%/.6&U13[YXO$L-3("SS'). MT:,,DCQ%"G- 3[4CRG:;6CZG.51C=&S#_>E;V2XV#S@+Q+F!,>%X=PH0>^ M.6#<,'+]T%0O[4'+\01'$JM5'='L9=>!4;*0M[=WAY66RVR;977)S9CX*F.% M+(MIECS]83]+CH[=C(U[%Z$2(+[N9:C"_);N1+NWW8WR+%VD[H^GZ^B/VJ\- M?%'0"J23T>OO!BDR[4-TE5RK+EV,KI2O?#=$G@_@=YYWV@<6T-VS7_X?4$L# M!!0 (%.!_EA2[%=0;A($0U 8 >&PO=V]R:W-H965T&ULU5M9D]RVU?TKK$E5(E7UK)*7:*L:R7(B5QRI-)[D(?4]L$ET-SQL MH@V0L_C7YYQ[9#L9>0X>?E>I&XV<7'7AFIEUF4X<1O3XI>%\^NRPU> _/ T;;\I:%JV;TXNSLZ]/UZ5MC]Z\DF>?M_)M7KN\:VYI/O@C]>EWZA[>F<7>OC\Z/TH//=KGJ^.#TS:M-N317IKO>?/+X M=IJIU'9MVF!=6WBS>'UT>?[B[7.^+R_\PYJ[,/I<4)*Y=$_7N1';+,RV#>N>:?MNY6KX^^/2IJ MLRC[IOOL[OYJHCQ?D5[EFB#_%G?Z[K.+HZ+J0^?6<3$X6-M6_R_OHQY&"[X] M.[#@(BZX$+YU(^'RN[(KW[SR[J[P?!O4^$%$E=5@SK8TRE7G\:O%NN[-E5VV M=F&KLNV*RZIR?=O9=EE\+P[<6C!'_HVY/BV=FLN#B[>/X(O6=9XF="[]D!>GND+/YUM.0^=AX?\WSZ!E=[S_?08-2_"IJS,ZR.$13#^UAR]^>,?SK\^>_D(M\\SM\\? MH_Y[[/-?$2RN@RGO M;@$#7%%T#M]N3&$R%V5;%V4 =&S(1 +95>4BP6"6]@!@\Z3@7)-D0+9Q/NF MTZ6-+>>VL9V-I&H;JL:%GOOB37!'+7#K0XM"$IQR_@XES(3D(5;-_89T0E'W MGN88WN.WC?'6U2>P5]>#*)@&Y@3LV3<4!5KPQ<*[-9:Y,-+:23&V]J!,VU9-M7T,4TQG8I$T[ICTU(;2S""8JVZ.B8>4?4WNQ3UFY,Z4 MOEJIGLTM<%_6 (K#_:A"6@^##JO'D8_)27=EDVO_E8V2!Q0IRG@0 1^7O*=D^+'P2V- MC9C<6T/!N-Y!:E@1&.0\]* F M2H:I>LA,!J TM[958=I;ZUVKMKA;6:A[%#YSTUA# R*.YG2D,KBVG#>FZ.&O M7DE:7_5K^"<84!46[V#'LH4UZI^1> (2-<@>EO)N95IA6'^;(175G3]D^+= MJH21!0.VO#/Z,644YU6'Z/F]&B\R>\4&C#2-2K=@8=QX]N'(&C1=XCW&$P0 M^3*D1]!5&Z4 >L+(\ "'RW;UE&?.52PC>7$+&R01R^W!>5E-"#A^;AL0#= MUBG4Y:"^ME.LE0A\!V^W7?'9AAMY_:,X"K_J\FLL\!W*+\&I^+;GVP 0!B-% MHU[* >TE 5"[X1;46/E@!6_$IMBVE()E,#R/H^&\.V2+%]Q$)UV8WK\%6U%/KYSPG,DR.";#76AT#U(.!,4!<1 M)<_+L$*H->I^+$>I$_4*[H)J/8SP?:09(I H!(@Y$F7*C2?E"+GDB ZO&F<8&G[&M*P\S@;.B[==S^!UTB&"I@5%B=.]N+1()JQY;D5CH-YLF9=D4! SU1O(*UE#% M!W,$"""Y]N=[+*?D@B,((P?4>!HN;@1>FAA@&DHYP[V_2A MV(Q.J[N*(!T@&[:@P@7]MJK$3ZY=MQY6,7D\,A*!7K >\(*SX5N,J!A8? M_@(0L0LF6J0\L-R6[%?2KF!&-GX0496O0= M_&Z"^X^LVZVLKX\9TP],(SU! M'=[K18$S#0#0A4>)B54=AQ=%#FG,NJ]RX$;S(!LMLW&@%CMWM34YBR@Q'G^#Q1K24H^5Y0-)HX#&Y91(;*6\"5UG1BWNP:4_W9,*"1 MDWC" V!#4WH^4R7VL@<5ZBO)9TCURS5)&5KA]0UMVZS*M$^5@8.5PD.ULBN M_F&V@U,B)R@/%JLK0=O6+-4] MEXT#Z,JJ5C":E11-.8R[R#JI%("Z,M$L>BI4^JJ0=87V8GQB6_PT,69M0O+T[9WHC@VK$A8&N81.VPS)*9&&*9)DB3$I-/!^U%I$&<+-L@=D,7.5&^(O M=A N(AU]B!JY..&Q/@IZ&_*()H$ M2?U2B^1D(+!>L."@+<1]V9ZV'A4,JI6)UT")"&7_$GQ'KH#^D@%O;)F4;C, M0ATKP@+Q=(/P>4)%7IR]?/?QNQ_EX_G+IX0%OB=1OW)W]"'3/O[U&82%Q^7$"W8,)JKT(>#BS$+]@9#F'NP@$]MQ#)2^Z=RVNMJ=Y,AO_>L38*BZPU9WU40LY+*S*=3J:..^I2G(O$RDO]3&9.I; MK*Q&);I$ UQ3]U8TAA>,>)&6JTT5KJ!G=*']:FK0S1VS*Z[SA("- YR)631V MEQ'SKUM+S5QUVH._8R'&_>3#>\0Q9!2/'"<=*65KR;D(DY5=KIH';(BWI]6H M=!_L+KU=6F(G;,1:--8KW@!?= 'DS0L>W='%V4%LD&S@[:(4BR:@;63XL-H MS_U_C:NELCWG?2<93OECRKQAF!(@\0%3)W"M;Q/"ST83;O$YQ5L=4PK'ZYJ MJP;V ;!(:2MHLEM!N' M6=ICL,WSM?HJ^HQ^W6MA/M0'WJPX<[^EI/ANBB=<^A2MW+290&7:,,M8YW5> MIP:?Q<&8=F4[[P,K\B1&D!Z5*=- 9#;#$AB%NN#:R']NGS04D2@90J1CO1 MPF-!5;@D3IRU/9VA,NE2S!Z8Y.4) K<8G +AL=B:F U6D@[9%JI+N<\"Q$' M*-?,9+_*MM"8@.D4V8:9$U*6RB$I5WRPL3=$'W%%NO1VZ3,:DD1?9\^(TD15MEUB:FP6I:?.+*M5N8L:K4$E(BQS%B0+2"HF;V'5&HYA[MN,I&Z2N;W#KDSB@ M.$X_Q77)8L,$HMR>_$TWBM:/#7^A!UB*0E E@C@@[4N6U6E6&BL#3 @W8.3ZMD2C).,%0RIUKY$#R#+P^CB?]:*+[.X**;O./Y#;#M.3#,"W1=U3S-HR+&VVR M;*IYQ[,<(ZDJXX;6/I*YF!E@?*W4FA?- MP9TQV2-D$D2/D;#@ZCO%KJ*%BQFXO%'/MZ+3@R=]8.A?G8TV$I[DC@EOO,N#F M;%<%,*)XDI\6P).15I-*C;%?2]9&W.AB MLE&DKOXN:/0E+>8(,U86U4"GJH.K29(9O@T2'&8]>:/,D["CTE]F,X.RT1: M)?Y23!K---'(/GM*>T1WAI=T#$K/QC7&$>*D5/C4!. 5DQ6XM6)-O(8\RYK*9R@$#:^ P YK.%M!"[MJ46..$7-2)WO-+],1B]K83YYJP-:D M[D.S%REI'(^^NMXX;93A"S@% G'^/ FD?J6IYV9HE8^36.W]E%R52="--0 M%[G&W02#ACU;3:N;&.C"HR)F]ZR>GHAPVW$L%%$].F'B-!MX@#H\U3902ST9E?"LU]0E"B+/%2:F< MV[G<0*SE_<\%5(#*>PQA31H4J$*>.!D[S$;">1\@!E]8UL:&2 MB#P9C30:U4DL:D1=[*IS[Y&;HU*Z$E&(EKM3$LKWL5L%&6HM+!5VB(?26U1RJHEBY!-SBD;=?BL2HDHX4J4 M(?7:#I/3'1Q*C669&EVY4Z!+X.RQ/=M2^)C;G4L TRHU!;DLD^D:I,Y%SQ0) M$E.Y0Y" U^-'GL"O^_469P5K[RV9I\UD'W(Y5"E6((_-4?RZ.QFLD EEBZ-1M?!%7VM+BA,OQT&?H/F-5=TA.&6E-+Q+LE79+O%B_#CX0_5TGA')PZB35ID,FMQNUZPVLJG<@V<2SL'0\2..5M1AN.BMIQ8BN*MMIDN9E8V]YU)]:7PI.BSL/>TKU15+$]L9[80*164B8UX0+X#*U/' MB>?_8_YL&*X:/.3S'@G#)%EL1\T]!]&!2A+D3WE&28P#K"QX,4L C#>9XKAQ M3V@H.U&S9'T+R;1GU]XY02Z!.HX9(ZG9(4[V;:B%B!P]R062N%+RI_;UY>@\M:F>D^*610]B>.>R<\7'J&=/?D!MCQHC/>2[CVN,1@DQK'MB4@PS W^QI/IZ:-TC8I7((*>RNE\9%2MZ6B#-..@18Y0 MY<2$-[A6KN$L-_JDU)"=S).Z6;PK-'3NTJW=1SP0:Z?]=#9(G>J MY2#[_LD M$8\VZ^*'N&;[G'**_CP3(=PCTTLW:/7+^[,&*7$*[(CZ,V^1X8OX_N/WK6N MCWDM;!'QQ14CV1,?*G&YR+RBS>W1+3Q-9MECYB6"UY2=<;*"UOXI?R,1 T? MJ 9<0#4VNJ+U UHZH('OBH^]+][R!AFSSA4?]9O ZX 4\>(,SO.$"^(&/WQ\ M>\4?^PGYT\3:.GD=&T&L$_C5MDV3(_N1BE[(4NR/R#./#1(:S<"-G;*):JEE@?M)53$._!'=V0[5W=.D,63\5C,_HH(O:T#&*#7GWZ;6"3&GWRPKP/8' M]/=X?-AAT>#^'4E*[NAH7)&+[R^OWL)_=>W5M?QR?/;-+'G*[HGJDY;# M=+<]1W*CZ[IIDIW.<[SKE^A]VU4IMZG&]WK+N4._/>ZS$[G4U6JFH&)XTJO(M>&NVA^VL MW+F#8E/GX-+MM='AZ/0ZAEQN21$CWVT8.\M5#H[KC1X"ZD3CRU>W-0_J.'ND M7)FH9!&^Y'!_S@[W00'XI_*>4U+UM6^>[_.UX7@BS?_:#[[Z?V;-R>#%&;UG.)P%#>QTK#JAFS)?MGLJ,_[=,[/MKB=/17[8P;U[\O^K%DUF7! MO,#2LY-OOCK2L4/ZTKF-_)W,W'6=6\O'E2F1C/D"?E\XUZ4OW"#_X=2;?P-0 M2P,$% @ 4X'^6'KPGBO^!@ PA, !D !X;"]W;W)K&ULO5;;;N,V$/V5@1H4":#:NOFBU#:0>!-TB^QND&S;AZ(/M#2R MB*5$+4G%<;^^0TIV[#0)BB[:!YNWX9F9,Q=QMI'JBRX1#3Q6HM9SKS2F.1\. M=59BQ?1 -EC322%5Q0PMU7JH&X4L=YBVJIC:7J*0F[D7>KN-.[XNC=T8+F8-6^,]FE^:6T6KX1XEYQ76FLL:%!9S M[R(\OTRLO!/XE>-&'\S!>K*2\HM=O,_G7F -0H&9L0B,A@=Y7VXN%\AW[M?"=?5DSC4HK?>&[*N3?U(,>"M<+=R-[['GX)Q>B_D+D[.X4.2O?,<,6,R4WH*PTH=F)<]7= M)N-X;8-R;Q2=N&%M>\9G7& MF8![0QL4' ,WA CO::%G0T,66=QAUFN_[+1'KV@?PP=9FU+#%:G+C^\/R9.]

M.]'.G!#%$3)&WCQGI[8X<6OX'U2:U;S/YGEQS_@PB54G<.M M0DTDL!U_+Q"DX?>+E3:*\N^/EQCJ#$A>-L#6Y+EN6(9SK[&ZU -ZB^^_"\?!
MCV^XE^S=2]Y"_\^C__]IITA0HU)FZ\)R];7EC97PX2,UMJ,SW)U!1O!<6VS2 M;DJ$0@IJ4KQ>G\,I&6)*V6JZHL^ \@I=7KW##*L5*HA#'V[82BIFI-H>H)[MV$\FB1OC>
(W2$VCE"('7C5*/O1)$893[,DM(8 2Z;R#5.D)AY!%$5PW:J: MFU:A#P5_M!/M')!%P3,\T!A'B?N1FT:::;7-X%I(M8TC3L2/3J+9KAN0=V;(F M2++$'P#'T12F?DH;-
W1V#A=9UE:M&AV+2B8D#L6].*NJ$7)+9&040]+4A>P$(C^8 MA&XFE?=BY,()G&X%Z34*RB["(M2Q@I;0^DS2H9!@63XB-(_2D:]YS&E
M9CQ)]RD6^U&_^7=D_,.'JR\+>(64\SRP![KP3S>P4GXFJ)U%W M_LW4.87.M^?JB+;$GTY'- E3/TXGAW8Z:5YGHK7I1HKZJ,IZ_0-UB0J8UD@@ MIQ^E09B>4?
4&0=3_[PB*1H0_L1,JZ#3M:?P;QI&/1[5&Z^>$]-42'X1 M^8&I-:\U""SH:C"8C#Q0W<.L6QC9N,?02AIZ6KEI26]95%: S@M)O/8+JV#_ M.E[\!5!+ P04 " !3@?Y8-)$Q]O,"
"E!@ &0 'AL+W=O*OE-U&Y>AG, ZAPRSOI[O7^(X[UY)ZOU-+V;]@/L3$% MEYUUNAG!I* 1:OCR7^,Z' 'FT0E ,@*27O>0J%?
YCCN^6AB]!^.CBZ:6AQ'IPN'Q>A(T8_'I8C^F9)R?0!7S2RM46WJL* MJS_Q(2F9Y"0'.3?)6<+_.G4!:<0@B9+L#%\ZE9?V?.D)OO<_.^&>X?OUQCI# M)^#'2S4.%-
G+%/FE7-F6E[@,Z-A;-$\8K%Z_BHOH[1F!V20P.\?^U_4_BWY9 MVS$E?*[1(.S]*TYRED4%FV5SL#6G>!#6=E@!5Q70A;6.&D+M@%O06Z"]P&DO M+N
/VOLA605D"_"A_(D+R3<2^T0[PY6#CLZG M\87$,!Z).\JJO"/ 6E+F)&59=LF2=$Y1+)E=LKR(QF)UZPWD8Y&K,Y9G.9NG M.<09*V8%2ZGYCV*:5NIGQ#'3NC-E31XS:"
(R*NLRN824Y5'.8A+W63LN#]MW M.3S#] MF5;_U!+ P04 " !3@?Y8"^V,32(# E!P &0 'AL+W=OB2*T'Y[]0@\BP;XVE3=8P=^=Y M3F6#K:*9Z]#*3NU\JUBF?
I=3YU%5$=2:?#&?G^6MTC;;KN/:M=^N7<]&6[SV M0'W;*G]WB<8-F^PTNU^XT;N&PT*^77=JAV^1WW?77F;YQ%+I%BUI9\%CO1,YM< M!N#A^)
[]58Q=8BD4X94S'W7%S29[ED&%M>H-W[CA/QSC>1KX2FER/Z,]$7#Z#/X(VSW!"\M!56 M/^-S43+)6=S+N5P\2OA_;V>PG)_8KY8/<*WG,);1K[E'\.#%YI*XZCW")\N
M"F(O%^+SL9 3X^HX8RB2<^I4B9M,IB#0WV*V??+/Z=G\^2-Z5Y/>U6/L?TS' MWZ/A78-PY=I.V3NY^Z7K+1-(%8-.5ARM>DF<[3VP:?:R2- #%]T'PEO=JP^\H/6U:+?
Q09-$*]KZF+3ZO0&7*36 M]\,\/2!OE-^)?S!8"W0^^_=I!CXUY31AU\5&6#B6MAJ'C;QCZ(.!{-?.\?TD M.)A>QNUW4$L#!!0 (%.!_EBKT:YX'PL ? 9 >&PO=V]R:W-H
M965TI"7]W'NO8?4ZYW2G\U& M",N^5&5MWDPVUFZO+BY,OA$5-Z':BAIO5DI7W.)6KR_,5@M>N$E5>9%$T>RB MXK*>7+]VSV[U]6O5V%+6XE8STU05U_NWHE2[-
Y-XTCWX*-<;2P\NKE]O^5K< M"?MI>ZMQ=]%+*60E:B-5S;18O9G=]*_<[;#EB4WXITJ?Y.%W;R9
MS">L$"O>E/:CVOT@6GNF)"]7I7&_;.?'3I,)RQMC5=5.A@:5K/T__]+Z83!A M'CTQ(6DG)$YOOY#3\EMN^?5KK79,TVA(HPMGJIL-Y61-0;FS&F\EYMGK][\W MTN[9ASH7-
?F'W9:\-HS7!;NS*O]\3B87[)VJ /#R9.O+RP6IND7>;O(6[](M\L0B,_:3JNW&L/=U(8KQ_LHW&N==%J_39X5^&-3ARR- I9$2?:,O+3W0NKD MI4_(N]MP+<[?.E-
O^1Z@L^Q&:UZOA;O^]\W26 T$_>>8\5YV=EPV9=65V?)< MO)D@;8S0]V)R_+UGO'M5JM[B*&'-(4=79:=?O/5/$FB5VX(/7'W M\:LSI\]A MJ[)$I2R:W
^!'Q2&Z)W$XNT*XHNE1#LHN-R[Y[Q T9.4?):FK<8FGM$3KV8\ M/6E?2\U$*=>25,T'Z N1VG_2'P,H$A;BRU=FY"/&+9OW"S,X2/1*KC@40:/[
MC,YZS\M&O$B@:KTGM;$,5A>R7K."[VDRPJQ6*Z'I$327JG"N]#-*/II@!4,@ M!,\W![O\G)#],D@P)Q#.8$9^8155ZH3Y%FL9R;3HVJQH
MG)Y#G0GB.PDL+"&;RTX&SW/=(1C'-D-I&TX$KQ6ENWAQ*40-6O,T6 -E'2: M0$,8U:![XCX'=/> "7F* E[[,?"H<"GE2OQ.PO1!>+R;ZJ9:^I >0)'[>!D/
M@%%Z2V,:CLKT,,,)J[WILLY!G\B.4;#;(+N0K:2!TK"::PHCE8=*-=!2_-[@ M>9LSI:"88\ZI/&-I<)EFP32*GM TP"@,XT.3V'&;^D54[4! E9:=QB=G'8*M MLAAPS#?P-,L!17-
$[(/2/L1M:SO=RZH2A01^$3(TFUPX0 \<$A#H80N,,0U\ M]4B-0O@H'XK(S:B(U_J+6A<>_A=U"%TGXW4#'LOBKA_88X Y .08)@Y86)*@ M9!H%L_FLFPN0$YZL#
[@T;"6X;;0(GVN%GQXWEV#D^!R#?!^2_P%< M5!N+I>"N_<-W+>ZWY!CI,TG+-=M8X[H64CBG@MJ"[N$3>$%:SQ* ++>IH'SA
M.ZZ1L;!3M%W.:W'>W;)"8CWHX^>B5ACP;JI(B(57C:U%+;3+=?%EB^'(]MJ% M"W-6MG6**XT(C_/ $TG^LJ1VWO[?)G4\#V:729#T67TLB[W.O9 5Q;//VNG? MG;6-
!3)JEQ#_SQG,_HX4=@@8I? ,*0Q6F$8O2>'X\HD4OK$^8-1'*3R%3[X1 M_>E)XP/.!]^L&DWTJDNJ#J(.\5!S:,23*AP(-88,"74X8O?M$DB3E9 D'-') M*5G*$CT>
''.L%V=CR+YW=>U;RO'OB'_] MVA$O+ZJK%! J'F.$"Q(R9(JX\3E(+UK?>TN# [7SG(Y4'.^["!N0/;._Z&\H!^TL'5^R^T%Z& MP66.X;NJ>L:F8D>(E 6ZQ""]/\#Z.XC ^P5]*?
W0_ M"T&I'[U.NOM+>MU++.2]+(B0:@IZA&5/COQ^E.8SX"BH4,,(A,6/S\+82!(;ACST!]I]N3X,L)_?$U()H ."[$[,*%3$M[$-AY^)K#?.<^BCW*/?0[Q#
M]R,W]';4/B]P[PUI:/>'&6VE,1*M'NC'RTK8C2]"MN2P'8J9:!O!6+QK>MZA M2 "[P429L\ZE;0(/3>LK)ARQAIVEWW7 4M<]6Y4/:1\>@^X5^Z%W9;D?DZL^
M\SE<)N_)4WEWEH&E*?7=5J?? D:+5[33I[0?1H@&.X>,DT;6_AR6PN.J(> T M;-<."EK@E0C&_AH(>6(?.FK[._ZP#?L"1B7\X-Z!PKU\Z4NX/WAU=:MHT+C1 MAP7M-
LA*A__9>L:[6I[VPL>*K6D984A[32=B2A//?I3@P=@$-L1S8+1+ BW66+##_]C/%!_: ME/N8'JP+;.0B/%+%]E*4Q8.",BYQX!!_"*V.J8C>[Y7;4Q_V_N];B% \=P^ MO)-
GB,$]1A#5RO/'M=(KI8^_)*V60_K[*;P#%HD8-=#&6<50.>[]L<1J!A%!-]IWGRNW8QO)0U^A@C?;J%?$H#[<_BPU?,'VC=#,< OLV:L;- MO"^#
[9&&*]'=:8FAHX:'_?.*_;/GD$/BP6X\-']KBS^[:5/I?5>/;PD7C]]_ M=#6?%G\W*%?_D"O!3O_E6_'->DU 1"@^T#%*;5!///OQ)W*J,<@(#/QYP."Y
M2]5OP8^=NJGGP2F+,^P[9D&:3MG7Z'RSU!,K: 1RFZ3! AN2KUD2SJ:]Z@4[M33 MF29G>!6'R9Q]U[/"TS2+@CB;GSEQ671$B3$!B2^#:38-YJT"V26[#.>X
MA$Y1UM,XJNQ$>I :PPY)CU\H]=>A!&>(@P*0.9ZY"+)Y$BP6J9LX3\%J%KB< M!EDV.WXX3 Q')ZP-.4D@ZJ1-$KI?"[JB+/7N0 M.3X(:\MM3RU%N!>EVCH%D%?
(HIG[CS+*AR1(LL3]T\3O_0&(FSBR81HLIG-V[$O6Q>"K9"7T MVGU[)3>CV?H/E/W3_O/NC?^J>1CNOPW_Q#78FF&E6&%J%%Y.)W3HM.EOK-JZ
M;YQ+9:VJW.5&H.UJ&H#W*X7&T=[0 OU'[^O_ E!+ P04 " !3@?Y8<5"M?8!(4,($)#@ :%G[]7L: "G2 MX,LTU97(UFH_:!;W*U=O1@Q_;J6_]
[[#ER6WXE:KKS)WZZO18L1R4?!&N=_TYN\B^N,-S+2R_B_;A+6G MZ8AEC76ZC)MA02FK\)_1AQZ&Q;3[VQ(XX;4VQT4>2O?<<>O+XW>,$.K(8T^
M>%?];A@G*PK*O3-X*['/7=_JLI0.*#O&JYS=CLK):B6J3 I[.7'00.LF693V M-DA+OR/MC/T* 6O+?JYRD0_W3V!99U[:FOG) WKQS M=^[ES?
47;OO+WLG;::T;8Q@[I96F>0,_]^#H6@Y.1Y)51'KVW-,W$U0J%8 M81[$Z/K''V9GTS<'7#CI7#@Y)/VP"\\9>U#<\\8>ANFN,=D:E<#ZRSZ!)EC= MOLGZ @
GV(.YM=@MT 5;:9T'\:159I!LA.).Y,SIA"T;QRKMF)*0%)^1@1P2 M_*YI7Q*@,5*4B8RL? M:CMFG]=BRS8"%I-J(S)MD,B,6YC!EU$# YN0,]B7@Y[P'I^L5C+WQB^Y(N$L
MD"JVPE?DL>CRF)[1?L!7\VK+UCSWZK;"JQ2@J=PO:.$(2 '"UI$QN]D7F^P) MU=^-"<7C&?PA\D4ZGH-HE)T"3W8K"4 ?S$;G[>/?43%8PUB]7%A2]&WV^AF
MM?:V5.+1L5G*2D*8_:+6"$:=T9G0N3()\O>&UTR!Y8J,?1_Z$3)MQ .PP63 MU8-6I$!6C,*PXB[T!4 $4;0 4UR6E&_2TI/"RX8TQ%!6Z#A H#$A]Y8-EB
M?,0'ZD+,T2TRTW 5D (G6)\ENQK@UNI,^NALI%LSY5U#RW*"6& &X*5CTE(B M+GV6N35'-G1YA#0#F@2=K++&&)&'Q"6#>:D;$#+LI&]!.Z\"S-PBI9=JRX0% M7F0
DL&OM\%H6.1M]@8-C=:%$P291$&3=6"[IP$X,%0-I51*X"'X&L@1Y5"6)10/ M_SWG)28-RRREJ*-4\J342TA*[::R#=B?PST?8* I4>F(+!HPGKQA%G#B;2$S M;VK .D?WT
"4.U97]!4<8 ^BNB> 6\2\E0MK &Y 3ZHAI%ONFSRO(Q\"&H& MX+\A!["7]ENYJL@DV.UQ(53(J+KIM.6-@008\WN#(LFEGXSP1"(^Q"J#!-]
MNRN#C6Y4'K,52(P=Z*5<0L'LQ)/=?,@3A50PPS:RB^F7RC>-><^?SZ8GP MMAM]U(:LKG;OD?ZW$DLJ"1G? 68K6/WNN1*KQ#MGRHTZV_X4Q&)0WJ5<[#%
M6ZF=QB26L]5-GZYJ^2>L ^0)!UB04H^BVQ=:LS.D\5)FIQ?S'N=E;W[>(,4 M (&6$JEFFHS*F]JF0H*)' FHT Q\7^LH]"_XT1)_!]://RS2V?D;.VCZ=VB.
MI.!N+)'L8CGTMDJS>*XNT%W-1&*C:[>*X/ MMB+>2X-(W@!52EYZJZB&D)6YH4$!$0A5P R7-N3WOBM[AO3TI^E0/V6:%TD%
M0DV(""CL(FU_03CE6*FUBRAMV>QL7\7*H.#CP%!S0Z47)2+H?\"AD.^<.5'6 MVE ?!,%LV^[28Z$Q^[J6OE/MX%L*)<'\D>517VW7"CU-$SD]<'A/,XW& MLF
MHR]$:7O->K^W^]8W(*[("KZ 2EZ!"'T=Y#),XX0/!,-H*E[(F-/ZADC&.($80 M#R=4#)2,D M&LJQMX $".3A&A'V)PB$SF M'U+/AY*P(#80NR^+*DX 3X4I\"NWU+L=9-
O#O8/\CQA,WW^S[8"#(L:85,>IB;*MH689D*'1)3@[M'IX MTMD?RE\'P-FGGIB??%PPOL !^Y+=R\?M8-K MT6_JRF531G]JO@W.H'$L+BY@OK6OV85>2I@@B14@A2OEI-
DW2B_.74=135/IS MP LV3Y.S:Q[9K!PY#ZI/3$4P.+3Y#$L @&29:'J?<_@1"XDIHA!^^0@#_ M(5/Z6[WP AF"8V'D^]U6?UD4]FP0U1?S\>GN] /[<$I:[$Y)0(0.0YAJU'9X
MHJ!}$$>G:; #XE(&4O8R M;KIW>/5GAZHASXO*>X;,T3T5@;EB#Z"8^!&[KQ(<_R!M.#+<045#[0$R_%%A M)^BYIA($@7_7&D/KFIM2"6OCI4$A*M^0.WTB]W2\
[8YZ=$!H<-@P[>P?SF=T M[B!=>QO'U,M%KZ%&NP,9^_N+5JYO,IK 'AY2I;VA Y(3H<+:HPKA&,WJ$ L)6O)'7_2UINY$V;4[=+9\V#)!'"L M/0?0;"%-F"C]$2XT#JRU
PSBL:<[/OGF]K1$*HP8/:#I$&BD)V+K/&@Q;(IO M:.B+=R'4*=I^W)MO@PF'TNG +=QI=PMW^K^]A3LH[G@+=[R%.]["'6_ACK=P MQUNXXRW<\1;N>
MWO(4[WL(=;^&.MW#'6[CC+=SQ%NYX"W>\A?N_N(6;]'[) M6 JS\K_7I,,00 D_:NR>=C\)O0F_A-PM#[\GQ3R[0JVBK ILG8[/3T?,A-]H MAB].U_YWD4OMG"[]1QR=
1\MP/L",U_[A11T/Y2]_B]02P,$% @ 4X'^ M6)[L+2GE P = D !D !X;"]W;W)K&ULK59; M;]LV%/XKA#H4#2!$-^L2US80)QFV8>V"IEL?ACW0TI%%A")5DHJ3?[]#ZA(7
M<(*AW8M2]0[S?>=&'JT.4MWK!L"0QY8+O?8:8[IE$.BR@9;]<]F!P)-JI8: M7*I]H#L%M')&+0_B,,R"EC+A;59N[U9M5K(WG FX543W;4O5TQ:X/*RJ]RLV
MI/K%]8^Q&L%EU=]W8/[L;A6N@AFE8BT(S:0@"NJU=QDMMPNK[Q3^8G#01S*Q MD>RDO+>+7ZNU%UJ'@$-I+ +%OP>X LXM$+KQ=
<3T9DIK>"Q/Z#^[V#&6'=5P M)?D75IEF[14>J:"F/3>?Y.$7&.-)+5XIN7:_Y##H)KE'REX;V8[&Z$'+Q/!/ M'\<\'!D4X0L&\6@0.[\'(N?E-
35TLU+R0)351C0KN%"=-3K'A"W*G5%XRM#. M;+94LY)049%KQGL#%?F(G?"[U)ITH,A=0Q6L H-,5C\H1]3M@!J_@)J1#U*8 M1I,;44'UK7V 'LYNQI.;V_A5P-
]Z<4Z2T"=Q&"]>P4OFL!.'E[R =T.58&*O MR>T4)/G[-PB[YYU2\ )SB-)R].4O=T1+6'EX-#>H!O,W;-U$6OG_%V<7L M[.(U].^NT8^CDL\-D%IRO+J8+6+HCH,F&O7P.3 -
,7A@/*^D;P"I2VK M(S"- G" FCV2=N@UL+U&L%-@[A2G@D*RQ$BLR7%;/JO>(RWDD?>Q;4-1(M71)=I'_EWA_(N^BP@^C\,R) MJ5^$A1.3S,\7PRZZF>?)&;D&(?
&!&%B^N-<((Z$/2+R'P4E->HU[&--0-%O3 M[ZN$?Z*F49SZ293[61JBO/"S,/&C(G+[<9SY:1J/^Y&?9_%S)GZ4>6G3$)Y' MB[-12$8AOIB$],RUZK1_Z=6 M1BLF*
[2V[X:P@#LH*=8)RV0]6CWUOE4V..^^31#6-UU@'R8IB;"4%Q=^ MF*;DINVX?$*>06DV[3BZ&247?I%%),=.#A/R61K,_UP)_D3F&"8FET3XVK,'
MRE%+6]:L2)$NLZQYGB-K<>IE#8XF(5ZY0OW&H'Q;@Y#<=Z=/RDNATGZK#Y\ MCWR@:L\P%1QJ- W^\]0C:ICQP\+(SLW5G30XI9W8X&<1**N Y[7$&,>%)9@_
MM#;_E!+ P04 " !3@?Y8ROL8!7P" "Z!P &0 'AL+W=O!ORBL)5[:V24/'#^:(QOV=1QS8&@@%09!J(_&YA#41@B?8P_+:?3I33 M_?6._8O5KK4\$ ES7ORFFTOVC:Q@X&#
MTEHJ7K9@?8*2LN9+GMHZ[&\EP!^"_"/ >$+@* %!.=F"%M >&Z&00NPTG&C MW18N(8K$D>!;)$RT9C,+6WV+UO6BS+R3.R7T+M4X%2_),]I(M 1AWQQ+ 254
MI@67M0!TB>[O$O3AXB.Z0)2AGSFO)6&9C+#2N0T#3ML\LR:/_T*> -UPIG*) M%BR#K >?G,8/3^"QUMP)]W?"9_Y)PN\UNT*!^PGYKA_VG&=^/CSHD_-_V1>O
MSGY0C*!['8'E"U[S"OHNNZ$+^^E,.;YO(BJ0P=73SDB VX,3OWWE#]W-?I=^2 M+'E+LL4;D1W<2=C=27B*/?ZAAX2^@-[_6H,<6J29!)OXTAN[GAOAS7YA^\(&
M8W=\&);TA 7#47C$MN@+CH MK9.*]9E2"6-LI(%'*:Z::%]EYNT%S;?OK MD7_F3>9>CS_1@ZF9(__HFZEV0\2:,HD*6.E4[M5(]TK13(K&4+RRK?"!*]U8 M[3+7PQ6$"=#
[*\[5SC)NG$=_P502P,$% @ 4X'^6!#"[$!$ @ B@8 M !D !X;"]W;W)K&ULG95=;YLP%$#_BL6D/;6! M0#ZV#)"2;M-2J5.4=MNS@R]@U=C,-
DG[[V<;PK(IH5)>P#;W'I]KQ"4^"/FL M2@"-7BK&5>*56M<+WU=9"156(U$#-T]R(2NLS506QJHE8.*2*N:'03#S*TRY ME\9N;2/36#2:40X;B51355B^KH")0^*-
O>/"EA:EM@M^&M>X@$?0/^J--#._ MIQ!: 5=4<"0A3[SE>+&:VW@7\)/"09V,D:UD)\2SG:Q)X@56"!ADVA*PN>WA M#ABS(*/QNV-Z_98V\71\'I]UM9M:=EC!G6" *-
%EXGWP$($<-TQOQ>$;=/5, M<2\33+DK.K2QT47O'+]TYG"08SOFLL(G7>[D;/\C#5. M8RD.2-IH0[,#5ZK+-G*4VY?RJ*5Y2DV>3M?F> E(]"0QH;Q 2RDQ+\ -WR$HN
&A4$X M&>!%?;F1XT47>.?*O$&[5[3FA.XI:3 [5W4+G9R'VN]FH6J<0>*9#T.!W(.7 MOG\WG@6?!I0GO?)DB)YN&P9H'.RFM^-3;;0DHM;_'W*K.PS,,5,P(#;MQ::#
MG.^"WUXA-PQ]2V[6R\VN.K4GD.8KPA??](<* M9.&ZH$*9:+AN6T6_VC?:9=M?_H:W7?H!RX)RA1CD)C48SZ MM;>OC\Z/TA>?S'(5\,7IFU=KM=37.GQ>?
W3TZ313:4RG>V]L7SF]>'UT>?[B M[?DC+. G_FGTK1_]7>$H+CCTCT M*.^)A>._$_6?^/!TF+GR^LJV_S)-6+T^>GY4-7JAAC9\LK?_H>.!GH!>;5O/ M_U:W\NS3QT=5/?
A@N[B8..A,+_^KNRB(T8+G9WL67,0%%\RW;,1<_JB">O/* MV=O*X6FBAC_XJ+R:F#,]M'(='/UJ:%UX-_C+T]$;%>C#PO2JKXUJ*T_4-3E?\)7J&_*=VG9K MU=]#+5+T-)"?
E=#7T:F@,5N*AE;K1U5SKOJ+#K^GWIC()+W4-D=5DV6'%GZ/, MU\[0;NN6J"UUKYUJVWO\KM=!U@9B]7//&UR#(3[]9:<=V6OUX*]_>7YQ!%3PH/7NAZ<"=
T'GMW5Z]4O]35E>TZ MXQEK'N#A2/SZW54F2Q!(3 7:O1M)BHYJ'8YS4EVVK3P0A561'?5>U<(%MINK M%I+P(UGIUI!;L_B'-
>U>%$*K3JHK[0)A*]$5!&8D(TH+:P,4437&UZWU]D$ M:88>@1!)KNW0B!!W*O60AK) 1UP6@RAV,X\+L>G!\ ',$2JM>KR@UME.M(M_"?5]UKHHU>&2&
MF(+84)'$*M7\3EC+2V?5[-;:*@=UFH$(7'DLED=@T;2D.^A,"8V$Q/QZ,,))Q[K1P3]_J[(,*O M[-'2T8.H8E,CW?\^]!*/V=:"F,8W0)"0I.>=)G.+FMV4Z67?#[3T$_LD+ >1
MNSH_._[/++0%^8N2,U4:<:GZD>31S;43H'YTSN'E$58O3*L+GX0%(N+-73,$ M5+ .W=Y CPY"!T?_:LIG<^F YPN O\#U, ^^)9 B51 MZ=_CG:)&H)$))JYN(X?0?
@P$4%4<#.G3JBZYT8EOLQ5,BN!9H#"M%;KA8P!O% M!B%0A)4.L8+]@9[7T11:H^:F+2 ^AD!ZDKB#,K#UOD4Y)N"<_X80Q"7WL:KO
MUJ#CJV9@K"C/<=1C;Z5H48=AY)TU^TIC2 JN6CC;T3+K1U*CV#7*U8HP$TXU MFAR?0DG:,3V!H]^(9-8.J$): _?
0U%J0D++,^LLQDEN7T_^BD)Z4:U0PQ=+2$8AQKX(V7/V@'C@[J+NDHX ML]]8 &/"#M$K9I:]<4Y+-Y;_/C1+/'-2_5K,4@M7D"")?_]^''#IWZ6%9"4"
M#1Y_KPP)#KE(RRIW1N-@6&^!4Q0':OK=SZ**DF($)(@!$AJ%TII@Z,8XVXLN M)/B,W&=.&8*& LF/!$J][=6\1?K5: &UVKAZZ,@^D5Q,0"H&*B\!>O\I;U<4
MY<&P_#0A2%99P_0I&^%DR0O\3JPSVC'.R,8K!C$P*(X7Z9W')ABA.,.GXYA< MTK]]$+08PH L(86^2Y^^(EFEF$$$*!)K!A:R4=4C_,V+J] VC%^$B+7Q;/!J MEU?
BA,YP9G7 03=E>@CQGV;$?WH0KZ\L*: /KF2R5^0O)E2?C/_"&WY@4\' M8> S+>"4$4BW*T!\94,A[T">,$LJC9AOEOZ?]%27#9,4;4TY 3'$ MBO'#_/<4/Y+M$]EZ+$".#N6
,P9ZH4 MLB!.VJQ#"D61AR$-F7RT/-.3QX9LK9UR7W1@IVWT/%2^5"$2^V)J%LFWD2H$ M,/;EE?+\6$$;5%[WK YQ,/;RJ*A8?)1 MIMPX4(XH#X[@8R)Q>+
[&W_3(_8P1M.H'Y%B0(?EG0[#(2G?VQE#L0JEL:A#S MPWK=IL">_ [HTG(H0^H7_/ZP1 273G4[.04?P&U2@K>#(X7%S9QDN]%O. +: M/H-(86+P!9?
^H89@VH$J*6(,ABL[LF,@6Z%=Q0<((?9M*KX34Z9-P^4DHIDH MB'!&P@LA&O);>JJU-1P+7_Y!N&46B.T498GE7M+ZN"LQPQO?IT38Z]%!-T)&
MZ^UW:3>LC&N.X=/WB%P#X@A9KRME6 >Z9%&L8A"_D4I52=E-D.='3>JAP+@ MLE0=Q,W<-D;GQ"%90(1N0B;5W!!5C=X"1P)2XIS^GHB6JR8W,'!'%?MBEE5D
M2-T07$D:>2_59#2-J?R,+VADV9_H"\(&J@+PA80-3L?T<4T S!D$A;>EJ$3U MID3+N;'KE:+BL]9D<#7C8$,!W=V/TPJ"(]0R "'B_XN6PHY<2_(P$.JUN$_T M%NS4:5<+>-
X8QJ8H<#^3+#!P52JQ3C*:S-Y,-$J'N%W1K\ O.MV2'A','0%/ MJ[4)9)04$X0'0ZMK1MM>+\4\EZTET)4*CS$:R=0D@F?.[9SUKQIR&#;ZIC%Q M1! M D7S/CU*+*),
[,XA<:@W\I1V8BTA'OD1W)Q%,V^ZPF)/]'>D*<7W7*<8B$LB2 M[+V(:1:CTI"2%LY#9R!(:]UL HK,AS0*@YYXKX/%$";%K S-HE9OJ?Q .O8L MIV//#F9'UYKKB-A@('O;E6
=)O%!^CIDJEZ(B4RH%.)L@].?"\XDE3(<:!^ MME@4NX[,:I09CWN#),Q4V"1=.U(7 1[7"2NC5" M# 4?%J1.8L)(108>]BRD7VCG_I\GO7Y_'"VBQP'G/,?[\A%2':0_"Z]'B8U
M#@"<5C8<_\AD5V:Y:N^/6T/DIYFA-,0INCFS-, Q4B+RPI@[.$V^+C/%NT7R;()84[@-7 MN:J?BD3:S,!"6%M<@,C)@N+GR8NDT2>"\2MRVF.4?ON3VKHE"R9Z13T-
\VW[Y[=S!10Z4%40O M9BNM]%H8$D5F:T9B,B+R^B#=:D"&GHD>AIYDSE&[6I)T8_M,2@Q4>:[)]P9# M-TA>7M(#IU>XL[W!2>FSKAY@Z<,3M&(GPO2V19
QUDF'4!0^BZTX*5PZ7CQ.[> MPQDE)B&E:7MZAY-+@&(4)]7[Q4:/KFB!G7J?:CFYG.,NG0U =0A#?_*V)#%N M3DV#9NER4?B0DQ6R*,.G-S&?

4EHFVCI*1,A,176)IKA>@)K4O M):EF':-/38D$5\CQ./& T$+B)A:=42GZ#M5XRHI2T5?,^B2V/X[33W%=TEAI M0*C-7N-THZC]6.]7,@ A*$2B)"?V%(*;Z44/5V7*
6Z(D<\'O"3C!%PI%ZZ1 M VX^D=7'AJ@;]9"_VZD.(/OY69D .#L(SS_!]/Z93*\T7-Z7ALO.N_]OH"KZ M-GZ?8*?L[F+SG59HN;"F&^YVEFL-\E-R14-F0H]+&#HF>W1C
MMZ5LQ]$ZN,_=*6C9P#U]O*Y;#Z%T$60_;IAF(H+VF5*UY,Y]X.^6*S2V(U%N M$0R]&*=&\6_Y1M9QN6K2M$L\KY34 I$H(>.U")**T:W(@U^0KU?G8TGXA[D,
M(V?:9L#.42,S3,7C12J/IE12=1Z,A'Z^LGA1Q1UG8_O8)BE-+;]QR.F11MW! M[>._C!M=3#:*U,7+& ._)L7LU]KPHH8PL0YD:AS:RJ=R@OVLIX; 0<9!^-"I M]]/98AGX+L1?
LDJCFB82V:5/KLE@SF0E 4[I4"U'/R(_40+:$C:<1 (0)%XR> MN7H9M1X0*.QM/^Z5S[*D\ET10,,)(*"L*W=(5#RO>DJF]8@Y9'K$&4>U:5]! M=.PFWXK#-
J#NTB1+.3E%YYZRC6[C6F6VY<1(6\3(QSC080Y,\O"@E^0K?\9K M!M11?'L A&DABYS,[X(19B/EH!,>QIN-0,OXR988&L'%%HF?ZL7[?*&R8ZMI
M3A4=G3F4\XH5H:TU[D;: \S$H0_E',\#C"Y'ZU1R;98I,[F8-DVY/RU7:2FQ M%N2:E1;W6MVSM<81!#?HG>LGM[_H<-QQWA5OB!#NM3A>.0ZN;W4\)>8Y2O'0 M+S1#O
MZ#LMO4YT0G/)GI(R]F3HFTBEQ)H1 I%XG+W%U)=O:_#'C;Z7<.78"6*_V%E) M& >?[]JWJ,JXB5SG\4/H=R]1D8SG I_LT^&VWQD1KX+--#(OVCG>F:$BWHPU'
MJ73.+-DQN;\LX+S)&K?]F&!,A[@4Y1P/F-W,8N,*UY2U/"%+">V*>4O8X[3 M6;ERTC3D0D% WR+QR6,+B/YLEGF*PV[F M3@8<*9=#4F2"WD"DE,8F-N+XP1:L3
TG3E>,^3.^#'+D3Y @*T =6\Z1 MU&P?)[LVE/2';]EX/">NY*@M/0PUNGK;ZOA^K;WB-_LK6]>9N#J/X:_$QA@Q MXO<\9-@?
9]_=>3>JXWB*N"X2ZC3^TQBX,;=1T"3A$3N]DZ(DM-O?3B^#_H;I MB%KN&I.N>DXZ8_*S ?3[^.=N2+ITW?AQAZ#R 2T2I5;N#4;)CU 8YYW25&3]
MLP[)8KM\D2H.NADHMD)1::IF.UIPS[O$=?$DTG-IFL:N^,%,[*)D8A=?&;49 M]UE^L7YW5O8]1-)H'&9,O%Q[2@=JE)E*\P@GB:TLOJ/F^R%,Y:ULBVYY] 3. MEP-W[,
(LSG^5+@57IG<1A=C&TG[2?84FI86N>++@+LE1YF!_'@@TTML5_ CF M8*7->:@G; _.M_ P=\9&ML5L?C*M^>^UM\H['N<'7\J8O.3A;&^'&)%WJ_

ZX*! ME'F.AOU^IJ*9D,^%ZL/@JK>8142$O<97P]ICL!2"O3@C1QF_R_#SA[?7^#'G MLK&+\>#\80+HD ;M@=+&NIHG+KC:YP$!.ON# MBVW*G-B/R .R]A,I(PZ:
[S%9M#P]CA"V1B9%I0L7[?]*&1NFM=9I:@2%M!E(H8ON]]RAX M]YHX6@C_H(#,HU?BS>#BI\OKMV2_LO;Z,_]R?/9LEM]ZV;SFKA[\9M?$W\7S MLXCWYO8Z9]
("=-9<749&\2\E^P6 MOY2N6GRN#'ZG&XIT3^?LL%R1%%>*A^3&$^)J;H* #;Z96"*KY-\#B^LU->($H>,-?D\UP,J 7N.;=6;HT6F50EV324 M&.]X4D51IFQX9BEY#'\V?
FPLU]DY/J_E/EEZ1M_V1D:ZVA@)EWM6^0A?,[@? MLL&]%]C_3=VA#RVV]NSQ+ELK3^ZT,3BT*%VB':X \!H1SZ7SU$X<>*""<#&T M?91@##L80Y^G3Q[!,O?<
&^87J-_\#4$L#!!0 (%.!_EC% M:W&K"@8 *41 9 >&PO=V]R:W-H965TRI=/4GW1"R$,^586E;[J+8Q97@R'>K(0)=?GJD$GSJELA@RWX^')<^KWNC2R>
[5Z%+6IL@K<:^(KLN2J^\WHI!/ M5SW::P4/^7QAK& XNESRN7@4YM/R7F$T[*Q,\U)4.I<546)VU;NF%S>17>\6 M?,[%D][J$^O)6,HO=O#K]*KG6T"B$!-C+7
T*W$KBL(: HRO:YN];DNKN-UO MK;]SOL.7,=?B5A:_YU.SN.JE/3(5,UX7YD$^_2+6_CB $UEH]TN>UFO]'IG4 MVLARK0P$95XU+?^VCL-+%-
A:@3GB[&I8LQWGJM,&N+RR MA_)H%&9SZ)G1.YXK\ID7M2!W@NM:"43<:-+_R,>%T(/+H<$N=NUPLK9XTUAD M)RS&Y$Y69J')S]543'?UAT#7060MQ!OVK,'?ZNJ/(A)
MC975G-QPG>MCGCV[]W'//BX$F:&)P1QO0$XV(&<6Y*H# M6>Z 5!W(L06)##"+O'*6S$()00JQ$C -][?M. '((3IR.-MOQ4248Z%(0)TT MN"!]9TW6&O-Z0-
XKJ37Y5.$2* *_@.)!+*4R%JF^V+-X76+&+;J5VI#WN.8T M^0!],&8K\K=<+XCX6N? YO+G<0&]UT:HDN352FC3I-4'6NW)1>$83 MTJ%%Z5>D&XKIAY+& D]%NTK-
BH, M02M+H28YK"SY$H?"?"Q+.I!]2@=.%L9MTTZU[:U4.!UN+,7&9MN1T,L IS/% MPH$5(1RM:'=T/1?59"<2-,RP90+0I!_29. $?IAV*M1G'@U]$L9>YN^&@R$.
MH9>F::,=L8$3A%'8.D)]!-H_JDP=4UM#9X0%@0OE&<*(GWZ4(BQ6S+R$Q;87 M>HEOYVG(7(#/2(R Q_&_X_9!;ORO_(ZR4^QN9D[-GV0VXD]IA,"'E@TXSR3P
M,H2U58Q\+PY2A-4+@G#O0!(;X1W=T(MBYD#LZIWD-K@?1\&&D$@1*PK#MGDY MM4&9:,/&&?ADV6E3PTJ2=*.3Q5Z8^"1.O "6]JB= M(C$BMM9._(&3!,B$UB$?
L8"Q(]H'W(YQ*DCY,R2"'?<3FVE6CL-I.)UY#'%% M)PH]GU'T,D0_9)=,5&[C.;20UXT U:)LWG@O+L*$ M*U>RFV>#/JC)NR$^%5_0J@6UP?!"U??'/6BHN^O!P26Z?
2'>'.3USBH+S8=''IQ% B(I<\++,YEGDT2X_<3;0I2\G!);29.7T=[>L@ M1JBM4;;I'+V!2!0@GWW" #"-O"@+*,HLH0$ND>[6L,7-I7R&*\UV[#4#=RAN M&-
_6/A1#NPAC9I\>/Q1O#GG^PW(GM2\+>]*^?3U01QXPG@6^.P++K'6=.R!/ M=JJ =1.GJ1,D>[6J;;N)0^HP4!E\\0/8SR+0!Z491+./5NI[2;BA3M \@A%]
MWP_=\\GY$7F9*R@H-78ZQ4;PZU@U&6Y].L/IN?N#)\NLJY,\Q7=2;O_(*Z; M3^_-\N8/#!S$W+Z>"C&#JG^>X.97S9\"S<#(I?
L0'TN#SWK770@^%&UL[5=M;]LV$/XK!RT8$D"+]6;9RFP#B9M@ M'=(V2+KMP[/M'2RB$JB2E)QLE^_(R4K[N9J ?JU'VR^B'SNN7N.)VJQ$_*3 M*A
U/%5EK99.H75S,9FHM,"*J7/18$U/.VL%G;N3JX6HM4EK_%.@FJKBLGG*RS%;NGXSG[BGF\+;28FJT7#MOB ^K?F M3M)H,J!DO,):<5&#Q'SI7/H75W.SWB[XG>-.'?3!>+
(1XI,9O,V6CF<(88FI M-@B,FD=<8UD:(*+QN<=T!I-FXV%_CWYC?2=?-DSA6I1_\$P72V?N0(8Y:TM]
M+W: 8._/U."EHE3V'W;]6L^!M%5:5/UF8E#QNFO94Q^'UVP(^@V!Y=T9LBS? M,,U6"REV(,UJ0C,=ZZK=3>1X;41YT)*>J,
M(H^9Z2E1\HQI&MSPFM4I9R4\:)H@<33<$B*\I8&"TX]L4Z(Z6TPT43,&)FE/ MXZJC$7R%1@SO1*T+!==D-_MR_X1<&OP*]GY=!:. O[;U.82>"X$71"-XX1'G
MT.*%7\'[(+>LYG\$SRO#(@VL^H,[B0JB@=;;_)(I!3\>;E16E(B_G4L0AV! MZ#@!S^/N!<-[D5CZ*L'.NQ96Z*A?B?IR$O] M;/VZ_MSRQK!WX3WJ8[1'@8_3_L("[BU
2E'ERN09L= %0BY**AJ\WE[*26E M+D2K:(LZ Y(7K;QO,,5J@Q)"WX5;MA&2:2&?#U!/(':C663;,)S!+=(A+D29 M :\:*1Y[;7Q_;G_F0+2: LFLQV39":<0A $<-/*FNM6H@LY?
S(=91T0>#XD7@>^Y83"' MN9O0Q"T]NX#+-&VKMK2G,4,**>6813B=NG$8G<%IU+4?A:;D.P$:)I%M@W@& M(ZDR'5)E^NI4(3:R)2;73XVI%NI8?
HRB'<^//2SVL%V8*2,DE)QM>$GUBF:_ M.5^NJZ84SXB$5!E+721/('"]F6_;:>(-3AIZ3*:%99/A([W0>KVC &:A/RPD M)7,2B[!(;/8$*6W!!&#'(GXE+
(IB*;PP;H4DM+A+!D4"]T@3&R;T)H1Q>)! ML?C5BG4F;U^B>$RR4;CODGV#9+-!LMFK)5LSU3E@.Z8@/[+2U*QCTHW"'I?. MP+J0&G!\ ;<6:8V6/#5ZV>??+-
_@RW_,D721.Y]/J>,G;IC,X/Y?QGF=EBW= M#DRQ[#-+U-N?J%97P)1" CE]+S3"_(QJJ.<%_?]>I&!*^#/3H;*:)&,RS0>9 MYJ^6Z8"N\?*8.*-@W\7Y/W$F!]?<"N767N9-
36EKW=UXA]GA>^&RNR:_+.\^ M-MXQN>6U@A)SVNJ=S^@M);L+?#?0HK&7YHW0= 6WW8*^>5":!?0\%^1,/S & MAJ^HU3]02P,$% @ 4X'^6+A)S?OG @ 5@8 !D
!X;"]W;W)K&ULC55M:]LP$/XKAP=C Z]^3](N";1=QSH8A&8O\8^ M*/8E%I4E5Y*3]M_O)+M9!FDV"/%)OGN>YW2Z\W2G]+VI$2T\-D*:65!;VUY$ MD2EK;)@Y4RU*>K-
6NF&6EGH3F58CJWQ0(Z(TCD=1P[@,YE._M]#SJ>]LX!(7 M&DS7-$P_7:%0NUF0!,\;=WQ36[<1S:[\O<-WCCMS8(/+9*74O5O<5K,@=H)08&D= J/'%]J1" =$,AX&S&!/
MZ0((6?TCSYWRF7%#%XK\8-7MIX%DP J7+-.V#NU^X1#/H7#*Y4P_A]VO6^1 M!U!VQJIF""8%#9?]DST.YW 0,(E?"$B'@-3K[HF\R@_,LOE4JQUHYTUHSO"I
M^F@2QZ4KRM)J>LLISLZO5=/0X2RM*N_AS5>V$FC>3B-+T,XA*@>8JQXF?0%F M!%^4M+6!&UEA]7=\1)+VNM)G75?I2<#/G3R#+ XAC=/\!%ZVSS/S>-
D+>#6NIZJ .A ^=K;3"+?&=$R6>"R)DS3'DUC6C&S'7/;, MQC/K0^9US\P'9G =13_SCKLHN45MR9,:A)L0=DBNS%"@H*XW%T#E1%_.#UAB MLT(-61+"P,NVC
MW\SS11C-IH:-[I%WQ$QA*=TNLTK4P+ 0QIUF8Y^=AFDW(M*TS'YV$QBH./%DB@F*Z!Y9"P97&X@&8=%7H23K(D#T?C49B1^9]B
MFE:H)\2!:='ILJ:AT&LB,$KK/#V'+"SB(DQ(W%=EF0#SCQ,F.:-T',9Q"MDD MS$=)&&<9'+M6T4&O-Z@W?J(9@NVD[=M^O[L?FI?]K/CCWD_<+TQO.!V3P#6% MQF?
C(@#=3[%^857K)\=*69I#WJQI*-V#O1^K91]7CB"_:=D_AM02P,$% M @ 4X'^6,5U21_D! T@L !D
!X;"]W;W)K&ULG59M;]LV$/XK!WZ0C1PU]1"GPXJ8Y;'PZ$N*FR8]N42 M!5L0/#RL$*8-"G@| 2PAH+8Q$8_59XCG5M@8C&CPWFH-_2&FZW M']
_.M_)EQNF\5&WWEIJM-!/H 2YZRMS95<_XH;?U*+5\A:NR^LN[49[5BT MVLAF8TS]AHONS^XVY[!ED '%_'+'#BU_ FU5,X;LSU3E@.Z8@/[+2U*QCTHW"'I?. MP+J0&G!\ ;<6:8V6/#5ZV>??+-
_@RW_,D721.Y]/J>,G;IC,X/Y?QGF=EBW= M#DRQ[#-+U-N?J%97P)1" CE]+S3"_(QJJ.<%_?]>I&!*^#/3H;*:)&,RS0>9 MYJ^6Z8"N\?*8.*-@W\7Y/W$F!]?<"N767N9-
36EKW=UXA]GA>^&RNR:_+.\^ M-MXQN>6U@A)SVNJ=S^@M);L+?#?0HK&7YHW0= 6WW8*^>5":!?0\%^1,/S & MAJ^HU3]02P,$% @ 4X'^6+A)S?OG @ 5@8 !D
!X;"]W;W)K&ULC55M:]LP$/XKAP=C Z]^3](N";1=QSH8A&8O\8^ M*/8E%I4E5Y*3]M_O)+M9!FDV"/%)OGN>YW2Z\W2G]+VI$2T\-D*:65!;VUY$ MD2EK;)@Y4RU*>K-
6NF&6EGH3F58CJWQ0(Z(TCD=1P[@,YE._M]#SJ>]LX!(7 M&DS7-$P_7:%0NUF0!,\;=WQ36[<1S:[\O<-WCCMS8(/+9*74O5O<5K,@=H)08&D= J/'%]J1" =$,AX&S&!/
MZ0((6?TCSYWRF7%#%XK\8-7MIX%DP J7+-.V#NU^X1#/H7#*Y4P_A]VO6^1 M!U!VQJIF""8%#9?]DST.YW 0,(E?"$B'@-3K[HF\R@_,LOE4JQUHYTUHSO"I
M^F@2QZ4KRM)J>LLISLZO5=/0X2RM*N_AS5>V$FC>3B-+T,XA*@>8JQXF?0%F M!%^4M+6!&UEA]7=\1)+VNM)G75?I2<#/G3R#+ XAC=/\!%ZVSS/S>-
D+>#6NIZJ .A ^=K;3"+?&=$R6>"R)DS3'DUC6C&S'7/;, MQC/K0^9US\P'9G =13_SCKLHN45MR9,:A)L0=DBNS%"@H*XW%T#E1%_.#UAB MLT(-61+"P,NVC
MW\SS11C-IH:-[I%WQ$QA*=TNLTK4P+ 0QIUF8Y^=AFDW(M*TS'YV$QBH./%DB@F*Z!Y9"P97&X@&8=%7H23K(D#T?C49B1^9]B
MFE:H)\2!:='ILJ:AT&LB,$KK/#V'+"SB(DQ(W%=EF0#SCQ,F.:-T',9Q"MDD MS$=)&&<9'+M6T4&O-Z@W?J(9@NVD[=M^O[L?FI?]K/CCWD_<+TQO.!V3P#6% MQF?
C(@#=3[%^857K)\=*69I#WJQI*-V#O1^K91]7CB"_:=D_AM02P,$% M @ 4X'^6,5U21_D! T@L !D
!X;"]W;W)K&ULG59M;]LV$/XK!WZ0C1PU]1"GPXJ8Y;'PZ$N*FR8]N42 M!5L0/#RL$*8-"G@| 2PAH+8Q$8_59XCG5M@8C&CPWFH-_2&FZW M']
_.M_)EQNF\5&WWEIJM-!/H 2YZRMS95<_XH;?U*+5\A:NR^LN[49[5BT MVLAF8TS]AHONS^XVY[!ED '%_'+'#BU_ FU5,X;LSU3E@.Z8@/[+2U*QCTHW"'I?. MP+J0&G!\ ;<6:8V6/#5ZV>??+-
_@RW_,D721.Y]/J>,G;IC,X/Y?QGF=EBW= M#DRQ[#-+U-N?J%97P)1" CE]+S3"_(QJJ.<%_?]>I&!*^#/3H;*:)&,RS0>9 MYJ^6Z8"N\?*8.*-@W\7Y/W$F!]?<"N767N9-
36EKW=UXA]GA>^&RNR:_+.\^ M-MXQN>6U@A)SVNJ=S^@M);L+?#?0HK&7YHW0= 6WW8*^>5":!?0\%^1,/S & MAJ^HU3]02P,$% @ 4X'^6+A)S?OG @ 5@8

MG!0'(,&'J'!^\Z_)W-GK>YD@ <8 P?%ET%0]*5X72IA|1 + EIM!58AA= M91'ST%4"()<80E<1JV5!X$ZTC2Y/.+%G8*LD8[VZ6;7)Q0IG+/((8@AE10;NI?
S*1E]F"EI.:V$)$;=W+U5CM*8.H(;T($< MPE"1,9LCO\;1TS-'%D<"])#+HJ1D4$HJE#;=>0"2Y!1*2IH0B(D$=?&;14Q(
MBEV1#5!)#]&F#E@DWVY5<96EF^@^O5>%U=B@F9I0VO2AMTZ/+XN2DF'/HL\! MY"0 .3F5DI(FUU3C$=YE?RQB-1[AKL &L"1?2$E)$P 9]Q&?B'YZ' !1_%(^
M*K;Q4=W2#C:AQ&$30)9X"AD5FRR3#5!:Q#R ,@9($ \AHVPKT\"-DU__Z!(& M<^0G8D @\;)(J#@H? FE37<>P)=X"@D56T@H6YS;LBSN. =X$]AHAQQ/GPO MY>]E]
(3-P4#%@$KB93%0<5!<$TJ;[CS -?$4!BHVJ:7N[<\KHAO5JEXSA'ER M1/G@396_D]'S-$ M2@8Q38<@+ ^[S(JU4=*V^53T/^OFUCIV84-IT'P!L2Y,%0B5!45XH;;KS .4E
M4UFHQ&276&+4D;!(B82[XAMP5/)"!BKI/R;E%='M >B4O)1^2BSDOTI$V(M.I[P2P"()%/(I\0DE5ABG"2Q2(G$E>Q) !DD@XDGU_HT<&_E[VCT53='+B,! M;)
(LBY1*@]*84-ITY[6JZTTJK]>?;/&*= KKM2OK#:6C?*$ ^I@!?X I\LY3@ M0ZT:?&A9=-6S/<$<.$L9/D1:#IQ4B ^97)1EH;>)N5=ZC%IU^-!0RLIW 0PO MU^?O;OSTS5*P#
[4]]J%E45K/]@1SX!RD%D:MJGUH4MD^U'_4RB_3,:Q5L0\- MI;3>W:K=5=\QJQYUXR=FED)^J%7)#RV+UWJV)Y@#9RGFAUK5_-#D[P%+[KN75G4A$S7&<3%%2ZGC/!
[>]^>5]/8O7P*U93P_C MRQW/D1+!{8K">%G4%PYVL3MXL3^ KZ]8<>?O/'+= QK08B>RK_^8!^Q
M.?/W,W[&YF" <+OH,%X6_X4#US*>IYAQNYJQO^)O;\B;#%>]$\/,C'M3,!'. M)]1QNV1P3\U@?^P/WY?YNQD_%BN&_:63QSMP#EX,M^HJXY["
MRGTO"'AJW7Z1CNUY0YN<[8'#=>L]5/=RJ]5D4C4/__)L^KYR_-V[!.KS^[^#]02P,$% M @ 4X'^6!EHXN[L!0 QR8 !D !X;"]W;W)K&ULO5IK;]LV%/TKA%
<,+;#&XD.RU#D&V@1M-[1 T+3=9\9F8J&2Z%%TTN[7 MCY)541(?M5LB7Q++/O?R'I*7YY+4\H&++_66,0F^ED55G\^V4NY>S.?U>LM* M6I_Q':O4+
[="T4UK5!9S%$7)O*1Y-5LMV^^NQ&K)][+(*W8E M0+TO2RJ^O6(%?SB?P=GW+S[D=UO9?#%?+7?TCETS^6EW)=33O/>RR4M6U3FO
M@&"WY[.7\,4%B1N#%O$Y9P_UX#-HJ-QP_J5Y^&MS/HN:B%C!UK)Q0=6_>W;! MBJ+QI.+XMW,ZZ]ML#(>?OWM_W9)79&YHS2YX\4^^D=OS63H#&W9+]X7\P!_>
MLHY0&^";%W7[%SQTV&@&UOM:\K(S5A&4>77X3[JV'3$P@,1A@#H#=*P![@QP M2_0064OKDDJZ6@K^ $2#5MZ:#VW?M-:*35XUPW@MA?HU5W9RJ9KF
GRFQ9Z! M]XS6>\'4&,D:/ >?*C4MBOP_M@'O>%VS&M!J S2^!OP6O+RG>4%O"O9N\'<*GETPJ_I9TJKU)7CZY!EXTAAJW/)] MK5JKEW.I.#:1SM<=GU<'/LC!Y^]]=09P]
= $2(6\PN_^25;*W/8N7O>5SU M;-^]J.]>U/K##G]O1,/8Z$H;KX,C8G?4)/.+>D??['RFTK5FXI[-5K_ !I/H M3QO+0,Y&G'"|&?J%\83P#GZ[YAZDELU02
"):_DUMHMA[:2MJUF3;I?(0*7 M_LA6Q.#DZC'C$B0G@0)0>*-^EXR<02/0W/Q,$8237A8,/"'SB/N><1>'A^Y MI(4MGMAH*TZG_6IB%M
13]+'DW@3HET_WE/Q12E4NXS88DM"ID(@9R.VBY[M MXA%386$,1Y9E<#IH)@IB&$7$/FYISR1]W'Q(S3 AQE$R86/"XCC##C)93R;[MN:3(C-80Q&@PYPJ!F3"8)AE.
[5'!2&MQY(WKT]GU&9"BU>%OH.Z[W"J#7E>G M)DDH;V/B@R($AI+)SE,HWH&\C7GKZ@!ZA3CP^M U-IR7R73J6C!I[)BW6O!A M$,4_?
G'HVALQ05,F@)8.0&,J6O:A7_>=2P,TQ1FB;!J3'4+$H9A02SB,?UTS MH;<..#DO GD;,]9% O2JB%C'EK\D5_\GQL>QND[_F.%P >RT0_3R0+!CET0UJJ/ M@ZC^|>L"-
D4=36MH"|:Q,& M_-@O_,Z% 9OJ; 9D8IQ=.SBPQ[^NF-A;!IR: M$J&\C1GK&@$'.=X_-B7,;; ^1$B8DR2!VC)Q6?AQ$^4](^E/5219/SSDL*%=: M:-W'?
MUWIX4ISK:03)2G@[6*8[^*O[QCU?I'9[%^'R>G1B!O8\:Z/L.I*)7$ M0:N#4-[&O'5U@/W'!X&7!,L=08*G<]9RWX <^Q^BY9X$D?L3KBY-.4?&:,9,% M!#/'R3+1HD_\HN]
<%(@IS,2XI[&!D*.)E]_B?]._RBU)$&O\T-Y&S/6]0%Y MS!M]8N[Y8QPAXS+)!\U[YX=,.EY&7[<9>K?75O]#U!+ P04 " !3 M@?Y8.ISA&,H" F"@ &0 'AL+W=OI4]6]W<.T!Y,
<8-6Q.]N!{M_/=D)& MJS2PE1=BG^_[/M^=L2_:;+AR9&S5]H8NJY,UY!<:.#0 GD;.]9% O2JB%C'EK\D5_\GQL>QND[_F.%P >RT0_3R0+!CET0UJJ/ M@ZC^|>L"-
MPPU9K94QN'%4X!7<@KHKKH6>N0U+1G)@DG"&!"Q'SK@WG/>-OW6X)["5>V-D M(EEP_F F7[*1XYD- 854&0:L/QN8 J6&2&_C5\WI-)(&N#_>L<]M[#J6!98P MY?
0[R=1ZY'QR4 9+7%)UP[>74,=C-YAR*NTOVE:^_8&#TE(JGM=@O8._K& 00T8V-Q7R;*93K#" M<23X%@GCK=G,P);+HG6'"3,'ZU8)O4HT3L5S3 2ZQ[0$=
58E@+TJ5$2?4#? ML!#8E!V=): PH?)<6^]N$W3V]CQRE18W%&Y:"TTJ(?|\%H0!=<:;6$LU8!ED+ M/NG&#SKPK@ZZB=S?13(Q.PF_ENP"!=Y[Y'M^V+*?Z?'PH"V]
;>Y[9BG9(L.279()1D\Q.1/2ERV!0Y[&*/IP(RHI N MKM2US4!!V H5(AO^SM/*K*!)3//VR;V(G>S7[.#'LE!C]E!CWEG4/^3SGI4
MLGYGRL94/]R8I8!T"X#2_02VI:Q_,&6=&ULM9IM_BL;7N6EGTIHG8SOG>*8QTK0W[4VF:>]>W-P+Q<@V4T!4 M$G'S[4]@ L8F"D[7;VS
[.\O=L6"UCO;E>LAS(3C(:E41(/'Q& M()DG"14/URSFVZN!/7@\|"5:;U1Q8#B?973-;IGZEMT(O3>L*6&4L%1&/$6" MK:X&[^U+XHP*@_*,OR.VE7O;J+B4.\Z_%SL?
PZN!58R(Q6RI"@357_=LP>*X M(.EQ_*B@@UJS,-S??J23\N+UQ=Q1R18_B<*U>9J,!F@D*UH'JLO?/N!51=4 M#G#)8UE^HFUUKC5
RUPJGE3&>@1)E.Z^C<_*$7L&FM-MX%0&SJ&!JX2!6QFX M?16\RL#KQ$J*#CJ?"];Y%HCA;TXJ-.EREM79PE!8S
MZU8)_6ND[=1\P9.,RZB,,E^A!1-*3T>TX&FHIP\+BRW)XRBD2N^0**7I,J(Q MNE7Z@)YA"GW21/11[TCT%MT(/>>%>D T#1'^D4=9<OWJ!72(M]W?!<:@,Y&RI]2<7
ALMJ^->[X3M/#-]%GWFJ-A)A/=ZP MPSXPV_L&^Z%V9>U/Y]&?UXX1^&>>OD.N=8$-?4R=F M\X MM;G=9=[RI5O/3;?DN4_P'B?
3!;J)J9YIK3F%_FTFWG]=$V?']KK91<*^ ME!E=LJN!SLB2B7LVF/_^F^U;?W1%#1(60,(P)(P P5K1]NIH>R;Z7K2S.MJL MR2!KP65G@MA1_9):/$?
OY[;E.I/9\'X_@$;M4P/82Q)#2I)CRCX MXVZ'CFN'CHT.#9Z9J^,CS9%E';AU?'17>8?G!,<-+8>XMD^YDW)2K9ALE>L(WKV9;;"HKAZR)Y)HV;*J7<4*"T
I6%0&H&BM:/;%'(< M^XQIU $M[H#2 E :!J41*%H[Z$UQQS'6$5Z<1BML:P7LC0_^UEF8Q4\.8Q]- M#*I).C2G4_^)1-I45QQS=:5H'%(BWS6012G*!%_KP71[&K19 Y06@-
(P*(U MT=HA;HHYCG?,; I:Y0&E!: T#$HC4+1VT)LJCV/N&GEQ-AT==|WX>RTL51A! MZS:]-#&H)NG0G%J'KZ7#O8[-A(EUV5LKT9+GJ=HUR-5'Z_[=]V77ZL'Q:_MR
M87<<#^Q+O.O.;?"[9N'/5*RC5**8K;24]6ZLQRMV_;>['<6SLE_TCBO%DW)S MPVC(1'&"_GW%N7K<*03J+NCY_U!+ P04 " !3@?Y8M>.': (# 3" M&0
'AL+W=OW.2VL7#BS'9;V* ?M9-&I0T5#WMI;.>>XW./;ZX[M7 OY'(39X*7JJ1DVM=G;FN2G,HJ#H5%93X9BYD035.Y<)52E02:65#!7=_S
M^FY!6>DD0[LVDLUFX8XM,-^;7/'7&94P5CPGRS3^II?D^.@#.2*X[WTNE@HQ M:NAJS,YH=-,FDXLZ$_^53+XNRU,2>"?$]_RP SX^@+^$%.$]"P]>PEWTM#76
M;XWU+5_P"M^M7-"2_:7&V9,M%VWMHBD3"0KMHQOG.ZQ5Y-?Y3&F)I?Z[RX]: M0-@MP'S^9ZJB*8RW)55%P\ Y 4 MJQ'KQIK2E7%-T[T-WM9U)1U T\-
J@%PK#5F%X4.&FKDWN5*:Y M/<(,5M@%*W-476)KQFA+1Q#Z.UKW8^*@URTU:J5&;Y):23$'9;HMUI21FV(- M8G-CY8+, 3J_L&A/3N3O2MZ/\<.H6W*_E=P_*-
DVB"X]_7T+O/7'3T=,/.C6 M$[=ZXH-Z[H6FO$M/O%=:0'_=@1U WV'"W6K:Y+K]3N6"E(ASF"/-.8TQ(MUE=0/=&BLEU\)C3>"7:8XZT-T@3@^[D0>C,Q%T/[/R#Y!U!+
P04 " !3 M@?Y8H$S3@!$# #K"0 &0 'AL+W=O_KK("2ZG-9@< O,ZE* M:K"KYKZN%-#<@4KNAT%PX9>4"2\=N+$;E0[DPG FX$81O2A+JGZ_ RY70Z_C
MK0=NV;PP=L!/!Q6=PQ3,U^I&8<_?L.2L!*&%9&$3!;.B][5Q.$AOO KXQ6.FM M-K&5W$EY;SO7^= +;$+ (3.6@>)K"2/@W!)A&K\:3F\SI05NMJ?L5ZYVK.6.
M:AA)_IWEIAAZ/8_D,*,+;F[EZCTT];@$,\FU>Y)5$QMX)%MH(\L&C!F43-1O M^M#HL 7HQ,\ P@80'@J(&D!T*"!N /&A@*0!N-+]NG8GW)@:F@Z47!%EHY'- M-
ISZ#HUZ,6'7R=0H _H09]*1+"NIF3--SL@(E,'%1492Y+@8(+H;O MLYI3P?Y0Z^W9EH]N?Z(A-PHTND/7WK>8]\F/MW=H&V[GGVUNU G${0G87]RE
MKF@&0Z^R.G+%YV+X$V;-\Q*Y9 MX&T,E W [S,IS;ICC^/-_2[]"U!+ P04 " !3@?Y8]U!3Z(")!@ M&0 'AL+W=OE _;'>_9K7SO6LF0&,B6^|<*64_]!D@)6;"/L@]I]
MAK:>,|>7*V'\E^S:W)"2?&.LJEHP*JBX;/[LN?6A!QA/7@%$+2#Z5T#< F)? M:*/,ES5CEJ6)5CNB73:RN8'WQJ.Q&B[=*2ZLQE6..)MFJJJ5X=Y2M2(9:(M' M3S(E"SPJ*-
S(*,$+9C&XYI+)G#-!%A8G\#0MN45&^DM MT/3MF_%Y^&G(G?]$]L*KN/,J/L2>/@!6R7-WH7)FRJ%:&X)S3^ :T38=)\&V M7\"AC!>J)IVJR4%5,_ /8? J-LB/OLVE(0)6 MB
I'[\|HT4WC:0*K:O]VE\B) .##$GLU:)> ZRNE[#YP[:#K_ND?4$L#!!0 M (%.!_E@;,ZZ.0 (,< % 9 >&PO=V]R:W-H965TZ/L3CQ*<9HXWTJFB:AU23FL)%(U8T0^WT,IFCD.
M\-'Q0'>%M@XO32JR@S7H[]5*&LOK67+*@"LJ.)*PG>.[8+:(;;P+^$&A42=[M9)5LA-A;XW, ^Q[Y-"$K(M&4@9CG LK2$IDT'CM.W%]I@:?[(_M'I]UHV1 %
M"U'^I+DNYGB*40Y;4I?Z032?H-,SMGR9*)7[HJ:-C<<89;72@G5@DP&CO%W) M4U>'$T 07P"$'2!\+2#J)$3VF;F9"V))FDB18.DC39L=N-JX]!&#>7V%==: MFE-
J<#I=",9,-==:9'OT#GTC4A);6'2U!$UHJ:Z-5Q5$@DH\;2ZT,"_KR.], M\O "^9>:CU#DWZ#0#^,!^.)E^!(R P\T9FKS7LM8:..+[K]^&QIOH9 M_;K;*"W-_-
[2%%+$0]3V)Z;J8ID,_>F:13(^#T[9M@XK\?TO>?R,[41KW: MZ"7VX\LJ^(WW1,BJE0-.;JBO/-<#]6@)1X[8CL&#FD0CF-_O9E"2A.>4[[[FX3XU1(&(P"=M9D?<5R)WE"M4
MPM9@_=&M(9'MV&@-+2K7>1NA31^[;6$F+4@;8,ZW0NBC89NYGJWI'U!+ P04 M " !3@?Y85H?H*# # !]"P &0 'AL+W=O"EMVTTQPZVTVI[_ MGFLG"|V6%9
B7EH[N>?XGNMCY\[V0EZK+8 F-R7C:NYLM:Y.75?E6RBI.A$5 M<'RS%K*D&J=RXZI* EU94,G

^Z<+WS, M&_&U@+TZ&!,CY4J(:S,Y7\T=SV0$#')M*"C^[6 !C!DFS.-G2^IT:QK@X?B. M_9T5CV*NJ(*%8-^*E=[.G8E#5K"F-=,78O\>6D&QX@0.Y@1=
MY%VM:PGD7*F: M\AS(LS/0M&#J.:+4EDI0,U=C0H;6S=O%WS2+!X\L_J'F)R3T7I# "Z(!^.(X M_ QRA/L6'O;A+I:AJT70U2*P?.%CM6!4*2+6K?SO'_$].==0JA]#VAJR:)C,
M'+]35=$+UM()WOZQ$^\5T-*1R+KZ0X[W>$Q]JR1*RISKA0I<(=QSRE? M$3SV2N.@X!ORK.#M/C\?*D:S0FQ7,%?'+O/3.(HG83QS=X="!P*C)$W"@|">
MB*@3$1T5\5EHRMH,S1[FC9.5U2;OG/P'%=&#Y*(X"5+/"^ZI>!@83J+$]\)P M6$731]8,@BC M:!J$DWO>'0CT@G0:)]ZP=R>=F,E?>+>LF+@%:'=R6" PC+W8/W![M(\
<]Z(U,8 _J)RDV!GSD&:T1Z)RE2R*;7:R9:5+9=NA(:FR[\W&) #-($X/NU M$/IN8CJPKN/.?@%02P,$% @ 4X'+6'STJ-W @ J0< !D !X;"]W
M;W)K&ULK551;],P$/XK5D!HDV!.DZR@DD9:FZ(- M:6C:&#P@'MSDVEAS[& [;?GWV$X:NBEK*]A+8I_O^\[?77(7KX5\4 6 1IN2 M<37V"JVK$<8J*Z
DZDQ4P,W)0LB2:+.52ZP]"21WH)+AP/>'N"24>TGL;#5P(Y&JRY+(WQ-@8CWV!M[6<$N7A;8&G,056<(=Z/OJ1IH=[EAR6@)7 M5'
D83'V+@:C663]G<,W"FNULT96R5R(![NYRL>>;R|$##)M&8AYK6 *C%DB MO3&&L3T>)PUK)/&O;@&?8070NN M"X5F/(>|!Y_NQP_WX+%1VLD-
MG(GP5["SS4_0Z'_9@5^$/7<9WH\.R3\W_1 M9_|<_8SRPJ[fN>,+#]8>I51E3*A: OIQ,5=:FA_X9U^]&\:HG]$VM9&J2 9C MSW0M!7(%7O+FU6#H?^Q+]DN2I2])-
GLALD=EB;JR1/O8MV71IBRP,?- 05\A M&HZAX[##8)7X,5[M9O>@1WK08[;/HQ&'=WI/"7+IFKY"F:BY;C[%SMK-E0O7 M3I_8)X/1=-
!C3\T<:L;&7_IFB%T3N:1<(08+$\H_>V]:HVP&0[/1HG*=;RZT MZ:-N69A9"M(ZF/.%$'J[L0&ZZ9S\ 5!+ P04 " !3@?Y8O'] R\X& "W M.0 &0 'AL+W=O%
(5#HFGF,*)!/)A=Y><6?':5[$08Q&S!4;J+(LH/MRQ,]M<# M/'@||3E8;T1V8CB[VM(UNV/BRW;!Y=&PHOA!Q.(T2&+$V>IZ<(,O76)F 7F+
M/P*V3X_>HVPHRR3YFAV\JZ'\6M8C%C)/9 @J7^9G(5A1I+]^%9"!U7.+/#X M_2/=R06 C(SG)6&:_T7[LJTV M0-XN%4E4!LL>1$%&S N \9YL8JKFY?
&HH+.KGBR1SQK+6G9F[R^>;2L2!!G4KP3 M7'X:R#@QL[_M G% [V./Q9DHT"*D<8IH[*,[D7A?WV5U]M$\B:3X4YK+YQWZ M2#FG>?/7%A,T"-,W\NR7.PN]?
O4&O4)!C#X$82@;IU=#(;N9)1MZ99=NBRZ1 M$UW2T8L"C]NTN;1?Y1=_[LQG"9 M;JG'K@=RYD\9OV>#V<_85/[I4L8D# +$F9#PAQ(F L$:\AK5,EKI*+/OL2<
M>LO>L2S$%=5^"W:,AXD/I++/%2VS3[OJKPR5=^Y A)FJ2\"00=&>8IT M%!5W2CQ!/CUTW:MMR&XYD# 7"-:0D5G)R%1?08U@U+EVZM*)DM57)Y P"Q)F M0\
(<2)@+!&M(95Q)9?S"2Y8QI+P@818DS(:$.9 P%PC6D>DDM=$.1/ELI$; MMGNY"Z/+D.7WK;54ED [N?_AB!6SU%;.3>BUW)BE><";+B$5F8RC=0711Z,I
MT2>MU8RR2WU%ZDQBZ".]-=.Y4&F;NB&U;HA2-\6*4^ZV% UZL4HO=<*<4E*3> M4H"D64^,$FO%#KBS[I =<4!I+A2M*8[:?,5*\ZW<]4;;,#DP5OQ_ "UVW-MD
M$\VIS:^:V5LFH)8J*,T&I3F@-!>*UE1.[:OBT0MO@C&D13D'I5F@-!N4YH#2 M7"A:4V:UN8O5QB;D9KA,=7S''IDZGI)I:S.L[E-OK9R9U@9-ZX#2W(Y!Z(9F
MX*,M?;/"M> ^*U<;KI]5*+DCD_F;[>-]1+%! ?5=0FO7$,,W2F>_|_H/ZK* T M%XK65$=MM6*EU0;DEZB3]-8-J*-:TAK?K+$^,KYS3$#3.J T%XK65$GMF&*U M9?
H]%;)64EMT*0.*,V%HC7+ M7QNY1&WD5N7?\L!C[>J_558*UM1';; 2XZ67)Z _J@6E6: T&Y3F M@-)<*%I39K7+2}3VI_VP99ZO\O&#^!GL8\X%9T_OBJ!S2F_O?
IXNHUU1AO[MC#:.>F"]RP!JPZ/'A.+&%_G3P"F\M:_BT7Q*$YUMGK*\"9_MJYU_A9?SG'' M>0M?VL4SA#6^>*3Q ^7K($Y1R%8RE78QEOKBQ5."Q8%
(MOE#:LM$B"3*WVX8 M]1G/&LC/5TDB'@^R!-6SFK/_%!+ P04 " !3@?Y8+7N:!Q<$ "4%0 M&0 'AL+W=O0[9Z0%E]#BU7.L!|8PW6Z$F[-ED M!S=HA<2?
NR63([MF27&.",>4 (;64VONWL=NH "%Q5\8'?G5-5!27BA]58/' M=&HYRB.4H40H"BC_#FB!LDPQ23^^5J16O:8"7E^?V7\MQ$LQ+Y"C!_()C9>M8(-
ES0?,*+#W(,2G_X5L5B"N M%[8 O K@]07X%<+#O"P@J0- 7$%: 0K1=:B\"%T$!9Q-&CX I:\FF+HKH%V@9 M+TS41ED))N]BB1.S^.L>BQ-X) DB*F5@F4'" 20I6
F:O'Y664C!@N9R:W)8 M))V$O^W) /C.)^ Y7J#Q9]$? M[NOD_+_5XW>OW@B&7V\8O^#S6_A66\B0;E?,&8-D@V01$>#E!*[MEO!43,^/ MD*7@G]\E)7@4*.?
_ZG9'N7Z@7U\5SGN^@PF:6K(RY+B4EFUL6$?7N M.S;N8-:2'M?3P'=+A6YOT4.N%>Z-I MH3<;AC?2^[%>K-1J)<^K*4/^TE/\0&G2)9X!@72B2YY7."OVT2?=LD
M[C1IB!S5(D>=(I\Q?P5KAA# 1"#YZ(A"9>?V'NDVI!.XM_M;;^>'XQOA+7S. M;9K;^/01&-<1&+|S NV[?*SW>'@3 +V9/[X)5-2/+FXQ<\;Z -S5 ;CK#,!3
M>Z8[@=_[;C%)%IDDBPV1-:+O.I=/2N<'?R)4#AC*HU&VR"A;;(JMF M)1%>=TUKK]W=R.]^&$RN14;98E-LS1Q<3C[NCS[ZN$;,//D;9(J-LL2FV9BHO
MYQ^WYP&H3UWKIAJ64&T">B&!6Q8,,&PO8N]U(>[I0G"N65[06K/LJRY3CMBF M:.]QD-]$67_HJZM6XSHG%V,__@WB]&LU5=M;]L\9$/XKA%8,"9!8(O5B.;,-
Y*U;!W0-FJ7]3$NT+40B79*R MDW_DI(E9Y9H9<6^V"3%N^>YX^FA;KIC_%FL"9'@IK)DO$"2S7E*U=L.,&I,2IR%WE>Y!8XH\Y\:M8>^'S*2IEGE#QP(,JB MP/SUAN1L-
W.@LU_XFJW64B^X\^D&K\@CD4^;!ZYF;N,ES0I"1<8HX&0Y>%(\?M5.G MP=2&A^.]]X\F>!7, @MRR_+O62K7,R=V0$J6N,SE5[;[@]0!A=I?PG)A?L&N
MWNLY("F%9$5MK!@4&:W^\4N=B ,#%/48H-K),*M@ S+.RSQ?,K9@G3 M Q.JL5;D,JI/Y5%RJ313=G)^_Z/,Y"OX1!-"=7[0XZI)BFX%&RY/E2AYR"
M6U:H.A#89/(2?-F8P?4.\Q1(->9$ M@(R")YI)<:;$6U?CO-2N%PA%35ZI -!TWJ4G?5*11#^D(?&94K@6XIRE)W]J[M*@%-%M ^"S?(ZO#/DHZ [UT Y*' XL]OLNH;?
WZ/O[_*8D$X8,LJB6_RU1EO MY2[H=J??S"NQP0F9.>K5$X1OB3/_]1<8>;]9R 8-V<#F??ZEE$*]@\|CH"BS(M*J/4C+_JA(2 ,W54U0&>=Q&O7(?&M5:
[1P&T3CR_7#J;CM(A0VIT$KJ=XZI M5(5W CX\@O<#Y$||KQL]:M C*_K]"^%))D[C1T?XEP@&*$3= ^-,&?VS%5X*S M)-F
^,?'^'[@P2#NQH\;_'AP29"Z,H;50WQ<#^,P"..^>I@TC"9V1N8-$F!+ MA$Z+UB?RLE'2KB:2F>53U";OI :J5D,]*[EOAZ1,Y>!%?C)5M=-#0I,@1L)
MW\/G0-.A57Z^F[M(,;K>$]JN5K"O9_# LX1TDH'_@P)!U#)&/ZE!*W..043'PK"*.I+:"OGT"K ;]1H()'*(40'3- HZBNU5JNA7:S?*M-
M+L$Q%SA"/1H!6XF&=HU^JU(#N83'7/Q1T$.EU6MH%^P3@C606J3);=Q#KA5S M:%?SH=HUD.7X72Q;R8=VS;>(V$!B<<>[%_>]>ZWPPV'*S]HCO@"[O<+A6N$X
MT2V(/O=$?1IR];%?XASDV:);[>R08_!*=+P34%3?F3 &*7X5MB_-]K) _ ^6R M^.F03J!&=4C0V\>$@I,QM1<.LEX/W6>$5RM.5E@2];4O>:8:N01L<5YVTZ\
MHH/BB7RO1Q=0>Z\@^[W2E^SW<4-'W,(@B/[%S3UHP@K"5Z;5%.KL2BJK?JQ9 M;=K9ZZJ):[=7O?!GS-45*$!.ELK4&XV5:/*JO:PFDFU,2[=@4C6(9KA6+3GA M>H-
ZOF1,[B<:H&GRY_| 4$L#!!0 (%.!_EBC,CYEIP, /D0 9 M>&PO=V]R:W-H965T%5!C?D:W0.3*FK(:" G(-C;?,L"Y!M65[3E. M9->X)%8\U7-+%D_I3E0E@25#?%?
7F#W,H:*'F>5:CQ,WY:80:L*.IUN\@16(MS]LEDT]VQY*7-1!>4H(8K&?6E7N9NHX":(L_2SCPWABI4&XIO5,/U_G, '@MP#_M1Z"%A"|UD/8 G3H=A.
[3ER"!8ZGC!X04]:230UT]C5:YJLD MZJ"L!).KI<2)./VR*\4#NB89$%4RM*PPX0B3'*T$S>[>JRKD:$%K>30YUL5] MWR[-GR^E]VH,Z&T" I<5?R>-

]BJ)2Y'GU<)>OOF'7J#2H(^%73'I1|^M84, M1&W'SMI-SYM->R]LVDE@GLLN@]9G'NG23\;4?. MD._\A#S'"PS[6;P>[IO"^7>T__L_2@9?G>D?,WGO|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|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|-VG7_7^_J+>W\!(^RV5%C[A6?\UEAR MRG<*/70[XY>[C=(2DL*OML5N["*[G4F4MVJ/,()P(!,J(@_$2;_^RD^\;VRD M7]-L]9IFZU[$F4;" MY43"^=R8TVY,J::3I.[$O($.Z3M_ZOG>W#WTU\ FBZ?>]*5L99&%R20:N*UM M,F\R"3O9"R)Q1R1^12)YD_5L3.)Q3&PR"Q.+S,;$)CO/).F8)!>92*I?]Y#< M\8%(^$HX9>Y*01ND;$"SKS2<;<1/]$SVKU7_8&>A*_!JK*]M1)M!QKW)^4$< M^I,I'D*U*:/$"_VI/^!J]0R")(Z# =HSGM!]8*<[Z>A._F>Z[2[].[Z3T7QM M2CM?JZ>5[QG/\WRG'=_IN!/]Q7LR%XQAV3.PXFM&,>V?/>_&CP;H[*IP@,YJ M"F8#9'95;,^];VE=PA6IN/"_:-_>O#UCN*%>(D2UTY=U, MX#S(YD[35+38UQ_M&Z'A"E 7"[@&FD|'PKA#Y53 ?=Q3+] U!+ P04 M" !3@?Y8K!F!;JX# !U$0 &0 'AL+W=O)ZV@% M(_$[@:,XN48ZE'O&'O3B;;:.P'.T14$BE1F#U=8 U4*I)RH^/+=3J;&K%T^MG M^H\F>!7,/1:P9O0/DLE\84TME,$.UU1^8,JM9.D#2AY36F=*?<=9@60. M^G952VS:04G_[_I\-_$(#&AXEME2!C|W)8J-NVAG;9QK)HX)J_$X:'WK)2Y M0$FIO!C0CR_KAQ?T;973+K&3Y\2N)A>!/]7E#?*<[]#$F?@#_JRO5_>&POE_MUI/_;+V7#*_K,L_PO%=X=ZIW,MT :BB@+:0U)Y*H+NIWS5G'))B7I-R?=LJ?M[Q08O950B+^&>]3QPA_V0L_<6U'A%!:6&JH"^ &LY==?N:'SPU"!QH3%8|*2 MD6"]4OI=*?U+].6O3*HI4#W/_J$NL*FS4 PCS""CS4Y8*JD!I_FQDA@C.@?ML\/2C<)I$,["N7TXK<* H!]%D1-, ^X+QM<3D"F(O,T&7F>!B9GZI=.<*)!FJ M:I[FZN>K2XF>D4-IN$C\U(8=$Q:/"4M&@O7*$G9E"; ^(V1..6)I)\S)_*HK+H11$)2/!>B69=269?1%S9S9F*<>$Q6/" MDI%@O5*ZSLLIR?DUTGO^O=DT=,\&SX!<-'4<[VSL7(E+_A779,4^.486 MP/?F_"Y4@'4IF__ZW6[WCN#.G(S/]E?N[=H=V(_U.P5S;'W!-R\DWF. ^) ^J_ M$X6=,N7<1,I7WISQFX5DE3G$WC.ICL3F,@>< =<"ZOZ.J=JT"VV@>].R_!M0 M2P,$% @ 4X'^6$+DZ6)% P S!0 T!X;"]S='EL97,N>&ULW5A= M;]HP%/TK4;I.K30U0-I 5D#:D"I-VJ9*[*D,=5JM)"H($^&P+ ^;%7:&K8"+G0@_";A,*W.U+-@C; MR748.+F1S.@@?+IX_W,N]>V[P-W//IR=M9XN;W?C%Q:X#".OZ,T!HE+@MNM!#=U\-W@%4/##+.&X.=T 6&_9)H396X,QT[V 9? M04'=?ER6QN%4D66[U%OK%G=L=$TS2&ZJ:3<1W0WU1SVINR MUV_2#4KV+/7GN9F.L'TH;'JO:,X6MK_(&P.8>AM7)V7)EY\XFX]"NLD?G'#8 M)RM>,).*O9AL4"H3$Z_J#)ZITFRR&?FE2/E(%WI53HL<]]PY0<]_=YVG5%!%M^*9I4_O'O,IO=AQW_Y5E^UMEU[#78_W6/G:3-Z=@,CD%DR=1D[U3,)D>O\GX M!#S69\NC,QG5)Z&-X];68:N)!G"H'83?X7C,UTF#\9QQS43=F[$LH^+5F87CMI3M0F%Q,9 M7=!L5'?5=&R;@6F8K/4%A%WDSEY^!,,XS(\ AN7!'& =%>BBGAW(,[?+X^>DYO+/-$WC.$FP%1V-O Y&V+HE"?SXU3!OP,#R M0*8_6VM\M_$*V5\'V)[NJQ!LIG@E8C/%UQH0_[H!(TW]NXWE 0:V"UCM0'Y_ M'J@I/R>.85TKB.$W]"&!^!W&,(? T MX@CF #Q@2!S;]^#.^RA:O:>B]?\OA[\!4$L#!!0 (%.!_EB7BKL

-8?20$3;8T.P6BP^0"X99K>]9!:GHI]DX8VYE[C\:*Y^,]EPMA#5*3;-|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|+'9J^VV@\[M)\M6J1-L^Z(_&5YO7Z-N7P&_^P%02P,$% @4X'^6+@VQ-RI 0 +AL M !H !X;"]?/L@*.!8*=*@/96UMCS^&W^RUK.O4)7I4)_C M_M#$WN54G>.|V*?4?#@7U_MP*F._;L+Y=F5;MZZ-N$_$^OMJK .G_7Z^Q3.Z8_![J=NCW$?0BIZJ[+=A30OW*5Z MGH[N?I#^;7+16V[F1;O<2.%R!RD$:?X@@R#+'^0AR.BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ;01Z&^IM!'I;9[.$M0&]#O8U ;T.JC4!O0[V-0&]#O8U ;T.JC4!O0[V-0&^>GL"O3WJ[0GT]JBW M)]#;H]Z>0&_?V>PFT-NCWOZ=>L=TK4)\JCS6^/QW4IUN]X;GX^_+Q\G."W7'MV<'OL<4O4$L#!!0 (%.!_EA3V2LIL@$ %,; 3 6T-O;G1E;G1? M5'EP97-=+GAM;,V9S6[",I"$7P7EBHBQG=(? 9>VUY9#7\!--B0BB2W;4'C[M.N%':D6C(BIU+K$2[\Z,O=)WR?1M9\@-MG75N%E4>&|>&'-I0;5RL3;4A)U< MVUKY\&J7S*ATI9;$Q'@\8:EN/#5^Y%N-:#Y]HERM*S]XWH;/KM3-++)4N6CP MN"]LO6:1,J8J4^7#/MLTV3>7T<$A#IU=C2M*XX:A(&)G'=J=GPT.?:\;LK;, M:+!0UK^H.E2Q;<6H?K_=!VU&PO=&AE;64O=&AE;64Q M+GAM;%!+ 0(4 Q0 (%.!_ECA(#%"[@4 +D? 8 " M@0T(!X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ 4X'^6.K'/B\| P ;0H !@ M ("!,!0 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0# M% @ 4X'^6 >@.MAU"0 *E0 !@ ("!YQ\ 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 4X'^6%+L5U!N M$@ 1#4 !@ ("!I3D 'AL+W=O&OUL4$L! A0#% @ 4X'^ M6-RR;M:-! *0L !D ("!?E, 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 4X'^6*O1KG@?"P !\ M !D ("!Q5X 'AL+W=O&PO=V]R:W-H965T["TI MY0, '0) 9 " @7YT !X;"]W;W)K&UL4$L! A0#% @ 4X'^6,K[& 5\ @ N@< !D M ("!FG@ 'AL+W=OP >&PO=V]R:W-H965T M&UL4$L! A0# M% @ 4X'^6,5K<:L*!@ I1$!D ("!7I('AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 4X'^6,5U M21_D! T@L !D ("!2: 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 4X'^6!KJ3 00! [!, !D M ("!ZP 'AL+W=O&POM=V]R:W-H965T&UL4$L! A0#% @ 4X'^6!EHXN[L!0 QR8 !D ("! M&L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 4X'^6+7CAV@" P $P@ !D ("!)<\'AL+W=O&PO=V]R:W-H965T !X;"]W;W)K&UL4$L! A0#% @ 4X'^6+Q_0,O.!@ MSD !D M ("!Z> 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ 4X'^6*,R/F6G P^1 !D ("!M/ M 'AL+W=O" &0 @(&2] >&PO=V]R:W-H965T&UL4$L! A0#% @ M4X'^6)3V%Q,J P 9 X !D ("!^?H 'AL+W=O&PO=V]R:W-H965T*NQS $P(L M (!+P8!%]R96QS+RYR96QS4$L! A0#% @ 4X'^6$:=,8K2 P MAAX \ (!& 7!E&UL4$L%!@ 0 U #4 :@X -L. 0 $! end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?window.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}}if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 176 217 1 false 32 0 false 5 false false R1.htm 0000001 - Document - Cover Sheet http://www.nautilus.bio/role/Cover Cover Cover 1 false false R2.htm 9952151 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 9952153 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss Sheet http://www.nautilus.bio/role/CondensedConsolidatedStatementsofComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 9952155 - Statement - Condensed Consolidated Statements of Stockholders??? Equity Sheet http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity Condensed Consolidated Statements of Stockholders??? Equity Statements 6 false false R7.htm 9952156 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 7 false false R8.htm 9952157 - Disclosure - Description of Business and Basis of Presentation Sheet http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentation Description of Business and Basis of Presentation Notes 8 false false R9.htm 9952158 - Disclosure - Significant Accounting Policies Sheet http://www.nautilus.bio/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 9952159 - Disclosure - Fair Value Measurements Sheet http://www.nautilus.bio/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 9952160 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items Sheet http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItems Composition of Certain Condensed Consolidated Financial Statement Line Items Notes 11 false false R12.htm 9952161 - Disclosure - Common Stock Sheet http://www.nautilus.bio/role/CommonStock Common Stock Notes 12 false false R13.htm 9952162 - Disclosure - Income Taxes Sheet http://www.nautilus.bio/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 9952163 - Disclosure - Equity Incentive Plans and Stock-based Compensation Sheet http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensation Equity Incentive Plans and Stock-based Compensation Notes 14 false false

R15.htm 9952164 - Disclosure - Commitment and Contingencies Sheet http://www.nautilus.bio/role/CommitmentandContingencies Commitment and Contingencies Notes 15 false false R16.htm 9952165 - Disclosure - Basic and Diluted Net Loss per Share Sheet http://www.nautilus.bio/role/BasicandDilutedNetLossperShare Basic and Diluted Net Loss per Share Notes 16 false false R17.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 17 false false R18.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 18 false false R19.htm 9954471 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.nautilus.bio/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.nautilus.bio/role/SignificantAccountingPolicies 19 false false R20.htm 9954472 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.nautilus.bio/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.nautilus.bio/role/FairValueMeasurements 20 false false R21.htm 9954473 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items (Tables) Sheet http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsTables Composition of Certain Condensed Consolidated Financial Statement Line Items (Tables) Tables http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItems 21 false false R22.htm 9954474 - Disclosure - Common Stock (Tables) Sheet http://www.nautilus.bio/role/CommonStockTables Common Stock (Tables) Tables http://www.nautilus.bio/role/CommonStock 22 false false R23.htm 9954475 - Disclosure - Equity Incentive Plans and Stock-based Compensation (Tables) Sheet http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationTables Equity Incentive Plans and Stock-based Compensation (Tables) Tables http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensation 23 false false R24.htm 9954476 - Disclosure - Commitment and Contingencies (Tables) Sheet http://www.nautilus.bio/role/CommitmentandContingenciesTables Commitment and Contingencies (Tables) Tables http://www.nautilus.bio/role/CommitmentandContingencies 24 false false R25.htm 9954477 - Disclosure - Basic and Diluted Net Loss per Share (Tables) Sheet http://www.nautilus.bio/role/BasicandDilutedNetLossperShareTables Basic and Diluted Net Loss per Share (Tables) Tables http://www.nautilus.bio/role/BasicandDilutedNetLossperShare 25 false false R26.htm 9954478 - Disclosure - Description of Business and Basis of Presentation (Details) Sheet http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentationDetails Description of Business and Basis of Presentation (Details) Details http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentation 26 false false R27.htm 9954479 - Disclosure - Significant Accounting Policies (Details) Sheet http://www.nautilus.bio/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://www.nautilus.bio/role/SignificantAccountingPoliciesPolicies 27 false false R28.htm 9954480 - Disclosure - Fair Value Measurements - Assets Carried at Fair Value and Measured on a Recurring Basis (Details) Sheet http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails Fair Value Measurements - Assets Carried at Fair Value and Measured on a Recurring Basis (Details) Details 28 false false R29.htm 9954481 - Disclosure - Fair Value Measurements - Unrealized Losses and Fair Values of Available-for-Sale Securities in an Unrealized Loss Position (Details) Sheet http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails Fair Value Measurements - Unrealized Losses and Fair Values of Available-for-Sale Securities in an Unrealized Loss Position (Details) Details 29 false false R30.htm 9954482 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.nautilus.bio/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 30 false false R31.htm 9954483 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items - Property and Equipment, Net (Details) Sheet http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails Composition of Certain Condensed Consolidated Financial Statement Line Items - Property and Equipment, Net (Details) Details 31 false false R32.htm 9954484 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items - Accrued Expenses and Other Liabilities (Details) Sheet http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsAccruedExpensesandOtherLiabilitiesDetails Composition of Certain Condensed Consolidated Financial Statement Line Items - Accrued Expenses and Other Liabilities (Details) Details 32 false false R33.htm 9954485 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items - Cash, Cash Equivalents and Restricted Cash (Details) Sheet http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsCashCashEquivalentsandRestrictedCashDetails Composition of Certain Condensed Consolidated Financial Statement Line Items - Cash, Cash Equivalents and Restricted Cash (Details) Details 33 false false R34.htm 9954486 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items - Other Long-term Assets (Details) Sheet http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsOtherLongtermAssetsDetails Composition of Certain Condensed Consolidated Financial Statement Line Items - Other Long-term Assets (Details) Details 34 false false R35.htm 9954487 - Disclosure - Common Stock - Narrative (Details) Sheet http://www.nautilus.bio/role/CommonStockNarrativeDetails Common Stock - Narrative (Details) Details 35 false false R36.htm 9954488 - Disclosure - Common Stock - Common Stock Reserved for Future Issuance (Details) Sheet http://www.nautilus.bio/role/CommonStockCommonStockReservedforFutureIssuanceDetails Common Stock - Common Stock Reserved for Future Issuance (Details) Details 36 false false R37.htm 9954489 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.nautilus.bio/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 37 false false R38.htm 9954490 - Disclosure - Equity Incentive Plans and Stock-based Compensation - Narrative (Details) Sheet http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails Equity Incentive Plans and Stock-based Compensation - Narrative (Details) Details http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationTables 38 false false R39.htm 9954491 - Disclosure - Equity Incentive Plans and Stock-based Compensation - Significant Assumptions (Details) Sheet http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails Equity Incentive Plans and Stock-based Compensation - Significant Assumptions (Details) Details 39 false false R40.htm 9954492 - Disclosure - Equity Incentive Plans and Stock-based Compensation - Option Award Activity (Details) Sheet http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails Equity Incentive Plans and Stock-based Compensation - Option Award Activity (Details) Details 40 false false R41.htm 9954493 - Disclosure - Equity Incentive Plans and Stock-based Compensation - Stock-Based Compensation Expense (Details) Sheet http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationStockBasedCompensationExpenseDetails Equity Incentive Plans and Stock-based Compensation - Stock-Based Compensation Expense (Details) Details 41 false false R42.htm 9954494 - Disclosure - Commitment and Contingencies - Narrative (Details) Sheet http://www.nautilus.bio/role/CommitmentandContingenciesNarrativeDetails Commitment and Contingencies - Narrative (Details) Details 42 false false R43.htm 9954495 - Disclosure - Commitment and Contingencies - Future Principal Contractual Obligations for Operating Lease Commitments (Details) Sheet http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails Commitment and Contingencies - Future Principal Contractual Obligations for Operating Lease Commitments (Details) Details 43 false false R44.htm 9954496 - Disclosure - Basic and Diluted Net Loss per Share - Basic and Diluted Net Loss per Share (Details) Sheet http://www.nautilus.bio/role/BasicandDilutedNetLossperShareBasicandDilutedNetLossperShareDetails Basic and Diluted Net Loss per Share - Basic and Diluted Net Loss per Share (Details) Details 44 false false R45.htm 9954497 - Disclosure - Basic and Diluted Net Loss per Share - Potential Shares of Common Stock Excluded from the Computation of Diluted Net Loss Per Share (Details) Sheet http://www.nautilus.bio/role/BasicandDilutedNetLossperSharePotentialSharesofCommonStockExcludedfromtheComputationofDilutedNetLossPerShareDetails Basic and Diluted Net Loss per Share - Potential Shares of Common Stock Excluded from the Computation of Diluted Net Loss Per Share (Details) Details 45 false false All Reports Book All Reports naut-20240630.htm naut-20240630.xsd naut-20240630_cal.xml naut-20240630_def.xml naut-20240630_lab.xml naut-20240630_pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "naut-20240630.htm": { "nsprefix": "naut", "nsuri": "http://www.nautilus.bio/20240630", "dts": { "inline": { "local": ["naut-20240630.htm"] }, "schema": { "local": ["naut-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["naut-20240630_cal.xml"] }, "definitionLink": { "local": ["naut-20240630_def.xml"] }, "labelLink": { "local": ["naut-20240630_lab.xml"] }, "presentationLink": { "local": ["naut-20240630_pre.xml"] } }, "keyStandard": 209, "keyCustom": 8, "axisStandard": 12, "axisCustom": 0, "memberStandard": 24, "memberCustom": 7, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 176, "entityCount": 1, "segmentCount": 32, "elementCount": 420, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 649, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.nautilus.bio/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets", "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "unique": true } }, "R3": { "role": "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations", "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement",

"subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofComprehensiveLoss", "longName": "9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "unique": true } }, "R6": { "role": "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity", "longName": "9952155 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity", "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-43", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-43", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows", "longName": "9952156 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "unique": true } }, "R8": { "role": "http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentation", "longName": "9952157 - Disclosure - Description of Business and Basis of Presentation", "shortName": "Description of Business and Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.nautilus.bio/role/SignificantAccountingPolicies", "longName": "9952158 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.nautilus.bio/role/FairValueMeasurements", "longName": "9952159 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItems", "longName": "9952160 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items", "shortName": "Composition of Certain Condensed Consolidated Financial Statement Line Items", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.nautilus.bio/role/CommonStock", "longName": "9952161 - Disclosure - Common Stock", "shortName": "Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.nautilus.bio/role/IncomeTaxes", "longName": "9952162 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensation", "longName": "9952163 - Disclosure - Equity Incentive Plans and Stock-based Compensation", "shortName": "Equity Incentive Plans and Stock-based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.nautilus.bio/role/CommitmentandContingencies", "longName": "9952164 - Disclosure - Commitment and Contingencies", "shortName": "Commitment and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.nautilus.bio/role/BasicandDilutedNetLossperShare", "longName": "9952165 - Disclosure - Basic and Diluted Net Loss per Share", "shortName": "Basic and Diluted Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true }, "uniqueAnchor": null }, "R18": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.nautilus.bio/role/SignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.nautilus.bio/role/FairValueMeasurementsTables", "longName": "9954472 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsTables", "longName": "9954473 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items (Tables)", "shortName": "Composition of Certain Condensed Consolidated Financial Statement Line Items (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.nautilus.bio/role/CommonStockTables", "longName": "9954474 - Disclosure - Common Stock (Tables)", "shortName": "Common Stock (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "naut:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",

"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "naut:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationTables", "longName": "9954475 - Disclosure - Equity Incentive Plans and Stock-based Compensation (Tables)", "shortName": "Equity Incentive Plans and Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.nautilus.bio/role/CommitmentandContingenciesTables", "longName": "9954476 - Disclosure - Commitment and Contingencies (Tables)", "shortName": "Commitment and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.nautilus.bio/role/BasicandDilutedNetLossperShareTables", "longName": "9954477 - Disclosure - Basic and Diluted Net Loss per Share (Tables)", "shortName": "Basic and Diluted Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentationDetails", "longName": "9954478 - Disclosure - Description of Business and Basis of Presentation (Details)", "shortName": "Description of Business and Basis of Presentation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-54", "name": "naut:ProceedsFromSaleOfStockAndReverseRecapitalizationTransaction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["ix:continuation", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "unique": true } }, "R27": { "role": "http://www.nautilus.bio/role/SignificantAccountingPoliciesDetails", "longName": "9954479 - Disclosure - Significant Accounting Policies (Details)", "shortName": "Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["ix:continuation", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["ix:continuation", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails", "longName": "9954480 - Disclosure - Fair Value Measurements - Assets Carried at Fair Value and Measured on a Recurring Basis (Details)", "shortName": "Fair Value Measurements - Assets Carried at Fair Value and Measured on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c-83", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-83", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails", "longName": "9954481 - Disclosure - Fair Value Measurements - Unrealized Losses and Fair Values of Available-for-Sale Securities in an Unrealized Loss Position (Details)", "shortName": "Fair Value Measurements - Unrealized Losses and Fair Values of Available-for-Sale Securities in an Unrealized Loss Position (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.nautilus.bio/role/FairValueMeasurementsNarrativeDetails", "longName": "9954482 - Disclosure - Fair Value Measurements - Narrative (Details)", "shortName": "Fair Value Measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease", "span", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails", "longName": "9954483 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items - Property and Equipment, Net (Details)", "shortName": "Composition of Certain Condensed Consolidated Financial Statement Line Items - Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "unique": true } }, "R32": { "role": "http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsAccruedExpensesandOtherLiabilitiesDetails", "longName": "9954484 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items - Accrued Expenses and Other Liabilities (Details)", "shortName": "Composition of Certain Condensed Consolidated Financial Statement Line Items - Accrued Expenses and Other Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsCashCashEquivalentsandRestrictedCashDetails", "longName": "9954485 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items - Cash, Cash Equivalents and Restricted Cash (Details)", "shortName": "Composition of Certain Condensed Consolidated Financial Statement Line Items - Cash, Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "unique": true } }, "R34": { "role": "http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsOtherLongtermAssetsDetails", "longName": "9954486 - Disclosure - Composition of Certain Condensed Consolidated Financial Statement Line Items - Other Long-term Assets (Details)", "shortName": "Composition of Certain Condensed Consolidated Financial Statement Line Items - Other Long-term Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCashNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["us-gaap:RestrictedCashNoncurrent", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCashNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["us-gaap:RestrictedCashNoncurrent", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.nautilus.bio/role/CommonStockNarrativeDetails", "longName": "9954487 - Disclosure - Common Stock - Narrative (Details)", "shortName": "Common Stock - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:CommonStockSharesOutstanding", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://www.nautilus.bio/role/CommonStockCommonStockReservedforFutureIssuanceDetails", "longName": "9954488 - Disclosure - Common Stock - Common Stock Reserved for Future Issuance (Details)", "shortName": "Common Stock - Common Stock Reserved for Future Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "naut:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body",

"html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "naut:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "unique": true } }, "R37": { "role": "http://www.nautilus.bio/role/IncomeTaxesNarrativeDetails", "longName": "9954489 - Disclosure - Income Taxes - Narrative (Details)", "shortName": "Income Taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:IncomeTaxExpenseBenefit", "us-gaap:IncomeTaxExpenseBenefit", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails", "longName": "9954490 - Disclosure - Equity Incentive Plans and Stock-based Compensation - Narrative (Details)", "shortName": "Equity Incentive Plans and Stock-based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "unique": true } }, "R39": { "role": "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails", "longName": "9954491 - Disclosure - Equity Incentive Plans and Stock-based Compensation - Significant Assumptions (Details)", "shortName": "Equity Incentive Plans and Stock-based Compensation - Significant Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-157", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-157", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails", "longName": "9954492 - Disclosure - Equity Incentive Plans and Stock-based Compensation - Option Award Activity (Details)", "shortName": "Equity Incentive Plans and Stock-based Compensation - Option Award Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "unique": true } }, "R41": { "role": "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationStockBasedCompensationExpenseDetails", "longName": "9954493 - Disclosure - Equity Incentive Plans and Stock-based Compensation - Stock-Based Compensation Expense (Details)", "shortName": "Equity Incentive Plans and Stock-based Compensation - Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-157", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-157", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.nautilus.bio/role/CommitmentandContingenciesNarrativeDetails", "longName": "9954494 - Disclosure - Commitment and Contingencies - Narrative (Details)", "shortName": "Commitment and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails", "longName": "9954495 - Disclosure - Commitment and Contingencies - Future Principal Contractual Obligations for Operating Lease Commitments (Details)", "shortName": "Commitment and Contingencies - Future Principal Contractual Obligations for Operating Lease Commitments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.nautilus.bio/role/BasicandDilutedNetLossperShareBasicandDilutedNetLossperShareDetails", "longName": "9954496 - Disclosure - Basic and Diluted Net Loss per Share - Basic and Diluted Net Loss per Share (Details)", "shortName": "Basic and Diluted Net Loss per Share - Basic and Diluted Net Loss per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.nautilus.bio/role/BasicandDilutedNetLossperSharePotentialSharesofCommonStockExcludedfromtheComputationofDilutedNetLossPerShareDetails", "longName": "9954497 - Disclosure - Basic and Diluted Net Loss per Share - Potential Shares of Common Stock Excluded from the Computation of Diluted Net Loss Per Share (Details)", "shortName": "Basic and Diluted Net Loss per Share - Potential Shares of Common Stock Excluded from the Computation of Diluted Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": ["us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "naut-20240630.htm", "first": true, "unique": true } } }, "tag": { "naut_A2021EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname": "A2021EmployeeStockPurchasePlanMember", "presentation": ["http://www.nautilus.bio/role/CommonStockCommonStockReservedforFutureIssuanceDetails", "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "2021 Employee Stock Purchase Plan", "label": "2021 Employee Stock Purchase Plan [Member]", "documentation": "2021 Employee Stock Purchase Plan" } } }, "auth_ref": [] }, "naut_A2021EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname": "A2021EquityIncentivePlanMember", "presentation": ["http://www.nautilus.bio/role/CommonStockCommonStockReservedforFutureIssuanceDetails", "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "2021 Equity Incentive Plan", "label": "2021 Equity Incentive Plan [Member]", "documentation": "2021 Equity Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r43", "r575"] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amortization (accretion) of premium (discount) on securities, net", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash

```
provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r66" ] }, "naut_AccruedLiabilitiesAndOtherLiabilitiesCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 },
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsAccruedExpensesandOtherLiabilitiesDetails": { "parentTag":
null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsAccruedExpensesandOtherLiabilitiesDetails",
"http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other liabilities", "totalLabel":
"Total", "label": "Accrued Liabilities and Other Liabilities, Current", "documentation": "Accrued Liabilities and Other Liabilities, Current" } } }, "auth_ref": [] }, "us-
gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent",
"crdr": "credit", "calculation": {
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsAccruedExpensesandOtherLiabilitiesDetails": { "parentTag":
"naut_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsAccruedExpensesandOtherLiabilitiesDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Accrued professional and consulting fees", "label": "Accrued Professional Fees, Current", "documentation": "Carrying value as of the
balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the
current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r45" ] },
"naut_AccruedResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname":
"AccruedResearchAndDevelopment", "crdr": "credit", "calculation": {
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsAccruedExpensesandOtherLiabilitiesDetails": { "parentTag":
"naut_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsAccruedExpensesandOtherLiabilitiesDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Accrued research and development", "label": "Accrued Research and Development", "documentation": "Accrued Research and
Development" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation":
{ "http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails": { "parentTag": "us-
gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails" ], "lang": { "en-us": {
"role": { "negatedTerseLabel": "Less: Accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
"documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and
services." } } }, "auth_ref": [ "r27", "r105", "r439" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {
"http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)",
"label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from
transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r13", "r14", "r58", "r111", "r436", "r457", "r458" ] }, "us-
gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang":
{ "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated
increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss),
and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r1", "r8", "r14", "r343",
"r346", "r391", "r453", "r454", "r688", "r689", "r690", "r697", "r698", "r699", "r700" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r625" ] }, "us-
gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit",
"calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } },
"presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label":
"Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or
stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r53", "r575", "r783" ] }, "us-
gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember",
"presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in
Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts
received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r470", "r697", "r698", "r699", "r700", "r756", "r784" ] },
"ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation
Amount" } } }, "auth_ref": [ "r638" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to
Compensation [Axis]" } } }, "auth_ref": [ "r638" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } },
"auth_ref": [ "r638" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO
Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r638" ] }, "us-
gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr":
"credit", "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-
based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional
paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r37", "r38", "r279" ] }, "us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net
cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref":
[] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present
Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r671" ] }, "ecd_AggtErrCompAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate
Erroneous Compensation Amount" } } }, "auth_ref": [ "r597", "r607", "r617", "r649" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label":
"Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r600", "r610", "r620", "r652" ] }, "ecd_AggtPnsnAdjsSvcCstMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension
Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r672" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r638" ] },
"ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories
[Member]" } } }, "auth_ref": [ "r645" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals",
"label": "All Individuals [Member]" } } }, "auth_ref": [ "r601", "r611", "r621", "r645", "r653", "r657", "r665" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements
[Member]" } } }, "auth_ref": [ "r663" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based
payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r308", "r313" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel":
"Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." }
} }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.nautilus.bio/role/BasicandDilutedNetLossperSharePotentialSharesofCommonStockExcludedfromtheComputationofDilutedNetLossPerShareDetails" ],
```

```
"lang": { "en-us": { "role": { "terseLabel": "Total potentially dilutive common share equivalents", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r160" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.nautilus.bio/role/BasicandDilutedNetLossperSharePotentialSharesofCommonStockExcludedfromtheComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r22" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.nautilus.bio/role/BasicandDilutedNetLossperSharePotentialSharesofCommonStockExcludedfromtheComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.nautilus.bio/role/BasicandDilutedNetLossperSharePotentialSharesofCommonStockExcludedfromtheComputationofDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r22" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r82", "r86", "r107", "r130", "r164", "r167", "r176", "r177", "r213", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r338", "r340", "r373", "r431", "r494", "r548", "r549", "r575", "r588", "r726", "r727", "r767" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r100", "r112", "r130", "r213", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r338", "r340", "r373", "r575", "r726", "r727", "r767" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r187" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r188" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r184", "r221", "r430" ] }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract", "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r185", "r221", "r354", "r426", "r564", "r567", "r704", "r760", "r761", "r762" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Debt Securities, Available-for-Sale, Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current." } } }, "auth_ref": [ "r182", "r221" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments", "label": "Debt Securities, Available-for-Sale, Noncurrent", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent." } } }, "auth_ref": [ "r103", "r182", "r221" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r660" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r661" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r656" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r656" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r656" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r656" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r656" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r656" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails", "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails", "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationStockBasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r659" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
```

"Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r658"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r657"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r657"] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r232", "r778", "r779"] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": ["r39", "r40", "r232", "r778", "r779"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.nautilus.bio/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": ["http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentation"], "lang": { "en-us": { "role": { "terseLabel": "Description of Business and Basis of Presentation", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": ["r42", "r67", "r68"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsCashCashEquivalentsandRestrictedCashDetails", "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r17", "r102", "r541"] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsMember", "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": ["http://www.nautilus.bio/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": ["r18"] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": ["http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash, cash equivalents, and short-term investments", "label": "Cash, Cash Equivalents, and Short-Term Investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": ["r687"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsCashCashEquivalentsandRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsCashCashEquivalentsandRestrictedCashDetails", "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "totalLabel": "Total", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r17", "r64", "r127"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r64"] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": ["r636"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": ["r633"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r631"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.nautilus.bio/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://www.nautilus.bio/role/CommonStockCommonStockReservedforFutureIssuanceDetails"], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r108", "r109", "r110", "r166", "r253", "r254", "r255", "r257", "r260", "r265", "r267", "r464", "r465", "r466", "r467", "r556", "r676", "r695"] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r637"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": ["r637"] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"CommercialPaperMember", "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails", "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": ["r72", "r240", "r583", "r584", "r585", "r586"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 8)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r49", "r83", "r432", "r481"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.nautilus.bio/role/CommitmentandContingencies"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r71", "r234", "r235", "r536", "r723", "r725"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "calculation": { "http://www.nautilus.bio/role/CommonStockCommonStockReservedforFutureIssuanceDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nautilus.bio/role/CommonStockCommonStockReservedforFutureIssuanceDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total shares of common stock reserved (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r52"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r579", "r580", "r581", "r583", "r584", "r585", "r586", "r697", "r698", "r700", "r756", "r782", "r784"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r52"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r52", "r482"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": ["http://www.nautilus.bio/role/CommonStockNarrativeDetails", "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r52"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": ["http://www.nautilus.bio/role/CommonStockNarrativeDetails", "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r9", "r52", "r482", "r500", "r784", "r785"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.0001 par value, 1,000,000,000 shares authorized as of June\u00a030, 2024 and December\u00a031, 2023; 125,406,748 and 125,068,601 shares issued and outstanding as of June\u00a030, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r52", "r435", "r575"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": ["r642"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": ["r641"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": ["r643"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": ["r640"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r15", "r115", "r117", "r121", "r427", "r444", "r445"] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": ["http://www.nautilus.bio/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Loss", "label": "Comprehensive Income, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": ["http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Computer hardware", "label": "Computer Equipment [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": ["http://www.nautilus.bio/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Credit Risk and Other Risks and Uncertainties", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": ["r41", "r94"] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": ["http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails", "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": ["r557", "r559", "r564", "r576", "r578", "r781"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.nautilus.bio/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsNarrativeDetails", "http://www.nautilus.bio/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit losses", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r186", "r221", "r228", "r229"] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease", "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsNarrativeDetails", "http://www.nautilus.bio/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit losses during period", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Period Increase (Decrease)",

"documentation": "Amount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r722"] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Securities in Unrealized Loss Position Greater than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r89", "r225", "r553"] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Securities in Unrealized Loss Position Greater than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r89", "r225"] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Securities in Unrealized Loss Position Less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r89", "r225", "r553"] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Securities in Unrealized Loss Position Less than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r89", "r225"] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Unrealized Losses and Fair Values of Available-for-Sale Securities in an Unrealized Loss Position", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717"] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": ["r87", "r223", "r553"] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r88", "r224"] }, "naut_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract", "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Market Value", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Abstract]", "documentation": "Debt Securities, Available-For-Sale, Unrealized Loss Position, Fair Value" } } }, "auth_ref": [] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "presentation": ["http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsOtherLongtermAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deposits", "label": "Deposits Assets, Noncurrent", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r686"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails", "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r5", "r26"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensation"], "lang": { "en-us": { "role": { "terseLabel": "Equity Incentive Plans and Stock-based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r277", "r281", "r309", "r310", "r312", "r561"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.nautilus.bio/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.nautilus.bio/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.nautilus.bio/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.nautilus.bio/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r592"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.nautilus.bio/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r624"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.nautilus.bio/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered

```
Year [Member]" } } }, "auth_ref": [ "r635" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } },
"auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic",
"presentation": [ "http://www.nautilus.bio/role/BasicandDilutedNetLossperShareBasicandDilutedNetLossperShareDetails",
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to common
stockholders, basic (in dollars per share)", "verboseLabel": "Net loss per share attributable to common stockholders, basic (in dollars per share)", "label": "Earnings Per
Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } }
}, "auth_ref": [ "r122", "r137", "r138", "r139", "r140", "r141", "r142", "r147", "r150", "r157", "r158", "r159", "r163", "r334", "r337", "r351", "r352", "r428", "r446",
"r543" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted",
"presentation": [ "http://www.nautilus.bio/role/BasicandDilutedNetLossperShareBasicandDilutedNetLossperShareDetails",
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Net loss per share attributable to
common stockholders, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available
to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the
issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r122", "r137",
"r138", "r139", "r140", "r141", "r142", "r150", "r157", "r158", "r159", "r163", "r334", "r337", "r351", "r352", "r428", "r446", "r543" ] }, "us-
gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock",
"presentation": [ "http://www.nautilus.bio/role/BasicandDilutedNetLossperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Basic and Diluted Net Loss per Share",
"label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r146", "r160", "r161", "r162" ] }, "us-
gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsAccruedExpensesandOtherLiabilitiesDetails": { "parentTag":
"naut_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsAccruedExpensesandOtherLiabilitiesDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Employee compensation", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the
balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and
bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } }
}, "auth_ref": [ "r45" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [
"http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized
compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "documentation": "Amount of cost not yet
recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r311" ] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype":
"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized
compensation expense, period for recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
"documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in
'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r311" ] }, "us-
gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockMember", "presentation": [
"http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-
us": { "role": { "terseLabel": "Employee Stock", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by
which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://www.nautilus.bio/role/BasicandDilutedNetLossperSharePotentialSharesofCommonStockExcludedfromtheComputationofDilutedNetLossPerShareDetails",
"http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails",
"http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails",
"http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationStockBasedCompensationExpenseDetails",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "verboseLabel": "Options to purchase common stock",
"label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other
restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] },
"naut_EmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname":
"EmployeeStockPurchasePlanMember", "presentation": [
"http://www.nautilus.bio/role/BasicandDilutedNetLossperSharePotentialSharesofCommonStockExcludedfromtheComputationofDilutedNetLossPerShareDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan", "label": "Employee Stock Purchase Plan [Member]", "documentation": "Employee Stock
Purchase Plan" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityAddressAddressLine1", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One",
"label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] },
"dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown",
"presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or
Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": {
"terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] },
"dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince",
"presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or
Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel":
"Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with
the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r590" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": {
"role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares
or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report.
Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or
Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": {
"xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [
"http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status",
"documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements
for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] },
"dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany",
"presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging
Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r590" ] },
"dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [
"http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation":
"Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
} } }, "auth_ref": [ "r675" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber",
"presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number",
"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the
optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype":
"filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": {
"en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following:
Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should
be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r590" ] }, "dei_EntityIncorporationStateCountryCode":
{ "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [
"http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or
Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] },
"dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation":
[ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current",
"documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405
of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r674" ] },
"dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The
exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r590" ] },
"dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [
```

```
"http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r590" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r590" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r590" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r629" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r670" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r670" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r670" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r98", "r118", "r119", "r120", "r132", "r133", "r134", "r136", "r141", "r143", "r145", "r165", "r214", "r215", "r230", "r268", "r324", "r325", "r331", "r332", "r333", "r335", "r336", "r337", "r342", "r343", "r344", "r345", "r346", "r347", "r350", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r391", "r442", "r453", "r454", "r455", "r470", "r520" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r639" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r597", "r607", "r617", "r649" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r594", "r604", "r614", "r646" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r645" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails", "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r354", "r355", "r365", "r564" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails", "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r354", "r355", "r365", "r564" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock", "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets Carried at Fair Value and Measured on a Recurring Basis", "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r758", "r759" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r250", "r270", "r271", "r272", "r273", "r274", "r275", "r353", "r355", "r356", "r357", "r358", "r364", "r365", "r367", "r395", "r396", "r397", "r554", "r555", "r557", "r558", "r559", "r564", "r567" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r354", "r355", "r356", "r358", "r564", "r761", "r764" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r360", "r362", "r363", "r364", "r367", "r368", "r369", "r370", "r371", "r425", "r564", "r568" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r250", "r270", "r275", "r355", "r365", "r395", "r557", "r558", "r559", "r564" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r250", "r270", "r275", "r355", "r356", "r365", "r396", "r554", "r555", "r557", "r558", "r559", "r564" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r354", "r355", "r356", "r358", "r564", "r761", "r764" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r250", "r270", "r271", "r272", "r273", "r274", "r275", "r353", "r355", "r356", "r357", "r358", "r364", "r365", "r367", "r395", "r396", "r397", "r554", "r555", "r557", "r558", "r559", "r564", "r567" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": [
```

```
"http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r564", "r758", "r759", "r760", "r761", "r762", "r764" ] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://www.nautilus.bio/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r7" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails", "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r216", "r217", "r218", "r219", "r220", "r222", "r226", "r227", "r251", "r265", "r348", "r372", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r443", "r553", "r564", "r565", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r576", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r717", "r718", "r719", "r720", "r757", "r760", "r761", "r762", "r763", "r764" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r601", "r611", "r621", "r653" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r601", "r611", "r621", "r653" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r601", "r611", "r621", "r653" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r601", "r611", "r621", "r653" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r601", "r611", "r621", "r653" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r634" ] }, "naut_FurnitureFixturesAndOfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname": "FurnitureFixturesAndOfficeEquipmentMember", "presentation": [ "http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture, fixtures and office equipment", "label": "Furniture, Fixtures And Office Equipment [Member]", "documentation": "Furniture, Fixtures And Office Equipment" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r60", "r504" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r60" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r231", "r232", "r233", "r359", "r361", "r366", "r450", "r452", "r505", "r539", "r566", "r780" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r232", "r233", "r359", "r361", "r366", "r450", "r452", "r505", "r539", "r566", "r780" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.nautilus.bio/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r131", "r316", "r318", "r319", "r320", "r321", "r322", "r323", "r326", "r328", "r329", "r330", "r469", "r563" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.nautilus.bio/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r90", "r97", "r144", "r145", "r164", "r168", "r177", "r317", "r318", "r327", "r448", "r563" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other liabilities", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r692" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r677", "r692" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r601", "r611", "r621", "r645", "r653", "r657", "r665" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r663" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype":
```

```
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r593", "r669" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r593", "r669" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r593", "r669" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": [ "r548", "r691", "r703" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.nautilus.bio/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r447", "r460", "r461", "r462", "r463", "r526", "r527" ] }, "naut_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname": "LaboratoryEquipmentMember", "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Laboratory equipment", "label": "Laboratory Equipment [Member]", "documentation": "Laboratory Equipment" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r70", "r390" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.nautilus.bio/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r386" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [
"http://www.nautilus.bio/role/CommitmentandContingenciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Future Principal Contractual Obligations for Operating Lease Commitments", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r766" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": {
"http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true },
"http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total future minimum lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r389" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": {
"http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r389" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r389" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r389" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r389" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": {
"http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Six months ending December\u00a031, 2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r766" ] }, "naut_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029 and thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, Due after Year Four" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r389" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.nautilus.bio/role/CommitmentandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r381" ] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [
"http://www.nautilus.bio/role/CommitmentandContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of credit", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": {
"http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r12", "r44", "r45", "r46", "r47", "r48", "r49", "r50", "r130", "r213", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r339", "r340", "r341", "r373", "r480", "r544", "r588", "r726", "r767", "r768" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": {
"http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label":
```

```
"Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } },
"auth_ref": [ "r57", "r84", "r438", "r575", "r696", "r721", "r765" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [
"http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Stockholders' Equity", "label":
"Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-
gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": {
"totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be
paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r46", "r101", "r130", "r213", "r241", "r242", "r243", "r244", "r245",
"r246", "r247", "r248", "r249", "r339", "r340", "r341", "r373", "r575", "r726", "r767", "r768" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [
"http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current
[Abstract]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"LocalPhoneNumber", "presentation": [ "http://www.nautilus.bio/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone
Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "naut_LongTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.nautilus.bio/20240630", "localname": "LongTermInvestmentsMember", "presentation": [
"http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Long-term investments", "label": "Long Term Investments [Member]", "documentation": "Long Term Investments" } } }, "auth_ref": [] }, "us-
gaap_LongTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": [ "http://www.nautilus.bio/role/CommitmentandContingenciesNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Open purchase commitment", "label": "Long-Term Purchase Commitment, Amount", "documentation": "The minimum amount the
entity agreed to spend under the long-term purchase commitment." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [
"http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r236", "r237", "r238", "r239", "r276", "r314", "r358", "r423", "r449", "r451", "r459", "r472", "r473",
"r525", "r528", "r529", "r530", "r531", "r537", "r538", "r552", "r556", "r560", "r567", "r568", "r572", "r573", "r577", "r728", "r769", "r770", "r771", "r772", "r773",
"r774" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r637" ] },
"ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r637" ] },
"srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r236", "r237", "r238", "r239", "r276", "r314", "r358", "r423", "r449", "r451", "r459", "r472", "r473",
"r525", "r528", "r529", "r530", "r531", "r537", "r538", "r552", "r556", "r560", "r567", "r568", "r572", "r577", "r728", "r769", "r770", "r771", "r772", "r773", "r774" ] },
"ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value",
"label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r656" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ],
"lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [
"r664" ] }, "us-gaap_MutualFundMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MutualFundMember",
"presentation": [ "http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Mutual funds", "label": "Mutual Fund [Member]", "documentation": "Regulated investment instrument that pools funds from multiple investors to invest
principally in a portfolio of securities and money market instruments to match the investment objective." } } }, "auth_ref": [ "r729" ] },
"ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive
Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r638" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation":
{ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } },
"presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by
financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities,
including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their
investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on
long-term credit." } } }, "auth_ref": [ "r126" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities",
"label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": {
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by
(used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing
activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity
instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r126" ] }, "us-
gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": {
"en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] },
"us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } },
"presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating
activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including
discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } },
"auth_ref": [ "r64", "r65", "r66" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities",
"label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": {
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0,
"order": 2.0 }, "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
"weight": 1.0, "order": 2.0 }, "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations": { "parentTag": null, "weight": null, "order": null, "root":
true } }, "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows",
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofComprehensiveLoss",
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations", "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "label": "Net Income (Loss) Attributable to
Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r59", "r66", "r85",
"r99", "r113", "r116", "r120", "r130", "r135", "r137", "r138", "r139", "r140", "r141", "r144", "r145", "r155", "r213", "r241", "r242", "r243", "r244", "r245", "r246",
"r247", "r248", "r249", "r334", "r337", "r352", "r373", "r441", "r502", "r518", "r519", "r587", "r726" ] }, "us-
gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [
"http://www.nautilus.bio/role/BasicandDilutedNetLossperShareBasicandDilutedNetLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss
attributable to common stockholders, basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax,
noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r123",
"r137", "r138", "r139", "r140", "r147", "r148", "r156", "r159", "r337" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [
"http://www.nautilus.bio/role/BasicandDilutedNetLossperShareBasicandDilutedNetLossperShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss
attributable to common stockholders, diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of
tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive
potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r123", "r149", "r151", "r152", "r153", "r154", "r156", "r159" ] }, "us-
gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.nautilus.bio/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": {
"role": { "terseLabel": "Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of
accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the
expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
```

"http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": ["r637"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": ["r601", "r611", "r621", "r645", "r653"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r628"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r627"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": ["r645"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r664"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r664"] }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "crdr": "debit", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions of property and equipment included in accounts payable", "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r19", "r20", "r21"] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations"], "lang": { "en-us": { "role": { "totalLabel": "Total other income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r61"] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": ["http://www.nautilus.bio/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": ["r549", "r702"] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": ["http://www.nautilus.bio/role/SignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": ["r545", "r551", "r702"] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations"], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations"], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nautilus.bio/role/CommitmentandContingenciesFuturePrincipalContractualObligationsforOperatingLeaseCommitmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Total operating lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": ["r384"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r384"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r384"] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": ["http://www.nautilus.bio/role/CommitmentandContingenciesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for lease liabilities included in operating activities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": ["r385", "r387"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r383"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Amortization of operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r693"] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Other long-term assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": ["r106"] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on securities available-for-sale", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": ["r3", "r8", "r80"] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofComprehensiveLoss", "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss)", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": ["r3", "r8", "r80", "r114", "r117", "r141"] }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"OtherCurrentLiabilitiesTableTextBlock", "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Liabilities", "label": "Other Current Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other current liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations"], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Other Income and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingExpense", "crdr": "debit", "calculation": {
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other expense", "label": "Other Nonoperating Expense", "documentation": "Amount of expense related to nonoperating activities, classified as other." } } }, "auth_ref": ["r62"] },
"ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": ["r637"] }, "us-gaap_OtherSundryLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherSundryLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsAccruedExpensesandOtherLiabilitiesDetails": { "parentTag": "naut_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsAccruedExpensesandOtherLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Sundry Liabilities, Current", "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date." } } }, "auth_ref": ["r28", "r45"] },
"ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt",
"presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r599", "r609", "r619", "r651"] },
"ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt",
"presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": ["r602", "r612", "r622", "r654"] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": {
"role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": ["r602", "r612", "r622", "r654"] },
"ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": ["r626"] },
"naut_PaymentsOfReverseRecapitalizationTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname":
"PaymentsOfReverseRecapitalizationTransactionCosts", "crdr": "credit", "presentation": [
"http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Payments of transaction costs",
"label": "Payments of Reverse Recapitalization Transaction Costs", "documentation": "Payments of Reverse Recapitalization Transaction Costs" } } }, "auth_ref": [] },
"us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of securities", "label":
"Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r16", "r124", "r181"] }, "us-
gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": ["r63"] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeerGroupIssuersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": ["r636"] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": ["r636"] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r628"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
"PEO", "label": "PEO [Member]" } } }, "auth_ref": ["r645"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" }
} }, "auth_ref": ["r638"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt",
"presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r627"] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PlanNameAxis", "presentation": ["http://www.nautilus.bio/role/CommonStockCommonStockReservedforFutureIssuanceDetails",
"http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]",
"label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r730", "r731", "r732", "r733",
"r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754",
"r755"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://www.nautilus.bio/role/CommonStockCommonStockReservedforFutureIssuanceDetails",
"http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]",
"label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r730", "r731", "r732", "r733", "r734", "r735",
"r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755"] },
"ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": ["r629"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r673"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": {
"role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r628"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": {
"role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r51", "r253"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized",
"presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r51", "r482"] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued",
"presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": ["r51", "r253"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [
"http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r51", "r482",
"r500", "r784", "r785"] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PreferredStockValue", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-
gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": {
"role": { "terseLabel": "Preferred stock, $0.0001 par value, 200,000,000 authorized as of June\u00a030, 2024 and December\u00a031, 2023; 0 shares issued and outstanding as of June\u00a030, 2024 and December\u00a031, 2023", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } },
"auth_ref": ["r51", "r434", "r575"] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": {
"parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets"], "lang": {
"en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or

```
consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r687" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [
"http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement", "label": "Private
Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance
companies, pension funds, mezzanine funds, stock funds and trusts." } } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit",
"calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
"weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": {
"terseLabel": "Proceeds from maturities of securities", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "documentation": "Amount of
cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive
income (available-for-sale)." } } }, "auth_ref": [ "r124", "r125", "r705" ] }, "naut_ProceedsFromSaleOfStockAndReverseRecapitalizationTransaction": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname": "ProceedsFromSaleOfStockAndReverseRecapitalizationTransaction", "crdr": "debit",
"presentation": [ "http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of
stock and reverse recapitalization transaction", "label": "Proceeds From Sale Of Stock And Reverse Recapitalization Transaction", "documentation": "Proceeds From
Sale Of Stock And Reverse Recapitalization Transaction" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": {
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0,
"order": 2.0 } }, "presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds
from exercise of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based
payment arrangement." } } }, "auth_ref": [ "r2", "r10" ] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of common stock
under employee stock purchase plan", "label": "Proceeds from Stock Plans", "documentation": "The cash inflow associated with the amount received from the stock
plan during the period." } } }, "auth_ref": [ "r2" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical
assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6", "r390" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": {
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails": { "parentTag": "us-
gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated
depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to,
land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r70", "r104", "r440" ] }, "us-
gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PropertyPlantAndEquipmentLineItems", "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent
financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the
table." } } }, "auth_ref": [ "r390" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag":
"us-gaap_Assets", "weight": 1.0, "order": 2.0 },
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails": { "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails",
"http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Total",
"label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the
normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and
equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r390", "r429", "r440", "r575" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock":
{ "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule
of Property and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the
normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method
used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets
that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and
equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." }
} }, "auth_ref": [ "r70", "r390" ] }, "naut_PrototypeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname":
"PrototypeEquipmentMember", "presentation": [
"http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Prototype equipment", "label": "Prototype Equipment [Member]", "documentation": "Prototype Equipment" } } }, "auth_ref": [] }, "us-
gaap_PurchaseObligationDueInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PurchaseObligationDueInNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.nautilus.bio/role/CommitmentandContingenciesNarrativeDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Purchase commitment, next 12 months", "label": "Purchase Obligation, to be Paid, Year One", "documentation": "Amount of
purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-
term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of
financial position date (rolling approach)." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs
Performance Disclosure [Table]" } } }, "auth_ref": [ "r626" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance
Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r626" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical
Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r236", "r237", "r238", "r239", "r269", "r276", "r304", "r305", "r306", "r314", "r358",
"r398", "r407", "r423", "r449", "r451", "r459", "r472", "r473", "r525", "r528", "r529", "r530", "r531", "r537", "r538", "r552", "r556", "r560", "r567", "r568", "r572",
"r573", "r577", "r581", "r724", "r728", "r761", "r770", "r771", "r772", "r773", "r774" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical
Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r236", "r237", "r238", "r239", "r269", "r276", "r304", "r305", "r306", "r314",
"r358", "r398", "r407", "r423", "r449", "r451", "r459", "r472", "r473", "r525", "r528", "r529", "r530", "r531", "r537", "r538", "r552", "r556", "r560", "r567", "r568",
"r572", "r573", "r577", "r581", "r724", "r728", "r761", "r770", "r771", "r772", "r773", "r774" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of
Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r594", "r604", "r614", "r646" ] }, "us-gaap_ResearchAndDevelopmentExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {
"http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } },
"presentation": [ "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Research and
development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost
for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business
combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used
in research and development activity." } } }, "auth_ref": [ "r315", "r539", "r548", "r775" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported
facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r595", "r605", "r615", "r647" ] },
"ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label":
"Restatement Determination Date" } } }, "auth_ref": [ "r596", "r606", "r616", "r648" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [
```

"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": ["r603", "r613", "r623", "r655"] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsCashCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsCashCashEquivalentsandRestrictedCashDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash included in other long-term assets", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r17", "r81", "r102", "r127", "r433"] }, "us-gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashNoncurrent", "crdr": "debit", "presentation": ["http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsOtherLongtermAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash, Noncurrent", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r91", "r686", "r694"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets", "http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "negatedTerseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r54", "r77", "r437", "r456", "r458", "r468", "r483", "r575"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r98", "r132", "r133", "r134", "r136", "r141", "r143", "r145", "r214", "r215", "r230", "r324", "r325", "r331", "r332", "r333", "r335", "r336", "r337", "r342", "r344", "r345", "r347", "r350", "r380", "r382", "r453", "r455", "r470", "r784"] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Right-of-use asset obtained in exchange for operating lease liability", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": ["r388", "r574"] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r664"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r664"] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": ["http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consideration received on transaction", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": ["http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares issued in transaction (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": ["http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Price per share (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.nautilus.bio/role/BasicandDilutedNetLossperSharePotentialSharesofCommonStockExcludedfromtheComputationofDilutedNetLossPerShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r22"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.nautilus.bio/role/BasicandDilutedNetLossperShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Potential Shares of Common Stock Excluded from the Computation of Diluted Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r22"] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": ["http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "naut_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock", "presentation": ["http://www.nautilus.bio/role/CommonStockTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Common Stock Reserved for Future Issuance", "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]", "documentation": "Schedule Of Common Stock Reserved For Future Issuance" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": ["http://www.nautilus.bio/role/BasicandDilutedNetLossperShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": ["r701"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r36"] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsPropertyandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r6", "r390"] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": ["http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItemsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Cash", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": ["r11", "r81", "r777"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails", "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails", "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r278", "r280", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307"] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",

"presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Significant Assumptions", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": ["r79"] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": ["http://www.nautilus.bio/role/CommonStockCommonStockReservedforFutureIssuanceDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock by Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r29", "r30", "r31", "r32", "r33", "r34", "r73", "r75", "r76", "r77", "r108", "r109", "r110", "r166", "r253", "r254", "r255", "r257", "r260", "r265", "r267", "r464", "r465", "r466", "r467", "r556", "r676", "r695"] }, "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Option Award Activity", "label": "Schedule of Stock Options Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in stock options." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.nautilus.bio/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r589"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.nautilus.bio/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r591"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": ["http://www.nautilus.bio/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting", "label": "Segment Reporting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r169", "r170", "r171", "r172", "r173", "r174", "r175", "r178", "r179", "r546", "r547", "r550"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r4"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails", "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r305"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate, maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate, minimum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "naut_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAvailableForGrant", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase in shares available for grant under equity plan (in shares)", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase in Number of Shares Available for Grant", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase in Number of Shares Available for Grant" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails", "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails", "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r278", "r280", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase shares of common stock contribution percent", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan." } } }, "auth_ref": ["r35"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "calculation": { "http://www.nautilus.bio/role/CommonStockCommonStockReservedforFutureIssuanceDetails": { "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nautilus.bio/role/CommonStockCommonStockReservedforFutureIssuanceDetails", "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Shares available for grant under equity plan (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r35"] }, "naut_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPurchasePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.nautilus.bio/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPurchasePeriod", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Offering purchase period", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Purchase Period", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Offering Purchase Period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": ["r291"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": ["r289"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": ["r35"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "calculation": { "http://www.nautilus.bio/role/CommonStockCommonStockReservedforFutureIssuanceDetails": { "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.nautilus.bio/role/CommonStockCommonStockReservedforFutureIssuanceDetails", "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock options issued and outstanding (in shares)", "periodStartLabel": "Outstanding beginning balance (in shares)", "periodEndLabel": "Outstanding ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r285", "r286"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of Stock Option Awards", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding beginning balance (in dollars per share)", "periodEndLabel": "Outstanding ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r285", "r286"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r302"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r302"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r301"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r301"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of outstanding stock maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum", "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails", "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails", "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationStockBasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r290"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": ["r291"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",

"documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": ["r289"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Award expiration period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r562"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationSignificantAssumptionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r303"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and exercisable, aggregate intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": ["r35"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding, weighted average remaining contractual life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r78"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vested and exercisable, weighted average remaining contractual life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r302"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": ["http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchase price of common stock, percent", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestmentsMember", "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments [Member]", "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet." } } }, "auth_ref": ["r532", "r533", "r534", "r540"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.nautilus.bio/role/SignificantAccountingPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r67", "r128"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r9", "r52", "r55", "r56", "r98", "r118", "r119", "r120", "r132", "r133", "r134", "r136", "r141", "r143", "r145", "r165", "r214", "r215", "r230", "r268", "r324", "r325", "r331", "r332", "r333", "r335", "r336", "r337", "r342", "r343", "r344", "r345", "r346", "r347", "r350", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r382", "r391", "r442", "r453", "r454", "r455", "r470", "r520"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r132", "r133", "r134", "r165", "r382", "r424", "r460", "r471", "r474", "r475", "r476", "r477", "r478", "r479", "r482", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r495", "r496", "r497", "r498", "r499", "r501", "r503", "r504", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r582"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r132", "r133", "r134", "r165", "r180", "r382", "r424", "r460", "r471", "r474", "r475", "r476", "r477", "r478", "r479", "r482", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r495", "r496", "r497", "r498", "r499", "r501", "r503", "r504", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r520", "r582"] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": ["r598", "r608", "r618", "r650"] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": ["r9", "r51", "r52", "r77"] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity", "http://www.nautilus.bio/role/EquityIncentivePlansandStockbasedCompensationOptionAwardActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of vested stock options (in shares)", "negatedTerseLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r9", "r51", "r52", "r77", "r290"] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under employee stock purchase plan", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": ["r9", "r51", "r52", "r77"] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock upon exercise of vested stock options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r9", "r52", "r55", "r56", "r77"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets", "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofStockholdersEquity"], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit)

attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r52", "r55", "r56", "r69", "r484", "r500", "r521", "r522", "r575", "r588", "r696", "r721", "r765", "r784"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://www.nautilus.bio/role/CommonStock"], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r74", "r129", "r252", "r254", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r266", "r268", "r349", "r523", "r524", "r535"] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": ["http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]", "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": ["http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockLineItems", "presentation": ["http://www.nautilus.bio/role/DescriptionofBusinessandBasisofPresentationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsidiary, Sale of Stock [Line Items]", "label": "Subsidiary, Sale of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": ["http://www.nautilus.bio/role/CompositionofCertainCondensedConsolidatedFinancialStatementLineItems"], "lang": { "en-us": { "role": { "terseLabel": "Composition of Certain Condensed Consolidated Financial Statement Line Items", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r685"] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "presentation": ["http://www.nautilus.bio/role/CondensedConsolidatedStatementsofCashFlows"], "lang": { "en-us": { "role": { "terseLabel": "Supplementary cash flow information on non-cash activities:", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": ["r644"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r636"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": ["r643"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": ["r663"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": ["r665"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://www.nautilus.bio/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails", "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": ["r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r251", "r265", "r348", "r372", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r443", "r564", "r565", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r576", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r717", "r718", "r719", "r720", "r757", "r760", "r761", "r762", "r763", "r764"] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": ["r666"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": ["r667"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": ["r667"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": ["r665"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": ["r665"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": ["r668"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": ["r666"] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails", "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Agency securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": ["r542", "r557", "r776"] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": ["http://www.nautilus.bio/role/FairValueMeasurementsAssetsCarriedatFairValueandMeasuredonaRecurringBasisDetails", "http://www.nautilus.bio/role/FairValueMeasurementsUnrealizedLossesandFairValuesofAvailableforSaleSecuritiesinanUnrealizedLossPositionDetails"], "lang": { "en-us": { "role": { "terseLabel": "U.S. treasury securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": ["r542", "r557", "r559", "r564", "r776"] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": ["r662"] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": ["http://www.nautilus.bio/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": ["r23", "r24", "r25", "r92", "r93", "r95", "r96"] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": ["r632"] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": ["http://www.nautilus.bio/role/BasicandDilutedNetLossperShareBasicandDilutedNetLossperShareDetails", "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)", "terseLabel": "Weighted average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": ["r149", "r159"] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": ["http://www.nautilus.bio/role/BasicandDilutedNetLossperShareBasicandDilutedNetLossperShareDetails", "http://www.nautilus.bio/role/CondensedConsolidatedStatementsofOperations"], "lang": { "en-us": { "role": { "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)", "terseLabel": "Weighted average shares used in computing net loss per share attributable to common stockholders, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": ["r147", "r159"] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r630"] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-10" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name":

"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":

"280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r275": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r383": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210",

"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r540": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "SubTopic": "320", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r541": { "role":

"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r544": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r545": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r546": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r547": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r590": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r593": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r594": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r595": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r596": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r597": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r598": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r599": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r600": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r601": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" },

"r602": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r603": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r604": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r605": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r606": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r607": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r608": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r609": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r610": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r611": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r612": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r613": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r614": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r615": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r616": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r617": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r618": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r619": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r620": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r621": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r622": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r623": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r624": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r626": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r627": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r628": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r629": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r630": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r631": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r632": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r633": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r634": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r635": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r676": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r677": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r678": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r679": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r680": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r681": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r682": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r683": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r684": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r685": { "role":

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10",

"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 64 0001808805-24-000058-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001808805-24-000058-xbrl.zip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

*M,/YDN416)90XE8UU.I94YS)^5QZ0FY(*Y2A/|52B=3+4@?SX FZ!LU>6_-IG M9;_1?LSU2Z_WG']>*L<:*325)&1E.=6=F9_'('+\Y1/.RKSH@GD=CJ@G0#^7[18^[T%R^R#||K!VT6O0NW\$;)V83EZ_Y:_XU_ZX3RVVM M1JW=;+_87*]%+[;]UK#M6K1_|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}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|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{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|ZE(,+QV+?P/6ATO(#"! M!] !I(9+H09A*UUD,2XG4AX"I^^$3]T9W[0H-P="""!< &L(&S 3;+">E9@ M? 7J_>NZS9(,"V$#8L.9&FOOY^.0SHI\|(KW;H4W/VC:Z)+)L"1O /;G5+MGB M@ME"V/"X)$MIR9^**83-1DBFD#;]*1A"V.2/@#1Y690A;!7GRV[(FE2W"S>)H<'JX2ICU<|$-BRU-YK*5(O#44*FTP[MN5TI.>(R.:*|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|5<\L MJ&%B;O+.A5N?02B5R%4HM[]\0BP4R@OB>LT_>]DE)4YU[!Y#;$13NY<$U_Q M0O&RTM!\0USW6!!H%TG;#7'JX%70'HT=;T+I8^B9OQXBWR2H&04+J[K*Q3, M"Z5S<;W=@F&^]8NO7XEO+2KKF?>6AZ?$]9XO"[^ 0S_\3$(:8UB#_TN?D_Z6 MHLK*7)HEAN27W8A!7-?]])6" 2)Z]R?'D&S$C*+GOTDI+@>_2GM:B'805PW M7Q"7IU!&$-:=WT9CWX\QBK*OC1#XX=4/XC[';|*/WVS7'D6CPW-8XP0%RG9A T47P.>GPKFP@:K" <%Y6CTK8.)4PF#F5#7S^ M,:V26BVM\X\|E53/M&1|*'WCG6MZ(W@P !/7NKRUSP|:4.S/=@U0Q_YK'BOX MNWT;P]/H>6J\EHPGE8=&3J1[6S+^5!X:.945(.-5Y:&14]DC,KZ5CT;^2EWJ M$P=(Y-H:V:X=A#[!:H3SMDAD1*Q,5'(JF^3\8VCG1"6GLDK./YYW3E1R*KM$ MW-@B/,&RG0A1,.U&=?MF.I%%K2^^-^+M&1@F[P>WQ'=M]SEXH/[CD/CTTV3Y M TX=#SN1-&B+&ZD\6SR?PH)LBQOW/$||GTANM\6-79XMGD]AZ[? %C3\>$L_L M,,()STV=1'2+&T8\9U2?Q!H3-QIXMJ@^E0 7-Z1WSJ@^L$WVP7Z[\FG@P9YH MP#\.*;'8XBW[I?<;_,,HP&YJM-$UZGI?I^U&L] [I#@;=IF4UVQW+;-%6ZQ]H ML$_O"<*) Y0PLMWJD-K/P_"J.PX_OMI6.+S2ZO4_5V8O(_XS7-GWPM ;X97P M-?NI$H<^]F]PI-^U{}O3GXW/M5? ^8}U]E=G,;MA62OD.3"_J>#XBJPO8<,@[H5?+'1\L. MQ@Z97-DN6R6[Z>,LB)NPI1?JA[9)G/@E['W\YRF>:G6.JQ ((K22-\<_U^"G M#XO? =SNU;GWY3_6:QK[_P?)S_&<+#08WN$>V_D"Y?>*49G;;.B-\3+\B*$ M\"+UXYA8%C#T55W1X_')TS^P;9^"7#1}*WKY^?WNZ?:S\OAT_73[F(L*3K': MQ]N;GS_NGNYN'Y7K[Y^5V_]{\Y_7W_]ZJ]SK/1%9DE6[5VQ>-(X'OE,!S;*O4#/GE_L/Q MY_7W)^7I7@$%_(1:5C.4^Q^*UGQGO5? NORA/_WFK9'1SJ]>O;Y[P9ZUK-&:@ MM%X49X0/6[,H>OJ+YROAD"[_)#2C<(=& 3^'6CL{!0=V^RWWDF9)SX)OJB-X MQ!!OJUID4IU0XE>IFY"B4>G]5^12;L ;=57!J,JN,K\Y*_.,LG\^Q]2UDM9 M7X2L?_+A=3;&7U8+^P%Q@E3:-RH]{\RE_=./Z^^/=TRFGUC<+[<^19)$B?P/ M4SI*%,#]T;*/Y+_*:&7^5!^]QMG^-D!ACN5+S;(4F %#(}NSX"W+-2(]_); M$_YJ8C!6JQK=AK&@N4X8BVAL90WDW?X/^LR*H-P0NX0E(&A5>M^O?S[=?? WY MJ'RZNW^ZO?G/[_=?[__ZOZIR]_VFMC54%E75P>'4V0I,[V[?B!DR:"C>0/%3 M*"@D4((Q-3'N;BFV]]AAH)A#9E]]SQ>07!6DS1W].;*M &J_F3NP:>@U0V\4 M8BS H^K-Y;?L\"A#;Q[5[N"P/#I5UW=A?BR9Y%,Y08]RRLD,+W)#?W+C6;.6 M/RS(Q!Q+2'%4&#YG:O*W*[W/U"&OQ*=[F"5I0.P"\?!$WN[B9!\O6IU52)U* MK]O!ECE.6S?6@KAH8@:=?V@(+C< WS%]5,"T\<"V\95_1KX=6#8;0 $"FTE5 M.TN]|%+_F;CVO]CG]RO]GX9S)D? D\J!8VGK$U@S>>7-M67A_);X/U_A>5HB:[J5GMZN:\HM M"4*'_*+*]0MU(\H^+X9Q=GOO#?QY[S]YKZD*T>J5WB,E8>@LJ!!UU[$T>A;]1DE3WP-<[X"RY3:P*!*$@A2_5BF=C[V$[T M]FR)(O_:IV2&$0W0-?76/!N^SR'P\9"7\S#TW+D0CM:H] S#J.IUK! K3((? MG"1$XXQI=.@O@1)2AXX1UHK+@*TJ{$>><"/>B@.]'8*_S/)0'KJ>K@=@(#$[M M7\!^_%<$J4]EQ@3-D^2S7#6P T"=@GDQ@-_@T?N,[64 *T0Q0$[20%9 MH'_/:H%3Q%RG%:!QR(SZL+-QY <1QLY"3X$KF)NAZ>_Z[U';8&CZV@RO!"X< MZC1KK7HK=\2K6:L;ZV-+6R?:&K6&UBHFXM6NZ8WN@2)>.3662*ERGE:RP<% MHJ3$'"HF\&*06QF<(UA\PH3XXV34]YQWP?LB@'+_J-R6^_P>1_L9]ND;%\P* M'"*O7H0W?3"5;'CMPX,K5@ 33>\S9DH-KB9/R $PV4$ 51D37WDA M3D25? V>5TAIF)95@N%N4^+*@'#,DY\<4Q"%2[EC06R;5..R$LLWJ[9T(^#9F M?Y{UG\-H7"8BPJU04Z"*?.=!!;Y@Q.Y@G6?-%2^?KW9-I:0V\C=+6)S4DN1 M8>3.M3#B3)7^!"Q@"L.89'LZY"R>#*\A9FDZSMO3(D =C.#MB3Q'%B$QG- MS#\]GD-2&QM9HS4!,MH@>+/6 .B6/ K:#N\=.Q3 MDS+=I^D*JVL+E'?P/*_')8A)P1##S._245%."3A_-I?R>PJ<8G\YG@/[U7F M'KS3^1[{0%7P>_^?L .\GET*-^$JXN=@65# %L$6B2Y#MZY89!+45IV5R1LA MNXE\'}["2XY0UH0DC(*4VCN5WO_28,%U5O{C3]UVH_51@?]}}^*/C8^E(D_F MR.0C3T0;8&QDAR'@&-Q@,_0]%^6B,U$HR,B)LD/VL?4PNVWC!ZO4E%Z(HC2]>L=;D2MOEK 6V:E5/-ME$-6(]2V)YZRG"_4&K5N04&)9J?6Z!;S**U3T[5B*HF-6O=@A<1K_?@3. Q? MD:FXC,TP#O^"<4_Q5;]YM{NI:GJ[T*IW^HT4B;?K"T+6^7#;+H7#_@T@^=GS M)TM<2'81P[P97S3U)O4Z^/++=/3AZ_1/0S2Q\7;Z{11),8_<6.$\GEHL_&-L MBYQ^P\7@+R]S,-!B@)X4!!L/+ZH90AD_^K&8LO22D""M{$=S"F/&\.2"C'(M%P/FKPPD-QP8&ZE1ST&-.8X/B>)^#M:X>9C27^J=VH-E,1$6"0'5Y7HLD!$% MW6C?*SITN.)(&7B>]R)OCR5QM>#:]57-B;AU[?BQTP5>@2U{2)@QXE5J3C MQ3@PWB*^%2A8LV=;JQ+/QCOR?JFW%XBXP)MVWZ;E ?B!WX[E W5AW M,+\!)H_/A(,J>,D-*R\|ID40I^@&=}#&!I1(O_^[\T6!+L.@GU>#E?6RA" MUC=I^NZ='CRYK1.DES7J8):M&NNZ*R1L=9HLRS6+P?U7Y$PX^/4F/W"O+DKK MM!/%Q9[!4D9N3:'$4O*@I4V"S>]-EQDVF#(!,]7ZDLR""S=RQ)AK%=<!ZD:CJN6%U?AQ8'. (4'90V,0-RL]#=;>T#15;W028"$X4KKYE:TVVNF->WGY^[;2?*

W]"?6M#/M-KW?E5)0,@ MI"OBO)))@'!:WO2OK1^JZY^ 9{B75Q"O/V2\M>4BZ.Z>KC]JO<76 S?WWY]N MOS^M[F1W^GP#B)-.NY-7"'5]FE%,7+]CU+1V,8]UHS.^I/(10@DG,2H0+)] M $&V^BS,G'3'M@1'.BB8MZG>/();!T7)8' PE/#U@?44GW6}BD"U^7@5K(D(MLQ9EZ*/E^*-)N:LI7^Z^7W^_N;O^"D(?NPQ>8VN7WSZ09254 M1S\0*@QLRXMGV{978//D N58)X]/(<3O0CI2M-H!([]2&!;$)*U*[TL:\$SG MEP4[R(G4_$(7BP]G%(*0@?FE0)4B40Z*U5"QOX$77__MIOPUTQ-53_ 66E[Y"CMGDO71?BOW)KYY()C2+6]47^:ME%YG=V9TME339RLS M=:FFI9H^'LD9VI9J&LNQ?#K$ 98O5/GJ!7/JNKSZ 4$0J^MR;^(\U#7NI.SJ M&O<@U?4ER$Y#]FNIKH](3LU';#:ZV M2[V!3:VX8(2#!4OCC>ZS0T4%YI MVF;*N=3K/Y/%/6ZE],JY+97S94C*EE3.4CD?C^0:K%_+1*&L*/257Y.>4/F=(M"NTSDSZE.68R\"^!\MD.S(C/}$.[-HESB2PF3,S M%9HH57F3'+SF!PTB9[YR24K0LZ$/K;->A)Z-Q#*DQ!*?(C6%"93#W[8P2\IE\Z'"O1+$4P-*9C*0))LHI , M^H ,)I0>?,^D%LHA*77.!\5ZM]S= 613$7'(J9-T%;E3JLK]TW_>_MB[I\B& M_3"D6.)U;)L5E$&)L->W5_I,W&X/F83AZ1"/B/DQDG0\W<#M&LI<,I DXU* M#T,-RA=BAIXO9C62269HRD*11K_0^TP%AF>&?8YP.2UW;S,224J? M\T'UQ4@?F8HI!4D:E=XWN ?LH0$%,RB3$I92YWQ0?#%2IRFE3AE(LE7IW;.1 M7WS'RIB7E31E(LEOIW;X-[;Z]8^]U*6:$Q&F[*2M,I(@H MA)P:>]7W>/?7[]=//W_XVD7,9=3JE>2F\QS,V"?FKV?? SJOQH@9L/]]+!Y-RV<:/C{'$FR@\Z}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{\4Y W8Y#AEK)E(?&$H+7'HV)N49IQ7,0P*:.A5=E+"!FD*"-!,M@ M'SC3)L_*ASRWPV")) M.67D6=3ASEB(VNH9'#!$PK1QJ>2:8W$-V(V@1.Q@R/"!_C.&B,#T"ZGC@(D1 M 9^ @@&S$*YGFH:'B1!3L=-N12:&;N"Q+YYMX1\6'5"4A@ZQ1\P@M=V!#RMA M-"%1>21#,.(',,,Q 0QEX'LC]L.GA!%OO%$?[',&T'G])*!.)HWT/8*(D0D!-@GDVCXFZ2==$ M,^V:.&.[)@{22.%,M _6ORG*_%X26)&R/.L0,N/3]JWJF#!Q /^Z%+U#^#D: M@*D+[J0?Q&&V\=BQX9/$1E'8X(D&Q@4$@6LRZ]\AKTSX N]'#1<#$N0'4I8^ ML0,Z#6DD@68>1Y%0+Q+]26X 0.Q3-$E8(A#)W/0C.X1+/;%P^E4C8D M###8_LU'&OLUU"N(+W3(/%^V9OR0"#B2_XDS*DE"%"VM(3'D)_H,9Z(2UB(S# ML:$/3I*$]H$BKHYG$D=%LX@E(E2%^SF$!Q[0O_73;RBX'AA 9;;5E@ MLN&O*E==W(K_1:R"+WH+!L%WURSK2QA?'L>/UI,@7^XB3$5_E,P0C/[L+R M7EVP2%QX5A)A]@ .'F9A| Y)<47Q-S,>!KPX)D,F6(PR6X@"6/ "3&6#*8/% M-:P4L/[3!E/59-1'*AS@]!%OH@Y*R>-D1,'L?[#+jCP+T=X987QAS M/[:^@ MB'F-*EX*6V$00%OK&>0A+"_6T],X>!((UZ[5976Q*.51)Z"O #.Z7:BZIOP5 MZ,Z-5S&'@(D7*9SBF4 !UC+Q&BM"\#@VF192!NNW^PV,/^^%^JKR"G>P\EJV M/J+ EZQB;DS!]DC:V_MD;%NPWM0^I>Z+{7LN+S-&0N7@@L?[SS3.*@ 1,RL' M_EL#4"FP<{9H#W@-HY28+HH8'<1,KP %))3G8B 'F 661P"='"T94QXO38@P M+jE.T;D%\+&!:L0.AB3$-|=^1W#2/R:@%$ 883R,6/-3.%JP9RHV!,!GU/2? @YZZ8[YK98N(#<{!Q M>36K):=J8C"}@O?()0*K9\TDM $6;N#AR\'NP^>@4>CCZ3HOEO&.@^'2V.;C MH,39C#B\!=C41VP%\6T!70,E{A-XF54SR0M=]S-LV-Y\'JS,+>0H_^Z?I*C_ZPSQ!0O M/DAJ/!CKD'% KY(_/L;RJ]@3/&"AD5)(^/8C3DTK>2"&G= M]2?;8\=AT;H&A7/GFC7&JBMF7'\B#HM'/0XI#0-VY35S8_\KDOJ*YR%:"I11$UVK7.MIZHMOV45JCINF-`M7(]:_7VCD>^.M8MJ[L-40O!-)W^^E-'".V9J>Q$\U&*G)UF()ABB:67TF9'R%%'+M6OB? VREY7(N=&H:GFLMR ^%C@'P$(9#Z${.J@:6J6G-]1.1_G; MA]F5]O[C3UIK6MVV"VH2UML:1;O;#%F1(QGD7!FD<0(&T2L]K:L:W;8@#%*0 M35,*G? @X]/RPBC5>6!5%@W"T3"&F4-#S06$I[Y>;039HD.LD"__%|W$HW+2/ MXF?:#Z>?8ILR+ZL8P"H-76IV. ORRV<9^E<2U0?H>F+@:0%S-AEK7 M-4&(ZY*L/P W.VDNEBDW,&?\SYUD[9V6;G99X-LCD%RR$,9@P;&L.C M+SNR3+/2,]1&MRZ(Y5* :2):5MI? !R:C%RTKJ"0%.1AK!F""Z GSSLY%B MK(V!L#F(>]9LL\E"WH=!VF"BM.MJUS *,E&VPU()+..+);=--O,^Y-9!J-ZBR$X%[6\GSAL;9&P*W^\(VQ_XDOO!3W .$:YYF4,#)[&N-MI[2UD9 M A:0DC9(V4(I20=*TM66(0HE78(-^]5SGXO)MUV&U5%0ONV[YYH[^8 -H))K M-=5&JR6(,2*-6@$S;KN35Z/2Z];55D/:ND>T=5E:S4DEL31O}S1OIXF/W1FA M6>EIJM;9.Y4FK5H!"6B355L$;7$(J BBQ=*DCQ;+DEM76T79D6=/BVX1_6U9*A+8JBM\I]Y&.J#,<:FVFP5=6A! MH,3GNB(5ULQX@2&R/4*JFE%;*H\S\'#@QUHR[.T2P@O)F<5G2E)!9@<9OPT2GN MOZ3#&=>FR0[$*V,RP2#4/B[,N:G{95L\'Z6^R4J."">.!T\5NU4V-+CK,+;VH MVB8!(BZ2(/O8O1=[,&R# -[?2FE6>AVUU=F{6T(9AJ?7]&\)(\WE7\UF:S<8HZTV6GO{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|^-I5;%C9L\]RTSYKCQ,.:4"1]BQL M_LN.LS)LL-#?P':).]K,)X4OV/GVD]8QMHZ[#.L1>P9-N53QV"]4 ?7VTK M"':,D+DK!F%]>@OIPPJBZ M@T&W:5G-=L.1TI[X3)7]\M.Q@#)E>YC*?K}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{U&GB*"WOL:VVUU5Q,/Q0[A/Z4!DA!QWLNFK%: MIV,I8UWHK<#5%L98>+A);ZBMNJ%J'4TREF2L-:2JG9"QUL6Y"EQM88S5X!I+ MUUMJL[G8+T8REF2L%;[,T4EU76"IP/46) A:B<;2U':KC(P5>ZC)$A*Z.0+; MK.*Z,5OT,5[TAB?(%VWQH@TA!LL.Q@Z9(!'2U2^\Q*LDX/8!W <6F(`_6O9+ M[S?X)[EZ1/QGVZUR"7/573;V^_AJ4&?'^(=4(28&G8@[85$G+X2GLV"3J]BP MLF><434F?JAX R4*:-EP. ^B.D.)8LJ*5B M?1XF\3+:.JQS[ 4VJH(KGSILFL7'5]L*AXFJSMP5@{`^O87T806@9E2>(B[P M]5G@9/_%]:,^M9L:;72-NM{7:;O1K'>Z@T&W:5G-=L]3\JM*!K#!*^*\DDF E)J%#(EBX:M(8AJD,4@9V4SP,TAXX!>)7]\ M3-C$=MGNV4T?9Q_77 S0,OSPGZ=KJM7YNF+I%+!Y_KD&/WU8_+[;J77RKRW^]MU[0_;Q.-YCN+U[J^5N]$^2)]CM;:2VGM.XE",$<#Y9,-'&X.77CO\T15[ERS M]EO?_]"[29GZ)LO4CRDK(__?@*#PZ1"N R95L(J2W?LT]"EE(>=\'^TWY!HL9 M!LHM/,]2_BMRJ6+4546OZPUV"?QA*.]^NB2R;'C#;&IBB1S=+$U/Q+Y*LO)2 M\$*C6=.ZK,6\L.VC-*W6:>FY'K7Z^X,6EHLZ_J+6/\J#5%QKLG<7+ELB'[G> M/8Z${&P2D+RA$9-A2V77%KWOSQ$B*V7YHL3>3"HGU9'I?MD#K^P07F9N4VU@ MNV#R>A$\U JV&H&P;5V_V)A'75W(;K?WZ4L.+F-?&7&.0)$TM <-R:X/\GB? M/-YWO*X/ANSZ(0GK IGK*%T?#-GUX2#,=5+M?3+F.NFNQ>OZ8 C<]2%&E60N MR5SE[/K0$+CKPY2Y+J'K Q_>@\YDH)(II>A$OK_::4;IF@-E\OX3WG])NS(.9Y%,K%5Z1ENM&U(32R:63'Q$Y[U()M.:B375*+!"_NA,7%03G!YK*K&R M? M.KK6_JC<_A'9X42071337HC+@Q5-AK9H+Y17*Y7]MD.^LQ3RKJ'5&MU\S7M6 M/:I3TYK=@MH Z3D;"I5K3?6&(==4UC4UU[]I15_=SA9]=05O'{2LIP=?*WA\ MGD^8;0V.&O7QJK7-H0M&Z<4VUVWH,M\[S4'!L7KPG(-:T5<@=?U0&RK:KO* M#1DCP@O 2.F!8YK1*'*8!46A[=J O:0-^&[X>"\&M-)HA#UP)[B2WZ)'H*K0-Y-B7(//:QMY$3C9%]0Y MD(^0D'W?MM<6C$3*QMV'KMP[4JIH.4H^$8>X)L;M0^4;\U1.TXBG.K6::EU;+(+=>]9,:?/>%YW9+G?N.D_J MNK/^D%C6 .>&|[)<-(Y&6^QW(WE\LY9\TXW/^_D+/)H5GJ-MJ9J7)'C'1DTO--K90LXO_S_$B>@*]E]0M"W6NUMR=TG(M1W*W1{J$CP"=.N1O9I LX2(7O+GY,5@0;)"1V//FU .:? SF.?'-(P*L9.\25 M'>8/Y<+4. L3DSIS0=M.E$CVG ME@,%.S(KA< RA8J-TSMR@$19:$BRN$2/1(_@WDPN =P020!?=F*&X:O:)[QK MRFA,W8"=L53H&_Z]VV2L\OK^,C0CT2/1(X*U/QU6$SQYT]/$>)CXSHV/$K, M)-=-QG1]8/^$=F!'=)'ZK_8)N5:Z@7/84IK+RU!JUFI6>H>KNH(1Z2 M&J6PD.B1Z!$5/07Z#<*)\I98HORRDRJKIU%?6,Y$!E(D>B1Z)'K.$CVY7,.C MSV=LM>5,\3)1DV1VH=$C]"S65DB1Z)' MHN? 8Z,EW2G[;27J@R*=V6>YX+)X?I*AUK8"QXY* A"*@;<>I[D4_[;HX]'/L M@+<U]>+[2T]VE&QYP6RY0}O7G-.J@:TK M&VJ[NSAE6#*N9%S)N#O&*A:.SN[3%+/=J/2:C59Y1P4+YI3,*0YSZOMTK,VI M7YN5GFYTU.Z2^D()O9)|)??FM8F-@YO$+6399A$EV2?FV_P#DNYQMQ M6ZYAN7)-TK7C%6_AH4:] MH79:+=4HP82WM,N57J/9 M4;6B"Z$D>YV:T'Z3O?)51"QD5?@ HK&7R1Z)'H$+@QWKW;T;U4|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}>;>:[^=ESR'9 M4TRB)Z>:W.;OQ7YCLO4ZGL]M+[J(DG{$I!_)WA(}$CW'D+[,=#?95_AV11*^ M!54OG)TC@\7)"HUGM<9?CN-IKZ%C>HYHA>SN!T/M M=/=F-SDE06AE*M%S:CE0L"N38TRVKFFL_8%D\9+0D&1QB1Z)'L'=F5P"6!=) OM %]V;H;A]\IFQ{(!H\GP6(6^X=_TPK(O,C8CT2/1(X*U+]C<:.UTS*KV6:G3W M+C:0U"B%A42/1(_@Z"G0;Q'.E#?$$N67G53AC3#,F488.P\Q+:^?+L,H$CT2 M/1(]9XF>7(B1Z)'HD>B1ZA#;0&ML.]QC\+RNM2L]HZ6V&_73 M#YZ7!'02"W_^NF(0S]':O,XLBW+H8<9^)*_UR/V8>?R?LMF[-NW?"Q^<)YX M')7ST(36/EI#2)P A0TA&W5DKT]}I\8=K}>)'/PHOL7Z5JEUV@WU/:2\+-D7,FXDG%W=#6{1,;'U/5*K]EH MR=GFDCDE<^[/G/I"U? _!&F_J1J6G&QVUVRZN\:,D7LF]Y\6]N;KF'MPDQE{4 M1E/5E[!LN4SBG-.42SWKMZ[GFX9;KKFZ$X#$_1&!VUV9()GFLW#R6B\5V..*2C[,>J5G M:VUJR]REFA&XF5W>I&S@ \8->R<>!:PH55Z3,5;;PO26%4>X!=.DJ-GEQ. M=N'<2_'#* VJTI/,71/JDFJS,W]V)DLV&A-:E$SZG%0,%>3)X9E$:STNL65; A24ARN$2/1(^H MZ#F2*Y-+_K8$DK^7G9*1(X!E6$:B1Z)'.%M?M+F11INE-YM[]F^5U"B%A42/ M1(_@Z"G0,1!.E'? $$N67G5&1(X!E%$6B1Z)'HN=\T9/K4$9SVS:QQ4\$-;I@ M&1B+Y^#E"&#A2$IRO-#HR<7Q"_[#T1B^41>$X2\|"R%'_L0B$2/1(]$CT2/ M1(]X!EKS*"-<&UJE9]35=GMQF)T< 5QN MK6PM^/?G1QZ$>.-ZF1[L<,S' MB0FC?K0^D0V#]XGL EX[W;+/9SE>CQ,Y5TG.5=HT5VDAVKU#!\I&H_@.E)(M M)5M>,%LN>#Q%MRUJ-"N]1DM3C4Y19PTEXTK&/4O&S>5J&OK1>OHU6I6>#@PL M9XQ*WI6\6P3O+K1C/QSOML%D;G55PUA4OY)[)?=*[LUM,A^\'7RC _JTV15; M2R*Y3*9BQ@15'?.]_%QV2CK3@\Z(F'Q(7=#JA 3JfZ).P%(*JX78A 91X&Y MB@TK>_:)HXR)'V*KG7!(XKT9N&A5)1Z+L,&&QTXL%WBFC9<'H3P!3MH4%L) MDW@9;1W6.?8"=HS@RJ<.">T7.IV'_.?*S%TQ".O36T@?5A"%JV\1%_C-N;!\ MYE}Y\GJG+GFHN,>IHEWJ2RY28K M6QY3B8)BZ(8$0^6+X[T&@JQZ[83D!HA2BZ7AE'<_71)9-NSH_9*4W!)MM%F5*

*ME(47V_6:T6X4,L!;TVN=1KY9X*N_;S3RW;%V4<8^LF9M\4))!*N9(QETW;W M >:DWDLATU8O:*Xʃ"CXY534/N(S2\ <26M2E,70]072L#WQLIWICZ8.:#MX%. MXPO8\<<9P%L819WI<-E\AP+V/BTCW$YS1YY*%$'*%?\]3IEIM](S6IJ[L3A3 ML(SG_"0{G"T[*5]MEDOH&I6K%- P0E-WIAN*$GJ*3P'GI@U^M!OK._P6_S;1 M>HDP(@&6_*ZFRTX%ZZ>XO\@F*&W!2> @31?+>U9X+PMA+L>$EKT?8 ^!??*1Z@XSN="@. MXV"@JG]#*BA7A00!#2_MX'F!$O<^_>Y7A.T/?,G]X&= KQ&N64S<?UEB#$=4E&\&JXVF@*T*9#6[&$#]BW+D@OTE /U/^WSLWAO9G.J"^3ZTX# %RG+4J M96&*8)F([E9Z;>WT\EIJ_V.J_\+(IU4\EG2-D T_9YOE'=*DMFGVI%Z(#F*L/\ZA7-B5DR3:M/?EK&_4;&DLR8-%++35){ MB=D}20K3K9JT6X]+'? =SY2_[BMX+,4=V%[VS50L)2^3N=M%J8N5+?4D23EJZ MY2:MW45P4.35PA2!T3ZWP3==P47QJ!W*^KA'S M$ [<"NMLCC)O=Q#=9MG] DYSS;8QVZ.9P.&2L8<\T[[<$A"$$%9E9SV BQ63 M ?!R7+B%Q5W3,JX+BX@5F*%-X/L%P/L(XO#:M;YQ($_N:!]=?F'Y'MT]4<\IGVP]QYY';+A 6;TB(GR7@'_WB'"[R5K?M1H%CQP3<[3)Q=+B,?,4 M15!EB[EP[68!#1D%RE,(;8-OEZ>()VL4UG7N 'F*;6RY8E=V$6&PF3P%?:.^ M:0>4Q<2P=YWBC9$]+RTL=JA$!8+TGD/T-@:UM4Q.MBL]?4G-CNS647YRR9-R MV)9<.I5>47:>5)YY9:8=!!'H3B8S36\TPCX=3'3")}FOT-'8\2:4QE^.X^"7 M,@;?^<+"7(>4JAB*6%:)WNZR27*")-9DW.J4HG05C73JE5YWL8E&J7.O)8Y# MY?)%+LWC/WSTZ4L"_JR?O\@S6J77;"UFS&1TZ3)I;8,LWH_6=)#/>ZOPLL2- MRB.Y{?C4BO+.BL^M8.J "725BW5,Z+X -MVX[Y!/@]"W39RWB+_+ Q#%2W5D M,_S_VRGH?Z70QN^76OVB\R5# [!\SUH\C60Z$8+T]LUDK:5^D)#>#@;4S)WP MZQC8+,W1V;L3J3P^(3 Y'R0M(3AA-RJ]!IX)VJ>(Z%A',)(5)$AK\"&O)>_^ M)DCW.*'5]LW6NEDAH=*GS[;KHB>&E5J.A63(:J4@:QQ0,><61WBDO*X:^YO- M,O(E(JEM<+>.2VN8U=? JFOOG800*X:V29*/;,MR:"DD.<5^3*MD^ &#&L(I MP-PC){?<-/G(%D,DT8*)*;:6=("4[3H3P'6]^1#R8<9/A3*GL02 T-M+QEE M(!HC%N+C%E]L9L!6+"_J.U2X.KB- 2SNO0KCE%9&/T7CL4#S$0/P)MYNP/E*Q M7W/L/Q_C#QGZ^F*_48OW=X\/3UG:,OW:K?0: M2PZ@EC98(_GA7/EA4Z:_$'[HLI88>QN,Y8HGG90$V,S5!5G)BM(DF>$6EO!6K.PGAFZ9X$I2__CDJ2-Y/@TI M<6C]$1S@<4E#G0+46CO% R+@L,D*

*15N'98X];OM=^=0!XGVA'U]M*QPF')2Y*X9@ M:?7H+Z<,"IG#U+>+"OC4+G.R_N'YD1;NIT4;7J.M]G;8,S7JG.QATFY;5;':,5OD_)KRH9P :OB/-*)@$2:A8R)8L&K:&(,9) MD=*G6&&A0H";0\8!O4K^^)APB>VRW;,;/LX^KCE>8'N&'_[S=$VU.E]7+ 3B M-|<_U^"G#XO? =SNU;GW3_6:]N=M+'>^LWBMZP/16ZM8AJQB"4[?%,)D!/>= M1*'M1('IRR08N-X\C\<[+UBU%AE'9YN7' MC[,S,&HI*7++XWLT@@>9B^[%K"T*0K@44'PF0:F;[,SL=>N]8D$=G_>/!! M;;DA"](_P4,^.9[Y:VKL&-P0L]V(6M=A_!V^ IY%QO"2T(\.7|:Q#!R)C*FB M0+G2.[4FXB6S1U3*R=99=)KM&+_-[CFEE!F0)D0 7\;;YUF,%"P(@B6 T;=2 ML(M4>VS]ND[<*>_ E%'0-]3K'V^X^<,^.1_?*P! HO2S-RFQA80A?!\?>SX3 M1K:KZ'6MI;S:X5!)OU>&E%A_1& Q49_-6'ZD) P=JBI_)\$0D!D"C.,R'$I\ M<\@^6/2%.A[/*RP|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|*9H]>I_IT ;V*A2V9[PM!6\\C/ VTRKC\-C;F%!MX]L!TZ72?(-M @[B^,>F(D!!Z@_7?(*AJU3D6)B&\6OS43\Q;?B<*OBO'FX;K!RPR$NH>I=A M,X^D6J+R8G'53VR3.'!KAY-YKN;6":YZ M!L,=\)@^BC0$6^03'H0%]X0)%7[C_&M?P3K&FX@%W&KJ941 E4I Q]U#,9? MP2IA2.]/LA#C6[9#MGB78H +%!^EOU+/%JAC$&%D+? \%_U^V"$/IU*KIMP! M@BWZ1X0^"+\L$BRK*+'OYY3E6'TD+'3"I7\PRQS\4,$;ALE1 M>-LLUIZD7:;JPT-?@S)<#:(0S"X6)8- -82PW5B%UID(:\^QFL3B#:48CM(TH M!N\'0&IA;@]TJNAGY\XP=;H;O(^Y]S+ M#W.I+5F!,JN&VJLK4&0QB2PFN<1BDKA<^-U- DO=^+\AFCEA>ZF5DTG\>9B?XNJMANI6"@CQ[+'[P>9-WWA!&"SNW*C7*SVM4UOL\)QN'&W'Z7-@?4$<'6] MW%]]&TLU8I-2&5'*OKG#3<78L,986=PH:Q6TYJU/:T6G3.X.\$.PH*MH96TP!2U:8L(EQB['R6'+,_MC0W_W"7(J*QGLX37+,_VJ8/.6,"]-Q0H.P ||>R":("6+>5A2112\R**1;9" M=B2*.RHNH$$)7ZD#W@,(F7"(USC@03"ZF9-98;Y@YG)CF/""F236QIVH%_3B M9YWAQ./$&"-X+/C!\=QGOGON?J1U-+$WF(&&1<>LGY [XU-G:X/PR2 H7[%" M"+&;")'0'B45/P";.(@9X--B5DIJ<>+BI.7U2+%WN>C-@2<;:PZ<5#7BD7V7 MN?$C/D:#DP+ZN5@:Q-QBP.VK[V%54NR%N-X8QI4 MB-V]V14N\:.{GG7S\"0,Z/NRW'TX[H=>4+QPIC@U76'9\5)T1\CK\N!@3],"(MBW"$-!PB J")A(S R,88TL[K=I"N M4<-X EQ[%J; (/@E>$;FSS\@L)0'VZY!BJ"C@*\%,R8"!FKBX"H S661$3"5@ M*.<5GYEJ"R9C\,JT<,ACM(;2$^->?5 L'.F*0\Q?09;CT]A4}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}$U> M$,=*,@9)!C*H,AE 6!5ENI79U?CXY- A&2%/QF2P\._WF3%1>%^&R4GJ$(4AW M"X/@2*9\=!7 PW^Q37P8QJJ9+7AO%@@<^^V2T=*6X#M3ZF#9E ML:,D93X/,V9*+L:>FZJ@Z2*B8*K5TDQ>9$ MWG2CFA#]^S MHK2<*D$/F$_/TT)&6$W?LVR:FIT)!<2*?VEPB.569D#+"C'].)P<_8P1%Y-E M4A03ARU9=QA>_123AI@5^MM6TZ%<2,6GQP0 ? '"S"$^3\5XS!U/-IE=[LKV M<,?:!T^!@&JMFO CFO+\&S VGVE\>BQ3@=>WO?&0^"_BTHC5!F!5+9C7>$9O M:N3S8"]S!H >?E%>>PNBBGM%/ ^1U'(QZ9,IU)">[$)SXTR @Y4[I.%/&K) M"YV8B94N3^4HTZAK'CVVXVV3:*RVH>G:|?GPB MER?(X,-B?<],.;$G6^ZPEL(ZL]Y'U/K+>YYSK? 5;'U9>G%XR5Y3?<5;0[27>6+(P%HK#6 MNA\;J7$^.CY;A8XBJ^9Y@3>P5<3/X5]2:_K Y+5++#(3$%DQH[@5$2SV%!0Q4?B'5 LTEIM@Y^U"'^D,|:RCQ2#9=9)F5A '+J \AQ5 MQ24*GCU2%H>.3RT!"^QG^>?+C?)WIZ}>>YC4J#>7R*[FT5.C*]JH$G^@&^* MDRK6V+L\YI7QPOF9? XST(%AR]M ET'B2'$A8T,=#&?R$"!XG M&63J#*PX=JR,A/1PR"^P_9,#M#?WG[}->RZY;.W,91EZKRB-,3W#0@+3@AH> MCV+9F2"(\U<,5" %EE<\W3 W;Y1,V).Q3W6,_B,)YIP36LN!%^@3>ORF(+ M5"?+6:'W8M/78 41Q>%:GJ8BLRE%GD3*=*? B%K 8P*_6,GB G7QPSB(G+BV M)8.>F%A9[F5ZTC2+IFN>_UG6CBK-A,05>?&[N<^[NCD&Y[NU+:B7M$M(.F*D M#!P+I=GA1X L$P^HO((U#S!<{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{%BL(G59^I_VCD?NY\54%">%G!>D0/F-,?I*68"'?V2@P@[C-U3@* MIZ4R_'TLKI$^I(S*!6V<=._*L_T2;Q<=+*Q6CL' *G5QDG6\3VXGSJQ5^],N6FQ9W*%(M+5[L>/WZ%T!W\R)2%TJ41?,*ZO&?F]BWY/KVM (9>AO3V[!{(GTO B6:<"3XZ*E72GN02[+L+Q?[TZ5,F:!,H(< NT8+95-?)}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sP>\1.^=XBJF$V]6!LHV MVEJF32[@_3--G<'Z74T#M-8_G/'XJ.<)%<$NRI I8T*4.E3O2BW)%\BS"%[!87XW60HJ23N)7,1%AX3SW+Y\N.L.+)&+ZCN M0K]MX%:#V3[SRVKWA,KW:+.<-RV.0T[O7%/S>DD]T[-.;LY M&=V..3+W"4?L&G%H]!0:U0[" D^)\PWNF)#"H$V4.,,K"ZU?;Q;4*JAWHI9^-M M2,RMUQU;9'"%GH7F^ M.0D:7*=8)=BEN3DB"<#A9+ (>,-4>/V4>COF+*R!6&V6O&KH=IG2N!Y14*5 MQ0!>0*#VN8-I(#[5)-UNELJK*FX,=B7.(:C,/L:[J\2KVT=YO3("?JI"U*MC M)43IR83QJ;3G:7TA4.KW1P6RC9\LVFYF]AFU?/[,Z2:F9J9FMF19U9;6XHT MTW9JR^J@SN>$FGY@$Y.MCMI-:|YO2QTZ=;53H- 9ORR2JM<3\TJB6M%5K6PDU MGT3.,LQ\OY_'F4=@E.*-W;4LR_P8A'=@#K]G]_%=6AF1NNWHM=/570%\'H'G M+YT@OA1O2- 'G>]G%WN#BRM#-0,>$/R_N4/?8)M0*M;:KA@Y2PJ*$I:ZP9.BM M%"W.@L48V_F3$'9^V+^*$D3UM)?_9F%0)3Q#[!I)*7=*?)3XO%;QP2#?3N(S M4N*CQ.=LQ2<3G:(@U3;1QLI$4T)R*D(R.(Z0F%TE)$I(3D5(AH<0DK6VEFDH M6TM)R.E(R.CE)<1LFX2M,&GEJ* M7)9YJ@\|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}3E0/%5QE='RK[KX\W"0!]WVW("- I37K:-PB/*H/+E[Q&;<1,1&L6&+ MV;!>E.=(R.N#+M@D_3(:4NWD&<6#;>3!0{)@4V;QP.#'LM5O*@]5|>*I\^+H M2!#O [.I BG%BN?"BD?*0QST, HUU&'8&A5+VW)>/!*8_.!J*GU!<%9L$F;> M'%?8.M.C?KN\P/WY[:?OZ_46[^D /;_9OK-7S&M-1'G3,V*/.3'>]HW"F3I M;_)VH$7&Q+:K-U- M!'2G)%:JYE!VW1@<-`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

*f.D99O0/RW(#5&L!AEAU8G*7QN_PCR7W5*=TC[W85]DO[49QO. M5/C_#R1&^8+,*M_#G0HO9."4(M:8S&&^,$CA[N$_(NFIP3D#_MY"N\"9ERR M$;4U(\XH;G'Q;F?%#40*2GD20<^1U1GWATT!%HZLWC;QTZ4(/<;+G;%T_]# MI^7RDY-">R(!U;(KEZB0WK$'PO?O^;\-#K);59)E;3CGM[%SXJ M<(,&6 C41W^9XJJ.LU&I>9^P4S(^.XK=&.=T@<+6X!8C&6%|PAHTS2/3HYO^KC MP[>3>+V@_C^9-]LUP%!N49*[RPMPXLKHZ>;W;9TA'\-!P@'CQW9CP,T_F MXH9A(13@/N?+'B&^LY2FNB=/;1D:75Q9ICx;-XR*HH);.W$;,O-,[7:..7V8 M? +;D46E1A)G?@B]>2FY^5.5EXE :?>L%3I"6B0B:[M%_I1_[,DQTUBL50- "VDRU\!:- WP'CHE &5,T #(%2MF0V;FADFTG3*V% 9 M-@1XNPBT $>Y]]S.PK&M,[MG=?=_\+%)T;5@E^G-U@?$'}-8EG0L!*+H]]# M:(MR$X"4$P0[\U, !QG(%6"S6,_+"1)"*"\;V,U\ &(&W35/>ZHF9)C..Y+,$' ML"(#T|1A+61K46HY+-1GG_(T$HI?EEE>3"87XF<_A(RK|O,H5KB%.T M&AQKB)/IE(6R/)B7<&- I,KZK|& -"[E8KII*S)L7XA 6DAR7"HP"Y/!B';L; M.I=\$EQ*8V[_MHN#]{L#*)!3IK"Y=5AH(75X@\$26"F-AF1OR DBJ\N;U*_#;J$ #41F=5EA3 M8=.RJO09F,H9H;%.'(PX&U13$03V^;93UCQ)R"5L&!%UF+ERC'Y%-:QTU[H M/*T5S#5FXWH#T2J?77-,"6DEDJ8B1=5]#NP[K\Q'B6*_J SOD8ERD)!7H/"M M6T92H'),AOPL*\3U# M QP.&25 KW%TRSW(F7%X.YU2D[DN)09;("AEQTAQG M"G_!16".A?0Z_@X+ZN,9>,;? ^Q+6"8OL0 O90A?Y1N2E^&GY(&A/K- =4GT(M7X&" L,.0BG<1%(NL9)2:/V6P2_NL;CH_G]A+ODME?*151#AVD'0^(8)FTQ6 M1@KMA.]%3F#SA1<\LQ2E35:O3=QPDLS11)F(_<0/Q9=Y> ($"-@L? KMC6O;. MC&DY;@K3\H,=^EB]^XV%!.A;+I#K6V4GL&^5$23.M"=\>]>@:Z@N+.7($ MV/D:C.X3;B2|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||5XW5]'OZL-AN=/<\47_-<3ZWC_H 3# M/:-]QXY/]>?K1>%D^@<4(V)]NYZ_Q5PV%+_DYWJT0_WQRTN6XG,-RU-/OG_0/ M['(A'Y2IC.M%L2DEY.9WIEL @KSVE.Z;6QN>[R 2VWZYKOUI<$ M,9J_3BFU+LK5EM2P*KK9X6R]S&R% [5":=.WY|B^N#+.O]XRA/NAOX4PG&Z,R$K82D?,4$>.((K(N(MW@ M;!L3D3$_14QSH(?]9>0.)2+G*2+#XXG(<%W(H8^'+161,XK M?K,A$65? +ZP4_=DR(^AEP+9.)-K]HF!;[8V2R^*NM=ZAN3+JO%PCEL:6RXIH M0]R[X8D(Y5Z>1N_BJMLQRCT!]HAA'P7Q[|YYL29\J12(4B -*Y!!XPID78BK M^8FL5"|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|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f*&?1@: +LD$':R7]? N%XLWA'$SPMJ M9VSG>46\,7J.X.C5>0=EF'5"\H%Y.RPDKIR#04TMW+&3*M">@>D&R_4$XP%9 MYH'}@E\,&=VE(2"$WB[5NH1#+LX34)2[H(>? #L=X*A'T>{X6C#FZ*C\83D3 M6*F.BTM"4.J@/]-N/6/>=)V.)F)OMJ9LL1XTB-%N/+FWW({61PO)XQ2=5*#WNQ4 M3C]-CW^\0_=)?M)=DVI5]MPESXV6&S- @0&X!P[N 18$9T'"*$<|D-=&WFHB0B MZT;8I-X#8\GF?;DG]L(E987=P\C+Q$|%7U|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|F|)X4K^@%?(>CGT M'IQEQ@S5]=]ZZ[71ZNLU=5-6AY*9ZLAKW?34D:>21P?0U"5K,SMTHL3E590E M[LT- 5CJ+=!(GQKAL\Z.11 J,&3*/A37$7=:"#UDP0:3/F'-P@*P_67R"T>>_ M@^QRA<^C8%ARFYEB>L$Y>0;*I88#ZL6\=@_"!]M/C?L0KTAX>:[<5W(EY+GI M!#FMSA518;2B.9D_7-!OBJ3W(ST#&E/H9*XR":<2>DN=[XUT(POSD]$=V(|_M&LH<86Z@N*%SB35%]]&\ C<'). 6$2@N*

J@&\JI;E_V?O39O;.))UX;_2<=ZY;]@1+1ZIVNQ1 MA"-D69JC>VW+(\DS<3\V@ +85J,;TPLIS^_N59E]0*2LD0""'PX9RP"Z*4J M*]6S:\Z*:NVJK=;IQ9-V'8;6XZ!>#)Z!2 M"=+R!]2Q=O%!6(*PMGH75\,_UB@O6WH%HK8MMSO(PP](OQVG"!S"%(`39T;W M?)8J/GUL9F-\OBI^-C)#X/NK]/'I%]7'GZ=%9;*)H&>O/!-@65=K&ES@GU(4 M67/NBB7!<26;5]'X"&MSLLR+,3IP>8COIQ^"R[!?9+S"M4Q!\F4&K.1ET]5$MAGY_YJO\AS#R[]8B,_CX=RN/ V'CE[TX3OOXP="N#]9]W&!NP6,_M^! 1X1\ M]>4?GY?P&7V0;U5 *A&IR!^9Y&F9,*=?P5W_.KH"?AWW8OWVOG M.7F?HY9!S83_L>$(\=(EYQFX;675)BORZM!3@" .'(0+5X(O1'X$V/5%-V_1 M]9$8D7X%%^IJU*P-.(%\F<\S<"$"?P'60^7K)9A\\@J)'RX+.'"-!5\;G"6,BM3I*W\.]2:JGDC_WET5,3%U|/^4/D2;N%?V27)3B7|,,XBDDVGW?KCGVC!?AO M'Y{*":Y67FEW+9T;/$[P2+EX-0 MP(8FESE$D+"6<^<6\0[T,K"]>&>(E"DQAG8&HM&EX[5%=._*Z3X"O5F-3'!&.]*7GI87%/4[2&\.T_ MNG).?B6]+SXOS@CIUFOV-F6LRM@[\"]>O/N_+^AM(")W(#089"S(3H%F@>BM M:.(7RS;PKT^PQJV#-?[++H\=/^MXRO>9O;WY[!8^+AK>J62JGE(XC_'53[\[M.8LOC]\#++F23\3M+G@*NCL)07}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}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|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

AH7K2[2-'7B=IS[XU1LKE+_M<^3M_'?[U.X<@EK.$[TAHJ1&("2=[-8\'8]&O:0C?\-U7VS+;"UV:9G5S!YM M/28>3$#Y%C\PAWDZ1,-S(L_'M3B)*

=M5T!\]S$Y=3F(KW7KF2#FB-%>(2_]8-_M'6G(9*D#:/3RL_1NF#[C*"FHXCQ =*;HNYUMMEHX!Q6)(^QHM1&)0RL^-)_ M-ICJ7SZC%*

2!&&:!'L\]#U:/.ETK@FAN.AB'?. M+<;#^E#3.K+5W6{)S1_FZ-75S]YKR[,781#[']EA@V.#PLD:(5W !ES1@"MO0

MLUDEH^S).9OEU30{)\@QMO5@K(,_%RVD'A% B2G0^A5NW(PW[(G$^NO5.L@ M[!)A19FADR&G'3285=GZM!:/@7V.P.FJ7-!!2R#&Q__@3*

*_1?/*T6TPL\S(P M.$)N.7:O\"NZSW,?N--99F7M[%454"7]TF"8)7$!8Q7FY^EOP3L/M/4,TQE MD%8VOQ(/.DN:-->8:,(I:LAOSKD%K74>(LL_>V=P{(4BP?DE(M*

*PSYHU/4X30 M>&"?<.I2GZ%Q672DXV(&5]D73R(.E2ZQ@1ZNO^+ M+C, T_&.>(0"Q0-EUT/C J/X8F\M*O31-$Z2>=$@%)!EHBRXI$R4Z3]N4MV4*

M:%S"^$1)>GK-B34XC0_../NF0]^#)I)3(N4D^49YXUZN(:&.1N=Y\!9@RC$EI'AE(O-)?M:5)=<9REY9J6J4XB\+G> M\8C] J@"0&'@[=PG$@T<$4_^_AR$*

*)&3==ZT^ 3:NL@2!+?;=*W*%R_CO.)8 M^"1)7N*43UJS8BMD,X&K(@:21%)QV%!G-#43 2N'+8^B$CYY<70L*.L MC]B P:,1S5*

*M!;3=D[@*45Z#NH@X&2#&6$[VQ0_,XKR_?0"KU%F0IV$5Z$+\F1;"(<[+I] M MM8U>!;,:Q$\A ^UU93F@"#19)2V5V=E7[T:YCWUGC'%.4]+*5])%J3.$]7*

*MU5Z/;/WGFH)8Z&*3*O1+.[KT)\G?!3O),$[S;T7_DP:DIB98$"BP!:L&1YB[Y"9I1F5P/Z O9M6B:/^<#\L M;R_/_ WS!Q_:=\ :S?J: \P8%3BW&?5{2) .6O \WP@?*

*0IQ#4S!>.%S0JN/2 MVPDT/9=]= !":DPBN@0X4M-#!?.^J;'1Z*LA6F3:X;C$C0_ M$B63PGL;6& OEE&,/.N;5-?DO/^}?G=GMH*8EK4A*0*>YJ!T.9>YI-)S?LXE*

MGMZ02]1%FJFI(&6HQ(N2]:]I6NIN,+ZNS#:EF M[Q3.$>FT8$Y(2H5(!VGK"/@2(A%PWH_:[U]YJL,S_A^F0B[/?#X21O602[6?

M0C%R!"3DHI2[]RPPBZ(HB5Z.&EERI<#+TMWDF%T+,?))\[F]'@Y+;F3SD?\)J M/>!-KN ?Y)CZNIUPX4#@6>H+X3W(E_C MDM92TBRE6U5@C;@Y?

*H58LE:\G:E4NC_WE'I2HX39*2I(*"0"%M]>N_>$)\D' M5@L@7A0$._9Y?1[;?9K#<>$+B[&F0C,CCE<4U5*R/)5BKG%NXS628(/){CF) M $M#OY4YY3-?*

$3E)7@H@2 MA KB49KK&5\Q#PT%0L9!L6I9RLP1?0EN M<,..@)PGQR.I%].BLI??1H%8\!>XYAXZ&T."4)I4"..'V>!A@'&2_.8O$S[Q

*MW)Q8WB<)T6GA^T4R"IS*K%R87Q(<39[]9:JLZ((;2:G,@B;LH!ZB-MZ))3 M%"L=ZBM)6S6<,/L!0$NJ\GC*

MC472/G%WJ64J9[WL.F)!CV?;QTTK6;O7D^'O!YO14-%PK23F4E5V(S+6:!O8 M//=EW;3JQIE182NJL&0LJ7A5LL^/>WS[>XQF1 {DM5Q^;|

{(/^L9HP#8PNQ+ M">\1)?-W((9,$T9;BQ6B1&&@D#G/:)"YK\J'5!FG!4P+:#;_5Y=+39PS^7Y\ MMB$:N,CR0C&M\"VN?#\35&G_(H,W<@,_/JP3Z)#85<"Z>1

*M$MTBCI_[(,6C/.V-/'$%R4QO"'!V=*0^;8YT@$D(&@YQTYZ$L4D!ZYW7L*D8*

*M>6#\YO!%%QC+S6DTRD5UN1\&CUA>'X$'2HQYE)2O+BE9%!=10MKG>2>P#T[M=$@(OY9*JX6,\L"-TFF8%3A3Y(E19X:=*48*!95#;F>I1O0Z?*

GJ\N)!'RLDA@NI."L)_62#Y&'I9QNJ.+2> MD-:<>X7JLHTY[N5=!6ADIK%-2^J09J.C)^HD&HCB;JVA$IE,&]S(11 M;$6 ,N1YXJ8IN@QEXRG$P2G-

*=H{J6RB4LC]WJ)WD>I?6K2RO8G4W72MH](Z&8N?;2N1*WA7*>L2UC>Z-)A%Y>PGK>E-5OT!,R8HG WGJ6M_5(W&YX$G"T:>D[M%;UY/*

K6+:I!7U&,.2\E6.?+L,<"\!F.O_5J.K4#B5!(LN_1X0%VQ]'&D3& MWT4 QSD\)<^"QUR4&$M!YVM/T9PG9JTY.6\JC?]+(- 8O8K5J/:/B!E76KC

*M.8K2[7K3TH6."/K"*2.YN-91@49S@(8KT+1<"@6!G7"'B6V0&2R9TB!6UC|< M5DKF<-V"XYBFNA7/WP^7'4S$Y-[ARO:EY,<<>K-'-+N2?\W2JTY%AOL*

*MAL{T.$?8'XR.E/7+2DGBMCCVW*P13/|"\K7&L=ABGKCKI">2>XD@0\HLADHZ+A% MCA^$IY2]S.&N$B>%*9PI)Z-<.[BXZ_13C7_6'!)D:#PHZ{5UC-J-*

G%0>,T M].QG(XWW@M5>1,LLZ]^$;@;;JUZOO,T9]EV&AE.$&XW=/7_ Q M-E' L%/&[?]^-W7!JS"&8=A+TW9#E'T/-V 6F^DE1GA"QU@"0[N^9YD(Z:H*

MPFIP& .ZA?U[>(_-2.O"HK).PQ;9"#3B\?>Q7Y1R?C0?H9=^J)>T^C,G MTC,>LQHD0:'VG$J.[K9!-[V4P2^Y?M#Y%HD8$OA@2O<\LG3W5C:EL!G?R*

MA@_WB/@00L4,M.3(L>/NZ:M%)?>X]4"S;E"+,#,L&-&N[O?+<6". ^6BGX9N MI@>=*6Q9>,W2$BS:>N=(M\U;A1'MYFVD=BK(P1ZJ,+K(5X'/H,!HD!H-*

PW.3/E3?JD\JHA2=S$N%I+H;G-X7 M5._1P%WWE&)W;T,*6_OG;7M65XQD4%2YZW"7JY4-]6)UN<2"-H#O7Z!=T M_'T/.Q%^&H J UI;%E"3A^J3)$8=G-

I&.E.9!/S9ZYIQ/2?8R-->D%!-44QH_V$:FC[_('IH-'%"3T67K$$!8Z%%A[PE9"!=P5VMF MIP_@V==M@Q3MIA-

MOP4\W3:1"]U@ZIK"X^%SNLP]959]HE@#)-D8[F#:.^^A\A[A LDJ%6D'IYV,E[KM$8/FKO9D+88]PE#!&N,I5;IQPK^"C#.1 M8<74XY2LX_(TY]KGVWF!J@!-*

&.H%WZL5/3[FUM8\?7#D3380'C&/T.B#7XX/ MF8Q\ V+X.2CDAD=GA/P7NQ_&M)TBE!F6 >>),-L%A]Y34$-CY.,>&)Z8#C" MU24L^[']SXJN7J.AYF464A";*

[CL%(\,(X(F):'YYP0R-JD@SG:>DX3:I/9AN^ MINDW&N0FCZ7LN]C<(3MKKWX!%E.(2X=B53X'JC/QMUVZ#LJ#YN57V(Z3:'7;2|Y%&+$4B5+ 'VVVS\|?*

*MM^M6MLL)T:5QWH?'E"<'.<*8Y*UJ_&T8R&6K@N#3PO}PJ83&V%[G7!]W^U9V MNY;AVOTT[W#++P?+NH#Q.$P\/H'|EF2YK7Z%KK>B:OQD*

*M(A(3C+6LB=I;,BJ98%1)@#9C-$F&6:@C?N?6\)W+N41K<-_%'^0 ;^D'@M M!1+;$U,6WLC%(Y$]0+OZ)fXF*MWQ(,CS4;$?=5W"TK51%C6:!$ *HL%:*

*A_M6=+8N;]R65=%=.L+4;?,E"OA@C5#/*ZK.IBP<4G^8+01IB9_ZYO8<^,=-9 MVQNE8RV'36$,GS0_D+)IE!J F0DF(@RV95F&^6*Y-*

*VI8K^J>^HB(ZC0_CF._ MJV3594BB[MB1@U=;5&8_L))+/*Z1*LOJ&D<3K3EO>P5NBQ4Z T":G,-"CQM1 M[N*1I+RY.9>BS$TQ3 W:&*

*[9R,+WQS=1X;YG9Q9W11-PE8PM)TAYPICNDY;F(MT]72O<_*MF+;*|/=XT;UU-#C)K81Y.8^ZD=;YBL1']6ANJ;2P-,#*"/ M(21*[#_1LVCU Y00\0@P532Y&*

[+H\>Q1W18-?;(F 4]D_A$#PR84.5/+EDF# M/S4U:;PU&R8-L]O[N3E7C?&U3(#7X@ $/>H$<8/F_2,Q(+>Q7[:IW2)7R!#!

*M5(4]BVW:'9LO12W+XQ"J!S$F9,]UD@CO7:HF3G_J2?&VO!O@4OQE*S[>]P M@TWH%SI'"*

*[!,3[3(LU598=+._SD@P$#CT35]\&$P>>]_@1RX.C70YB&\>\77 M"(8LO*H0Q'7KC0S;E_0G %]_AZ.THYTD^E. Z M["'M)D":LO\D{J4&82J7\K@QME3X-*

X;$@<4)E;-D+1/#R(%D[GM#32+DU_;; M9[K(BDYGS>KX1V2:\M/F_5.ZDE/V$YPR8QC B5VBV:99@>1)-%?P)/D=1V@5 M-

!+)99RZ94|Q$ALBQ+5L8E/"&06Y-&>@)HMD)^2ZX0}6B \[=?(F(]W\2$H_ M[I)WU@_N9."$C,9DSW-<9HGPK*60K]'A===D:T8X]'$:&8 &_7>.+[7$)}]NH\ M?

*3:,IVHR%"K%0R0=O%K+2+UE:.D1E*CJF*;M&%+32OD[FQ/ 0LVH#F9&4XN MW(."^(I"U'A$#OA.9P*Y"Y,MO$5C:S"-7ES'3*

MWD_QSLD)&81XGPRNUE1.F:L.A[R!%9+JH:#1YMN(Q=+/NK99'B."DPXN#"2Q MPC7#<2\8N3F"?Q@8G!IS;UG@E3OB]MIA8,+B-MYS"X"("?DE!*

[F>L2G8)OF MFX4:KJERR]'"%LU=+-8 LB$AL46>7W(U=YPT>(IUD0RW]%|)1R'DQKL3)2ZU

ME0P,VL#.T2[HYC$B"LX%A]WX'HZQ.CTA//HQURK]J(1++L$3L'*

*%^Z..R7**&UK#/$R=/[_/5O!V/E3TJ*;^L6\8U5+DSHH,S6 ME\C=7# 1/(801G6KV!/(VHQG,19,]6AO[JE%!P?Q-!598*V*]6|\<;F!TAM@; M_V0>&M-*

H#LF'0N9RE7EN-+Z>K!ZCO/ZN&YS{2 F);(>2_@ MN,RV8<(/#WT.FBM:K9Y6^I,KV;?#!QK6B=|>]f+K^_D)#RZEU!,E]I6 ;N:V ME=#^46=

(55A'1;PUKTFGNPW189LDFU51Y=/:8(AF&MU,QD4&09_VZ;@J#W< M W$GGTK/ ?$,JP(I7<8CRZ*C_>;&$2N=RO&L!9,<|S,3-AW!8,W+|MRS/F)6 M0A*

*/UVL<](DCQBZ,@.+F7[6)<*RT^!6NL)1IL7%+6QM!")"&#XV%$!$?CKJ*]= A'W=2[VX.1*3QJ-(J* M:=2B&D[8$59Y]Z%9]I]$)+F]2OPT_+R.Z!V#D2L?*

*I!^&GH/ ?GP@W1S[N7[K M:H'\C^ 0@*6JP&%8%9AT1=64P]/KA%2LD&9E!<\PJP5=Z8=:SO)J3E5>ZC2' M:S_@KC$:\,,EB+E@M-*

U%F/A'C^,$0&J3NYVPHY!,PY?G@0A0_]\I3VSL9J97OF2AQR:9@&]=*CMP)\:SQ1,/Z.L=\%1+/-X_K(;%3$4]Z]%B3-?A[

*MX@Q0;0>W/_5+QH?#9O_YI;WP)>)>I;_V2OG4MT^;%55AUWT.:B1'5^D _[[MRK)_<6-^1(N MM]ZDUQY&B^IGF(AF1!<#^G1U3I*_Y1=,N=JEG85:?*

VB\AE_$D;NIS6='9NK]-MB, (TV8/0G-?R)![.B/.A7MO,# 9!!X*WVLLN2X\P0& 9L(L9DD6+&3=;=I(M-=1H#DV/:\##%#<6%6-I1$Y2 A

M]$5[.7+RH9G+17+7$!&L7V517]1JL=3PT\X[S=]S@0*2'ZZ:SPF5P8A!KZ] MF&:*%L_.2^?^XT,WI9\!6=M1?J6D.NPWQD5%(+;,+SS[F,HW?^1"BVVQ[0VW*

*MF\+^<748R^6NWL\UOJU.#QBD4F@$C@/=#5Y),:ODR]> %Q MY"FX4;'MI5/0>N(A0Q 1(%?2\>YU7Q@*P(-C%L*?]750)4FB +QQ9@%T M"+*

*M55Z@6O|@^>23'T$F49'^E,|_0A@O&N$EQP_P<=U!! WPLJHW@JU>GOP$]P*U M\#SY&5DAW*?GR5MXO8 ,_YIGB=_[Q!Q7>?PX7LQH,F/>*

*<5PFV_0^<"28?*Q MQ"$E69.\AP4E*/>W\MMN_>!]3GT>A.5>5\GKO$%E]-X7CP*X*1**"\#MUDI M?8>7AU9RN60<(G3)2$WI+GVU_<7_[IYE)6G[>PYA0,A?*

+JP M\@!?.5]T)>E9\PU,?"RC/$$\<:CID$!,3]D=/=0,.\3 X:!EN4F/ADI$"ZAU MG+HKI3N%_A+XRJBY*9,K,8P]?$B7YD(H@[KC>,9)F'F7J$.V:I7XEKCA0

MQNZGG;AADO\55N#Rf;$UL[!.>Y>-F7WNSB1S]"IW'(%)QOQ568LZH4BX=E_S*)3=!Y[I9.NQ"58N +\C'J;]ARG?$[NVP!NAXD8_?LQ@85XZTMUO B:5C.YX'

H/1K63GD4P:NCS22HIFW2 AF MICE,)ZO=:L@LL;YMLY#Q H!VP#7D?.JL,OHBM7[?DVL"|SOX#R5P90+U[* M6/%%WLSQI,FF4 %VKLQJ$95VX%JV#,\|D*

<\!;R=8QPS 0#-^S0R1H/YXF#I MF3,F@,X,K$)A=`7C.8UD.EG&'&RX+';MX/M_B,_-3\8(Z=D? IXD?ESZ(P2) M#

*((E2:S=*JM5CY("%$E7!8HW\H34IF7'PM^8@+_-&U;/6\.L'86@R_[<(5KS MIG%K6.&%,;%OEJ;?P1Z,0(WM[^ IZGT?>$2+)>2E5E_VU@V_*T7|/%Y4+*DP*

*M3U^K+ ^*H6[>2):M EL[=HL,.]Y+?# ^\5Q?W5L)TI[1+K:S#\^&#)ZE_%9U.KT MF;ED"+K1M]V8>4#3@ZG3),.I&/R?B?8$='>)3*C$*\?'BZ>O3KG#GSD(XS"B*

MQYNW:FH_1-PML^Q-J398]4RB;>G8G.@TS$S*Q;$.#&!IU99&'9=$\U% MON&Q C5S5A"/31\1WA>C_NLH?L^*3VAC&XB?&)715PR6E#FA;_?2/JK%#U;*

*MJH^>52]*WA=LV,**W\BW]5NQ/=>+6FKBXE2@(N8#8D.9UCG8#GNDGN!:. MN/"T&-)+9:.Q33T,31,$H[>I0$PY$YW%I.!7/A\:.$TIZI8/-$Z<&2< /6I%*

*M1/U+"T!O^X;.)PU]8*KZIO21T$6' 2+C8VRF#AKL@]%8[*N0L]7L*1_+#>W2 M6POYMADG$V&PV?(<@F; ",^PQ._C^LY*

EM!D9W/7M<)_K/4;XA3!:1C$MY+- M(0Y?2S*-X?S^\MBVFI=*F_*B%/(=!6?[N_&&TXF$QUF3,S$@([JZM##JFDQ7 M"'R,>S|W_RKCY3D-

L;JE.4@M1U6X#8Y\4%N:HB'@-9PK7(<7C#'KF5,@'CR MNF/FX;I];K.\,C;/'!$$0YA@-_&*E3CYD!?]$B+#5#.6&02_$,#4%%%B+Y$_ M5?

8(,:5=53[@44X1$7S#"::T[3'OX- S1XK"B", 7G2< 1..";JD!"Q29X MI2&WK=P7:#W[O4%T1DMIOXS.=5@V;2CP]Y#HRK"TXEK1;%K'U*%C&<3S*+RW*

M7)1K)%<\@AQV@!R^/X(^@C| M00AY'7^A!>.I:LHD(DR@WB:$'%B(,\B%23^ZML)D)9GO@CC">}@)53.I(7X5 ML/8.4\XV!E@IST)=&0O L$IH9U

{@LQKR51F\RZQMP/VF M0;\&WH<@D|_Y722,-=DCOBPHJ19M5J^S\ ]7;7!=AY3$?=4VQ3W+NG8XY)9\ MYJ)#-[V-YO%AWD=;Y:/"L'1"YCM\,J8JR=&"\&=?*

>FXY[9^1&<:R!;Z-^T-1-MQV_X6C|IXZ)7^GS)$'6RST@/2RKP+A4#Y\2:UDSJ M)C94FN1D8F0_HFEZ)L,>;B.^W_9.HT&)L<-"&H]),UNC9%%WOG)'?

7;^L3H M>G G5W6V%O.KI"MJ CV<^: MR-X@0$(N14]&L;VDLRFBCQH4B&*!2O?D0N>!EU3?1.JS1SF[33GCA,BJ*S*J*

*MYKOR(]\KECM.GN+.1#DJE*L7]P<_YE5BP?]>#"'+R1PRW30CUCCO\]?U&.,<, M8_:!++]DL&AU4HLF%E4/]LCG7C*1@C8\;=1L;Q7[4@T5-)%S!!ZQ*RQ5"/'I-*

*M16Q)K@^NX0&U!V;._U=\QA.Z-4FN;_ZO(F]SF-/H^059;F6!U[46]EWC6E M)C5W$;GS9E67- RST8=%/4Q.8@7@^2DVY1.:T_"6*0@O.:CJ*

*M!>6V%9Y[HDG"JIY*W65A%(KW[2IP+BII+8TWY'.ZPJY?NDT/H7;[&97[*[/) M41$_ZCG4]#86NAI:6 E&A]<I[N%/D3PPHP(RSF:+IM()9^*J*

MRP7JP1R6$M'LYQ;M/'6X(?_JLKHE$C&&YM$4LAOM4KPOT3O3+(-VC=V$7=M& M59O>$!F>[ ):KAJ4&G"7)&$>2)M=8G=95+-84:(?*

7$B=J&@G,46;/W?@[MS0 %])$BG.+\>EQD49D1#X-P9LP/6G46G7:_4NY[Z4\87)E.@@)I9T-3X%'A MC ?VD].1RY8P:WISA18*+M0Q"4 MO&D$;*

*!)>4VW#I"_N"N51=O&7GT_#4FZ\U7>N@_>-!:-6SD8D(TPJ0N <B884@GNDGN!:,

MSI)638EW*D)!8WWM(BL(*6YG%T>#VKFPH.-7E"]+COJ%GA)/'3;'"S]L?2"\ MK-GTW/8>+<&9R,TX\K2=J5QDNX!9}CMXCJOTZJ'9M\I"4MLU\^R56[;>P.1W2 M D0]9=18/B6((0Z]#"?"YA{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{C,(TD!{7+(RN$Z[B5.6RP%<%47 M;M8FC0-IRUGK.C$L;!4Q1F@5(\6^>2G)=HI.96#+ YYEX6$\..'*?91EH%N(MWCM(-I >[;_B3;_46O& (Z@#SCBT"TQTW$++S0)D5X9#-D41?&I-:-&(-`SLB ME]/U]" Y\;4KZW@/P0#O&>V>(T+I&^Q.-J1MKN M; Y(LXU'7.MM[:!A70P@YG@+0[0\]$9T>WW?B Y[NZI!;/S0R,V=-XFB@< MH#G_:XLP5!]*6F3YVF:VQF6G'3=N/30N%:L[Y2*6/ /TZQ[;2D=_J[3H_M[8]\XJENR?_T@<+H6!+"XPGD MBAD#UWF94R1"^" I&AQ@U.;%.=>HPZT@SD{GV9C$A1W<1.2.;W7:_G:04"1LE %A*5>8I1#HU4-AE8T.;YKA9MW389-KW\ACDW)-- M'3N!HBY#O\)8VDB2P=OC'MWE'ET|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`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|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{HI&27,/SZ_L3BRTF"^6HQ5OP M6\B_?O US+=8('?)-[^__^W#VV_!{M7&T[7KR\1&-IL OA=/(^\;"VL4,[T6 MV"&ZAV=']G)V\,7:!]PD88R;Q<*8;X!;E;O+E$607"K7R!\EGU+G%R8?S1=C M ZNK.Z/6D%9 DHWF[!{).YI[.\AO8FP@G5,E^YAB.^[M#9*N@3F"KTB; &=]*'M?\LPDL%YUP2@2#$_%Y8DP5==QG7#C\X;JE;EK(F\N M:G[;]M,PJRHK,#"%'2)0.&%F.7MZE[WQ85EHW4R846Q-Q";9>;=0%S#F!](M:?[KKO#G *[@0!M3>F%)E?!YSNS&.+ZW0X; S;DK(=0K4;;13X!EIX\(BP\F M@/!!6$O(3I+7L,%PY!'N0K4T.G6^>\2_2IK "0(K_A,(P7H&MO'LX>EC]5K0 MYF).<|/-"HY\>:.X+X.|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{+"Q[$'EAZ6N2L6L"ROI&NRX?Y7>2ATT_C*0A)R[K91$<0#CL9X ;@C MD60OPMD2- <<.2I^ZVF8%M1ENE6>S#L_DWU0]W@.RZI\T,_\VM;N:FK%>TW2OW9P3\3F M61LUOI4$J;(01U$'.K>`'(,B_^B(D3+0LA.!AO_FS+67W $C&#KB-R3HG?@ M!KX80XAD:*!2W6BAE6))#N0#(DT+A[I&>+G\JM M\"!G@2-:AWS*T#RWX#-D M.H5AP;%5L/3#;91>`JQKO_)K'U1X3]UZ4U1;+5%/Y,:PZ$DL_XRL9#>:TQ0(M:R9PL_AHQ$M9.X7 A0WOD=QPTH'66:?+DX[&>20-6\ (^O/[2W@Z628&=A"RS MF7SZ \HH-?PWW-,59VT:E#BVH*F#WTYPR.6",QAON3D/4'CX'#]FS3A,'(OE&].'I<^M*43.3 MM&6.Z[@R?K>(Q,(34I_1*%"8$JQ9! (#,U4:Y[L==K1O,GNK"R?' M-V=@:P8.S* U1_HLC'7R<.:!%\E,N5(^`$'O5$\;]6!![IL2[W95:R MK"Z]?1>%\5[PS=565=&P^(K&".EU(_&1\?E@(I@/F!2A]8X!U%S/%]G- MI/JC6ZS6C!"2-"V#$/S9)P2'3PO^_EY!F'ZM3]DGZ7>/S]\GW%S?R&NRG7^U_MP@!G:ITG?E!ODWR#3TO)H*?/\1=\F6\U O2GDA(_V$L- 1['8)C&QV?7>6'&J M"28\-UT-AI8UZF]9D:W=HLX_B3) [P16]R/GC7AN4D(,4@0D((7OGRPP3.+3 MJ3(WVA0=$\>=6,A19'"TQOR8Q1Q=$7!XJQ95$"'>B"3E+0J0)5K.M'?@C MYYX^E:Z:V@#8#.H(W1\JJR ?D@551LUKL 2,;FUB 7YE)Q2=CC-!9OFN#.S M;U2,71K(U#66@D%[Y4=K-_^;HAA*,%,SE*08>IJKC..F!)YX)UOG59+0H;$[#6ION9+3M M9CS,= FV"358Y4X(,T]#!O*FU9)^X2B= {FE3%R/)268@X\RR:>F/ZP^B#>,R4RKDMJ:,EI?10118 U$^4]HC M6 V/;)"&'1TMPQ5R(4?==&U(D\_J3'K[>' <5VXD(6LT%^>_] M/',WG<42LPMR4WY? K_K4'+.?3_&>H{-+&_[N3Q7IN28Z6X4R&'6*0M#Y(<* M'[R=@,)4IZ:(+Z5B*=4]4WG@ZWXL1H$]#%CT#\<<*5%%S8H\;,:VH:IRT-J#< M-%7K3)OY++'@%^04Q #?E\=20^F#?HLIP*5?FT1B\FB.[Z7E)-I/85/VI &A MDJ_7:$6WZL\CC=B4/H>&L>?"#6J6_>(PD]K.%0=`AW 8.!" MC(FFK)I=8&6BE$YW+$4X*L6OAX}>CBPKK48(^_P[\&ZRZ("-0AYG87[7[&:/ M!LNT->''YXY4D'N]M %Y@ZJ1(G\4,T:W M*>5? 6)31NAA%U!F&16H5Y"3(R((>;F96+;/V)(G@^`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|R2*R+#O+W\-7%:Q$TP8NA*P>D%6M2,R HOAW; M^10M9XWCZ\3PMFJ4+>O0'CH>DI[6 I)>3HF09YX_NEJ=3?<3/F?@$Z(?60'F M:Q% /[:53"163=H2S)0&<+L&OI-;V=34)&-$!=@L O'W23(N;1QTNVEKSWJPYJY"'"?<&4UCC(E1^!BY"\+ A/T^ZSR@=U5>J MW2*'U9ZG+Z+>MC^5\Q.4}HF7Q6_(TV'3^KM.2H9PU![!7C7.)X(SNK;,A2R M^&B]_-,,DFT#@ED0)G1SB$K7VY>N4K2"'TRF-,_/K:+T9%5IIB3A-M;;&?7YU'N >II97 -1-(YN%<-6Q.>ZZTVKA3(CYH/MN>323 "?IYMBS]D^U M&CI? BPV&NNXE9V^?0J&:/)&PPX('D?^1_R+G(`GC)D-8I@CW^+:RIP5KWJ.] M)[;#LVE=<{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{6'ECO(@6++P4N WU/X4-6+W:U_$2]5PO

MQH"W^/S3Q;$J.XGDB.XE_&M;D[\W200L;4IK5/9_N;&6'H&R.SH7B_)X/*"" M=B.(U74'= FVNR0KL^[!TB 3,SI6QMO^3^QFAYA=&#ND MQU]>;Q^U7K4+1-2P81K3K(SY$=(NFKQDHF#8) M+EU/7I-D[O&9-E$AH'MFW,1)R!M3&""'53LRV5WQ7W-J<0UM--F\2=#}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{15RE56U-MU[7(E'5F<)F4SB2&SK3O&&(D:W$L -8FGE\C;[D]^.11)TR"+@VI=R<#L%%ZGK4T*,2Z;2?8% MK>D- _<06&OJIZCW%H427)E!Z/R&.D##I9124B[[S^Z)8+1Y#0'C2N"6;9A[& MGN-ZSK,,.NVJA^TAWBWM:B& O:#7[B)-_YOM')B:J;GSKI:_(SD_#+XY7\4- 6G8UUQ;:*Z2V' MH3OF%[<,V=T0$6EO=XI2_V0D'ITPL(!2\[NF(Y,|$NC6)9TZJ7^.+\UOOKT MHZL_? J"9O*^73,H990Q6'44X^(X.F0P*A=YVWZNC94PXUHGE8CDN=VC4J!&R M]I8(>?PF>#%K:G:IQ1FH^!8PLGV5N: G-F77M7>,^A8>?\Z.0#4DD9DI.-O? M;N/SND/S$RB6?L#M<0|0(/):.;(!BT2)8QADFK7PH:$!OCK^)7H@QDZGS>: M+)'TZ^$O&1AA1*B!#.CR\5PNQF6='U!VC;(.3_3<9H<-$#<&#C)."QCW- *%F> MXG]XT8#3;T);IE=%A-@@">O)&=IFU,95S .:W7*29J@3I7? \O.]>BUEN;=>*IG-,WN2*\PR^[6)6[R!7,TU9(=/NP+/TZ<^]GS)E!;2\ MB:7,B..GRGH<= <64@Q)I#?ZMF&CW:ZM]>86&N80'Z6^G/#3AC'%$JO &3N)I M!X)DJ5EA@T8/.DDH8P=+>"WMXQ-;[<%##\EN7?.4: *;E^#$3_:GA M2=P^3>T&R,;@P0:4A@R+2;+<>])D7C$V?+$F)9.<*K)S>?|F^'N^=Y!KS;KM M=8!XU?#RR'2)+LFR2KE@;(()VGY DR:'J3YS[K)HCE-_R#6J M95_]-G !5T,,^/N;=(]9NTFG5Y_.T2:^+6R7&=#[J0-3SS1"Y4;BB:S*6&>(L72/DX;8H M)D\^RS8'!P\,2.4H2ALOF]-UTQ%[@"+;T[1DE$2RXKX.XCP7[5YQ;GMI\OHP M$U,3+/3%S.&P"W]!5M8V/<,W*D=!(3<.DY_V0DGCGZPK-B);[]N(!;6OEYO. ME-'X>7IR/>F;;PA'3K:/V%L?^\KY30^=/72Q$@G MYX@&27C1>FN>3U? WW!#;XE9$G! J,LUN<)C-VC D"1[?J'28B1Q1Q M)53,D20->]EO,09QW $M-_5O@S&":' MU9$]_^H+F6=9<,+AM#?*CDY6 MKI\3H+|_N21%SAY#*%+E6O'3'SVG\4!5I@O0Y-/6'0S?M, M"X/!0.<|Z!XP*.2L];@E]6VKFZU-V%RW&T7GS'3(')ZP+50"8BQ/V7;X%[%'7/CH M]^QH]XZH'=TZTNAM1P3-#:>OQU1^#*0^85L=N(29-LXPC;EU:3-S?(F=MG!< MUYG_NP2T*;@L V.=G,YRXB"'>,UT;=:7BN.IBN- GEXKCVYE)=Y+8%0^.]>K- M8[1Q&+;XONVJ-A.2@6+)$0V47I!L,1MIQ)O, ^DU$U>"N/N M.D-9>9(\%")6 P8@P#A4D-2GG;IG*I?>M4:R-J[>\ 8G*(*9!L7[" TY#83 M#?5I@!&0A-;A;\'*%PU+[6[H^F*N"?(PG\ 'J502TO#(-$BB\Y:O@PM:;L+;'GEL2) +_<8RC.)P\[A98\CD^##]DO%\Z58L1I< _[CF!D=8%@M5]3YP(@U(&4D^*>WM]E2- ML2Q'C=QW@L*)]{.GEPWUKC?4734-FFV[3_H_%+|;O!Z_"?Y7P@8TKV)ON\,5 M9F@[TF:Y[(S'M3.(1W2RJ&F@- &H$\IZ'B5KHL_N21%SAY#*%+E6O'3'SVG\4!5I@O0Y-/6'0S?M, M"X/!0.<|Z!XP*.2L];@E]6VKFZU-V%RW&T7GS'3(')ZP+50"8BQ/V7;X%[%'7/CH M]^QH]XZH'=TZTNAM1P3-#:>OQU1^#*0^85L=N(29-LXPC;EU:3-S?(F=MG!< MUYG_NP2T*;@L V.=G,YRXB"'>,UT;=:7BN.IBN-GEXKCVYE)=Y+8%0^.]>K- M8[1Q&+;XONVJ-A.2@6+)$0V47I!L,1MIQ)O, ^DU$U>"N/N M.D-9>9(\%")6 P8@P#A4D-2GG;IG*I?>M4:R-J[>\ 8G*(*9!L7[" TY#83 M#?5I@!&0A-;A;\'*%PU+[6[H^F*N"?(PG\ 'J502TO#(-$BB\Y:O@PM:;L+;'GEL2) +_<8RC.)P\[A98\CD^##]DO%\Z58L1I< _[CF!D=8%@M5]3YP(@U(&4D^*>WM]E2- ML2Q'C=QW@L*)]{.GEPWUKC?4734-FFV[3_H_%+|;O!Z_"?Y7P@8TKV)ON\,5 M9F@[TF:Y[(S'M3.(1W2RJ&F@- &H$\IZ'B5KHL_N21%SAY#*%+E6O'3'SVG\4!5I@O0Y-/6'0S?M, M"X/!0.<|Z!XP*.2L];@E]6VKFZU-V%RW&T7GS'3(')ZP+50"8BQ/V7;X%[%'7/CH M]^QH]XZH'=TZTNAM1P3-#:>OQU1^#*0^85L=N(29-LXPC;EU:3-S?(F=MG!< MUYG_NP2T*;@L V.=G,YRXB"'>,UT;=:7BN.IBN-

B+2BY)_)DVGCF[X3?H\LB%0P&5&&!1/0)7^GM_M_WI?G.48,@_-9])P"A"N@&8@K*D4+?USZ08MHAZH;SR62+&0I:'+:D_0;IJJ M<$%UB(.KL.G104+MZ=H$LQD955XW:>A@E2[.'[*J]/5=#4^&+5O;31FVL_3W M7M-+YF[*L0['F%W\E/J!UNT\@M"=]4+JA-]{%LQ<,65>KE^NV M=/LX= [+L.H/CK^D:HUNG#D{)Z0'',3F8NKG1)I2ZH8N&+"\A#9?,SVIB-.;D MT2EQ5*_/+Y-#{C)UT_/<),_W9,7WEP_V5:;\),OK{ZB28KRLUG&O'I5]T9[M83OG'HTSKCL'=^SH3AZHCCZQX^N.'HY?F_Y^_$WR4!GS\P]Q^\YPU(6/UHY MP^_3{(N%TAWI<^L\NRO/-E,?<3D_%*A;SB MR){@>N$_1/%P9, [%XTJYI1+O,CBI46_"]$+17]&D&/]\J5A*226RMQTPI*Y3 MFTN6R)3TQ_Y0{2Z+_^X7/PU1+*(F&DK)\5X6X9TO@F/S0@IC6[@@4G.4O$HN M<@1$>)R>3; 74A_WP06I2E7%=#*X2*7CB\@QR&4IA49AGMMV$UP#7ETEPXB_M3>-* X+YRD7%Z!'W,E0HA8U+(H,_>\0'[E@4TY8,P+X(DIHRDK4_Q_A#|*P M8U\;BZZ,^$#[]"8LD_^%R"MZ#*9*N5MH\@FHXE*]8J.JWH>(.M$,9OG!C_MI<6>HN<.>*HEV!96M,RK<=PLM4=0+RS++FS {G*_O/M%'66A&!Y'&?]#&7YE MZLA-F:1 /+FR0^UD<1P09%(\T787=B_9(@?39&ZG>9OH5[JL_7M=>T4UTJWB MM+ +YSE*FP53UYTJ5C[.=+WT+@.'8.!7+EVT5*FFG7XPS)ROO*TK8<#U5;((MFV3FHVHM;2]X&"1NK/0EE=>AB?@')){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{3 ./ MD$-A#)EV*CXJNRJX2_-/(W=3Y(W,!#O\M7/*+3&O1!D'?)-GTS9/8+UGP&%% MPE4P.2K;< P(:TD8JQ+79 V3#'/GK- ;V>_[S#>W_X0?H3VXA18H7(&# MOKAEA&73)PGAZ<:5#)Z_N*FV3-BRY4;W"WSN!'SN3Q\=?.[<3 BG7=CWLE:. M>BM-(BZ$,8:$-SIY;7?BX$69Q<@9$'/?2]KN89-.,_T-]QXT!LCD;]PY- T\^&\T MH]QD@^)VJ*H^&R6AS;0<:VC5F+=V$-3;L/O&IEK{JG.K-)*D&B6'[N^D#.QIT07B5"34?Q.-JWF=K%035AOC:'V654P' M?DP.,D*,BCA)]H2@EXT;@N><- B4C>H[&!@>@8P&/L_H4P*F6@U*/+!T%P", ME.36Z+<>0Y1^(Q)HWI!G,C%IH[!T#Y^Z;&(2)(V@G"[%B<3(C*XW.!YA)U7+ M;7M"7044; <*4*L1I9!16<4C\N7",F#ZY9,F8H@W0#**\8KA4%/TSV-MFW'1%+35-$>98C?G\F D1\F\PI2I&U;QHBSM,ERIQA4^(=D)|C;YD&F3A^<9 M/6'-1*9QOC/YBC2-]ZV(X+9"'>86]N1N6AP)H2R*;HVSF'Q2\/X%]FO)X6W M96Q2U>*LGGN.R&Q'B0'K6][48)PFEZHZUT;)U\Q8_S6V>@ON5:AZB7CX<(SV MR|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}4[I]>Z\1DR2] (V;CAFN4P)XBH\&! MFA!HQ[1,N'2"K=A]'@6VNP MXE2@T+TRH0+7@(47-*S(*NP#2BYUJ+3JGA:.+3&#F T@P4D7!96U](!^L&S)FB5OM<;GGWUJ2D 87BY/?ZCFIP)/G-(S*1Z!K><9B01E'XGB8#) MZ_E/_SH;%TQ/O1-'-1#AR1SL$A4?=:UMF!7&=I6Q*5)4293#'/,,G^74WI?$HT.M%>Z8H;"3@{'SC(>!U!2G,4G8? *D2G M*J=.U*D0N +^("$=2]@_#*'UVU!*'0J;@{[I=(3]CX4'@X-4RXP'@M(PP(C$_2@ET[0JB))>'?2#!)\)3(4(_G#_M%F3'KHW63I- ZB),,0$[>]B/*265OX[XO+"Y1=*-HOXI0+9)$ZQ_^%4YT-LQ(MQ_ZS_M% L9{(YA84=/?M[]TZ?WXUWV[.=#OG#Z CH>$[F^Y4F 7+4N<4$0# M6P]352R:DF_3\)=4H%51K+"$X8IH]S<5RF8O*_,N-M6B7]7<.IAXA-9]IL#, M:"W" X]+.KN9V&_L[RK{0[)$X"P-1#\0GZ6UE*M%IG+1+/X][&MJ)__\T\^_ M+%*#M99F4WROY -$CI*6I2X@T+GCU6+F'_M]1?"+Y1X6-&OR0Q@8+P\$I[S"FW;U4NIZD?&%BO(T#\B#QA"'F1-7Z;U;8XIF5)XY'>_M- R)G/H6%1UI%=>4NF#'O;_']4_+_MH!Z-I/58A]%:1\O_H)5%K-KRFQIK8\QME[1*9WZ2E((,B356=8:9M3C(^1L M5;%W9MS5V_"I? E7NV1E,EQ]OISAI_ETLN"NINBH_LV_P,3Q+_M38L\2Z0C?WU?-JT+23T[9B<3(6F8$&6 M5=48AHOI*K1!+W[#DA**U]N9 M2<62F=_(=D>/U/(HM2]1(57O+=PWM3@\BRJ8]A09'I;.^)AQ }IG^"E^M$?), MZR%N^A"0@7[=?9;^^/MZO0X6B?IL:O%]%1R>-8Z=#NG^: 2GD9NK)1C%$0Z)CB?-YK)9@M!-E7A$*BS)OZII]#$O#3IS=A MUBCXP3_>^ILXZHELE?-:(LGSYYME%Y"[JA;&=9E@U1R"!,8,5HUX<6>M)LG M8@T7W@@G\[%&<-J3V4=-]@,"*[10!Y,MUK1W#}<@C_63&F+K$EXRX<+"UY"G M=[@AD%4,4HC1]>KWM42=8?W#=S R0:34; L(W^=']:+X44RX5V- .:*#W/0H=:_M]Z)[G_&8=&@0).]8'[;RW'UQ$!#/%4*B$0&1&YT4HZS&D[JZ?HZG-[)>*)-4 M7'XF4+IP+HUYT?;5)1B#:&^X,!7O"2B:%A)) M% NG2,X2>CC0P MV;OH^PHGRSVY@4+B!PWUUQKK3V^PMINPD:V+GI+SF%,J1V1F*5AO.R3DEVON M19""P1YMPKN4X*0,O]I62#D#1S!LN=G?R@#!SC^AO$Q7K? FZ2N4^>:ML]+A) MA_0MA^^]D^36[C"%-199T3MF\K@LM\X2?5+3TT\KEP U-ZT3,'(N_SID{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|PV?6&F6522K!<%)^:W0+(4FHKJ$>B#F #W>X75.SGV)-2T=,_8J M[P[A/R*/UR&I4K%XUPOJK@*J['L6)4E1RCEV)C/X4OWLAO<)>Y37*L_387J1 M$B0U*4N"*[4E:.'^H7'(0#'JBVJZ.CZ'P.R/WC#Z9C=.)_DUL,=1%UQ"$074 MN;#)$BD.YD /'_;7\.\M*13KJN^'7,MS;F0 & M)D..?8HU#C!P4&U.K3]H"G$TZ8#8PR07BWFXAM&%)IZNE,!4/3061)AGY<\ZQV*C-U4W>57R/@ZN"G35K? MPB'^,ME(R_]+Y;!(U5WH,0KH!*\!\R[J1LA"RSO%7*2\<4IUS*..KIG XS . MOADJGT"/NXU*&A)/,=SHB-.1_[#(KJ_)AR4C6@?^\@!{LF.F8"@2PKZPCN%C M=W"[G\3:B&9&JHRYDJ$[#'1<^),J$.(ZN\5%V=#EO+HA"CP1&J46)HD7UNEY MHD()VS(VCY7[>AV^22V*E7D((O.(G1BCG)RQ9LZ; <9N*G1GU9=+F^]1[B34"_M=80C;WO,"F"KQ HS=9G!?H;9;TC'9GP\.$6LH-[E4?[2^9MC'S-QZIL99]|% M#2$RJRLIN- POMG+=/M[^)U]C7GT[#>%BO1:IG]A$DN*DN>&I\HG1K-M% .:^>DE/YRW$V:\R3%Z(`M^\,2LG/>M+>E-EN+M-EWGHQZ;EG&1{88)>XGPL_Y'+[%I#;U7. (]SYW]1GTR MJ9Y55ZV_ZH4Z\L9?54;P\`R1&.?+OS\D3*;Q*=Y6/&9+(("I@N'5KXQL[2P=2 M2K"11D9SG>X5%,Y>-74[\EHF:-3QTXV9? I8SD2=F<*13H2O>S'\&G{|(V%W-MBH7CH 9UKF7C*,L:-L1F\5?=1HL?R+: W#E\X,>R*Z\7WX<7"+;A(<]YH?OO M8^)6_MF7:B%++C!CUJD1D9GY150*OKB&;>>64)1{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|R:%#8G- U^! M);@^)IT0[!,D]OG- K]MV;7H0/"YUZ+PHM?/+'NKTV=963#@(B_#IX4G3GY$KEHJ)BF8BK2TL4'#R5S-ZAA72@5%]P%&$NNZV7E>B"]@@#N"_BUB*$,F4-MM)E676OW &==>E'$_0!>P=(DH-M9LAZ;6D.VJWB8,0-@7-G{GC;H61GJ!IN-;&)>82Q^#/C_4'W/9_!+(WVAF3O-MD5)'-!<=S2H+EM.WWLE%Q\Z@:'& {BOFD+9"4#+A9))]*3ZNM,MK-M)O#^E7U;'Z-Q(&17_<,26]>Q&NJAOQ^_;_I-SW.Y'E*!729D6/-+=;5X/]+) M.[&P#ID)=HRW+K+4J,@WA?[=BO?50=PH>D M@0CDLC457_.XK621*!/T:_WS)B&M;Z40D^40K_\Z$JA'V@F?30H@*B9M+O3 M+&/2{]"_:>//BLZS.U.1,VRKO!&BE\A4,'@'K_9##^B?,@ZC%Z=,;? [;"@)2]HH.P*B;#0B>RK)V+NJ&W;ZZ/#[KB.4:L$PWT=9KKL>#(HR9E) M%*RYI6URHE*G*.V\4^2BTUX@A_?A6AAC,6, MXBFB'2Q2)? @KI5R2@KM+8R?,W!J7Z%P>KS2@^1Q%JDL{,0RQ MQZ1(2,F.1*&YW\MUS01R=(^NN+Y-;>;\?^'AFPW^JY4&-RK"U[4/43([JA(U!M'U:#!%@2N? N?)P(=DJW8E6N5*7&:%3NB(IJA7]$TJ+!\-+M=\!5RHF/YR$L[B3Z91TK/85XZK)NIX1*_M& $Z@"DORJF[FUFN:TY72;Z/>!B=#Q-YH",S9A.#XE\L&I.*73"W ME,-<14P.55MWS"\V\9 JK9F9?VUFZYR#A<#@)^WB2[J18P7Y3DDF;\GV=PF=X MVFCD-EQ)V1?ISC?;.V4:Q-[$):UE0UD:#W62+-UH(!L.!N38^BLC).MES M6;&"J9V/HY*0VZ#QX7'E'IJ4C9@B#Q.)/A[-WZO([^#T2*X]$?NOU.S8SJMFX M3%'E@Y(XF*,EV:23:5NIL\TT<4M?+E5>IRI-IILS;G2W9!(U&T=V H9KTKA< MZ!:.|\YNZNFZ+\--M'0QX4Y?Y MFYOAK78TPB_>&UVHN4F"^4QIC$>B8X5R@>$B >E?WU2A)'PO/,Z%$=>&B M@!GETE$_ROR*6I[9(;M7I- %OY:INPF*2,O#AYKDO)0JY*B3=T D0(M6[]B:M9KJ3'FTV=DYF!W+ ^8@)PGAMMTD(H:^90ID3V_-F'YR)0HL+Z$LF0S\ M7IL,G:A&%9<*ET96;(-Q><2. J4<,)PL!4\5$RDWW!_D2<>%%28L/!5.4#7Q M_0) Y$?7,>4*'U6)5T70CWN3?(X=P--F1="/;@*/W+[U(TN MF*$U7H*2>X<)XD*? K,HO%U0<{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|+>+S0G9[W,TV?KQZYN.ZV1_T73 M5L^1Z(BM:!U!$*']*>FRB>GZ6W5-TD-ZY6K9+1%"B7'):')#2+$EU=6U]A'] M9]FOR]\6 K][P<[4]_@^CKFSI>K#:.YZ%$C7U8XD{3MLW=NR.T;4LRJ6P8,5 MU6{)"LYLA75;];CL9-$+AO;C__O@>:!]8%362L5'8=VR'V#%DF2W43;>JFC.A M%,,!"YI:DAG?;-OR,%6;-.D9@$;891@!%TD_J2U_-R&L"}>A> *@"E+F$$I: MKOL3G4+"2X;JKK-\2E6VK_= ;5F0AU[Q2& 19:GD+67.3=$G@JJ;UEA;%V-A MT*KW=-L,;>8XJ^K-F72Q{^4<6Y\?#.[\^!G28PE8LK;6UFO.2 M/1&Z9!LV7A_J/&?R7BK/WSUOPE2HT^-"S:/%F&X%\>WUR@Q>?K MIV<8[#_=4SZBN7ZRK3;A)U]>?463E&;27:9^&IJ04|)R9HCHF7 DL+$12)Q\ M"EUR_>0M-R5:EUQQ3R|;XEUOB2A6Z'G=T4-,_ MK-M&?*

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|:B'&6#XX"/?*<9>E>N=+E:MD%#%QO5"P+\{'A==E6Z'C9O@ M.1CQ/S"A]:.^3S ./$:SX4[5"ST,!=L'XF$G$@7=J[/5U2.[9O%!TO*@%PV@# MB@FF1]>YP8]Y*5"F+#+$(UPX?#W;7"M&\9-#HT&SE)^B<*L!\# LN+XI$BK M5QKF4=\AMNH5ZVX#9F:/5DG3Y\::"DG3=V]HLF>90*X6?Q%*;0%4KZ,Y$"0B M*VTI+X4KM]^+=BR$='PKA5]@HR6.G9H-T"[TV>1+[QIM< ;HA(EF5\!451[0 ME$&4)]JY9G!U(?MWF4EY0/YBI2S0T>11/9>V\Q!7VY(DRU9,8!2K"3=@"[>] MHX),Y34IN1PTF,!7C%2H8UNG&^C458OA%I'E 3P@F!^1ADR<63>ZE--A\6+R M0Z> TU%U<\TBGJ<$917Y 8$#UV)HO'[O>H46]F[31H*567X5\|+L< M(Y&*XK'7Z'=!HW"8[C5I&M-*<[5?00L67%.7>Z XC@^-&VZ493A^-A+%=>LYCW-^2L_JW@2^> MB-%^A(#UQ^8BE=;%&(U<+=N+[-E3R\K]!JL+NOP84[*MNB+]DZ2G? ZJ5LE2!EGW54/,S_5SE681&AJZIKF*-\N"WO"1;J199B@3)4ZF, MM+X1"C0X;*3]UH!3OANV4G^7MD)/:U4N;/MHC2KOP#2@*06O:X{JS;A^E^WV M@0SSCA 5RF_%W0W(F5]C/3."7];D?9@ %8UPH&C_WRVU$4$43I^,IN:10EG MN82OZ:7_@'Z"X,35>YH*[PX*]ZQ$,5"^+-.4 95SF@.8D2:",?#M92Y^]8H: MP/K4P:R;$.ZR_C85DW84)Q%.Q7$UQW$1F+-K;\LS;?]K8XT*YA%D\?RF&A\ MC)RT+37$@^!3EX6O2^>I_&X7&<("+#U]_.I2(DGC"O4U?4(8O(IKM U M%9&2L8CI'=KS22U8%=T+GOM7RN?]H1^Q_OB_-4;___L3G4'5B_4[KC"9 DAE MM=<5$_0C^Y*0UL4=0YQINF'XCN9@9{Q?;J&?*@L>4OL1-+VDSUCE$ M+ ['F!- Q9R95JW+$!\KGP=)[?ZB]\QL>)*IF0N/-L@ MS4:C(>GZ,& M"F ABXFU3G/VN!WHW\YC"/$)N+M&8Z,:H5D;3PO_M+!4-T6C M#UKX1[A\/PY=/Y1,P$JO^&S'VE!TJ?U$C- 4SOU$BC)ZJ_^$KB!\X&_AG9_\M?:}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|%?:87#&&R.>\0!HFIY/P M4W&:GKE?? HM?/N<':S*%"8V?XXQ0#>]&4(Z*3E7M 2##V3CV5X/7NR.C*39\+\G&_TQVY0?\"!.*72&-L-V2_<6%,Q1 M>@W[512WPA\4>K(HEI(K='S$/]G_P%=[6.);GD Y2-S)3!XPK8J"<^62658W-MY793A#^7O}?3YT\F"}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{(N:? $Q[V^VJ-QQ6GM=,H)(L M<-0[;>S1?${D/?(9E8!'.B;6G'0%I"5BJKE=TD-P'));WJ-#Z/=R5]]HJRW-;H5#1HQ=Q.U[LIMG4((:-T30?K MP-8UDV+BS/;*,/0I:W>RI* MY'3,)S2TSO,^>LT4[\B(NAVL18E3*0;H&_,Z[M#7'HU+P9!BAR=^")@X)22C MW[C2.F3$L(WI1J(OV). 6=)S_C%APMADE(>AYQ-KJY4O .[*X!L\.900^WC7 M;AT:FE)*[X8'+A]?WU)4FQ&U5R7UI*D4);,4 XZX^LD% # M"N0FL^Q*@EQ@=[0P])N^+>^O{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|]E7\:RG,H!MBW8U;"@'0[&X3Z].]S86FD;Z@^C2K#]Y*H MZ^$CP;CMRTZ-,8/TEH.RM-?M&OW,^-KP29)6X5&GB!'T#(#"22>7_"K<->B/K"]#^A7.D07+YKM.!&UAU1XUV->-!K]1UH>UR M8L)UFD#]9MW!0EVK_++0-969-G>=1B7D)S<.L.B;KSA/9Y0S.SO7$FL*TP M'$*EQ5PK_32W'13SE//+FR-5Q^7-!TQE.,?AHVLV M$>5N65\/_-=."7+?T5-)3L]1@)!7EP87ABE2O9-[*'R(+[''4'PV'1+@$=ZI M6@-C<#!BT0(,)7\ &XA7!"FB;LK39%=1^H[5P>3OY)12\/44(QF&Q"S\/"A3 M2DC@>N'JHC8A)2- 6XEIA/1CRSM&;8![@H/8'/Q+],].T$#$-YUR?<)_YI<+& MHF60TXI'_A9B':ZX[RHBLXI,YU.)MD0+!+0['<"IH5,J'@98F M47R07_%LQ:|>$W2>IRE_? 1]OFAQ&8(B.,&/,E$(__8MN\.<.=Z0&?((L2MDV MA'|E)UR3H!L]SOF|CV%G13)M!V$_$9,F<=C!L5YA2S(ET=2$WE4:<;W?.'*O ME3>UC67[KZ+*FS19; IDDPB;NJ*XEMZ6[GGOW\3GFR=W%*,V\D5-9;%&.@B7'; M'_)56UW+6Q%63(13479G+$RE [9FN>9/4J7PXVF,J&$AL) OH$CT",8,P06D MP% Z8(A;S9DCRC- #Y:::MZV*=ADM*!((# ,7B:$.T1 -5\?4'45%_RP MW5C%!;\I<(20"KKE0#J5YU6OG*231K>DY:!9AZKWR#12U*XBQ6[USK C| ;YF|-- KYF8JOM%#3O4%!P&#Y M.G\!S.=%M 6*;E R8WCF+]O->BN 1+.V=:HVE^V& 4M_=S!(1/_N=*[>+]M1GL;IOQ\U_[%^X%[;AZM36[OF.+DKOK1SM#E M.,':]D'$] P[6S[/@5+0:+OQ[L\TS=)8E#U +V\]/"]5?"<)G(>Y53CC6]37&BW E M>&ZW^4QBW=WUB'MH: 8V]VXH::PHJ&H67C!V5H!:KM/_H>%VX;@=Q:D6>_- C MR>@.54{[M/-K@8T*@VR4)*RQFI1T=G;")99[RCXWBZTJ"+ET7_! R)D9_,/! MAT2U&5@,I]?. f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|[1M<.;D,SHA*4<)Y\%4^)29)K4RD>2F MG=HU6%P(#T>'"%7>?H[&H\|\%8==#3);KQ:FLX$N MPA5^C,F<(-:N@S&R7K5[D%/8Y M'5OLXYH..G/UBRW1!& [JJ=SZ0CN&C0VQ<@=*XW)E/(\I0VU]M6B-&W6I65PN M$ZIR9_&P#"U!M_++5$F=45$Y2[3&M6:PK)QL)NVA*CYB:QH/X\3IA*:@2E7A MCN=A1V3V"Y3&+6)~ D5HA9-2-,& MA1N2F1+Q4'XK*J3$M<5.4,@:]TT:F^4<6+8E7!P@,)A_Y+G@&]X4=0P5Z%4 M%]+7NO("4&D8-R) N%6]8.0Z- +K@&.]DSM 7Z0B,/!?LJ9F$Z1@G9(_M]R$ X\BILR1(48DR(A=%Z@$;^8N"RL B#(VST)EC]4&QYYL)6O%E+]2)Y.%- M--]K\S_+T#UI5.E'=!)GZ=E,,8'"@$7,L? +Y WFR#T%L3T8)]{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|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{'IL6L)03AIS'9^H94LT&4 MX623\#:/]OOO[P=Q?IN$T[TXI4'HH<+R-V%&V(*T].%4FG#^6M[3/4&'!4X M@_\'.K)\78>OUF<_WZZW=]NEWS3]S84^;]9W=A9{4]6<=G;][=;&@Z]:IS7R M.F$K<>___];]QM([]:S=:]W>!TW_CF;,VYG='-WZ%/[5><+.8T1&)}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

*&EC).GNVT\%+8UMHK+H1U(Y][_?(758MFQ34I0VN_(#_M'JJ#NW3^_>_M??R+X_QQ?GM-+KD;3B%0Y$(_5>"11Z8F1$V_(N+'^R!DH%/U8B+[>-\,F07 M?/8LV'BB2*_3VTN:)6_%R; +>P?'GNNX1^_Y>ST7G./>P;$##A[U>=V_T-WO MT@_C$V_H=0YZ[, YW]7@[*5W76=X?-1S7.\/'<$+G0\P_1)GDAW E-*L&N! M/'F2IZV)4K.3=OOQ\7'G<7>'BW&[U^ETVW]\N;XS35MQ6Y\%/Q9:/PV%G[3? M;>O70RHA:1{04"TTUP^8'\]=(>-MW=W.P6XG::UYL0W<62 5#=R4NZ>$HYYG M(+NKB?!]6[_7@CI.I^OTNBU"E1)L&"KH(P27,**ACR]&P9\A]=F(@8?X^] 1 M7&B0>:VH&((Z2]<@9]2% OW[](X0;78VG7&A2) C'5$Y- "I+H0Q9BT0077.7 M*N-YNJ7$IJ9WN?9M\)74=XZ^VWF27]M=7&HHG3&ELU*2LS21]/A)&0TR_M8] M/CYN/VD'6]W!2H\P[1U]Z71[SFZWA-AUKE5<- MXY"5T=.LP'3SD=$KH7ZK!R MM*SS!1NEN9<%U3",)+@[8_{0]H 5\S&0M&/'] CS1F)PEPMS!*(F NOJX8'>:?RI_3KU"2 R6IK_7\PXE++0?G+8D MXN!#9**WW'\/1F7[CR0L8/\7O??IL&SOD03__F.N]0OVW$D<4._BM=K\GN\ M3YAWVKK@F%JVB'[V[?9J?2IA9$:.-$VX)OD#?NJ8_[K$F6>A#C%4'JO+;9>X MA!*\F^"3N5X>TC%QW&0#X9)1"M,MCJ&59/'#Q'@;31IX$" Q7DCN,T]GX>?4 MU]/TW01 R>+VMG+: _,,O\7ZONZ_!N$-30HI&S)-DF9*8*XG8;M'*V'A !79O M HJAPO5!M\C6BF.O"H[D_8*4OS<=U]2 DH]N,$;'5\V'->PM.*Y6PS/.7O" M1V0N8(ODW.P7?(H]G& ;](@#77-8':)ZS%=>]*K@NR'"%:T!;?.0IWBKL)MSW M0,C/?X9,/=<&\ K65H3WJR"<%?2WOQ{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})}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|^3I='!\LC M//B? 1??/Z8=P\'H6EF71'0/\LOZSIXN3S]WT_='R0#"ASA\[_VWW4^2HC,\) MDL,,2B0$+XP%M$)PI6W2//S7^Y]RS,R(8,#+@*"X3!"]$Y"RP9P*)F1Y_=+9 M=/|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

{'4LMN5WW;6DH?XN#G0=/V7Z`]~M7/3B.+R`C`7+(#)'HA*Y;!-:$H0.).@@LQ=.I%R|4^M2-`^&#)447G%N"?2*
M1N^:Z=>;43DEP'>CT5\R@+*%71L\;J"8&'),^9$7=E>]=Z\?N;G_$#V_;BAH< M(`?R\IL?3XKK^Z9IRQG2RZ'/R\/2;_+_E>ZH73]WDT=*4FYE9,2(TFP04B*N
M--!@F7NC_B*NGH;W#4Q[K#$8N>'R :UYQ#W`MZ.]_QRLM_;INO^1)WY21'@`M=S3+*\A-"U_\}Y&R&+@EGTGY/Y$\ERMD4!)166G:4V\E.SB5P1+7(BTI55
K@@*@$3R8"WNG:GEU6Q/9&PLOV6[I$,W_#C`M\C"!TI+W|'-=D\_$S5?%+7L#E__X8].--^Q-O&V(0[4+V996|I*;B`Z,VQ@8`MH0P\SK!,HH.@%8F!.VX!A*
[>B/Z!=A-AU&E=VM1GEW&B9)RJ`M.!_L?//C[":R#G>'ZR:RCMWWIIO(DB+,Y`6W`C7JRYD&F70HKE8BD`,U@@I0
MM'91QX,M]U^+%RN#>Z]CGWTOGEY%E]=R_V4TK4&0(:NH[V/=O6>L$I8Y(0DS`M`$1*L,1]X0F3*?)@?#56POL/U/O6>Z`/T1=PZ@#$/268F&3:7(0-
.'4*B++`M757>@B-"1YI$2E+JIWKN(:R\>CWW.B8.8'?@YK+A;(4U3!L<2^6LL4>WV'NO`MB9.)"P:1>TOLJ66H`7+B*Q<$:US'>12.! D"5WB12<@8#CD=
<76WSEA9NS[N`MD=1S;[:8#6"^~8X-+$_=OVZF_7@Z:V;=S;G7"WM+Y>67`=7G8S^R7`23HB,N`M>TJDE7S1U%N*`E88)35OG.JNA_~^F;.)AF[W3)B
._MRI;H%?'N$NH==-V7`M`S]E__\Y$%W1?8_H7${2L% [>AA4H.U3?\>$`M;`.;5+0.XHL)=RK4A[;4$4)[53C@,92V/<1FP7'6\;4LT6+0)K+1G.);>S84
M[A#H:2CL"UL&*]O%VXE)8^LHTR{B.NJ"**T@DTH`H:`\1H=[1\;<.[?BJL\TDBDP[3'NID'BD)8Q$`OYSC[^6;/J9T_6Q;8[P`M+X_]-)4CRT?ES??
0;U!0044%8JKMZV[2O74IX_\,/'3_N6%YYY|T4%XGX++`$`M6$I*2Z0.D=B(4R:GZ!"H@`SVM0\UWHUJX|/K\0#2K%R+NO19)X6,0%,YADNT`M51&EIX;@9,"
(=SXYEY06OO[]URMBVU;=*E(KX[+5N>\`M&HP+FIW!"#4["T0&738;G4+E90DZ4!:J]SA=`=:N:I"`H4,SK%D&B'>62X]?`M<+
(7O@K$@:J(5X"WF^+@ZJ9=E3H;VF5'%$(W*PKN).')E6Y%EL@K2?1!NJ%`M#YI:VK?,[8PZ=U3K[@-SUC%'}4XN/I3"JZ8]/D-VVE_&2N.#"D1(C(@D38+,
M[\+3B6O]WA4=M\@XO=`M9J@2TCC-B0"1B73!$*LP%LZB]/O(DM4OFK@%SL-A1&W=#],;^VC60WN5K9R!
MC@(EU4'K4K3+B(44B'4.;)SS%**6U8[\E4!X>'6KHO&)BKD@*(*),CCAMD'F1.,,F.9\XR0(@Y5C_5`M?QN>AT.)ZMJ_S@PU6/0X;UHT"D)&0(>5.%UNW`81B--
.$)&]M3EXJ7S.5N`X`M1[1'[*B3&*UH@"&:\YT77_T*1RW$\.(9)AQ-8*[V:3KI*#A_?:DP(M<"IQK`M8K(HXX]-XVLA/W!46XG1MUFYNL]!*.0(2B;RTVT'!64
MHB8A`R7.@PW&6\_"UC:T$,^#(U$UY0]2=G'.ZI'EG%L)&'0+BD%WV7P/+B)3`M,?26FBHM;>V]O8O/?W"&O[=RMU;>`<-A,/_=-_.O"CY^@@_8;I-RT;V8E$'O;
M=;/2XWFSDH7[/*E.&<+&,E8J+7@!\5WW(<\!G//+,8#Y33F<*;FX1,4""^C4
M2FI\M!:@MMMX(Y!Z!03S[WUU/"_*8F=2!54NEG*$B82+GTR,N(@1@8C.XHQG`M0-':I\EO@;.M,H'-[;V\,F`S'>]-,0!.N^_]X6(G2;/$?`(,[&A$`0S%*9>F`M3'--!'PII.QK9]LO/G_WV_L;VO2]TW%?W0IA?9Y@.4D0K(O]f%WZ2TAVM"%_`M;\LL,?$&:AW>V":-EEEJXJR.Z-^6I(TVBB0OJ*$^B9#\#VCDN[;.!+Q.MJL
MO1W^$A7-BH?<'[]%5VG:C([#@7?:SR8)E9GQ1&7*B>0<=OH`?$&/6<=LX[4`MW.4GKO"<'00)&YB@&49_%=-7%Z"A)}|<`\S7H8^S-A[X[B+`8!
{@=RG)P"F1`M!:JEFA-'?1!6VL2I6,/`MS_M1S=S15T.,$=_/O`MO/+S2NS#{YS3%K>UM:V?`M?H5%A<`Y1S[ZXWE_F+]]F\|/"GST5_[4=@A-:QY#`@GIPP=$HY
M4O9PF&H?+#[,.N[WD_3>/JU{2D*`M!#IQY\H]58,(U^0-6%>-2,K6+982J)SA)0_FC<^\EB`M3)VTH-Y<34&-)%A-T24DFOIRW%@Q%RI<'47O/0ZC\K$-
,KF;/;!"0K>BQ)7RNO>>LLYI++Q)`M7(M$HBP530)GJY`M)YHCQZB.W%5/`F^.NF+&^"XLW3(PBSQ9EAD,2Z@OJ@21`M#@-LYT&4VZ&<5L(I7SUU6
W\MK+16V:I++;GK+1I[7Q+=`_BG9R:$HY`3!G^\`M5*M(4)$$@QZ)1V{-4!S8Y<+6DX!ZVV$4@OE01YY.TY74`MQ2HR#91?'T*>W63I-
Z#)NB'-MFS\H_"7!\KF]Y*Z*$K;-`O$EEMSK+`JTY@9`MVWXLOC>\O6/C8<]INXYI:Z#KI,3L22H6+$U*1$&$X.@CC@N*,TP2+84V4C`I`MJQ_XO
'&k]@/JW=NWJ6N<`?*,ER`M,DRGAY*R$1!XJ3/.#/]Q">>).)4,-N!L^GXY],%& #R3FC`%4EJY@D40EG:5R-L;]"]N>E;CL`MT.^_MR4&J+]]POQ5T#R6@IBU+'-
[L<1]U#I\08S3,45^"7#F7C=;2YY8(8PW02IMQBYRPN/\Y2]+\NU)=S3^H@`O28A9B`8=`4QA3>4IS4,O.<%`M,1N:N.(N?
Z2"&!D9AZ0CZHIQ(1,M3;DT(UZ%'"@P(4SMYOL/IR!FUWL6^T"*`M?:J>`^<-_'Q`.,#L_&\BQTL1W/HZU/OH<10H>DK"(IX>(N@\`I@F+`I3RS2;@8
M':OMV@PERQ/9=T&*H6;V:X4\U^4*5^4Z6Z3:<<<30]4*UR$<,?9R$WSTQ:GHIVI*_XK+C<7"IP7&V4+]VOD+#B=4SE"PJ%TO\$`,J'.H\%QGIC2/NY-`M`?
L*\CSQ?E?DJ-@Y:[.EZ^TTMJ5#Z-OIG?&T,%HGRTAFPA+I'2<81EL2O>.:`M)188=\/Z*"MC?32\WD?,7Z>VWEEX^=OWIW&I.:]U<,DB:,JS,X125*V41I"@
MM2%1)ZTU3]]D\V@>EJX%_-*S>K=FO\|?LS">Y>#/E[*!Q^_]%@UA:I8V_C1-,`MTSS_XR5U+L1(;-FNEXYYXA*3)'|'V?R.*;\W&?!5A7JT`MW\81;I;W?
3/]!ATBGXO6?6EZ/{GX_NNFZ]\W_7]#_PEB\W4Z#SJXE4IJH0CG`M5J/OI3/QFJ$5:%`BRVB8J-W\:#!A'AWO]X,6U_GN]I;OBV4-W;.3E\KG&'II`MHESBY]
MBZ51=TJEK,\2YGAI%ZP-JWYKV'8E?!H9^T.@&W:1Z*[/WGX>HRAY`M'$N?R?.5<%L'<6]_^K9/Y:ZAB_TYHLNL9"Q[34]ND$B>-7'HN9,8C.'4%;OP`M?
7%CW^W?$=TDH@H!W3N89M82HY$XB$!$`&.5R3G&`5M+]M(4)$$@QZ)1V{-4!S8Y<+6DX!ZVV$4@OE01YY.TY74`MQ2HR#91?'T*>W63I-
V!'=M3APZQ'==6SQHQQQ`M7$6FIR.Z:QW178LFVSCK>!\_RC\A6!C4,R0(`2Y]M&C.RX->N>9)6LA,ZZV`MWK!D;WB{UA'=O:/M.J8=^HCNI9-
\3C!O)$:K3!LH-R64*S109]X`U2Y204/M`M1/)#/W*YEJU7/G*YCJ$JEC=W;3_Z5+0Q'U8,X1#EBA:3,7_\(@)4#;A`MF(>5BC/Q6R\P!7\
[9\FE!SY.C^W^.J]8]W@&XH1_J\!8Q[E:A0+UIX6[_:-`ME`_5?!MHKN(:'I\VLG4E1XNR/3XQ$>E'.[DE-N*$J.QTI421:(4Z@?Q7+T5(4DZ2"'
MN@:19@_]]H&3NOM!C'TZQ7B;9/_13/!K)N/^N!2EG,S/HW()#RK:$>$-QNC<`M%P,$2LJEHEP'2:7>F!V?M:5[G$-B_XBS3Z?:UY#TL(\`$_2)T^RI0Y7/8XQ
MOXR,I&Q]B,8:";?C"Q"IYEH$G0VZ!DZ(;CKT)2`MQ;B)6;+[:?R?ZE[_B`%Q;YKLTXG,FP3\-.[^>M,"O)WVT$+77UP2*<]
(&_.NXR!6Z"9GMS/'--V9Y&Q3Z09I\.;JXLY^EB2(H+47JBDA6X`M&-I(/)- 1%;:T\1U%/*&QQ//M3^D&;IX7*,F(E`M2.*#BTD*16VHG?
UY8.6R:W'@UG+9=6SOPY0;KB#34[GL6N6R:!%D*W6'I[#Q`MC\)?YKQ$%ST18*9L[2N44BB%HH(.6B<0U>?"'X>W:Y7+!AUMUS'M5LME?>#)`M)7
D.582Z[FTO:*"1&.B"H+)"(/>;_`RV77LO7*Y;+K&&J`?70,1IM#A.7[`MN5[>E3\HJBJC32=F0>C2NQ7"XOXHQ[TE4;ML.$M12%.90[? >=Q>7BT[#;")
MM@3:R:A9!=Q`SMNMP'CA54SXVKTV.`&`ZQ6MX.4.:E@=&F)07%ZU8@O"_X)`M2!ED%B$&J)TSV@%*!{G!W=L./=50
"_*E>OXA0>XY/X*WV#2'!6,)YG.TXN\`MDE`!82)R0R!<0+JHAU,3(MM;&V]HUK*\#:OF=3T9#-L%88P%GY',;0^@DB`M?)D.4=5=O{C?_3)
(L#9%GAW1*7,BG2G77FI)DM6J%"92K6J?%%L)V$,B2WU+`M##"OO)S,/P/I9L?M!.N(96."<)%H6N[C<`[C2>\-R:@?YT'{G*N:?]E\)V1[&
M3<,FU0>%$L+YVM^].V.MMLFZ(:\&2*T.5=U:\%?'-W_!23,*"TD*7%>=-D0:*H@WJ!F%SAK/`M@E);.^?!:A1G]_G"
[9/TJC^U)V09PK>_$=FE_CMWXQLH[W@7MAUM`.\+&58B`MZ8:6W`7C4G`Z"L](MB81&70B(2E:.,Y"*I$3E[6[(NV&:7=MV?ZH1%O'@%O=`MS*54&.JY)MD+
(+)DW%QIT*(U:B!&07WU2ZWV:#.WKMU6WIA=1^FU+Z^"Z[YD`MFWT6.67"951$.F71B\IN\N9._]#WH@OJZNTZTM+RO/FB\/FIFT`M`T7*
L]6$!6<)3)BB&4-8E^%[]GP;R8S@EW^9O7RBNN@W);IRCN4X'W`MHQ4);N@$_7%I#`_AV3RD`K657)S+!*EUZE'C);'#RD\B[+*5\6_
M_\7[]`L71Q1LQ?/B_M`_\NO=1Y3\Y7`]Q`_X'`_V?R#TOW`_^^MEYOV+K1U'4`MSKM2D%IPYX^\?G#]!^'\YZK\9`Y.G-LEJ;-5^8C0?S2OO5L]O93Y`4/M^*Z/`M-
X]M`EK^C7H"1REGB"6"(^PS@5(`BI&(?=`#8"LTPPX?)FT65>`/-OZA]**N%(\HJJ^??`_)0UT]`_^^FG/`[X`MXZ`?:;G\ZZ[\`\EWW>"GS=-`Z1[`?
O3\'T`SM)>FZ4`-7[>/5OFI!^6RWD__M^Y?/W]B#>"0H+ZJ:%$P!J/*`5,U`W71`%RSCZA?D:,QY#Z"'D^"KR`M:]`X7`[C?SA.RXYRM11?
1>:H`__Z]=-9D.E/ZHF?"G&O\O96I#F*?ZM)6?\F`M5"PE!LUJ]`5/GCTU\LGLH179ZV659[IVJL$P5EEZDL/R?YX#]=`'Z`MEO"MCW&U@%Q@#[A=;._[Q]
(LU=.^DAA#3([P#J$/QYY?=([?D17UT`M`0_ZX?OP@F;)Z$>++;FE:LS)_4VU\E?0OAIUD0<8K\-*8(.]!'A"48`M^8)A\D$SL)H46[E8R$*].NW#1D-KO,@^A<
I^LS&J.4U6I=LO:LE<@K.Z.E`MYS|NY>`M<0>7?YI]68*VI$$'-?@X?9R='M(.?7'ZSW6(.PWF5TZ'N[-!WNEC|RCTS^[A`MBNWAN506TZH\9/"*S<;@G2:K)(<;
[F:DH@V+.QQ^4E;N3V)95YM/D/JD46>3`MH_G3D0ADI*-?#^Z)WZ257)S]^1ZN&V7#WG`M\J3Y^>57B>"GXD:J,$E"<7_-ZOPYKW-17=.J+@FK%]3W:!K*
(\#CH72*W!2C`MA*81$IGOIV%$A`MO'!6&WP=LD48=D9,L1]ZY\-K[Q+L;#C8H"V^CD38:3%V?E`X_ZC^K-!V-GBK
M(^.'7]LM^]'98N_LT'=^WQ#P_]H[`J;DKZ6C81(49ST6IF3RX9$P*2S8<5"5`M]>*K.HE^$8]4E`L:"1)EG"__8`QA/XM1DC""F$A#W`?2(".IC@8_6'=BI?NM
MEERIZIR1I?.+(-6Z;$V\W]^O'DE>G)?%05X,;[\+* 0:LZ;$:2N:,Z0,Z0;Y`M2D\OR-]V.N%PM5G$^`P)&\D[]V=#V^F9Y/+WI?BX*K^1I7@O:/U-L'792B1C`MZ\?
U4D4_EY*4?ZU*`59YO\MN!+LGT6V*L4=^,X0`7.)O3'RI!TW##9C96&BD&A8ZS`MP^?*V>*+)&RD.);?
[;!T&C2='9Z.0O3*H0VJCL35HLUBDW6VC!0K.,UKE=AD`MXY$98G5QF"KE(E^\6SV+KYY_D.ZU,RQ]V`MHGR\TBSB>):`C4B=?
\#,PE#&O_KOP[`6^:,43>DI?!5RY9Q)<51_N"[X_@>\`M)!M[`>E+2(&MI%2W_Y>_+]?[@OS#=_:@3"$51/J094)^IQ@73(1IBDA(4H1#`M7_[$4XK\B
CA!0Q'2O:VUQFC!^>\Z(,$`,S5SX`\]+A`WF'C_`[?'Y481L5`MP[E](SEB1X!#"NZ46_*:O\,,G)FW7\\:>KN;"M1OS:8U@9T>@E?.#G>G?41M`MX\&'^V^T1#F?
ME^.#5T_7CE;TIP-;IU=L621S8S\K*;;ZVS,`MH8WW2EB8G7J?A?0'Q3;(]5E!^YP3FB_S^N474BO+].5.6:QWXGO]L^3V/Q>1
MZW+`"2("RD,FCR_Y4]DZ,Q3=\O2W%C+GV_H,K]O+I+L?\+.&1) M1YM@,*NBO8!%A]KRDJ7,5-XO:R6['|<%]X+,L*$G@JYA#Z8?
NA(4Z"%HY8G%J8/EM,#T0TO[U(^'EHQI@HF0)CF@P-))U(T"2_LK`MS198.DE`/[!T^@&82`C&%]?+9;=4+_`NHZK2MQI=_;(VI,VN62V?S!>H#UY.*
M408,"XE-VF$R0+G$#4B67Z(XAQG=2-;KP+$*F2]\YK2?AXN@2@&\`M;MRUY8OR(GZKMED?.]])4Q1UUIK\[J.?6]OATKA'SG/UUUY&E;Z,.G%H7%9M
M,P=ZA:+)%^D[VO0:H90,";06@-D$&T)N7\!![\$%_GL3>2%[5Y1-,$X2T)>`TP^8A3%4P2A?`M+\5-
]H&4A3PU5>QXD]:>L^N"O\^7:Y4EM!\F]&)/I!FAB,8!0SC-7$09\Q#%`ME+LN3MW4UTHWO!"/J2.X'58]A-O@T5PM=9@TIX%*]5#726U%"K`ZR)#W>O&5
M&3@*D_<^.S,$&=D,9Q;/7*^>7+[2='(2'_L"YU4YY'F*$1L++" M!V"X2I,%W:EL*WHU2]E9[.K\LO-%KD9)VXM;C3\-E\A;\O*;.EU5?QS5#V:W
MC9_S0GRJQ6.E\6W46&6ZKZ4$[CPW=N(&?._+Z/RN,`:-%"Q](0'$>S==:? M[2L*(+;_786\9O"E%:+\>[E:/S5M.!K#\&&UE.]^K8OKQUKW+!E99N(#14%W
M&O!._]`I(>!\%76Z+)SKQ]5:MZ.$#F,T)-D>3X\2?#D[8%*L1ZB9!(^L/9_T`MZA&Y)[E:KQ@&DQY697TGRL=/Q;/HZF0WV3$D]+A(8\09SA!.*4>IEV+D8N*&
MC`F:"&#+F7.@I@X)*&+YI"%=`G1{4"1)]`MQHFSUA;E+*"9&YN,$7S.9,<.HMGRD05#U#]G#T*EW'*.IIB\OW9%B9`MS,IH+FP8;)"RU%X.3>9TV#F7#?
%'2V3#Y%S[N9G,N\ZE#9_>!O,WD/I,3!=`M^Q2PQ]CVD%#+-9K?C0*W[?%W,8!9#@=K?-B<'?86-#,.CZM1SJ1K+Q(WB+@:`MNRCU8XYP%F4H36-?
_AI&!">>Y_LNQ%;4ACSQT;&K3U@V=1W+#BZX990^*_7,`MR4D8!-/X)TKQ5!#RL!1FBXD]/NOQ9W,HO5.=%\42P.$Y]1+TL0CA.,T1C[]$X" 7.A!<(3\O;U(`U
ML0^R;$6YIF(GV>`!3"^?)'W<\X=\:?4O.'C_,;#6#KP7,`M`M,C<-#&&EEB/BM*CY8].TGS%:/TP@NS$3E;V2Y[EU?5;LD.^IG?J@J`MT].02!,B$CY*/!
(@Z9G$;D)#-Z,$XH0,01M8[T,(=#]&V:7G:%AC`M`DQV>_3O)S,D5BH1:,E'\Y(8UJQ^@Q;9A[Z"WMPTXT7ZE!!CINF`W?UX;LH`M65X)OL">1Z*
()H13P0BQMR#B/@HQ%E#TZ*#N@M/KUIT`M8&(_SD8]T;?*',-HVX.TI<&U*+2F!<7BS*@)M\@^5@?Z+AJF)`M=X_W2L]\!J0^G7QONF!]
TYEWJF{U]Y1]=EVGM,@9>8Y=T?YTEJC7#6X)P(E."/(%X0R`M&F0L2[7:S.J!FU@,>RV!FJP!U0Y,(Bs*!KX,&F&;GG5FCQDP`3W3NFLJWTR/`MS`GI;
[V6=Z9'N$Y7+6O^V;MFU%ICZ#5YB-7-NE932U7KAD42!I0FW$72%'+@):.[1$+`91'TS4NYJ.VIN!]FY(2^ZCW\$-IL=XB#W
M.$]516Z,,ZDNLS!&1/@9BECD.P\G<9#PQ=/!$-39^\@(6)N;/XO[O%!%@PXE`MR^9$GX9]/F5^EDK.A7XH$$[#!*4DP"A,.9;PS`T)#SOV;>9PSLR\TY-&!UCW
MH?VZ3/&%B=@ATTGB=].26P!RZ-G!HBF-M]DNZFFJ`MM[`W,"UG881JB[L*'"=[?+VWQPT!,V"(JB.+7WN(ZAB:?XXAJHK,MC9$51>>
MV=EP)B7MBV3BNBPE#@L6BB0BL;2?_2Q!.*84I9G/4292+PTS-^-,JYY!&^+4`M@;_SR:=7S5A3-?VZQ<1Y6I7Z&?
3Z+-73N%89!0P7#C00W\&WI_FT2;6DPL:A`MS:J+M,D_5"KZ+QI:CN)>Z;&OHA&$XOYVM#Z?IH@X@72#,PP`M0T0ZA]++#)]$;$^E@APQD!NI
G=JF:W%PMD@`C34MQFE:7K;9`32C#CEQY;2P`MG=^[_T_3E@I"M2W++1@OFO&8*A`U'-@?H913O*=>%BG'"??QL!`MJ^K'E"2/*05/0@&-WS_!"3[S-*83),8`X
M>*:'21HI77+SYO#L=)PHX2-DX`97CF[JK1;LN!##CMDS@"9/SI*P'&FXM&&0)B#"5\LE*:O=1]##8R#F>`M:9ZP%C@<!%2[6]N&_[`M?I&/-
/]LD=38`X4I]!7G!#;@MO(K]WB"!;ONY)&//ZMT-D'OFT@P_#Q^A\`M*.IFY-7W3UR5+V4Y:R)O;5AMP;/,37V<2HETI5BF$474ITSZKD$8^#Z3+.*/1/<,KSS;*
M1XO_F@?O1?,3M)KN2!7+9#S9[$;Z][SL$C`I-WK87F*,BJEE\2(!B1`,;69`M[YL3`@H.V8,X,1"W`?O[.!?7>*3CO)0[^BUR1F88%_(%/"9K$NH>-Y%-RL`M)
[4N\8>'MO9[9HK@BZC58-`,S.G?;TNJJ73O`I>TI`M#C#=`M`&"KGI.8AEDP?:'XU`PZWV"A[OA_`^+5EVH^]!-OK<;Z!E0>< 9;4" #PK`H%
MSI!#U6*PPL6!MW>KHI+`RL:4^2J8D&J-W^QU.\NXCR,UX%9DOM0S;A`AFL0$`M92*@,?$\SXU!9=$@Z!/;(7L{J`9^#0:.2>\^,`^:"PW9V6791+&^?>5]I[S+/:
M'NXB)M@/^VG`?JU8H#Y;!@*$@$6F-G&N;27%D-4+-`_"8Y!HNXE1@:>]X&4I]`MX2$6AC1,*&:)7!^@@N`H3*V'U#&>+5=_=!7+#>Y!>3\OD'+
MHB=ESI/9C:(M`F_4.#IDD++F1=+22F;KZ]=M=V=0[ONSFD'TTC,AOFEZ?#;X@+P`M:A'* +@3KT.8+:=]$-.\3KH.V4=.N=9+YIV1?
A'UPXKODK0A$QN/7Y_ZQK#?`M)ZD%##9S,>(+B86&T1"SP$O"83LN=,33(NJ@9U.&;L[>#.D/4J890YOZ%"]5=
M250!\W59_OSRJ>"@&:BGWIU8G#J0_0K1ZDI%3R1\Z3_S-5G]B]=)VL=EZU*R`M88*E0;'=.:=#Y!D)V,D%9Y.N(7+ZHC7XW,QE_5T[P=]$50M^7? /WY\$4V/&
M5^JCKLN@0O_17[_H)YY%B6Y%YO^@TVR{()YG+E10%#DA])-=$F 2.;&R.=9`M0EPWQ8D+J@M]77(F5BPM.7T`MOB,,*M78:?
7QE=.C],K9T.ITQ&Z;M[:%!&^@(X'5;7OMO@5VB/ES=#>PNG'6`M>B#8Q4%=#.^"L>|%K7>_+8C/HS0)/.1G'D4X)BXB;>JC).+"C=,L
M"ACH6E87\,1'V*YW/# !59=O>B?))%-R`Z7P%9R\1=8L2RE8E4DA9S$8%DFLK`M*U47[+S9J4!F'&6I0M^_<)[&SR^]*1,?
2_&OM2C82Q/P3/W$)5R%A:,X19B2`M%-'8"U$B$D*5!\'8!S5QU8`YL7[H@76V<(U"Q3K\TU,6EKD"TQ-&##&?LC%.`MHNU9&P,07V?

BQC@+SL[=T'C5M/1LL$VD%{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

*[J&XORV]0@KPI^+;^O&O7;BJBSNZ_+@JKY^6=/E?95?#INO!0!>>VLW9 M6C_O'\224PU5;N7SZHQM!Z1+#_N:L?7C>DE4JLW/HA!97C=S/ZZ72^=6?KO5M=UN5E%1=<^RV+XNBC!R*0)/P!_"""'*

*O$B=IIY@6!H M\[F*IHS8\R>-%[F@2:M:O10/ZKOT+#X5;/4HMBD"\IM6[:4([.(&7T1]D]V1 M[[?M=)#K6EH\=%VKM^Y6MZ1I:)]PA#(: MY'DH]?P089=1E'#L(IH(SW?#6*1,.S3&F?7GR>UH0#H;F-!,CGV&#"M4"V3" M%"" 0H/,C)-T7)"*L,_>S+D?)XDY3K8X_1C<,7VW^B:63G>& M"!*

I5.^4%K#3009'@T[2/>[K74HR3'),J07Y6T,D&;E4)Q>54W3C&XSOWL A-+5 ?748"OH.&4\U2/BY(5@F'RU>UJ[ZU MF],A19=9->[95>5)V8LX5+?728IB M-_8SYJ:!*T"CU"Y':6(1;^\[J>;]*#V^%|5+3)QJO_3B_/N DSO7'PQ;3DS MU#|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|&>.L"FSGP9, ?UM)\6 MQX:5FFT^P'35D*$V|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

MNW1+SURV=4S4<3G6B6?,A.:SJ"HA;IY$*5W_TAEL_BEU51/U0+%N"4QI&+1.01-68V06G*Y'G)/<(SEJ6A"W(13!&9 M6!CE-R.$":$Q1_4$=@X^P82[Q4C9RQU.3H/4E;-%ZTIY&51(,SOG5\Y_"5(Z M-X7%2.V7\L22TC!&8U8%M=V@+WPK8@3;_ !8W=.'2]&'EARJ6]MX$GSWZ4$98)&C,3,#3S/K$.N#?0F5G+]EK"6.O1T_6.A#1GV]K0)>_MA9W8&:E:MQOSX?:;|XXLF9H>V00N1G;@@K:]-AEEO:NO%>1>J>FO3<:>[PEL M%8IA>?]QZL_F;6!!0QH$OG!1F(8AP@&.48J]% 5I&''AAY[K,U#Q\7E8(,4* M+RW>3YY1F4C .N,!+NDI-TNTPS259L[0U>33$36HMU7X.P!IWK+><9/BG8U M7C%(TMG8?C?95_&LC)*O@I&GO%:M0AK-2HB)L4QQ1+7R?2<,KCE&4N!"" MF%%$/$)0&O,T\0+N!E2K6O=Z =IF #TEC@;!W6%-,S"Z8\ M^GSD]'$.L7%ZZ#1E7M,R$) ;-"DCS?*%+#,4ED5DS(_!S"+XJO-E&QE3O)>! M9+Z*F3UV*]DMRE+P#V*M[55\LZZKFA1A!2D'_B@LB"^D$>QB*F7M)3X12&21B["0;E@2QA2QA$<1)EG@4ZU2DG, IHYL=2"=#4Q' =6?X'R2)\," M;(-2F,0"B00-<1ZBQ&B*\|D%9QOC/$1.?X[SX',&Q=K-V"7Y{O7WO%IX ::"

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

M@=]PJ$ODD_#EU\IL,>@:8VP+!JP67>A2;*_X8A3BW$48NBPX48RA_>K%#0@_M?%?SW+LRKT^/3TH7Y:RKV=UY1&8="/46GUA)+;4Y=;6]24SW2(F''/04U> M#FN-6=@(TR%@#DIGTZ:;>3%+;#0=U(3X6ET'80P9:#L(7,BT4<_0-.F#:(R7MA&'F,8R26/7EBL,4$3]-4)RI-L\^29D'\A\AP&<,=1TYB$T<9|?!]JG>.79I M^CE1TNPA!7SZ^N5;I&<(3<5XZV[BI,RR[,,K+^-0-E)DR!C:BW&B0[W1;ZM0SL'<,&Y3WWLQBAS/8&PAP/5?;ZIF?)"'G.68M" GT%H$VNHKQ10$F:^F,HK&,VHUG39AM2W;1$>IR6>&DCH4MW

*M$7H;../>F%\47IXM.F5W(4LLM'[#>"E>KW3Y:(F=Y^\E;0& A[/N2B[!2,6? MEPW,]Z06NM&J4^].K!EWP!P%33_4=)+.\4C2I23"%,Q=29K""^=[&.[H4@Z)!M0V09!7M.+CA;+&>(G'ZH9O Y,V/GBZA5-L%MN7K.N~ _O_P|!?13T0ZFWEMY MS>K\N76H-A?'4>9Q+R$>$J&;(QR#Z4X2%'-DBB.&4W2!-0(H[""U-=**G9[<8X+V*I?(@0#&%*,<(L MBQ!-/(8R-_;]3+A2,X$@@G,4.4>Q$BQ$L]FKE! ME(%N7L_ F35+K.OSEC>0S5N\G6.9WLEI@1$PP=Q/*

*VMA7CDMU$GRODZ193_7 M:P_*:^5WG2)U(*?KY./P_##O^J7ZS]*7EWS?WPLP)E:9UZ?.OSUK[5*#VHB M?Y4C0:^KN@D/7CD?5ZNZ6$%"8N)GX:=$^0,S5"IM%)>6[-V8[* M$;+Z9^78H^9]Z]?RN[\ME^WZ**F"/#<3 H6Q1Q$6889((#B*L/1(HX!R'X?*

*MP_(4G.D/RP:J({44_V,H*QC$'.UC\5*2P<=B2^T6XB1]I0:ILMA^_A24V5O/ M#Y!ZJNW\T.-3)!=]564L4H]EH0A"%',22,N7$Y2*+$#,=R,OI21*(] "@LX M@01_EG84-ABMIQAF9A],B5BN.YLKTO#$MS2D$/4P>D-YB2 6PM(584O#W8=/ M197+)^]*?*

*KM:YDQB<%NNV#5?/01>P)*MPX4MW)0X2],$,4XQAA''EA&N*44U#CIF%P$YM> M.SE\VG;UZW5^O"_!TPY'N*>G]NSQ!*;,1IH<_GV0'?;:'.Y1.76CPQ;8VVAU MN$>X=K/#_;<,*T;4O4Y[H_>^C/%?=M5MKWI:?YXT'B6+TA,LS!(0T0XB50' M-XQ(&B4(QZX;LS!Q@Q*

*4+8:C,+5?)G$AF(C2P[G,Q64]W3_LUANESG1*9"_J]6ZR,,6;:K0(9. +S5L(8,^BHY,5\)7B, M3HV]L$7_V&)C<^H\S93PL9Y4?,*4R MSHH)$@&TZ36*QXVO/EL\3IO0?CQ._Z4)F@5T]^,>=3.6<(H(9=(OC&F(DDRD MB"=1YK,@"XB;66L9,$LBP0R- T"Y!98Y I/ZL28"$V0=_.B=HZ? :V0C %@ MZB\PSY2KD1DFO8FO0]+OJZ6RVQ5]A<77'0IXRE!A/ 88XYHFZC]>@:G74U2>'BVW,7*.OI!/P MML9;9!X!%8TV%B]<3D>ET_K$]5X+(/(NR%;JZX[ZES*4RP-'Y]@5@8"):2 MB!(.S9P]!VOZ[-GC4A.RA6ZQW*3'/CVM;XDI,/5\]NS$V0&>L/+DF+]IJD]Z MD%ZW N68Y-$JE!.OF(FWU#-Y=9-=,Z;]_%1<3*6VO+3_[D(S:4;4(H M"Y0$B.(L1BP(_9!@'KH9A4BZ'MB)A;Y!0EUDW.]'I)XU2 S19)^>I-MG"DSH MM_S887#5IH^],+]W_Y^DLR:,<$OZ0!/HK*H!QHA#+0%\VTQA'%@=7];*L;[) MWN?+M?RTU4X](V411ZE@44809RE'F*8)2DFB)AB0A'A!H"9F+N1:=*6K.X 8 M0.2ECP?8^42D\S@Z\V'=-E!1EZA/ZZ;K02%J9ZF2R+>S#1Q2UV5.UW73MK9> M[=VXMH7"TL'A+6GF5@ATTTB4)@F)!.(\]1%F*44)IP%RO4AD6&0)24 !APFW M[))HP?]_-DSO@)EP&V GS9&3W]*R[6]8[?OT'8+V#AQ#1E@Z>:#09SV"#%ES M>!:9+@._;/VE>,K?YQ6[RQ\%_[@JE5_]&UE"2B$&EIA8%?WRY?:3HT!++;.6 MVJ7!?P)&>^WY0K.DCKW_5.L22\4M62]R :00((ZR6/&A0:W2Y.K3N;-*>]&L3U+M+U1U'C?,KI7;_D J<4.7^7V;W[L6GXHOTBB]^T,LG\4QJZ)^]!8LP4F89M+PMP$F,<,8S1*@7H(B&D1>D$>,X!;79ZL&=.M^VPZ(Q%O)Z,U|=>E*>[SPV& #3 M;379]6<63, DF/!O^,/#X$K95E0XMR3G5\Y_"5(Z-X7%GNU

FFVEXVI"G3_'|WR?BZ\ZP&.)0)S\]BICPX01&.6(C2D+O(M#8C'8S=F@4@73VTB7$W*>@X^'8+3CTZ)^[PHE%=&R5(E*%_,'C_V8H0@H(0MNPC[DE%4A$Q^GTCLDB2E+(D[]GPH^'S,V0@39LV'Q(:VQA>]4^,R2F$'1+O^ ME7-]X'S?$KL]([_39#/A=A__FU)PD\F3![^DG3FX;FV_GM08CZL]H)=>_YM/:\6(@@2,PSK)]Q[A<@; Y+.9=-GD9]PRYV->2/"Y/-HVW0^VV+AR-EP:88O! M%<(PS=8N#?-)/]SJ)6UZ2 M9,KTX%*R8X]26"2(BX!Y;A@)/P'-TQH#.+&$=^";PJ@& 9A4C[)+3[IM,@$F MY3WZ6]C[45I;K6*AA%H2[5%PLXJX+O&'HJ[]GF$;]_I!-&&A4CR(HLJ?I:?' M5H]"-;7Y(NJ;

*[(Y\OVW;GO=MM;M5:ZDMN,MQD ;2!:%8NB4TDF>]GZ4H$:E4 M%4*Z=%D(\=DNQ&<6!V^E<&PNE;9(.GF#I?.#NEP"7@U=N@4IHZZ,I"Y*/%]M M@?R)9*I-"/,B5WH\"16@BH4YMP"NLV_>%O/U5/R,+(6=_"TW]S!S/G7<5,C] M>.6H82+R@) 8JMR1=@#"U&Z,)7[9F@5P(3;S#@NPP[JC:0*6EC4[I=3LY>:FMZ!=!U&U2T[*WJVK9IBH_N^HC$<0BC ,?T=*XI05#%$_H\AC6 0^<2,1@'(< M=(!.K.QV,Z>OG"UDF(+3BIV>%K/-$)BJ.LF+'"%$SB@K-VJ-,K,!@;7+)9*M8CO>EE8[VXT(6?!2*W3*0S_5,5, M RRV7.TT!&J*'N'O5BKO>;U:5Z?;\'I^>QE]4WY>20K*!+WL0*?(>H4@CG&EU++#2&(.K5?/Y#"-&'%\K;I

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|ESSD7!OY):+$*6] U(AWS&[J;4.)\'=KA

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{DP]H?H0"T3"Q$\$I7[0!;+&,")9?-& M:C;GJ8/ML"UPX%72&-K[]XI@ M^?OS7=C97 ?I3T[_*BS&^? M[$X(/T/"97=+

M2@.9"AR)@J8BRWW($:D%U76>I@1>JZ7ZEPX:P!9"6@S4.T^LLP6F|B]R9.8U M.'A_M#^=!,I U-Mƒ#:0%<|IV0! VG+4 KUL?!''A.#59XEZG2>UXE_(1B51 MO=T5ITE4A_2]N=(4)"XHXB+U$4YRC#)>~<)2I&0><)6'!,^#EG D>KA,L6JP\ MM;/>5NV1 %_:&7%<^R+/-1]A>NB8A0IJK95V2"E.;J1L6KT O(9! M]BX%C;"8^J+P&E;U7!Y>M9QY&\9%T\)5Z=+U2B6OBQ63*Q]Z<1[.]B0-<1%1 M@@0O(H2CD"'J2PV7^;3P:4@3$B0@XP@$WK65=$"F,0VZZ,";+0+8]FDR.6,6 MT'8:XM/1_%0WMI,1&RSV5P0 G]RY(IPQ?9T5#5:YN@MLVV O* ƒ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|<(-M.0EBU< 687E*JER4&.6%B%"1^JF40ZI&/D!.3BVHCL6QQ:&^?B1'6,"..53T. MZAVOUOD"$]PN2XX1V+O!]F]L0#1;.GCU8$YZ (/8<'H0PUXV&.E]7ZXW;_7B MOAZ]_5(!!2>,QU(SB$*5=3*"_E!P% 4BQGE0Y#G32G4=A.(\+MZ"]<0.+F"J M]476#(N\-8*AH>X=K7N0)J.\+Q(-F.1M@WBS0=X]3+ TQGN,IL$IWA=?GFZ(M]QC^1S.\1Q^&1^6_KE>_2H76WN]]%!4K%W7:/W@NSOA*CK6*1 #}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|-MMI!KYWD/WY, (_/3Z_#,!O'F6'ANMLDQ-_[WF"2X<9UU*S7SGT=6GM]-MXW50M&>S3,5'2\;/==QU;;;K(9H6JY^Q(UA]7@]C< @*H0\@T*Z M/BJN]* (I6F[B$KH^4L[KYWJ?,A4C-6JI?%F7M>C6H9(/*N>Q?/NPYF(>)PDO M**6(Q1E!,,D21#(,(\'XF2!Q0GVB929IPIM&T(Y0F#61/;\^06M$/(4)5/Z& MV:@KD-.88R2A5_"%0'"UJ+U"DH:?GUBTM8@]EW6]UXS[CKZ4XDF>VXM7T8Q< M:QK'GPXS\',>1X4O4! &/L(4)RCCN8]X*(_;B&##A"U#QK"Y@]TE'!S2\W]85 MO+^Q'Q_TW!477(I@6.&-"A,- H"2+N]7JAZ8*=ND0IB1D_G5-C(\-#J0\FE M)WJX@^+S5+HQE&/WW(LW34,_>CH"47CH5!S8F!"^5 2-1+HU//GB|<%WY*E M-TPG*.,93Y)1@/-DJ(9P5 MOG1(:8AR/Z%9[J>4Y*"#\GAYYS' W4#<9CHV\+;OA!5Z9YXY@3 ATJ?-(*&V MCP1K6;-'BT^<&MM'V'G^:.^]3AA?KN\3[MKA3K? NY%/^Y%2OVUB:*)0F)1)$& M*$I4)Q=EC!(_R5!!_2@308Z3. !=LH_#=*QX'<#>'K)A,*<]7FD*U&;L0 MU<'!BBF3PI\%*)72CW# ^ A;=# W@Z MZS%2\]2VSA[@:3[,&5>5,R"J;1D >D"G-0Q C#@S&&!OP^/:'Q:,MYM2D#KR MZE,>I1GG*&8IDQ8YE]8"SPL4AVD1YWY !-5NN=A=V'5H2L5C%2Q@,/[(JO&H MLRE%P+"2'C&@"'(?YD:AXJ.%)HL)]Z'?#?[V_MWL"#WO:WI#57 MYCY*25+(8U,(1'T:(1H)GS 1BX)'D&/S,BC7XM) \Y8'!#3'Z6AP2>],M$,[M3+#Z@^A[?^S@6CSZQHFS=-P-)KTB!\G^/18TW@#'F:],2H#"TJ^.R#5&,RO MZ\T-7[^HP>'0^ MJ1T+, (N'MPMN[DTWU,BS'@+*MVI^C<3,.U'3#^7JJG+!0D1HD@$<("AX@PFB#,PBA/B6!A CKE!V YUAHU*"\PC(CUL 88";N. M8)C4'UKJJ-L>!7?FM? 0I:&&L0:+M^%)>UTF^6*\;^ 5PWSWJA*;_20+ MZA,<)'&*,DZ(E%B1($H+CCA-:!Q(MY6%;+Y9;\A23V*/5@?)Z!Z&_G6E>L5C MK3%*:LC [/$C7NB)J#&%,*%LP#B8V=&+OZU\Z*.UITU>[B/K+-.X]Z$K[V/O MB@^D>OJ\7/]9[1TYYH=$BA9'!<]3A$.&42;%"9&8RN\I." (661'D0U*2BK$/TJ2AKO6,8F!;RX!=W+T(E M-Z\>?U.5;+LHVEM;[U9]W(I_"E)^EE^:>8#C(LRE4"=)3!&.!$%YR#$2&$=% MGB9X0!C+WV@L(JEA C^- TD#P!-E[0(@QYID!_;0I\C8,:,C(*CU5 M8H,!,)5A1CN\;=L(8,8ZMUT",VWSMA%BS_JWC3U_36?%_3I_RDR^.G M+F-:_<);.8(UGSZOEK2A!L!)-:0^ TZU)N!- PUN'[0 M14^CQ&>!U*4\"2C"&(H3 MPK#(0,IC!)YCO3'1X'([(\O=*8/Q8>63S2BW+/]CT'ZDN>27I%[W-3.!ORL? MR6KQ7_49J0: K)<+WHRG6O% [^9T1[43HNV+?%W=_]IK): C\)(BR!,6)*)!4 M E2Z&FF"\C2)PDSZ&0G,IK'"'E6/ET<5QYAUAV6;$'O!420&'MLX'5(WC+G:V M34\O3;X9,.TUU3Z 59U5OEE2B'9PFE1M6F7CJ7*UN[AI_YKO@FW+VA^Y>7R\ M>26+)6#$\\ 2KH-8CX]E';[Q.H"J]P*TSTI_Y<-ZR2+1,$W3VP'G@(/7PP^K MDYLUB+ZB1T[_NA,WS!DD[KQ[SO#C<''\])^;MYL_2U[=\''^OVMQ\33'L>76: M]^VMZB)C\\AWZX.H+81^]X\)W):E&ESCJG%@ARDBH^M:,3)@&B.D*T=!C MANY$?^K$/"QPGN(P1R15;>XIE;X!81D2/HYC(C!-0] %S@4XCB6NJ2E8[Y. MEG73\TZQ+]"(O\ L3;/\>A8 #>V+R4\6;>9AHFQ9P1>@3&O7#I-Z9JF./&XF MKU_%1D42[\OUZX(+_LO;/RK!;U>ML;MZO- E'RN=4I#EC28%BG%.$XRA A(4I M\FDN?%X4*2ER2#&0/FB05,,KA20BS9W\2XN*&C)?[-#H7!; I!O 6CV!=\,P MF Y0O*JO"'X]O/I)(>(M5C] [>UR\FW&N@94#G &6] 4 *0]!,Z04ZUBL(+A MV.A_K'BY.?'OL6.SZ+N[%!1R?]Q*DD##5]_D %C@@NI?N<1O,"LDPV6[&0O?2 M;-6-'27-? IT[ZK3#H > (NQL]O/@P_'.&35?2,>)U\[LE>9S'/HTH*;@ZID-5 M;X]1+H(0<9JR(;%B,):+7Y2I[%/*!AEL5Q@2C+1600 M01")TQ#Y@C!,_$(24\"FB1P#KS>K]08TX72(,QK&GRVF $\]&#^< M##O5(-QPT.G0RA,..=4@\'C J3Q*'ZG(&M'"%K]&(V5KD"D^8QACCHWJ1-K;7N%&/P M)FY1H4G^>9*W1<-!9T"];Y=BKOBFY!''_X)M!%=AGYM5_4-=L;V2I;I4.YQ2 MJ2_"K& 8L3Q2$_=XAB@)!/))1B.6L)1Q4)&[0ZN-4.+D4H*.N!4AS>!RL* MO9KJPRW38 IEAX+\?E8]G;Z. ZL,J_J7#B[M:!,W$[JN8(DMK6. P,1ZR)Q% M9YKIBJ4, \6_*M?D(JF(?9<[4)CX_\7';N30(-$CE=(E-0:>0@$8*NZA7#-0 M?!W1)F'B Y'>@0$6X\.7*3*/#O>L.6UL^#)19Y'A@4?M=68-6UN6)7XD@B!# M<9+(L]X/5/IV[J,@3203$XZ#$-1N8@"68V%L.I.&UW=F#:_NS&I ,$P0+W=F M#2?]S!I.UIDU_%$ZLX;PSJRGKQC:\$2=PK6G\'6KU!/_4#TMJMNJVJH[VP>I M,2I2FV?S0M"(''E(@)CA'.)6_$3_C*.(T*WR2AC2'=9@$ '=MM==PO44-V%NL MO,T!M/>3_'=5/P#U]R'\->;WRW.2;S,7* U8IMEIO.)";>L MC% LT"!^, MW&HM)/YV!!RMSWR#W3%)0;SN5WIKI?5QNR_\7+_5DO,(/DAQ+$YW@0!Z6 M.8Y0[F<92AG+>1HS'/M:K>.&P4R3CM)"GGD-;$\"!PX-'L,S;(Q\FZ::4 M&R2K#!%V1OC+X]+778Y^>7Y;K-R&^B_)UP41M4?]'"*L&[M.OMF66]8716L5,? C:O%?@M^+7>RT)*FD)SUJ.!3W2_YXBAUF\!;>/Y3G>%CMA]^4;1%4 3MZ/:-750 M5RXW?RTJW3O'GE<=Z](.1. ^CD L\+U:M+R$_UFQH=XEJ'=_J*II*AKM00K=X? M"KHU7^DB78:NT?EZ$WI'"%XDY=GPN/P;W<]HJEK<@I ^+S5+,:9_Z11[FB-$H M0%CULR5=TC>EOHFXV7=O-M,E-E;FIFVL#; NM5'9!W(KWL?>,#Z0LE1E]8VN+_R$QS'&*.5ABC!- MI&V9@$ M=[=Y$F7GH]WP\303G@Y14Q0C' AG6@:2\M=IZR Z=[===ZL#L_YZU8AT/YUY+2ZN6,,7;/N\ZR3\/JP[0N$] M6*A]B!FSH3G(U.OUZ>0GD5^?4/ %)SFEC.G2&U6:UU&3VKIVITFJOB\7Z(=>!UQY#T_2YE-S0.^Z,;>5:KGU M*JK-0%#%XGZ,7_!;LA4P53[I+ECN*WPU.XUNG\RA3G9'=35CNC=9UR_FNG_J M8?Y:&.5!&(8H#$)IR_MYA/(D39":?%R*(8X:3(H!X_G 4I@@#J/EKE:=V?-)6 MJL 8IEO>P92<06M5)[%,Q;4)%;[]M F8^=>WC7KVW96; M U-ZAWUQFS$Q00)0E"ZP/P]0FU@")IS;4T*.&Y2#]BB;[,*Q"E_;96 N$%RVOH/IXP^*_YP"\U,W^_K4)1&:IVN M),X9\Y,0Y2P,$"X"BDC 4D3R(*-QD099!E+6/3 <;]H=Q$;1PE1K'T?T].*5 M=,*4VC&)#GI>#5!C287T09A4_@=(/\?>H4<-)8^4*RG*U;TH=V*_8'/N%-(OXUDAI3"}$ [R!- ,P30*JU1)R$(IK.T=LO.6ZJKP7:>W4[I-'-IMR M0:>;NG1RL_98)SO^:;V47)-G*U6XU6VLN-1OZKYJOP"PHU4_;]/"+_R,$D2B M"$N.9ASE@4B1SP(;)3SB89C,7T5)UY-QMPOM;\]?32UY+<^ >K(%YTEXC84W M\VJ0%C7E$$6V=&4OC&FUY1"99_IR\&$SC7F[8J6:__A1- #]O5S>,J9KL2EI+ MZIL_CY-<,HY$*(FPZN6992B/"X&49..4"8$#D/8@^1;"&YKTTX&!2.LXO M/8FUR@68],Y >S_M@/^L0N9{OMR\ 4LR]JT6I+K<7B3RK@V^:?RKO^B;31[M+<675Y\ERK4-=B^_)6]*$(T&:),QH +-1&Z6BA-UCW%OJX83>F)G|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|>)G7Y%3.9[FGC27"<,Y\)%&"L M"KBEHY%'.$<9S:.$%HPF0:+3+O8R") $&_:%]=]\"GB#W0'6Z.GKE-U?W3G M':?$DE"'<5U?2<0)/1=!JG|'?[\WJ}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|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

FQAXUNYVJC:>OZ|5Z5_6RRVO*4HSS.!4H"RA&&*<, MT8"&B/I9%"UO?RZBDFC4UIE YVD5%Z-S17T6TDCPVM79#V
MD[S&J+)T+W$1S*27"&/$GD;\1Y\WD|@F0>/{1HI ?45 JTU)V&:N+G@S/V2Z ,?QH=GF^NS!>G_L ,+^R^Q24|<+1 /
MDU83NL'B.D*5)6F|!&5281TA]516QQZ_LIRI_?';8B6">49$$B<\1:*0THJ+ MD"&2!3D* ASR.(UXH=?,:!#*-,[AOL*G_<53L+V[E>;9.LPG79_Q2NJ-
G$;E37V$75_@=+!3J^Y0X)1%VLX3-RM> MG]^':O##W^89QHE(DQ")K. (1X0CRC."6"X8%X3G#-:ZYU]$' M|B\S.;FZ] MKM>U>;D\($^G] ; ^US?
#+.@@_\&B/OIQUN/ZNH]8[7W2X{AP'3G>X3&HPW ML0^L<,N>(7$=.E-;'%:8UV.:V%GWZF%3MRO^E3QK=^;N?]NQKE(@C.<_[0@< MOT:
[GC:8MCB=Y33S)$AU6|8E2V^0YFOF-9V096,ITV!)Y]]=$+2P(2ETR<= MMI7Z)!0]8B47O2L.T;D93A!-5AY040KH-
J,9XJ3S3#&Z6NJZ_B_L=_#Q+_7Z)@YJGOE(.&5/VK3;E850M6I\ %H.E:>OXM*);S4D|@/,,P\\OA8UOD.&5X;P&*6XCFV1]-4H>FOMQ!&&JS(\&J">A N9$
M7>;+>$3\;FIAB@Y,J%'&1R\Q5^5[*\X>;9'+T%]N1{]#QH;8UM:+?B"E&_? MR5+<%77;S+IZ':=^+$4N1)2&L32HN$!YP0BB 1$%BWTL8"V!+D)R[4=*:,J/
MJ>&-5;T#>;1IK-B@'&AK0(B&VP5C!-DZUB_"F?94'B/W|% =?<'TBN15-/4_ MI]WF6)12Z?((E-*,(%S$!6'Y\@^+9Q4K_/+U_E8-?HIA4CA$KO>'@FVI%FB8,*,;E
M+3G:3,DQ2]R9EY$FW M SKF<>*+-/8Y$BF-U&0.C A/ I0&+"$!%6E *:1_G2Y@D*3"6]LU]6S%=K,M
MQ6Y:0+>L4PA>6B3<3.RP/*KC1{G\F'XRQWM<:"BP/|IU18<9ID,X#+7)BFPW M\^_L2?#MLFEQ_{O>U5;[-U&)\E7PS^OR,O_Z,L,:9 MYM!0R]4G@9]$?
GT:7]@DN/!&A]VYX6]!>%^WFWC,AS:1/ZF.0%R^&67P8<: MIM?3'=3V7$8]$HTP6B9G)/#"3Z+G'?";>7L, MD401*1QGW@%+3Z'I[?"<>8>1LN"Z/HO;
+!D)M\,, ^/&VK98,GBLLFW0\K$# M:3H3R"IGCFPANRN;WC& O"QKLX(L?R%+971]?O)BY\5*(KL@RT[YI\$F@!Y@ W9 +[#GBJ] Q[F#A=>BX=5X=!J_5H[F
M5)]PP-K-. #TQ)?E<*:R5!)Z\[S1O9N[MN(!C1=*!Z]WL,WHE^/5*K+?527;I\WH[, D%P)5Q+]8*0V :P"8O0.[L**U&
MWNSE52=S9D<)Z_JRXP^[O=>KIVY+3HMYBF,B4DY1D(81PD7&4)9ACGQ>%$+D M.98&A?7"]"X&CH5>?DU2-
U=Y!Q!:O=,SXHS+R[U9TWZLQFGZBX[XS=DQ\XW> M_T->_9VOQ_0.\'PA@XD'8GW#-ENR7+ZI+P[0+NA_V[%^N/]TY^V@-GUQKS(# M+G!@W
:XGGB8"KB,;M@8A$'2S&8A]"\YW4"$09*.IB(,/VF0%\?__6%=+P.8 M!G?TDNLLN'V[?76&=+]5@)EPQU2.BX\Q@3"IN4R;U<%PO=28Y;D=K31=>EL? M
4=9;;T/F!F[]HZ5XD:+5=@3^XDIOJP!+=5RWG!0]PHEK>]@ZX<1PC MDH@,^=(\S%D>99A]9H 8+H^N'H, ^AH)L08!C]3HP*Q?'6;JV;N6600\WEKN MM-
],7\:!&9>BX(]@Q9 KR435@?BI$8K@ 6G9BKDU6MKMN[*9O#!%[%Y6O,F M>5V(3M')+V_G#^\>JQ,?Y@%-J2!1C,(\X BG,459*!(4"L(+'%)",3,K\[H>
M,=>Y;'OH:K)$.T*B2=;;X3'SCDNI5'UVWVN[Y]ND+.,*,PL[JAN_?Y]]@L;W MP5LT\Q]DJJ/[<$71FSV&6:<3LX#:.Y76V6/]Y6H\BS#,B]H?2K]+@&;B5US
M1G-&TABC/&,8X8 $B+ B1D*U+/']{@HBK<+#E$!#'FG1?\7V V\XC@Q>WG_%G M6)_9HAJFEPP(-BIROT31577N9XM.7NI^B;R^:O>+5Y]+X/^S):7\EB_?
VF^8 M$"3!89*@0OT'ARQ2O9>EBT5(DD9I&)!$RP8:@#&5 .[!&LO?*7/TQ>*D@VE M3YM:(^&[0,]5LG>ZYN2B=X&H/LF[]*B9UW+(*JI=(>D8==J1?
A%$7>OS.RGD MRNE7UXDK_G6]*G?"__(54BZHQ<";.^VG$U20#OU N2XJR" ACV\ M)G4QK+/SU+ ^P#\!,P=XPJ,:W2Y4\6(><5%"Z%$]"6D^OHAEEH;(\OXK-
7:% M_IK[.,QQBE.4TD0E3.0896F>(5X4/@FBB(9Z)8N&\%U?WARPV063N_AXBV:T
MRD]+B=+/,%T9;2>1G3(/N#54(=S3:3Y"!6O'4KSD\+FYYDG$5*Q%XF2/15H MR M+B@X*?
5)U9LB:4Z5ENHSIR)LV\MU8DE+KJ9SF,37W8QJF!0M1E*F&K4&4 MHCS/(OG/A(DB\4F>:GM>0X <*YMV_DL+V]L#]QKHT+DW%Y@U[HG98@%,89A2
M;S#\9IBT*^;?7%AXXA$XP^2=3\$9>=[,CO@F5%F"X+LAV^T4\=PO N)G 1#S(5^,|:-:1]%L6 +S0C)"'/TCOCK288)Y@[> M85ZZO='F>C19.I$O
)GTX!TF]/I\'7G:5#*K3;E0H^P_D.I)^A'JA[JE>"5+ ME?PX+XCP19ID)Y =%CG#NAXB0"",1%((P1B@3H!SH,8",I?4 WF,2L++9EULN M_[58[29-K5>/2*
f\;)0B,LI/7;&VQR6H@.\9IP8GZEPYTFZ*N1Z5 M]UV4KPLFI(=907*3^P@?EE4;-,-D207NV-Q/.$9]G\K35IZ[V, ^E M@4S# M$LR7D2QUF0A[#.NR#XD.^O43?
>'3;(.AX58V"MZV:3#73WED(W4?W6[J/E6;M7I8M5BJ5*[%TWHH[2=531X?TDUVJ6 M!D;C8-M%?!;F<9 CRHH(817YS N<2U/+V0; M/V>]R>7H-
(G976[$('EYE78V//,C-B@B4S#09[4IO-B"VG!IS9 M(G!K[OOF/^Y+=E<^5.6G:K-XKHLOFDROU0V\&3>M.9RW'RJA)E[TOE;FS+KV' M!]^\ RIM"J> ^Q.?
%G'$++T#9?8#I"AR666U5 B3:R%+4 3&8Y0LCM6I*@!]PL MR^%F/!_6*WDX;!?;JK\M3Q!^J<=AWI6_K5>/HNS$,M5C\RQC<4Z2!$4Y)@AC M-7\|QAQ%8>&+
(J8IBT#WN4ZQ=:U]G@KP^=2CROO5_FY7-W;/)&5%X3MO%&8 M4>-V4_6,H!]FJV *<.:!6;%O4'; ?]!7F=R[A@.E6!LJ9EXWV*^>MV=O3<)O
M2_:96UPGM>I MP%%D6-O5!\ZU2M\#/ZW)TFI5:\(_/>5KCRM <_(ZAMB9^G5&I\O17[]-V]D7 M1KC6$++#SMTPG@;%2]3_Y*)J?MTV3ZS90TQ0N?
5LOEU)+J;DK0^$[U@U!+#Q?MKA\[,R^[HH_9^[XL$_%%9 MBQ=074"YKJ<_'/(2IE %J-1&%&E^%F+?@$'$A6 DB!&6KJT4,(Y8(+%*5Y[',:!R(K@#G(_^#<
M)QPIR [:5NC1 M:"]'> C8U"G!&H3W9 #KO 4/9'_Z2WI+F\6K^"'']G,=U^0;I[]3[LF.YWHG8<1FR12?P3*NA>C5891_ M+)[K&_-Z<&BG1?7,DZ@L7A=|*\^\0;
[9XB.$&T^2?32PM/.$QTA[VR]Z-CS M9K:K:L>_*;=.Q?%N5_*@?)2[NLOXCL(L3S(2(QXQBK#(!*(X"E JDBA.?)*$_M@D(LUR%@CF6V"U!]H5]:X#
[=9!;>E:J+1[Y/F4_!U7=[M>=F:?_?)V>*1M*UPKF;L7]6 E_>)"+-0$ MN4IB)LK%FL^9B#DE/D-4)=]C'%!$LU2JA8*KG'M*TL2?K^K6]/P!$&^WCZJ6 M&.6-
&)TAK"U2+6#I^!GGBKG8)LUX_CMQW>P20&&":E1.^AX?!*V;UG6>:W'V M;J15[_0:[9G70;S6@S7J%N\/W/'5UJ6# PRGO:EPQ^*SZPV'H-XCNT9UEW]X
M(OL+V]-$#.83GOBA,O6*4*IX&B/JIP7B"4U9)B@M&"AQV"FV/T9VC4+R'5-K MQG94[S3X8?)=B[82ZTYVL6&BA\WM4:3WS]$:LT8KG^CU!I-MMM-
K=$%:MJR MXO-B*BPC'JDD%S7B <)P2E(=Q@@HB*!9)RHHX@76J.%K?=8B[:=%0 M@]Q'@*%M*8X9,JP^+9
)#'"#*#1H/=%+QO4=)X[7F[C11"\QY_TE^A\S,\^:-M-C/-[5*G0=;Q^/5Y$$DB",D1]V.?84(8RM)$(*[B:F&2X*@ A=6TH+HVE]HY
M]"1!JVFHU,$$9A'I,5'/LK'.&IC MJVEVJ8Q'03:CGJ>DYF=(*(MF0EZ,"<] M[D%L.#VV82\;)[BMG\5^\NUO:F/EF?]Q_4P6JSD/I1,6$Q_%<1XAK-PR2H(0
M)8$Q.&!*.6!@.MME:.Z3UU0[M!U)3 MMGS9P9[MQ_N.LI4DZ6R<7'LI9@.PIDXH&R>[)WU,XR7#^4?M$+^'J0W[S^VB M%*BQB-)V:CV'
!G(@$9K*;M('LMZ.'< M$TVZAS6!%9)ALFY&+2C39I BHQ2;_A4GRZT9)*B;5#^IH.EPP\6K//ONEX35 MED.;&2*BO* 4YRCD!4$X\U-$ D)0QJ*$D3JP\SB"S3/L
^-8]%J@WAXJ=%1A M+VLT3]^K"08>LJ>T.LB3&:;)VM#!7B 3SQD<(O1\M.#@TY?DLKLOO\G?_O=_ MVWTB_T.E3?F__]O_!U!+ P04_" !3@?Y8NI_-
/,%O|*!887YAS^FJX_K#[B#_\Q7_Q]^B7\\/8L MK,I\0G@W!8?>SG_&TQ_?!Q]8-@0EV^{?*OBW^.')7Q.4%RF$&)A.'"%L8!6
M"*ZT39J'_^O#/^>8F1'!@)__NN?/JY6G__YQQ__^../W^-B[,_SQB-]+?_Q?_WUU_?I(WX*,)TM5V&6Z@.6TW]>KE_\M=9[":BWU[]+UP]9WU-_@\FU07P(N0/(_?
UWF/_W;/_WPPT8WWKD+)ROIF?GRS_'Z?S'\'H8?7\)X)$$3]^J.K;Y_Q7_^TG'\Z?(:7KWU< M8/G7/]4/0M4LY+5!_Z?
FP_^>/WFL2G5^]HDXW2R_M87<;E:A+2:%#1Q#1OOA0!50@:'_M*8#,QG"I/0M!WV:YDKPDFM=*6&+Z\X?YEQ_IBW^L8J@_K.6QEL6]QVWD%1;JGV]N
O7C'CY_#@KX(TL?I6;[\=%G,/[70U6K>0'(;M1"Y?_]'_MN"ZX6&#^=:.5KXF(ZS[_,\[^T 4]LUC*B M%U!44:"DU!!BL;2'"I.BXA8C-@'$K@4$3P62B0(1H??
(BXF7/*40DR@ X%9.9*(Y\E#T<*FY%A&%XY"P]TG[H0"W2*CI)@ M%]I_AQ^F50BSU6_A$_D\ANATVH'U0M>XR4+P#H'IF*4O.6',#1!P^ZD[H<#T MCH(C)-
D%$EY3(+\@$[86_'N2/[ZQ,NT)&"_IQS>+W^=_ MS"8\:1NYM2 <,E#!2(@L2N#,\4Q;*>.RA0=R[\&['5VQ)X** P7:$R;66^.;
MQ=O%,.MTEG"2$Q%*U@TT=Q%4TH1M@P4T4T9G'9)@+3:4AY^7^A<SHZ/MEL)MJ> M(/)VOER%L_W^GGM.K'@@S,HH*1,7#"-
Y#51*&:8I)"L%&OR<6<9VY^]&SPZ M/O!L)-:1P5&MWHL%AHTGS20GIPA!Y5#I]N1)2Q% R: =4S%%+X^"P\VG[0:
MCH\X#Q;=R"JO|Z)G;S_.9YLA!)5X+3=%<3CSK#N M/G$WU7=\E'F4"$=6_WM,YPN"+A?Q]^G]#"?.619+/8"SBCQ@B9R@&RUH-"5Z M9;UFQZWZNT_<3?
T=GV$>)<*1U?_[(M3D M@8C%4V#D8N;I*-W?>MQNBN_XV/)PX76RZ'_YFCZ&V0= M$3BX]=#=<-#]:>/A@NP"![]\PL4'VO+^LIC_L?
KXL'W@X^MU\MR>>?K[^X\D MM^6;\U4MZJD'+A.=,=->2!Y1,K;>J!2("A$**]*78*51QU62?)^&W4#2\;EE M8S'W 1J2W"* @^>4B)!"%I4PQX M7-[#K;@="
[@G21T M*VYE8EJH+!JBXL:C=ZOQZ_CLLHU0FR'C7WZ)\A?Z87#J_3)$9HM =,/R_G9 M--=V## ^%[S3X8?@]M7"UO<[!K"?]WO[51??]^U!9_'^^A
\A?)ZL\R0K)MZ4 M5], 9/6Q*P)AOCB>N*9ES#[S"$$E66]+$P3$VE;!F(),%NT?*ZDM81G74+AX MZ&;=X=EJ>?G*]0+!N$?2G L YB*+2C6LW!
M>,3@K$_1T=Z;'[U_/QPS=P@9%SK',/9!D!PCY@ZP\C(L/[Z8Y?K/+_]Y/OT2 MSHB9Y8O5R[!8?)O./OO[.#O'"<5F2A1MP"GT%+@Y8D!,3V**I>0AFH2/G:0?
M@IV=".L!2T(|<721Y33%Y<\85]>_:7:8JA))D MDBCKQ,0!Y0,Y>"PJ*$Z5XKEFN33?W/8C<9R&*L/!;D@-=0# MPO\'*;YEZ^? MJ]=*Z^O-ZB.%*#?%.
(F8I61*@0Y6P2J6+(U M$B6<<>1*VSM-^Y UCBM6H8# M6FM=-="NV\2C,B274.HL^&.%^4<[6>,TSEKS:)/*(1WP:RI[V.G:'",,JZ . M('C#R;O!A-
62\Z0=1;%6@&+$1#]@=>6' ;+4V2/U8<=9+X>(F20[3*@78R%*4R4[RU=[1Y\CC=SP8[G=Q+D!VX
MS+].0YR>K>T=^6[K5+*/\S,2^K+Z<:MO5Z*Q&#"']$$$8\B38P:B\AF0+*!0 M2F3Q:$'((0#9E;9Q7>G![T8&45$'EN<&7WI,/"IU(XL M%)
F'SBRU@[1=FK&/?,>1OO;(7;,*CH U8N4:CO!Y=OPK;IXEP<9.HFD&3$?I^>[6=[S01X1.S;>H+"S.
MZ9&W5MO:P;LOLXF/16D*"8"X8\18]3=#)"M9N$*GM"_BSLWN_=R1O9\Z[B[7 M&#G#RKP#.W3[2..2G\MZ\DE"ABGH
L9)#L]:#)X32P4CHX#2<6V:QV*/4C3N M6=) =]FA$C]U -.+PE'D(8M:4FP#*.T2.,L0M.$[&.=IZV\=M1U!HF 8[&!H(
M.D<*NX/(;@OX;YQ4!-0E%D[A;,:VIOQ2J"IB L.3<PDH=I> MPN[(M5RQ>GJTSK#:E9SF>LBP%FJK/B*Q4> MJ_(Y*.%M.SG=;&G#X:B5,CJP/X]
(B#/+6DDG0;MY*9@W-6@]$^:.&*<\WC M_B//*0>[^#@}]AJHH@-0O:U\[IJE31XH2AD*2Q(BH]YG^Q9B$ C%L>R2%%*H MQ\J+#LQ9NTO&V*4
;31\/U'M*'%W@)@;U?@;^KV11=E83*+++V M7![J0QDA06B?PW'C@AL>$5LF$K>O?OD_5N#[X0%AKK(P.X'5?4!,E/7(F-
E_GXIQLY4&@L^1PN[@9.E[L>W$VNBRQ]I]$TE& M(BL*)0*'D*3TDCOIV&-C,8;(7AH72]<^]SQ>++I4R[H@ZE(/24QM15\X1)=4J?LZ"ZV#QMTH
M&_N8[C%R'C^P.]*>#ORNVUQMFD]^.^}G"^F_X5Y(I5%7TP$R62M@Q &@]U#
MDGRLD]$,JOQ82\;CP7:7HK'/MTX*LJ/4T2FX7B^7Y\1)E#YRAAD\DY[C3@&L#35CGWZ- *H#U- IH&ZVP!4N!(W!@]4F@ZI9J"$Q"4*8 ME)TN,OC6!9O?
(6GLHZX1H'6H0CK UXV+AJT,/"M:ZSJ,G&'MVQ\S@BKBC@<<71S3W#U&'JN))=>]J$NMR7B[2I^FOS8Y2MWS]<,>HN_#3Z AU<|5\|< K
M$#*1&4LF@M>"MC)N%)D@RT'RX(P5//K2.N%V"RG-"ATNNIQ=E_,7X{7F*8!* M,8$2F" FY\ 8YZ-(0L;F2<5;B1GW.+0%"K;6,1PE]PZVMW>D"R*@-@+]&;_@
MV7S=ONJ"JTG4W/(0R,ECZ])]E8 BU0BQ2.NT5X:IUE>'CQ(T+I :*?U> D,K M#70 I[_@C&1T1KR\R)^FLVF53YT.>\D.C\Z{$!)P+ Z4Y0C!6@:%IQB*S56*
MC0'U'E9+558]H -0[,$L=7$V=$*$[+1 QX-+QZKFEC4?3I M>0+&J.]20A9L%S54%%YH,OFKGF+:+O M$3'N2?DPP#E.TATDPZS3#3<;?FW'>%3@9*+84R97NWO6+D51H\",
M*0_2!FPK1>-:GT$\HW8:Z,#TK >B"F]_FL_GE0JF-/C$(5017$$PU-MIT(0=]HPB!E+""B++ZTKT7>A:V1GJ2$.Y@,KI0.@K<5UDX?+O5J+7)++Y/$I
M8D8I17MUL0*8T3J0I3?"M0;7-EI&=I6& U03X>\/(K\!T0P_U'.1WYMAZ28G MM],(1(8.Q IQP2*"TIYV\UK]P9P*)A16O&^=EKZ5F)'H^'0U$;\'3A39$:O
MBS4FCAYA4TJUF1417YBOPD$0/N<2F"M9M\Y!OT7 N'@9PE4Z7+X=@..RWN+R MSOFGL)RF211<6"-
J\%$OGNM)!0E&0@[16IT4EN8%5P\2,FZNR1!@.5[>'7@Y M=YGX>7!VOJJY5]$DH5T!@3S2 @BTXS(5P4HK4!CN.6OMY&PA9=SDD5, YQ"9 M'PR=+
[B(\T;@^0^LS?$QOZ O#1_PM_-/$1=ORKVKP,W**,[&H#3Y_Z*:4Q$$ M^*("%,FXC8ZYQ%L7H.]%X+B9)$, ;3C!] R_B^5T_T):1JE5S@QTXAI4C@J<
MDH9@X[Q@RO/V):![DCAN LH)(=A$1PU!>.JT@5OUUVM?>HCL@?M/.4T2P7>X M:U^.=14V/E#7?@7C$++V44F?
(J*I[1C_YI#4PR;AWB9%@6WO">Y+8.#PL.C*; M'6!=K&MW- I.NSSDHGA![DSK*H;|P\-3E%PU1\=WPL8]Y-Y!!+!+/XC- '9Z M?5&;1/Z,FW^O9!>1^\-
&>W@R6C;$L!GZ0&SS=[R(M&U3KH[GNINBK4&A^>) M-=PQIJ^&+97Y8GEKV-*+_/^=+U<7@^(V$IDOUF!8K1;3>+ZJG_I]OBDRGH1L MC>.:D"
(D4I"E9+558]H -0[,$L=7$V=$*$[+1 QX-+QZKFEC4?3I M>0-)%<(<$,ELS&!YD5;8*M'8\C2>[@'$T_]^A[@Z.R1_@!*KM ME?#<:H<:C*LGN")9B)
{6;:Y#D3"[,%SS0??;R>FF\G=P#Z653IY45Y:,;$?,# M#7F&.:!#8UO=G\!.:[_'7_DC@D29"SGMGZB0@)P,#I7F$&)T"@Y:YXB*7H0QW
M$+!K1^8CN/^]VN=)$$G&Q!!$]/DVAFL(PM>E:9CG40J4K:]P;E/0S0% (RS< M[U1VL+P[\/*NJ-](D)K@^:RNUA=?
I\N)25II*PLX[>KLBWT<)Z@1+!VAZ&VB.%GL'&+K#P_S3V$ZF]2.,$%+#D;7.=G&$Q.9O,+@ M31$)K76R=73\("&=8.9X1=^}/SY:ZAU YT;IZ%^Q7@I-
O!>%.^?J6&N*DJT7 M$.I=DZ.0@G.O#,8!>U=LB!@7,@T4N[U]P I=P"3+6VR+YB1SJN2K0033#U8 M80(B1.%0:!%9SH2DF*0Q9!XE;-
QSA/;P.2?]'J#T_1I%pXP)ADZ6R"$F7B?. MT'"'"H)T^\Y"'SKFPW']RQL[$CT7LIL_#$!M%*!W"[VP;[@MFN&,F9+8'4@-Y=X":*Z_Q5^+.?VXG.20C,W!@R^,
M@_(8Z"J2SJ,,@@ (OQ@BQNYGG $.ZP=,HANYP,!X2]&C'MH96# M$?9Y?4%):VFQ&FKF!K-:YAP#2&HD-&0FJ=0'[@H(0AZ\-/ MAJDC-= 7DC:M[GX^7]""V-
RE;],)^H|O/]\7OWR%1=INL0\L=K8PM&"<%Z2 MV&C9A!@H\N!%":&4-KRUD[X_E:.7WYT6B<-IL(-==0N'ZQZR#S/H5/).)T:. M"2I0KD@(W#E
'I7@0HD06GMU>Q,Y>LW?V AMI+]^;J9@K]\^GPV_X8;3M^> M+])'$O?;LS!;UG)(7ZPBWR-(6X5*$3TGQSJ%X#SS@LOUQ\F2;<2.<=IOF' MV?I;-E.)9?
2NT.J%4J?^*%_3Z%0R$&,T119KL7FCK:%Y&KU:\F1+H"MT=+!: MCDU95D$'4H8A;TO*VCG?030N@2G!>A4U1;*#=)T;.$-]L$;BI\3Z*77; 91O
MUPZ6(ET16@/7)68C4GS@N$.PP88B3'8^MDZ=VK]FTS\F!TN]PY \^AQKRY) MAE2=GFQUC2P+N%04+0!4.KNL9?.\W^,/X=ESP%0SM1QY=OK++
]U!I]C+"(& M(EL7 JH"F03MXD(RP_OCJ,_S%0 M>FND02HB1G7QG4+ GA+6L_K'X[M/0UBB=I\T M6GFV$!\>B6C*^T+^_;GLI,TB&,1](''G-
:2Z.G#';ON20@46A31U?A;YDE(2 MW38CF,"8*4I]VWP$54=]5X;6]J-N_#ZB[P WMXYUZIG,+$W/\!9+O_WE684

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|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|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|>;=VD\17,%6^_(MVV@9US3V<5;31$^=XNWRDIQKHW,,((N5H&*|!T):GC)E(4P67/#65QK;J1DW MS&VC[1T@=(#H.P#1PV-]++WV$])(7,@&CU5;C(;:>10T)>;Q:T$^;VO'[A%Z M^@/2(3I_H)"WB0(Z ---#Y<<7G/#H.";N(>E:"!B8@RA5A&BB*D%ZF4OKZXKM MU(Q[$C(0D!H)^2Q6&; .9Q\>YL)KB2%;0WN^18I8"OF2-ME#8!ZGK0YP(Q[T4$9%8;F3W# MN\.]NRB5^'6O)]6#19)]N/'C(.*#Y7"WEN].I=\GV@KJ+,?:HF;-Z$0K)IQ* M'*PLM 5@SN!KAVM>1+":(NED6B-^7QH[R7PZ/9SF)}3MX=B=K\+9*;[W9CN M+XOY2S7JR>I5!$M)E'IO/ M6FU"'^--/%!L7^H>C8/QVG=MXO^,[MA0FS(9BD]!@9,E 3F&N|U,2=$8NL\7@M3.O&)[O2]O0/T8?!<1-=/JF6$K?7)M;9=5?O6\[+E8#*70'5F[7,'WX[7TZ/ M'.-W:A*':TAQ*KF>HE^%T)+ ^3S'P12$HEA/$1';.FZ*]BIA,&.RLH>M^%9QYM8ZQ$*+Z0Z?&VYO9'\7X8&LG:B$&*[=^QOTJ[L';?[*GP3Z/RXABX';^D+I#V6%:U4Z$XI3APG6OI M4K;@+0[@LHV9.8*FNY2X9]&$<9QR&NEMX0N'/^M'%?123I(2J4Y,7(K&0 MY^U-(@_&>>M4ZRS0IJGP3Z-$X[@-> !5=@#1MF?4)G+A$GGCC&, 56B'<-%H M2%%XX1"EB;VO DZ?K=/UE6^#T'TT1'2P'+9?E+R|-%X2S9EX^B=:!P)RYVNT4Z"C@^7Q M>)OZ[PGA5UPN?_\89ES\E=[Y<7E'*!.OM621@EBLHQ5H^PS@>0P4;B3O2U:6MQ]8'#X,R-/($H7'!NM> @U,BY\DOHTLAQ%G4G%T))HCX(1\[+7A4*'\'OM0E_E'[",J<1"6Z3S MH()U$+G.P-7+B:6@[Y3Z;ZE1*L).4_[CXNP!A)L=W;|\'W]PHG*D9L@%;"H MR'RH%,%CR2!5""5E5V<1=N7[W.5@G)AA+/P-&B3L!88GOQ3N^G:3{'CQN6;QM!LE\U=+Z&R"POPP12+K'6Z25L.QMD4GL52. H.W2^%AWF>6.UK._($/EOB ML: "+TL!9K@HVA@5M>OE1_'=W\2L&Z@V&;>^2F*$GX+BSJ%^PNV+B6X|\7# M%0 \SL,ITO:=X4J*X&OSSP2*&P%.6 _.J5!K8XQSK=?]D&G[#:.<69RLIJ)9(M'D]MSRN0'"6:WM>H6*13.G\W6_J6V8<1U% M:0+HG%W-V=_0C1!U;(YR5A?A\;2'V4<,I1[^_*,'L.ZELEYK"%_./WV^<#_F MY24N:&N;D=.=<;.L_1QFR_G9--?CPZMTH_?TT/6,>'42]'8Q_TR?_!9FN?8+ M^US_^!NNCMCK3T!5$T?AU-)KY&6\67P(L^E_K1F^IK*NX5E^>T,8-Y+,KNB^ M7F\8 I)#:B#Y3.O-95Z[=TDP6 C^40K=W&(U(?SHEG+I(^;S,WQ3+E7W]BS, M5B]NZ.\B.0E9KCVMP#A- C+, D4-'((/V?NLC0RMFZSN2MNX/L?I\7>O,]T0 M.NS]=C*S4_?:MKHNI)(2%:\Q0#%.P3RJ&KBIM<$\I+01,9C\S$C.Y ^BI* MP<-\6.7TC+?*T$4V,NWJ20JO0&I?NJZ 5&Y_E%%F2(@;G6*#76NW>42UJ.231:&^9)MO-M< M?UL+SFV/Z!0IAVIRWERL'=BA7^LYP]MZ=;Z835?G"WPU_;I:'U;- M\IM2I@GO,E!%HO6Q9-KN=]K&=G[DN/5N@VYKPXA]M;#"1R%;S^LZ[3,B4,*%B@#4'2U41A8(>C @Y1T=_NCL380MVMCUAW-[.@T*E MB5"[V*W65:"I*N7UC+CZ0%JZW'DU8B(9>/#"$LJQ"'#U2KL(7A!C*JEY6ZO'.MZ-D)3N:IP:FY)CI U59979U>3Z(,(4>5(= : 65B I]PT<1^_?I6YB>.^QR%,&"+MK!L#1_(*H@>5BD\4BPAOF\\L:$1[IP ZBH+[.6&]E9_?<#6)":-F18/2 M@N2:DX%8D($/Z*(-+O!XLAV:Z.GTU&)@L[FO(CH8BG%S{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{J27/A5M MG9#C9=X!<-8' #^%]6WCIUHO=Z&619A!$VGSNNWO W?ZDLQ_@B+_-MY72?$ M_OH$X68K^;_09U<3M-*85&M_,5V,S?-:>ZA]S;@I7AK>.H-A*%[&W1D;P.QN MJ-6#SI\R]M\]KF^|>6RVD0P) $T6WH.*T8+2I)^06 '-LN/)FB!8ZX./YDR, M:ZP[0GL3+7< \YOGA.'S=!7,-NOW\J3PU=V3PHE"9QC%6F!8*+2..:5=TFB-H MY$4%%,:6 7I_[D?DN!EG[6$ZK)9ZS1]C&&W^"'7\/7['\)+3'OJ|)F?O.]#8Z M6+|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

B3KQ#;TJN%; "ZRAD S&3CI(E MFY*Y-J%Y<{(A^=EIS9C_7C/# N7).E&O9VF!].+KV7?/*J0U)CL.A4L'*G@! MD:&#%
(R(///(A1_6K]J9UIW6A'UF;Z)`/2REQP29?WR]?-TL7[SA=N9T#!1 MO 7&2!5*60G1& O)9&.,R,;+U@UNFA&_TXIPSVQ%C N!7K!_B-Q?A>EB/3#E
MQ7)Y_FE3/ES+JFHKZ9^G7Z899WE]+A<4|SZI!*[>,2G/_C,%43A&4<94PG= MW'#LRM1.:\4_Y[72#60Z6$-71]*X^#)-^+!\?IO/ON"2.%V+8OE[K36^^?=:
M9O/;?/6_T,E*#$*YVN#4%@N&D-1:U+"I9+EOW7QR,F=VN M!]DS731]8.0Y+Y;-_DL^Z,5+|7V<7%')1=&>?,_$:N. 7/.('7 O*.1(QO+0
MNG#\M!SNMJR>Z[5{QVAZ%H7B[Z?$>YDFBNIN;-JG]AI__.FG+R'?0QI]U).7 M[#2WD@%WF0+QVF[4>5II)8=HI:WA>?/A)\^DGCS+I&,D'Y3I5.]'60*/"4%&
MM&|;4E(:I/7U/W]^3Z8':Z>?!_U=^!5W2XS3:&({#*G"8. M"Q?ZY.G>3[R>?"]8G:*>?!\==X#S|>6B7O)@%6T[W%AB).J#U7&P2(S/C') M8NM3R^_J?)]6;?
E>.-FYQGPRY;S[FW(+#4(40IUTTF M$](LI">!]PI6Y. ^]0;*Z+=KA-UZX'.IYCUD%_G"]D.2;AY+)/@=%Y_X M1'&EF*3
6)BB02D>P6NR'IJ7%)B.6;%:J@4'X:;S^*\Q+EME9K4%22_+I77> MS;_/S^AKSJ:K;S7SYL)KFM0Y0:08#S+4B;NUT[8WD4&)00D3%5.FFTUD;^Z>
M?/GMT/1,.>*X*[M6TP'0^:YK.%WT^7?7RT07\^(0%RN;F[=3!2A3(Z (D50@1L(DG[UPA>&PD;# MNZD9WI.W)U] W,V*;@6@?
XB%=;EI,^M+4@%T=I(V;9<@<(4@BS:!96&25$]N M83V3*N.^%]8! 'H6& MZ-U-OROF6*CTL+=4?[E."L?\|_FZ%^!F.5:VES>2A)>_?,5%FI(<)L$PYIV*
MH'GTH PF<#0D],6348ES'9NG!^Q-Y1.]2!D0Z,]>G\H^PV49_@A;)(*.O&6 MZ-@%IRMR=Z]6]B1ZH7C6"!@5@E)9U*F#"6RVV7 E>3'-ZQG;L_%$[T/ZM?_'
M0N7Y+)K[OJ/)40H> XAD R@F ^E%%\BT/3(>-808_5UW]+M@CH/)D2'& M+[/D U3ECDC0>5:I1B=AD#N)3BA+,_1.98':45_ M M[.>\(G6(.#I(0X91BX7SFS-
+[^02XE*^SHD3"LDN=A,1;GP M+H)TDE@QD O6)D_%0V0U@Y6DYA5'[40WR<\'#V=&Z"MA8D/GB^ M_ZB @I;"!*> %%EGYL@(D2)M,))
[EJ4-.0[2O/PT[#V;FZ,NUN1(L'L*N^/W M1'/)_6[2<8EL5' &@JG-4:UA0#ZZ!2:8"27GP'-WBW(O#I_-+=>36)?#@>\Y
M+,T'+D,>E4^]7!16IHN+\A("N.08%![L5HSKH$Y>)M&8QV=SX?8DEN>0 'P* M"[25JY[%1J84<*\=*%GSO5!8":F]E8J9$I_H"NPS*) 4Q"DW>A>9:D*@/8,-
\ONW0(^[M$\H5YWB$(BD>5SE'"$C2$M%$9ZSEV9R\0 .@'(];L_C\EN400.ME6=ZKR-NA M:!5W'8EW6-
LAT^LOY[.U5L_#66U.)28BDY!,89"9E*"4].!=*&""L]D&%IBQ M0ZS%T[(Y[AC6L1=@QY!Z!JMN;QNU37)\P@V+J=:"DUVB8-MIR-Q=U*S/C3I$=>V&-
#H]>ULD1%N:&*;DM"#YQMB0G M(H?$*.A55@MP0EK(W-BDF,I2=#.*_+OLNFCT4R(5EL4":)3%-,(SL#E4COX<9%T#BR6UDT?G\N$
MRZ)E%,9;X&5=167J4 Q.&V91#+5"@_J_)UP.L1_L@]GA)ESNH_X.7*7;@^]0 M\UQBH2C(Y@!*.PZ.'+]:RI"RDIJYV#IW^%E.N-P+!(].N-Q'(QW Z7#!/3+5
MCON@2E(9D-LZ9JA&Z5)K$@F::$Q&V1R50_#1TX3+O6!UB@F7^^BX YQO'Y88 MHL@^HX?L>>T?7B)XQOD:Y..DJN$K<\T_Y$F7.Z%DYTG7.ZCM
[01\"_!.Q M05Y1E=FO]0-5M'5EF\P=2J,AUQ'?"G4"+X*#9'RQ@NL+KD?(>2Y3,8_9 MT%MIJU_@7;Q-5;*.EI@1@M':-,1'E$(
*A55D3%%;!TT/DK0N.:OF=IW@],! M.N@ 4.]O]T3 1S+T/^,7/)M_KCQ=G(]<&&>1!8[$%K&$!137"$$R# 8#ZL1CH V5]PAIMP1AR]R)^FLVD]+ZA'=
[>90N=R M$L6#R46 \N1>D P59&=TG5K&C&[=$W@GPL;=0H<#6GNM=_"U@Z_@?OW_V!NR MWKAU)?T^_T5SM2\O SA>S@W@8QN.3X
\&127MN:H)1)]{<3_?LC>W(M::ZF+ MGIN7(+M7W%4O%8I';] MG=O_;R^-CLGSSLR]!MY^D2[_#V?UIJ]G\K,E@B!V(FKXIJ7F<.0:A)# $#)Z M1(3[1
CHBG@WS31?P/[RV&=$9X\7;8$O4T7B&)&0 =7Q M N'9(O:$#5T.ZZ7@V!!XFVZJZ(+AOQ%[H&:9E>2R.;3N(H.^DJZ@: M[EKF?)XW!5,...#]*U??
EVQVRZ5QFPWX9^(+VR8R{6#"4@WPIF] #YE!G2BR M3"]R'1?Z7'"])KBKD/.Y%P /&GC3+:_^4L'MQ*<=.=L\>KL.SS&&)Y1/;X1
MAAO:GD$".S!H0&3:23P>A=#W0+3IA'MOPQD_G9#W.'Z)MJ0=QLW%/^A3^0A$GC+H0<<&NAY7BA%UF>$1)3J"8#":<5",/V
M*3,MTQ'$.WB]Z;A*,'QXW,N9IG>\,Q'SB<+BRD9\RS2(*\.] M;Q(24LYBU\+*(W%O*M(O#/;B:K@/YA5)L_?!OS(F453U8LZN?U'Y7]?58TIL
M.9U,UW!:YVM"4N5_HF=QP'#FHL'S/%^#G-D_H,C;"23A7;?L*U(LWB:7] M;7[*U"7TGRDJNE(.Z&RR0>.!U!^GK?>BX=V?@<$6+*G)H8-!)R
M^>]&D4%82*6UH0B$'WLQ@;]KI*>*N+LJY_1 $)(T\,%#S%03B8T"C+GC&BR@ MPG!CP@SB>Y;AT% NL2+BB'#]A+=[1)ML(V02?
QH/^&"OD1X8:RRQGPG;I, M$PGA,M^C!K56)UZ)3^\\VS#!V/:<,;/%X=ZIMF6:CU/K%Y(4IC!.WO@W3A=% M4B6\W#!R(QG9H>-
>'"]JT.KKN!:;GR969$4:1_+RX,OS$-G<,Q^2^$|>^"A[MR,!:H&F1IX_'G;Y6].P4:Y!WCK3YRWN]@.4-2I2$G+D.-?S(#]2S\XY! @F*
MYYF>+1S3M,%KEA.;H\N]I^?WTL-+"31Q&6UGS\Y5B"R.?.H0RQ!AP.1ZPF?J M4089F(1P7,)1S':AF]S:=$*^XE07Y^GDU .9U, S3]^C*0<+3&+[AB .-UQU
M)U@4FQ(T7R)&J6,2'_K$IJ:7G\)RWODBTSX$H-88EEUZ>W9LSLRK"U_7UH2" M"(VU*NRT"XVSJ3N HXOAK$G9'Q_79[M;1+A(G"$+U2#B6.XH2-G24A=
(_)#BSB1$X<$>]D$I;LN%^I^]DQOF#-_DFP M:=TSK=@6H6-X<207M51:'@;RL^'+SX?KN9[O$^CC.R"*Z_A1GJKG8!U_@ /@ M]|@M99><_O_<\>5?
HRHDI^_#=^A%Z5FH'M*P]42YWD+0O@0N+DSVV,7.6L\\0)ERX],M'I[E&=T%,:US#[\Z.-^F8#ZR< MF>M'4N;+&?F1<@V-'JU D1
MQ*QM3S]>O>0,F*\#F2BK@V%LU:.A"5KHUR47IZ>I%70=4=)AXY:5<5?*G?*ONLK,?;O:UR$I6MA9T.DZA.(!#)S#/NP&@PP;'WH/0P'L0O1^;GFZQW&D6-
8("3A;J MF\0G>RBG+$KBN_OI_I7_B#X9M))S'=0:N,-2MXM7.3Q-EE \JJ-IY;>+QV^3 MN$7[>+@-!V=TC\[08RZD&;\>,,.!%!^K^REB1OL]V
M&DSGU7C>;J5V"NTF/FM-D.A V?6O@CX4"0687Q^B.I&CP=;;D?$Z,/*_)4 M5Z3B-R0IOI-T 4!-CF3+E2+UD=/\C1?O]^)HK"-G&.3W MG088,6774C?
#C*\RUPI$*Y#UX6=WLC;!@AQD'WFY>:!=?0-&5YOXY*QU8A[MW@F$_^A]@$FRDZZD_-X!^+T#T(N;NSR[XSD$*?N2\';,FK#.6PS7Z+O"LY4_!/O'
E&"VI#,X,N,&&'O-FL6ALUNMJT+PJMDW$H6_50(/.S42@C MZ7N9E#!-.B>%HG4UCLR]3*#S-ZWZN^'@MX73V5Q75;)G*RVEN#:O3L-@-;R M.)35/K A,[S[
#)<*#TM%:T'KA;*,_^I?;ZN;0S$WE!EZGU MV&#;9QRTS6X@AKN J'"MWY,\71];_W<^YY?]I'KQ?DM^3L%]XV!X&^>0'M %
M3PW=0%K\SX*DB4CH6OLG\NL+S[A{JM'-$H,&Q-NJAW2'KKCJY1(RC*4D6RO\ M=?ZJ+N64!JR?<@3)W8:-B-<; .04_9#59P4&F>(UB,5K(!8A.F9Z]4H"+R.
M/A3;B42M:EWM&&FT*Y#S4]X+'_D_BZ38QA68H-QCF$XD:U7ZZH^AKEU #V]3 M=0#M2P;I_FE0%J#SYX&\?U?
W,,G5UIQDE$,W_G21/V)>2W#&[_ILA:!MN/9@ M87=&'EJ/O2'TB]/E%6^7,DS,\N)[=.M(O40\F@[QSCL.CUU(3M-#]1(.U$1R M6C!>]U4C%7D_7)"I>^_Y $\?
4C![2MJQSAL,QV_RD2K=@=!Q* OO4&]/4DZ M\+M7\9Q?FM_]B;_[$_MQP_YW^3;NZ^CIL2\)K8VJ:7;4&HM-0)INU8*9&H?B M\#
[KM7#G76S')F4VJY:GEK(R^T[DY/VVF,]7=:NRRI[B]"8O+E[3./U10'#6 M>S3,3.T48SD ?!K0KG26)I;?WNAE60&Q6RL4,]/K2&(3&-B+'VB>!G,TS41K
M0S_O!H4F+#T4!3A1AS+QYM,_KDX @EVE^Z=ZO_A9L%*I"$!5G3R\JX([A;T& M"'0A9^)TI,\X>'6\!IKJV/PT.8>H5E)G,H!Y?BXH=FP]0/L-AW=(LR?G
MO1%$IOY'<9VQ&W?=Q;W8&O%'D2G%+]*]J-0>^DLFUUD[*_LK:P8@ ,,'E2/ MJ=^/WQP.;&1?4RNWR7!LZN MJEI_EW,(7V_='L!-^H^&EA3"N,=@>/6)(A?
EO5B;<2^6'KPU]@[!@^*=LP3 M/(8, AN[C7FC^$K?C!U_-U>:[R9E2]LN\XR55X7\"Y3G *F =K 4QH]@B4#V
MJJLWQLK[XKYZ*X+]:PCN\^VUMQ5ZN<_RT>14F764Y4J@-0+%5 N!3$^VN%6 M&\"\"I #[=1=.5%_/O_P_AJQ 6[O4RJPK:]6/="")%3*O\(BG$\;U#66BWI R>
<[58X#-T0:L%2=/W!YV(P(*+J1*+= MAS*C=A;:K83(2!)K),-=[T( )<-8.D02K>J@@?4DY+Q+@89$U?;@$+O
M\UDDU;MZVF0%I5S>S)=/N%TE0BK#I;50[/8<"N^>D(%T#X,2>]EX$&:^E\N/ MR/+QMY<\E2@_5E KR7Y#X5TQ.KAV-P1*[?
B_X]77C.9SH!IZIP'P;AH!X_HT M,-HQ?%1DGHKIAH$Z,:Y5]6@ C,C,UX0?9?FZ^ 5#>M-BSFL2+E!2W25D!;G6?EMJ)3IW*6:T 81-X'%G&
M5D).B.S4K:!3,:L9&O3*_R;XPQ/8)KL3DSJ5LCJ"A4CIYGWR;>) ^FY=-_5I# MGH'?E]V)1%T*6(WPH&<[!YGWV.E7*[373H5I)I@P;ZA5B54RB(@PNKD=>)+
MIX)1 R@ZE/A!7C7;%=2)()VJ/'4PH"A6R8V.3GSH5(,Y,%Z/-N_1=/3M M5[5U*I-HV*::9W_(Q&6MV!4O:9$LMV& ^E3;Q7E.@$Y5D19PT#L(
M/DY_P;4*U,OL1)U.99 6<'1}?>!K5B82S*>"+%^>+ K5-ZU>53BH (Q\BJ!A M&)!W";J. ?!(P=%01VXQ\++?DV+'5*"WXKZHEVS&/T]0*Q#Q)MPV+O9JS@U@
M8.\4;%4;?9;T0!0:-XUHU[*BT>G2BS2MB24PU^6>%JP!5PTWY[8"\OOF=:PY
M]/L6]M^WL/>K.%5%^L2+>7DOG@HF_0LFFV\0BS:'^N4{<"@9PI**XB7&_P
@L_*X2+EEQIZELAJ6OU:4S+1#KGWXZD%$OQR_A2<-8A%.]7>C[9V8+0(@$N]U"$84D$$P3UQ:"?:.MAP3".B
T"H9/Q3RK8&/ACDBTL^S#0^$Q('I%0B#"3DM%,\8^*@YJ1]MFP5#,_MDJ6C\$"1\% BWLGU(='P!!Y.<'7IZS4I(*DZ$(AW+GT(4_5H.$'4U6*E& !%
M6U%XI\R'D'.(@!:T?.-T4215PLN+V>SBC23IZ/,-#7+QSHD/(:P1F\^Q'?R0 MIPF5!CP4.9UP.WAOF FV@T^; ,X=O#O4D8\ | O7RQ^U:,(6SW9%0ZV]VZ5K
MLG7&AI8FET,S(Q+7$R,C0N:'1M4$L! A0#% @ 4X'+6+ _^"+(! T1, M !, (!UA4 &5X:&EB:70S,C(M<3(R-"YH=&U02P$"% ,4 M _!3@2Y81 (Q=7OQ 0!0EA,
$0 @ '/&@ ;F%U="TR M,#(T,#8S,"YH=&U02P$"% ,4 " !3@?Y8U=Q^I$0+ 2< $0 M @ %Y# (;F%U="TR,#(T,#8S,"YX 0001808805 2024-01-01 2024-06-30
0001808805 2024-07-25 0001808805 2024-06-30 0001808805 2023-12-31 0001808805 2024-04-01 2024-06-30 0001808805 2023-04-01 2023-06-30
0001808805 2023-01-01 2023-06-30 0001808805 us-gaap:CommonStockMember 2024-03-31 0001808805 us-gaap:AdditionalPaidInCapitalMember
2024-03-31 0001808805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001808805 us-gaap:RetainedEarningsMember 2024-
03-31 0001808805 2024-03-31 0001808805 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001808805 us-
gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001808805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-
06-30 0001808805 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001808805 us-gaap:CommonStockMember 2024-06-30 0001808805 us-
gaap:AdditionalPaidInCapitalMember 2024-06-30 0001808805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001808805 us-
gaap:RetainedEarningsMember 2024-06-30 0001808805 us-gaap:CommonStockMember 2023-03-31 0001808805 us-
gaap:AdditionalPaidInCapitalMember 2023-03-31 0001808805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001808805 us-
gaap:RetainedEarningsMember 2023-03-31 0001808805 2023-03-31 0001808805 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001808805
us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001808805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01
2023-06-30 0001808805 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001808805 us-gaap:CommonStockMember 2023-06-30
0001808805 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001808805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30
0001808805 us-gaap:RetainedEarningsMember 2023-06-30 0001808805 2023-06-30 0001808805 us-gaap:CommonStockMember 2023-12-31
0001808805 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001808805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31
0001808805 us-gaap:RetainedEarningsMember 2023-12-31 0001808805 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001808805 us-
gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001808805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-
06-30 0001808805 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001808805 us-gaap:CommonStockMember 2022-12-31 0001808805 us-
gaap:AdditionalPaidInCapitalMember 2022-12-31 0001808805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001808805 us-
gaap:RetainedEarningsMember 2022-12-31 0001808805 2022-12-31 0001808805 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001808805
us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001808805 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01
2023-06-30 0001808805 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001808805 us-gaap:PrivatePlacementMember 2021-06-09 2021-
06-09 0001808805 us-gaap:PrivatePlacementMember 2021-06-09 0001808805 2021-06-01 2021-06-30 0001808805 us-
gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2024-06-30 0001808805 us-
gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-
gaap:MutualFundMember 2024-06-30 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-
gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2024-06-30 0001808805 naut:LongTermInvestmentsMember us-
gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2024-06-30 0001808805 us-
gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-06-30
0001808805 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-
gaap:USTreasurySecuritiesMember 2024-06-30 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-
gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-06-30 0001808805 naut:LongTermInvestmentsMember
us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-06-30
0001808805 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001808805 us-
gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30

0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001808805 naut:LongTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001808805 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-06-30 0001808805 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-06-30 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-06-30 0001808805 naut:LongTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-06-30 0001808805 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001808805 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001808805 naut:LongTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001808805 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001808805 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001808805 naut:LongTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001808805 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001808805 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001808805 naut:LongTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001808805 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001808805 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001808805 naut:LongTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0001808805 us-gaap:FairValueInputsLevel1Member us-gaap:MutualFundMember 2023-12-31 0001808805 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2023-12-31 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2023-12-31 0001808805 naut:LongTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2023-12-31 0001808805 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001808805 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001808805 naut:LongTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001808805 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808805 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808805 naut:LongTermInvestmentsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808805 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001808805 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001808805 naut:LongTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0001808805 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001808805 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001808805 naut:LongTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001808805 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001808805 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001808805 naut:LongTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001808805 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808805 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808805 naut:LongTermInvestmentsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808805 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808805 us-gaap:CashAndCashEquivalentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808805 us-gaap:ShortTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808805 naut:LongTermInvestmentsMember us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001808805 us-gaap:USTreasurySecuritiesMember 2024-06-30 0001808805 us-gaap:CommercialPaperMember 2024-06-30 0001808805 us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0001808805 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-06-30 0001808805 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001808805 us-gaap:CommercialPaperMember 2023-12-31 0001808805 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0001808805 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001808805 naut:LaboratoryEquipmentMember 2024-06-30 0001808805 naut:LaboratoryEquipmentMember 2023-12-31 0001808805 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001808805 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001808805 us-gaap:ComputerEquipmentMember 2024-06-30 0001808805 us-gaap:ComputerEquipmentMember 2023-12-31 0001808805 naut:FurnitureFixturesAndOfficeEquipmentMember 2024-06-30 0001808805 naut:FurnitureFixturesAndOfficeEquipmentMember 2023-12-31 0001808805 naut:PrototypeEquipmentMember 2024-06-30 0001808805 naut:PrototypeEquipmentMember 2023-12-31 0001808805 us-gaap:ConstructionInProgressMember 2024-06-30 0001808805 us-gaap:ConstructionInProgressMember 2023-12-31 0001808805 naut:A2021EquityIncentivePlanMember 2024-06-30 0001808805 naut:A2021EquityIncentivePlanMember 2023-12-31 0001808805 naut:A2021EmployeeStockPurchasePlanMember 2024-06-30 0001808805 naut:A2021EmployeeStockPurchasePlanMember 2023-12-31 0001808805 us-gaap:EmployeeStockMember naut:A2021EmployeeStockPurchasePlanMember 2024-06-30 0001808805 us-gaap:EmployeeStockMember naut:A2021EmployeeStockPurchasePlanMember 2024-01-01 2024-06-30 0001808805 naut:A2021EmployeeStockPurchasePlanMember 2024-01-01 2024-06-30 0001808805 naut:A2021EmployeeStockPurchasePlanMember 2024-01-01 0001808805 naut:A2021EquityIncentivePlanMember 2024-01-01 2024-06-30 0001808805 naut:A2021EquityIncentivePlanMember 2024-01-01 0001808805 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0001808805 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0001808805 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001808805 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001808805 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001808805 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001808805 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001808805 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001808805 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0001808805 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001808805 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001808805 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001808805 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001808805 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001808805 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001808805 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001808805 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-01 2024-06-30 0001808805 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-01 2023-06-30 0001808805 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-06-30 0001808805 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-06-30 0001808805 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001808805 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0001808805 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001808805 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001808805

naut:EmployeeStockPurchasePlanMember 2024-04-01 2024-06-30 0001808805 naut:EmployeeStockPurchasePlanMember 2024-01-01 2024-06-30 0001808805 naut:EmployeeStockPurchasePlanMember 2023-04-01 2023-06-30 0001808805 naut:EmployeeStockPurchasePlanMember 2023-01-01 2023-06-30 shares iso4217:USD iso4217:USD shares naut:segment pure 0001808805 false --12-31 2024 Q2 10-Q true 2024-06-30 false 001-39434 NAUTILUS BIOTECHNOLOGY, INC. DE 98-1541723 2701 Eastlake Avenue East Seattle WA 98102 206 333-2001 Common Stock, par value $0.0001 per share NAUT NASDAQ Yes Yes Non-accelerated Filer true true false false 125411248 24885000 19397000 142558000 154021000 3490000 3419000 170933000 176837000 4694000 4267000 30474000 32634000 65466000 90647000 1180000 1180000 272747000 305565000 1627000 1639000 3239000 3945000 3815000 3538000 8681000 9122000 28787000 31090000 37468000 40212000 0.0001 0.0001 200000000 200000000 0 0 0 0 0 0 0.0001 0.0001 1000000000 1000000000 125406748 125406748 125068601 125068601 13000 13000 474791000 467834000 -546000 -255000 -238979000 -202239000 235279000 265353000 272747000 305565000 12436000 11912000 25366000 22789000 8353000 7104000 17030000 14287000 20789000 19016000 42396000 37076000 2798000 3222000 5675000 6320000 19000 14000 19000 17000 2779000 3208000 5656000 6303000 -18010000 -15808000 -36740000 -30773000 -0.14 -0.14 -0.13 -0.13 -0.29 -0.29 -0.25 -0.25 125317650 125317650 124603181 124603181 125226552 125226552 124601762 124601762 -18010000 -15808000 -36740000 -30773000 199000 -1430000 -291000 -535000 199000 -1430000 -291000 -535000 -17811000 -17238000 -37031000 -31308000 125265015 13000 471193000 -745000 -220969000 249492000 17838 30000 30000 123895 289000 289000 3279000 3279000 199000 199000 -18010000 -18010000 125406748 13000 474791000 -546000 -238979000 235279000 124866392 12000 458191000 -959000 -153529000 303715000 5000 6000 6000 59507 92000 92000 3098000 3098000 -1430000 -1430000 -15808000 -15808000 124930899 12000 461387000 -2389000 -169337000 289673000 125068601 13000 467834000 -255000 -202239000 265353000 214252 275000 275000 123895 289000 289000 6393000 6393000 -291000 -291000 -36740000 -36740000 125406748 13000 474791000 -546000 -238979000 235279000 124865485 12000 455330000 -1854000 -138564000 314924000 5907 7000 7000 59507 92000 92000 5958000 5958000 -535000 -535000 -30773000 -30773000 124930899 12000 461387000 -2389000 -169337000 289673000 -36740000 -30773000 6393000 5958000 2160000 1806000 1028000 826000 1453000 1412000 71000 787000 -308000 -199000 -706000 -117000 -2026000 -1375000 -31723000 -26073000 53500000 32249000 15694000 46844000 1159000 1155000 36647000 -15750000 275000 7000 289000 92000 564000 99000 5488000 -41724000 20399000 115477000 25887000 73753000 444000 323000 0 7623000 Description of Business and Basis of Presentation Nautilus Biotechnology, Inc. (the “Company”) is a biotechnology company incorporated in 2016 with corporate headquarters in Seattle, Washington and research and development headquarters in San Carlos, California. Since the Company’s incorporation in 2016, the Company has devoted substantially all of its resources to research and development activities, including with respect to its proteomics platform, business planning, establishing and maintaining its intellectual property portfolio, hiring personnel, raising capital and providing general and administrative support for these operations. On June 9, 2021, Nautilus Biotechnology, Inc. a Delaware corporation (f/k/a ARYA Sciences Acquisition Corp. III, a Cayman Islands exempted company and the Company’s predecessor company (“ARYA”)), consummated the business combination (the “Business Combination”) pursuant to the terms of that certain Business Combination Agreement, dated as of February 7, 2021 (the “BCA”), by and among ARYA, Mako Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ARYA (“Mako Merger Sub”), and Nautilus Subsidiary, Inc., a Delaware corporation (f/k/a Nautilus Biotechnology, Inc.) (“Legacy Nautilus”). As a result of the Business Combination, ARYA changed its name to “Nautilus Biotechnology, Inc.” and Mako Merger Sub merged with and into Legacy Nautilus with Legacy Nautilus surviving as the surviving company and becoming a wholly-owned subsidiary of ARYA (the “Merger” and, collectively with the other transactions described in the BCA, the “Reverse Recapitalization”). In addition, in conjunction with the completion of the Business Combination, certain investors (“PIPE Investors”) subscribed for the purchase of an aggregate of 20,000,000 shares of common stock of the Company (“New Nautilus Common Stock”) at a price of $10.00 per share for aggregate gross proceeds of $200.0 million (“PIPE Financing”). Basis of Presentation The condensed consolidated financial statements and accompanying notes are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and regulations of the U.S. Securities and Exchange Commission (the “SEC”) for interim financial reporting. All intercompany transactions and balances have been eliminated upon consolidation. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements were prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Company’s financial position, results of operations, and cash flows for the interim periods. The interim financial results are not necessarily indicative of the results for a full year. These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 on file with the SEC. The Company’s reporting currency is the U.S. dollar. Going Concern The Company’s condensed consolidated financial statements have been prepared on the basis of continuity of operations, the realization of assets, and the satisfaction of liabilities in the ordinary course of business. Since inception, the Company has been engaged in developing its technology, raising capital, and recruiting personnel. The Company’s operating plan may change as a result of many factors currently unknown and there can be no assurance that the current operating plan will be achieved in the time frame anticipated by the Company, and it may need to seek additional funds sooner than planned. If adequate funds are not available to the Company on a timely basis, it may be required to delay, limit, reduce, or terminate certain commercial efforts, or pursue merger or acquisition strategies, all of which could adversely affect the holdings or the rights of the Company’s stockholders. The Company has incurred net operating losses and negative cash flows from operations in every year since inception and expects this to continue for the foreseeable future. As of June 30, 2024, the Company had an accumulated deficit of $239.0 million. The Company has funded its operations primarily with proceeds from the issuance of redeemable convertible preferred stock and common stock. In June 2021, the Company received gross proceeds of approximately $345.5 million from PIPE Investors and the Business Combination offset by approximately $18.2 million of transaction costs and underwriters’ fees relating to the closing of the Business Combination. The Company had cash, cash equivalents, and short-term investments of $167.4 million as of June 30, 2024. As of the date on which these condensed consolidated financial statements were issued, the Company believes that its cash, cash equivalents, and short-term investments will be sufficient to fund its operations for at least the next twelve months following the issuance of the condensed consolidated financial statements. The Company’s actual results could vary as a result of, and its near and long-term future capital requirements will depend on many factors, including its growth rate and the timing and extent of spending to support its research and development efforts. The Company has based its estimates on assumptions that may prove to be wrong, and it could use its available capital resources sooner than it currently expects. The Company may be required to seek additional equity or debt financing. Future liquidity and cash requirements will depend on numerous factors. In the event that additional financing is required, the Company may not be able to raise it on acceptable terms or at all. If the Company is unable to raise additional capital when desired, or if it cannot expand its operations or otherwise capitalize on its business opportunities because it lacks sufficient capital, its business, operating results, and financial condition would be adversely affected. 20000000 10.00 200000000 The condensed consolidated financial statements and accompanying notes are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and regulations of the U.S. Securities and Exchange Commission (the “SEC”) for interim financial reporting. All intercompany transactions and balances have been eliminated upon consolidation. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. The condensed consolidated financial statements were prepared on the same basis as the audited financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Company’s financial position, results of operations, and cash flows for the interim periods. The interim financial results are not necessarily indicative of the results for a full year. These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and notes thereto in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 on file with the SEC. The Company’s reporting currency is the U.S. dollar. -239000000 345500000 18200000 167400000 Significant Accounting Policies Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determining the estimated lives of property and equipment, stock-based compensation, research and development accruals, loss contingency accruals, and the valuation allowance for deferred tax assets. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods. As future events and their effects cannot be determined with precision, actual results could materially differ from those estimates and assumptions. <span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks and Uncertainties Credit risk represents the accounting loss that would be recognized as of the reporting date if counterparties failed to perform as contracted. Financial instruments, which potentially subject the Company to concentration of credit risk, consist of cash balances maintained in excess of federal depository insurance limits and investments in marketable debt securities that are not federally insured. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk on cash or investments. The Company relies, and expects to continue to rely, on a number of vendors to provide services, supplies and materials related to its research and development programs. The Company relies on single source suppliers for certain components and materials used in the Nautilus platform. The loss of any of these single source suppliers would require the Company to expend significant time and effort to locate and qualify an alternative source of supply for these components. The Company also relies, and expects to continue to rely, on third-party manufacturers and, in many cases, single third-party manufacturers for the production of certain reagents and antibodies. These programs could be adversely affected by a significant interruption in these services or the availability of materials. The Company is subject to risks similar to those of pre-clinical stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, the impact of negative global and national events and the need to obtain adequate additional financing to fund the development of its products. There can be no assurance that the Company's research and development will be successfully completed, that adequate protection for the Company's intellectual property will be maintained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company's development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products. Segment Reporting Operating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company's Chief Executive Officer is its CODM. The Company's CODM reviews financial information presented on a consolidated basis for the purposes of making operating decisions, allocating resources and evaluating financial performance. As such, the Company has determined that it operates in one operating and one reportable segment. The Company's long-lived assets are entirely based in the United States. Cash and Cash Equivalents The Company considers all highly-liquid investments with an original maturity of three months or less as of the date of acquisition to be cash equivalents. Investments The Company considers investments with an original maturity greater than three months and remaining maturities less than one year to be short-term investments. The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as long-term investments. The Company classifies its marketable debt securities as available for sale and reports them at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For investments sold prior to maturity, the cost of investments sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in other income (expense), net in the condensed consolidated statement of operations. If the estimated fair value of a marketable debt security is below its amortized cost basis, the Company evaluates whether it is more likely than not that the Company will be required to sell the security before its anticipated recovery in market value and whether credit losses exist for the related securities. Credit-related losses are recognized as an allowance for credit losses on the balance sheet with a corresponding adjustment to earnings. Unrealized gains and losses that are unrelated to credit deterioration are reported in accumulated other comprehensive income (loss). Fair Value of Financial Instruments Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. The carrying amounts of cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other liabilities approximate their respective fair values due to their short-term nature. Leases The Company determines if an arrangement includes a lease at inception by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. Operating leases with a term of more than one year are included in operating lease right-of-use ("ROU") assets and operating lease liabilities on the Company's condensed consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments. Operating lease ROU assets and liabilities are recognized on the lease commencement date based on the present value of the future minimum lease payments over the lease term. The Company uses the incremental borrowing rate commensurate with the lease term based on the information available at the lease commencement date in determining the present value of the lease payments as the Company's leases generally do not provide an implicit rate. ROU assets initially equal the lease liability, adjusted for any prepaid lease payments and initial direct costs incurred, less any lease incentives received. Certain of the Company's leases include renewal options which allow the Company to, at its election, renew or extend the lease for a fixed or indefinite period of time. These renewal periods are included in the lease terms when the Company is reasonably certain the options will be exercised. Lease expense is recognized on a straight-line basis over the lease term when leases are operating leases. If it is considered a finance lease, expense is recognized over the lease term within interest expense and amortization in the Company's condensed consolidated statements of operations. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's facility leases and to account for the lease and non-lease components as a single lease component. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less. Comprehensive Loss Comprehensive loss consists of net loss and other gains or losses affecting stockholders' equity that, under U.S. GAAP are excluded from net loss. For the three and six months ended June 30, 2024 and 2023, net unrealized gains and losses on marketable debt securities were included as a component of comprehensive income (loss). Accounting Pronouncements <div

style="margin-bottom:9pt;text-indent:18pt">The Company is provided the option to adopt new or revised accounting guidance as an "emerging growth company" under the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act") either (1) within the same periods as those otherwise applicable to public business entities, or (2) within the same time periods as non-public business entities, including early adoption when permissible. With the exception of standards the Company elected to early adopt, when permissible, the Company has elected to adopt new or revised accounting guidance within the same time period as non-public business entities, as indicated below. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which amends existing guidance on segment reporting to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The ASU is effective for the Company for the fiscal year ending December 31, 2024 and for interim periods beginning after December 31, 2024. The Company is in the process of evaluating the impact of the adoption of this Accounting Standards Update on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures," to enhance the transparency and decision usefulness of income tax disclosures. The ASU is effective for the Company for the fiscal year ending December 31, 2025. The Company is in the process of evaluating the impact of the adoption of this Accounting Standards Update on its consolidated financial statements and related disclosures. The Company does not anticipate adoption to have a material impact on its consolidated financial statements and related disclosures. The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the condensed consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determining the estimated lives of property and equipment, stock-based compensation, research and development accruals, loss contingency accruals, and the valuation allowance for deferred tax assets. These estimates and assumptions are based on management's best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, which management believes to be reasonable under the circumstances. The Company adjusts such estimates and assumptions when facts and circumstances dictate. Changes in those estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods. As future events and their effects cannot be determined with precision, actual results could materially differ from those estimates and assumptions. Credit risk represents the accounting loss that would be recognized as of the reporting date if counterparties failed to perform as contracted. Financial instruments, which potentially subject the Company to concentration of credit risk, consist of cash balances maintained in excess of federal depository insurance limits and investments in marketable debt securities that are not federally insured. The Company has not experienced any losses in such accounts and believes it is not exposed to significant credit risk on cash or investments. The Company relies, and expects to continue to rely, on a number of vendors to provide services, supplies and materials related to its research and development programs. The Company relies on single source suppliers for certain components and materials used in the Nautilus platform. The loss of any of these single source suppliers would require the Company to expend significant time and effort to locate and qualify an alternative source of supply for these components. The Company also relies, and expects to continue to rely, on third-party manufacturers and, in many cases, single third-party manufacturers for the production of certain reagents and antibodies. These programs could be adversely affected by a significant interruption in these services or the availability of materials. The Company is subject to risks similar to those of pre-clinical stage companies in the biopharmaceutical industry, including dependence on key individuals, the need to develop commercially viable products, competition from other companies, many of whom are larger and better capitalized, the impact of negative global and national events and the need to obtain adequate additional financing to fund the development of its products. There can be no assurance that the Company's research and development will be successfully completed, that adequate protection for the Company's intellectual property will be maintained, that any products developed will obtain required regulatory approval or that any approved products will be commercially viable. Even if the Company's development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from the sale of its products. Operating segments are defined as components of an entity where discrete financial information is evaluated regularly by the chief operating decision maker ("CODM") in deciding how to allocate resources and in assessing performance. The Company's Chief Executive Officer is its CODM. The Company's CODM reviews financial information presented on a consolidated basis for the purposes of making operating decisions, allocating resources and evaluating financial performance. As such, the Company has determined that it operates in one operating and one reportable segment. The Company's long-lived assets are entirely based in the United States. 1 1 The Company considers all highly-liquid investments with an original maturity of three months or less as of the date of acquisition to be cash equivalents. The Company considers investments with an original maturity greater than three months and remaining maturities less than one year to be short-term investments. The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as long-term investments. The Company classifies its marketable debt securities as available for sale and reports them at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). For investments sold prior to maturity, the cost of investments sold is based on the specific identification method. Realized gains and losses on the sale of investments are recorded in other income (expense), net in the condensed consolidated statement of operations. If the estimated fair value of a marketable debt security is below its amortized cost basis, the Company evaluates whether it is more likely than not that the Company will be required to sell the security before its anticipated recovery in market value and whether credit losses exist for the related securities. Credit-related losses are recognized as an allowance for credit losses on the balance sheet with a corresponding adjustment to earnings. Unrealized gains and losses that are unrelated to credit deterioration are reported in accumulated other comprehensive income (loss). Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. The carrying amounts of cash and cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses and other liabilities approximate their respective fair values due to their short-term nature. The Company determines if an arrangement includes a lease at inception by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. Operating leases with a term of more than one year are included in operating lease right-of-use ("ROU") assets and operating lease liabilities on the Company's condensed consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease

term and lease liabilities represent the obligation to make lease payments. Operating lease ROU assets and liabilities are recognized on the lease commencement date based on the present value of the future minimum lease payments over the lease term. The Company uses the incremental borrowing rate commensurate with the lease term based on the information available at the lease commencement date in determining the present value of the lease payments as the Company's leases generally do not provide an implicit rate. ROU assets initially equal the lease liability, adjusted for any prepaid lease payments and initial direct costs incurred, less any lease incentives received. Certain of the Company's leases include renewal options which allow the Company to, at its election, renew or extend the lease for a fixed or indefinite period of time. These renewal periods are included in the lease terms when the Company is reasonably certain the options will be exercised. Lease expense is recognized on a straight-line basis over the lease term when leases are operating leases. If it is considered a finance lease, expense is recognized over the lease term within interest expense and amortization in the Company's condensed consolidated statements of operations. The Company also has lease arrangements with lease and non-lease components. The Company elected the practical expedient not to separate non-lease components from lease components for the Company's facility leases and to account for the lease and non-lease components as a single lease component. The Company also elected to apply the short-term lease measurement and recognition exemption in which ROU assets and lease liabilities are not recognized for leases with terms of 12 months or less. Comprehensive loss consists of net loss and other gains or losses affecting stockholders' equity that, under U.S. GAAP are excluded from net loss. For the three and six months ended June 30, 2024 and 2023, net unrealized gains and losses on marketable debt securities were included as a component of comprehensive income (loss). The Company is provided the option to adopt new or revised accounting guidance as an "emerging growth company" under the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act") either (1) within the same periods as those otherwise applicable to public business entities, or (2) within the same time periods as non-public business entities, including early adoption when permissible. With the exception of standards the Company elected to early adopt, when permissible, the Company has elected to adopt new or revised accounting guidance within the same time period as non-public business entities, as indicated below. Recently Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," which amends existing guidance on segment reporting to improve reportable segment disclosure requirements through enhanced disclosures about significant segment expenses. The ASU is effective for the Company for the fiscal year ending December 31, 2024 and for interim periods beginning after December 31, 2024. The Company is in the process of evaluating the impact of the adoption of this Accounting Standards Update on its consolidated financial statements and related disclosures. In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures," to enhance the transparency and decision usefulness of income tax disclosures. The ASU is effective for the Company for the fiscal year ending December 31, 2025. The Company is in the process of evaluating the impact of the adoption of this Accounting Standards Update on its consolidated financial statements and related disclosures. The Company does not anticipate adoption to have a material impact on its consolidated financial statements and related disclosures. Fair Value Measurements The following table details the assets carried at fair value and measured on a recurring basis within the three levels of fair value as of June 30, 2024 and December 31, 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Reported as:</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gains</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cash equivalents </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Short-term investments</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Long-term investments</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 1</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Mutual funds</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,260 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,260 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,260 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. treasury securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,124 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(129)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,012 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,996 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35,458 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,558 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total Level 1</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58,384 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(129)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58,272 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,256 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35,458 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,558 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 2</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,457 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,446 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,446 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate debt securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,984 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(24)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,960 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,960 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Agency securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">149,447 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(417)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">149,048 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102,140 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46,908 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total Level 2</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">174,888 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(452)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">174,454 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,446 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">107,100 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46,908 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom">Total Level 1 and Level 2</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">233,272 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(581)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">232,726 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">24,702 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">257,428 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(998)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">256,430 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff

color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">142,558 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">65,466 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:22.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.141%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Reported as:</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gains</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cash equivalents </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Short-term investments</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Long-term investments</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 1</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Mutual funds</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">590 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">590 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">590 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. treasury securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,115 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(247)</td><td

style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73,972 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50,638 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,334 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total Level 1</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,705 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(247)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,562 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">590 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50,638 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,334 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 2</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,653 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,644 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,644 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate debt securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,950 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(37)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,913 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,913 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Agency securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">163,849 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(424)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">163,783 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96,470 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,313 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total Level 2</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">189,452 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">358 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(470)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">189,340 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,644 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">103,383 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,313 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom">Total Level 1 and Level 2</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">264,157 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">462 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(717)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">263,902 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19,234 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">154,021 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">90,647 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Short-term investments have a contractual maturity date that is one year or less from the respective balance sheet date. Long-term investments have a contractual maturity date that is more than one year, but less than two years from the respective balance sheet date. The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of June 30, 2024 and December 31, 2023 are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td

style="width:1.0%"></td><td style="width:8.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Securities in Unrealized Loss Position Less than 12 months</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Securities in Unrealized Loss Position Greater than 12 months</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Market Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Market Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Market Value</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. treasury securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">67 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">26,444 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">62 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">22,754 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">129 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">49,198 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,447 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,447 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate debt securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,959 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">4,959 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Agency securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">163 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53,020 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">254 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,593 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">417 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138,613 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">241 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">99,911 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">340 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">113,306 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">581 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">213,217 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Securities in Unrealized Loss Position Less than 12 months</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Securities in Unrealized Loss Position Greater than 12 months</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Market Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Market Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Market Value</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. treasury securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">85 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">20,408 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">162 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">30,230 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">247 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">50,638 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,644 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,644 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate debt securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,913 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,913 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Agency securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">229 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,039 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">195 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,704 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">424 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">110,743 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">360 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">131,004 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-

align:right;vertical-align:bottom">357 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">55,934 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">717 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">186,938 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The Company reviewed its investment portfolio based on the underlying risk profile of the securities and have a no loss expectation for these investments. The Company reviewed the securities in an unrealized loss position and evaluated the current expected credit loss by considering factors such as historical experience, market data, issuer-specific factors, and current economic conditions. The Company recognized no credit losses during the three and six months ended June 30, 2024 and 2023, and had no allowance for credit losses as of June 30, 2024 and December 31, 2023. <div style="margin-bottom:9pt;text-indent:18pt">The following table details the assets carried at fair value and measured on a recurring basis within the three levels of fair value as of June 30, 2024 and December 31, 2023:</div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.797%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Reported as:</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gains</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Cash equivalents</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Short-term investments</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Long-term investments</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 1</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Mutual funds</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,260 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,260 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td

style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. treasury securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,124 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(129)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">57,012 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,996 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35,458 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,558 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total Level 1</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58,384 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(129)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">58,272 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,256 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35,458 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,558 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 2</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,457 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(11)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,446 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,446 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate debt securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,984 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(24)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,960 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-

color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,960 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Agency securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">149,447 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(417)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">149,048 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102,140 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46,908 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total Level 2</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">174,888 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(452)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">174,454 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,446 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">107,100 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46,908 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom">Total Level 1 and Level 2</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">233,272 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(581)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">232,726 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">24,702 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">142,558 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">65,466 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <div style="margin-

bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:22.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.814%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.141%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Reported as:</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized Cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gains</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cash equivalents </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Short-term investments</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Long-term investments</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 1</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Mutual funds</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">590 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">590 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">74,115 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(247)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73,972 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50,638 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">

23,334 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total Level 1</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,705 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">104 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(247)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">74,562 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">590 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50,638 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,334 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Level 2</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,653 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,644 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,644 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate debt securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,950 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(37)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,913 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,913 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Agency securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">163,849 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">358 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(424)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">163,783 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td>

<td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">96,470 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,313 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total Level 2</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">189,452 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">358 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(470)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">189,340 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,644 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">103,383 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">67,313 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom">Total Level 1 and Level 2</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">264,157 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">462 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(717)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">263,902 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19,234 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">154,021 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">90,647 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1260000 0 0 1260000 1260000 0 0 57124000 17000 129000 57012000 2996000 35458000 18558000 58384000 17000 129000 58272000 4256000 35458000 18558000 20457000 0 11000 20446000 20446000 0 0 4984000 0 24000 4960000 0 4960000 0 149447000 18000 417000 149048000 0 102140000 46908000 174888000 18000 452000 174454000 20446000 107100000 46908000 233272000 35000 581000 232726000 24702000 142558000 65466000 590000 0 0 590000 590000 0 0 74115000 104000 247000 73972000 0 50638000 23334000 74705000 104000 247000 74562000 590000 50638000 23334000 18653000 0 9000 18644000 18644000 0 0 6950000 0 37000 6913000 0 6913000 0 163849000 358000 424000 163783000 0 96470000 67313000 189452000 358000 470000 189340000 18644000 103383000 67313000 264157000 462000 717000 263902000 19234000 154021000 90647000 The unrealized losses and fair values of available-for-sale securities that have been in an unrealized loss position for a period of less than and greater than 12 months as of June 30, 2024 and December 31, 2023 are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Securities in Unrealized Loss Position Less than 12 months</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Securities in Unrealized Loss Position Greater than 12 months</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-

family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Market Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Market Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Market Value</td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. treasury securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">67 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">26,444 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">62 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">22,754 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">129 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">49,198 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,447 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,447 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate debt securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,959 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,959 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Agency securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">163 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">53,020 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">254 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,593 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">417 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">138,613 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">241 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">99,911 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">340 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">113,306 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">581 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">213,217 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.278%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.079%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Securities in Unrealized Loss Position Less than 12 months</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Securities in Unrealized Loss Position Greater than 12 months</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Market Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Market Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Unrealized Losses</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Market Value</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. treasury securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">85 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">20,408 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">162 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"

style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">30,230 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">247 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ccceff;padding:0 1pt"></td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">50,638 </td><td style="background-color:#ccceff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Commercial paper</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,644 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18,644 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate debt securities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,913 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">37 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,913 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Agency securities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">229 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">85,039 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">195 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25,704 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">424 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">110,743 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">360 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">131,004 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">357 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">55,934 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">717 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">186,938 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 67000 26444000 62000 22754000 129000 49198000 11000 20447000 0 0 11000 20447000 0 0 24000 4959000 24000 4959000 163000 53020000 254000 85593000 417000 138613000 241000 99911000 340000 113306000 581000 213217000 85000 20408000 162000 30230000 247000 50638000 9000 18644000 0 0 9000 18644000 37000 6913000 0 0 37000 6913000 229000 85039000 195000 25704000 424000 110743000 360000 131004000 357000 55934000 717000 186938000 0 0 0 0 0 0 Composition of Certain Condensed Consolidated Financial Statement Line Items Property and Equipment, Net Property and equipment consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Laboratory equipment</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,474 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,337 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer hardware</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">335 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">222 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Furniture, fixtures and office equipment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">324 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">324 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Prototype equipment</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,476 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">996 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Construction in progress</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,601 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">904 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,328 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,901 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Accumulated depreciation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,634)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,634)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">4,694 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">4,267 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> The Company recorded depreciation expense of $0.5 million and $1.0 million for the three and six months ended June 30, 2024, respectively, and $0.4 million and $0.8 million for the three and six months ended June 30, 2023, respectively, which was primarily allocated to research and development expense. </div><div style="margin-bottom:9pt">Accrued Expenses and Other Liabilities</div><div style="margin-bottom:9pt;text-indent:18pt">Accrued expenses and other liabilities consisted of the following:</div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee compensation</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,071 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,590 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">342 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">731 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued professional and consulting fees</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">522 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">245 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">304 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">379 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,239 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,945 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt">Cash, Cash Equivalents and Restricted Cash</div><div style="margin-bottom:9pt;text-indent:18pt">Cash, cash equivalents and restricted cash consisted of the following:</div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">24,885 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19,397 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted cash included in other long-term assets (Note 8)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,002 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,002 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-

color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">25,887 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">20,399 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Other long-term assets consisted of $1.0 million of restricted cash and $0.2 million of deposits as of June 30, 2024 and December 31, 2023.</div> <div style="margin-bottom:9pt;text-indent:18pt">Property and equipment consisted of the following:</div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Laboratory equipment</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,474 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,337 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">118 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Computer hardware</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">335 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">222 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Furniture, fixtures and office equipment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">324 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">324 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Prototype equipment</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,476 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">996 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Construction in progress</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,601 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">904 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10,328 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8,901 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Accumulated depreciation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5,634)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4,634)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">4,694 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">

4,267 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> 6474000 6337000 118000 118000 335000 222000 324000 324000 1476000 996000 1601000 904000 10328000 8901000 5634000 4634000 4694000 4267000 500000 1000000.0 400000 800000 Accrued expenses and other liabilities consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee compensation</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,071 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,590 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">342 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">731 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued professional and consulting fees</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">522 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">245 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">304 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">379 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,239 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,945 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Accrued expenses and other liabilities consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee compensation</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,071 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,590 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued research and development</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">342 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">731 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued professional and consulting fees</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">522 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">245 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:100%">Other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">304 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">379 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,239 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,945 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 2071000 2590000 342000 731000 522000 245000 304000 379000 3239000 3945000 Cash, cash equivalents and restricted cash consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">24,885 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19,397 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted cash included in other long-term assets (Note 8)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,002 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,002 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">25,887 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">20,399 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Cash, cash equivalents and restricted cash consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">24,885 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">19,397 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted cash included in other long-term assets (Note 8)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,002 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,002 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">25,887 </td><td style="background-color:#cceeff;border-bottom:3pt

*double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">20,399 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 24885000 19397000 1002000 1002000 25887000 20399000 1000000 1000000 200000 200000 Common Stock There were 125,406,748 shares issued and outstanding as of June 30, 2024. Common Stock Reserved for Future Issuance Shares of common stock reserved for future issuance on an as-if converted basis, were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares available for grant under 2021 Equity Incentive Plan</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,449,238 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,279,560 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock options issued and outstanding</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,545,835 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,676,335 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Shares available for grant under 2021 Employee Stock Purchase Plan </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,631,929 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,505,138 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total shares of common stock reserved</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,627,002 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,461,033 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 125406748 125406748 Shares of common stock reserved for future issuance on an as-if converted basis, were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">June 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Shares available for grant under 2021 Equity Incentive Plan</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23,449,238 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20,279,560 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Stock options issued and outstanding</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,545,835 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,676,335 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Shares available for grant under 2021 Employee Stock Purchase Plan </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,631,929 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,505,138 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total shares of common stock reserved</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">45,627,002 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">38,461,033 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 23449238 20279560 17545835 14676335 4631929 3505138 45627002 38461033 Income Taxes The Company accounts for income taxes under the asset and liability method. Under this method,*

*deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. For the three and six months ended June 30, 2024 and 2023, no income tax expense or benefit was recognized, due to a full valuation allowance recorded against its deferred tax assets. 0 0 0 0 Equity Incentive Plans and Stock-based Compensation On June 8, 2021, the stockholders of the Company approved the 2021 Equity Incentive Plan ("2021 Plan") and the 2021 Employee Stock Purchase Plan ("2021 ESPP"). As of June 30, 2024, 23,449,238 and 4,631,929 shares were available for grant under the 2021 Plan and 2021 ESPP, respectively. 2021 Employee Stock Purchase Plan Under the 2021 ESPP, participants are permitted to purchase shares of Common Stock, up to the IRS allowable limit, through contributions (in the form of payroll deductions or otherwise to the extent permitted by the administrator of the 2021 ESPP) of up to 15% of their eligible compensation. Participants are permitted to purchase shares of the Company's Common Stock at 85% of the lower of the fair market value of the Company's Common Stock on the first trading day of an offering period or on the last trading date in each purchase period. The Company offers a six month purchase period. Participants may end their participation at any time during an offering and will be paid their accrued contributions that have not yet been used to purchase shares. Participation ends automatically upon termination of employment with the Company. The number of shares of common stock available for issuance under the 2021 ESPP will be increased on the first day of each fiscal year in an amount equal to the least of (i) 3,734,500 shares of common stock, (ii) a number of shares of common stock equal to one percent (1%) of the total number of shares of all classes of common stock of the Company on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the Administrator no later than the last day of the immediately preceding fiscal year. On January 1, 2024, the number of shares available under the 2021 ESPP increased by 1,250,686 shares pursuant to this feature. 2021 Equity Incentive Plan Under the 2021 Plan, the Company can grant incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to employees, non-employee directors and consultants. Options generally expire ten years after the date of grant. The number of shares available for issuance under the 2021 Plan will be increased on the first day of each fiscal year in an amount equal to the least of (i) 18,672,200 shares, (ii) a number of shares equal to five percent (5%) of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the Administrator no later than the last day of the immediately preceding fiscal year. On January 1, 2024, the number of shares available under the 2021 Plan increased by 6,253,430 shares pursuant to this feature. 2017 Equity Incentive Plan At the time of adoption of the 2021 Plan and the 2021 ESPP, no further awards will be granted under the 2017 Equity Incentive Plan ("2017 Plan"). Stock-based awards forfeited or cancelled from the 2017 Plan are returned to the pool of shares of Common Stock available for issuance under the 2021 Plan. Grant Date Fair Value of Stock Options In determining the compensation cost of the option awards, the fair value for each option award has been estimated using the Black Scholes model. The significant assumptions used in these calculations are summarized as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term (in years)</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.3 - 6.0 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.3 - 6.1 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.3 - 6.0 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.3 - 6.4 </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 99.7% - 101.1% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 103.1% - 106.5% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 99.7% - 101.1% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 102.7% - 107.5% </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected dividend rate</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk free interest rate</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.17% - 4.60% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.58% - 3.87% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.01% - 4.60% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.50% - 4.08% </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Expected term: The expected term of stock options represents the weighted-average period the stock options are expected to remain outstanding. The Company does not have sufficient historical exercise and post-vesting termination activity to provide accurate data for estimating the expected term of options and has opted to use the “simplified method,” whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. Expected volatility: Historically, the Company has been a private company and lacked company-specific historical and implied volatility information for its common stock. Therefore, the expected volatility of the Company’s common stock was determined by using an average of historical volatilities of selected industry peers deemed to be comparable to the Company’s business corresponding to the expected term of the awards and the Company expects to continue to do so until such time as the Company has adequate historical data regarding the volatility of its traded common stock price. Expected dividend yield: The expected dividend rate is zero as the Company has no history or expectation of declaring dividends on its common stock. Risk-free interest rate: The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for zero-coupon U.S. Treasury notes with maturities corresponding to the expected term of the awards.
 The following table summarizes option award activity during the six months ended June 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of Stock Option Awards</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Exercise Price</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Remaining Contractual Life (Years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate Intrinsic Value (in thousands)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Outstanding as of December 31, 2023 </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,676,335 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3.63 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,423,900 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2.65 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Exercised</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(214,252)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1.28 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(340,148)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">3,40 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Outstanding as of June 30, 2024 </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">17,545,835 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle">3.47 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">7.8</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle">6,304 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Options vested and expected to vest as of June 30, 2024 </td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,545,835 </td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.47 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div>Vested and exercisable at June 30, 2024</div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">9,482,993 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle">3.83 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">6.9</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle">5,446 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> As of June 30, 2024, there was $19.4 million of total unrecognized compensation expense expected to be recognized over a weighted average-period of 2.3 years. Aggregate intrinsic value represents the difference between the fair market value of the common stock and the exercise price of outstanding, in-the-money options. </div><div style="margin-bottom:9pt;text-indent:18pt">Stock-based Compensation Expense</div><div style="margin-bottom:9pt;text-indent:18pt">The following sets forth the total stock-based compensation expense included in the Company's condensed consolidated statement of operations:</div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,146 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,048 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,242 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,023 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-

align:bottom">General and administrative</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,133 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,050 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,151 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,935 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">Total stock-based compensation expense</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">3,279 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">3,098 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">6,393 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">5,958 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> 23449238 4631929 0.15 0.85 P6M 3734500 0.01 1250686 P10Y 18672200 0.05 6253430 The significant assumptions used in these calculations are summarized as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected term (in years)</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.3 - 6.0 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.3 - 6.1 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.3 - 6.0 </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.3 - 6.4 </td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected volatility</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 99.7% - 101.1% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 103.1% - 106.5% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 99.7% - 101.1% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 102.7% - 107.5% </td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Expected dividend rate</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr><tr><td

colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Risk free interest rate</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.17% - 4.60% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.58% - 3.87% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.01% - 4.60% </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.50% - 4.08% </td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> P5Y3M18D P6Y P5Y3M18D P6Y1M6D P5Y3M18D P6Y P5Y3M18D P6Y4M24D 0.997 1.011 1.031 1.065 0.997 1.011 1.027 1.075 0.000 0.000 0.000 0.000 0.0417 0.0460 0.0358 0.0387 0.0401 0.0460 0.0350 0.0408 0 The following table summarizes option award activity during the six months ended June 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number of Stock Option Awards</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Exercise Price</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted Average Remaining Contractual Life (Years)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Aggregate Intrinsic Value (in thousands)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Outstanding as of December 31, 2023 </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">14,676,335 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3.63 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,423,900 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2.65 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Exercised</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(214,252)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1.28 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Forfeited</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(340,148) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.40 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"> Outstanding as of June 30, 2024 </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">17,545,835 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle">3.47 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">7.8</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle">6,304 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Options vested and expected to vest as of June 30, 2024 </td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">17,545,835 </td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"

style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">3.47 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div>Vested and exercisable at June 30, 2024</div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle">9,482,993 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle">3.83 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle">6.9</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle">5,446 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div> 14676335 3.63 3423900 2.65 214252 1.28 340148 3.40 17545835 3.47 P7Y9M18D 6304000 17545835 3.47 9482993 3.83 P6Y10M24D 5446000 19400000 P2Y3M18D <div style="margin-bottom:9pt;text-indent:18pt">The following sets forth the total stock-based compensation expense included in the Company's condensed consolidated statement of operations:</div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.364%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,146 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,048 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,242 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,023 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">General and administrative</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,133 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,050 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4,151 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,935 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">Total stock-based compensation expense</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">3,279 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">3,098 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New

Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,393 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">5,958 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> 1146000 1048000 2242000 2023000 2133000 2050000 4151000 3935000 3279000 3098000 6393000 5958000 Commitments and Contingencies Purchase Commitments Open purchase commitments are for the purchase of goods and services related to, but not limited to, research and development, facilities, and professional services under non-cancellable contracts. They were not recorded as liabilities on the condensed consolidated balance sheet as of June 30, 2024 as the Company had not yet received the related goods or services. As of June 30, 2024, the Company had open purchase commitments for goods and services of $2.3 million, of which $1.7 million are expected to be received through the next 12 months.</div><div style="margin-bottom:9pt;text-indent:18pt">Legal Proceedings</div><div style="margin-bottom:9pt;text-indent:18pt">From time to time, the Company may become involved in litigation relating to claims arising from the ordinary course of business. The Company may record accruals for loss contingencies associated with legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues. Loss contingency accruals would be included in accrued and other liabilities and general and administrative expenses.</div><div style="margin-bottom:9pt;text-indent:18pt">U.S. District Court Proceedings</div><div style="margin-bottom:9pt;text-indent:18pt">On December 14, 2023, the Company filed suit in the United States District Court for the Northern District of California against Somalogic (now known as Standard Biotools, Inc.), and the California Institute of Technology seeking declaratory judgment that the Company does not infringe any claims of US Patent No. 7,842,793 related to DNA origami structures, allegedly licensed from the California Institute of Technology through Somalogic's purchase of Palamedrix, Inc. </div><div style="margin-bottom:9pt;text-indent:18pt">On March 29, 2024, Somalogic filed a motion to dismiss the suit. On April 19, 2024, the Company filed a First Amended Complaint addressing issues raised in Somalogic's motion to dismiss. On April 22, 2024, the Court issued an order dismissing Somalogic's motion to dismiss as moot. On May 16, 2024, the Court granted the parties' request for a temporary stay of the proceedings. While the Company believes that it will be able to prevail as to its claims in this litigation, the Company may incur significant expense and management distraction in prosecuting this litigation. Moreover, notwithstanding management's belief as to the strength of the Company's claims in this matter, litigation generally, and patent litigation in particular, can be unpredictable. As such, management cannot be certain that the Company will prevail in this litigation. </div><div style="margin-bottom:9pt;text-indent:18pt">Leases</div><div style="margin-bottom:9pt;text-indent:18pt">The Company is obligated under certain non-cancellable operating leases for office space and laboratory space. This space includes operating leases in Seattle, Washington, San Carlos, California, and San Diego, California.</div><div style="margin-bottom:9pt;text-indent:18pt">The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of June 30, 2024:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Lease Obligations</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Six months ending December 31, 2024</div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,931 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,182 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,874 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,889 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,816 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2029 and thereafter </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,207 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total future minimum lease payments</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42,899 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Imputed interest</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,297) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">Total operating lease liabilities</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">32,602 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> For the six months ended June 30, 2024 and 2023, cash paid for amounts included in the measurement of operating lease liabilities included in cash flows used in operating activities was $3.5 million and $2.8 million, respectively. <span style="color:#000000;font-family:'Times New Roman';sans-serif;font-

size:10pt;font-weight:400;line-height:120%">The Company has $1.0 million in cash-collateralized letters of credit with one financial institution in lieu of security deposits in connection with the San Carlos and San Diego lease agreements. Indemnification Agreements In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnifications will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by them in any action or proceeding to which any of them are, or are threatened to be, made a party by reason of their service as a director or officer. The Company maintains director and officer insurance coverage that would generally enable it to recover a portion of any future amounts paid. The Company may be subject to indemnification obligation by law with respect to the actions of its employees under certain circumstances and in certain jurisdictions. Commitments and Contingencies Purchase Commitments Open purchase commitments are for the purchase of goods and services related to, but not limited to, research and development, facilities, and professional services under non-cancellable contracts. They were not recorded as liabilities on the condensed consolidated balance sheet as of June 30, 2024 as the Company had not yet received the related goods or services. As of June 30, 2024, the Company had open purchase commitments for goods and services of $2.3 million, of which $1.7 million are expected to be received through the next 12 months.</div><div style="margin-bottom:9pt;text-indent:18pt">Legal Proceedings</div><div style="margin-bottom:9pt;text-indent:18pt">From time to time, the Company may become involved in litigation relating to claims arising from the ordinary course of business. The Company may record accruals for loss contingencies associated with legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues. Loss contingency accruals would be included in accrued and other liabilities and general and administrative expenses.</div><div style="margin-bottom:9pt;text-indent:18pt">U.S. District Court Proceedings</div><div style="margin-bottom:9pt;text-indent:18pt">On December 14, 2023, the Company filed suit in the United States District Court for the Northern District of California against Somalogic (now known as Standard Biotools, Inc.), and the California Institute of Technology seeking declaratory judgment that the Company does not infringe any claims of US Patent No. 7,842,793 related to DNA origami structures, allegedly licensed from the California Institute of Technology through Somalogic's purchase of Palamedrix, Inc. </div><div style="margin-bottom:9pt;text-indent:18pt">On March 29, 2024, Somalogic filed a motion to dismiss the suit. On April 19, 2024, the Company filed a First Amended Complaint addressing issues raised in Somalogic's motion to dismiss. On April 22, 2024, the Court issued an order dismissing Somalogic's motion to dismiss as moot. On May 16, 2024, the Court granted the parties' request for a temporary stay of the proceedings. While the Company believes that it will be able to prevail as to its claims in this litigation, the Company may incur significant expense and management distraction in prosecuting this litigation. Moreover, notwithstanding management's belief as to the strength of the Company's claims in this matter, litigation generally, and patent litigation in particular, can be unpredictable. As such, management cannot be certain that the Company will prevail in this litigation. </div><div style="margin-bottom:9pt;text-indent:18pt">Leases</div><div style="margin-bottom:9pt;text-indent:18pt">The Company is obligated under certain non-cancellable operating leases for office space and laboratory space. This space includes operating leases in Seattle, Washington, San Carlos, California, and San Diego, California. </div><div style="margin-bottom:9pt;text-indent:18pt">The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of June 30, 2024:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Lease Obligations</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Six months ending December 31, 2024</div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,931 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,182 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,874 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,889 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,816 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2029 and thereafter </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,207 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total future minimum lease payments</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42,899 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Imputed interest</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,297) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">Total operating lease liabilities</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">

32,602 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> For the six months ended June 30, 2024 and 2023, cash paid for amounts included in the measurement of operating lease liabilities included in cash flows used in operating activities was $3.5 million and $2.8 million, respectively. The Company has $1.0 million in cash-collateralized letters of credit with one financial institution in lieu of security deposits in connection with the San Carlos and San Diego lease agreements. </div><div style="margin-bottom:9pt;text-indent:18pt">Indemnification Agreements</div><div style="margin-bottom:9pt;text-indent:18pt">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnifications will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. </div>The Company has also agreed to indemnify its directors and executive officers for costs associated with any fees, expenses, judgments, fines and settlement amounts incurred by them in any action or proceeding to which any of them are, or are threatened to be, made a party by reason of their service as a director or officer. The Company maintains director and officer insurance coverage that would generally enable it to recover a portion of any future amounts paid. The Company may be subject to indemnification obligation by law with respect to the actions of its employees under certain circumstances and in certain jurisdictions. 2300000 1700000 <div style="margin-bottom:9pt;text-indent:18pt">The following table summarizes the Company's future principal contractual obligations for operating lease commitments as of June 30, 2024:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Lease Obligations</td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands)</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Six months ending December 31, 2024</div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,931 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2025</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,182 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,874 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,889 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,816 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 2029 and thereafter </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13,207 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total future minimum lease payments</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42,899 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Imputed interest</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10,297) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">Total operating lease liabilities</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle">32,602 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table> 2931000 7182000 6874000 6889000 5816000 13207000 42899000 10297000 32602000 3500000 2800000 1000000.0 Basic and Diluted Net Loss per Share The following tables set forth the computation of the Company's basic and diluted net loss per share attributable to common stockholders for the three and six months ended June 30, 2024 and 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands, except share and per share amounts)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-

align:left;vertical-align:bottom">Numerator:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss attributable to common stockholders</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(18,010)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(15,808)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(36,740)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(30,773)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Denominator:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,317,650 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">124,603,181 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,226,552 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">124,601,762 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss per share attributable to common stockholders, basic and diluted:</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.14)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.13)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.29)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.25)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Three and Six Months Ended June 30, </td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Options to purchase common stock</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">17,545,835</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">14,699,055</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee stock purchase plan</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">139,861</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">78,003</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">Total potentially dilutive common share equivalents</td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle">17,685,696</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle">14,777,058</td></tr></table> The following tables set forth the computation of the Company's basic and diluted net loss per share attributable to common stockholders for the three and six months ended June 30, 2024 and 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.970%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended June 30,</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">(in thousands, except share and per share amounts)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Numerator:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss attributable to common stockholders</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(18,010)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(15,808)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(36,740)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(30,773)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Denominator:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,317,650 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">124,603,181 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">125,226,552 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">124,601,762 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net loss per share attributable to common stockholders, basic and diluted:</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.14)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.13)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.29)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-

color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.25)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -18010000 -18010000 -15808000 -15808000 -36740000 -36740000 -30773000 -30773000 125317650 125317650 124603181 124603181 125226552 125226552 124601762 124601762 -0.14 -0.14 -0.13 -0.13 -0.29 -0.29 -0.25 -0.25 The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.335%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.363%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Three and Six Months Ended June 30, </td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Options to purchase common stock</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">17,545,835</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom">14,699,055</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee stock purchase plan</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">139,861</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle">78,003</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle">Total potentially dilutive common share equivalents</td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle">17,685,696</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:middle">14,777,058</td></tr></table> 17545835 17545835 14699055 14699055 139861 139861 78003 78003 17685696 17685696 14777058 14777058 false false false false '

"